Gastrointestinal symptoms, nutritional status and small intestinal bacterial overgrowth in patients with cancer by Grace, Eva Marie
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 








Gastrointestinal symptoms, nutritional status and small intestinal bacterial overgrowth











Gastrointestinal Symptoms, Nutritional 
Status and Small Intestinal Bacterial 











A thesis submitted for the degree of 
Doctor of Philosophy in 







King’s College London 
School of Medicine 




Oesophagogastric (OG) cancer patients are at risk of developing persistent gastrointestinal (GI) 
symptoms and/or malnutrition. It is possible that GI symptoms co-exist with malnutrition rather 
than simply occurring in isolation. Eighty patients with OG cancer were recruited to a 
prospective observational cohort study to explore this relationship at the point of diagnosis and 
at 3- and 12 months post-diagnosis (Chapter 3). At 12 months, GI symptoms and malnutrition 
persisted or developed in 71.9% and 59.6% respectively. High symptom burden tended to be 
associated with poorer nutritional status and low symptom burden tended to be associated with 
better nutritional status at each time point.    
  
An effective nutritional screening tool is essential for detecting malnutrition in the OG oncology 
setting. A validation study of the Malnutrition Universal Screening Tool against an accepted 
standard (Patient Generated Subjective Global Assessment) was undertaken (Chapter 4). The 
screening tool had a sensitivity of 61% and a specificity of 74% and thus, is not suitable for use 
in this setting. 
 
Theoretically, as a consequence of the treatments received, patients with cancer are at high-risk 
for the development of small intestinal bacterial overgrowth (SIBO), a condition that implies 
abnormal bacterial colonisation of the proximal small bowel. The incidence of SIBO after 
diagnosis was measured in a sub-group of the OG cancer cohort (n= 17) and was found to be 
82.4% (Chapter 3). 
 
There is no gold-standard test for SIBO and a new, accurate diagnostic tool would represent a 
major development. A cohort of 200 patients previously treated for cancer and undergoing 
testing for suspected SIBO were recruited (Chapter 5). The metabolic profile of their urine 
samples was assessed (using metabolomics technology) to establish whether any metabolite(s) 
could separate individuals with and without SIBO. N-acethylglutamine, a modified amino acid, 
showed some ability to separate the two groups.  
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1.1 Gastrointestinal Symptoms, Nutritional Status and Food Intake 
in Patients with Oesophagogastric Cancer 
1.1.1 Classification, Incidence, Management of Oesophagogastric Cancer 
Oesophageal cancer, cancer of the gastro-oesophageal junction (GOJ) and gastric cancer are 
collectively referred to as oesophagogastric (OG) cancer. Patients with OG cancer are often 
classified into five groups according to the site and histology of their tumour (The Royal College 
of Surgeons of England 2013) corresponding to: 
• Squamous cell carcinomas of the oesophagus  
• Adenocarcinomas of the upper and middle oesophagus  
• Adenocarcinomas of the lower third of the oesophagus and Siewert type I tumours  
• Siewert type II and type III tumours  
• Tumours of the stomach  
 
The three-category Siewert classification system is commonly used to describe the tumours of 
the GOJ, as follows (Siewert & Stein 1998): 
• Type I: Adenocarcinoma of the lower third of the oesophagus which usually arises from an 
area with specialised intestinal metaplasia of the oesophagus (i.e. Barrett’s oesophagus) 
and which may infiltrate the GOJ from above 
• Type II: True carcinoma of the cardia arising from the cardiac epithelium or short segments 
with intestinal metaplasia at the GOJ 
• Type III: Subcardial gastric carcinoma that infiltrates the GOJ and lower third of the 
oesophagus from below 
 
For OG tumour staging, the Tumour Node Metastasis (TNM) Classification is an anatomically 
based system that records the primary and regional nodal extent of the tumour and the absence 
or presence of metastases. Each individual aspect of TNM is termed a ‘T’ category (that 
describes the primary tumour site), a ‘N’ category (that describes the regional lymph node 
involvement) and a ‘M’ category (that describes the presence or otherwise of distant metastatic 
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spread). In 2009 the Union for International Cancer Control in collaboration with the American 
Joint Committee on Cancer published TNM 7th edition, which has become the standard for 
describing and categorising OG cancer stages and progression in the United Kingdom (UK) 
(Sobin et al. 2009; Allum et al. 2011). Using this, assuming an assessment of the cancer can be 
undertaken, there are four sub-groups in the T category (T1, T2, T3, T4), three in the N 
category (N1, N2, N3) and one in the M category (M1). Further detailed information on the 
classification of oesophageal, GOJ and gastric cancer is shown in Appendix 8.1. Of note, 
tumours including the oesophagus and within 5 cm of the GOJ are classified as oesophageal 
cancers and all others are classified as gastric cancer. As such, the majority of cancers in the 
GOJ region are considered gastric in nature and therefore incidence statistics often report GOJ 
and gastric cancers together.  
 
The precursor of squamous cell carcinoma is epithelial dysplasia, which progresses to 
carcinoma and then to invasive carcinoma. Causal factors for squamous cell carcinoma of the 
oesophagus include alcohol, tobacco, caustic injury, previous radiotherapy treatment for head 
and neck or breast cancer, low intake of fruits and vegetables and high intake of processed 
meat/N-nitroso compounds (Navarro Silvera et al. 2011; Napier et al. 2014; Enzinger & Mayer 
2003). Adenocarcinoma occurs when the squamous mucosa undergoes metaplasia into 
specialised columnar epithelium and then becomes dysplastic. Causal factors for 
adenocarcinoma of the GOJ include gastro-oesophageal reflux disease, obesity, smoking, low 
intake of fruits and vegetables and high intake of processed meat/N-nitroso compounds, while 
for adenocarcinoma of the stomach, causal factors include H. Pylori infection, atrophic gastritis, 
smoking, low intake of fruits and vegetables and high intake of processed meat/N-nitroso 
compounds (Sehdev & Catenacci 2013; Steevens et al. 2010; Navarro Silvera et al. 2011; 
DeVita et al. 2012; Trivers et al. 2008; Shimazu et al. 2014). 
 
The past decade has seen changes in the epidemiology of OG cancer with an increase in the 
incidence of GOJ adenocarcinomas. In fact, in England, adenocarcinomas are now the most 
common histological type of OG cancer (Cancer Research UK 2014). This probably reflects the 
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effect of chronic gastro-oesophageal reflux disease and the increasing incidence of obesity (Wu 
et al. 2003; Lindblad et al. 2005). In the UK, this increase in incidence is more rapid than that 
reported by any other country in the world (Bollschweiler et al. 2001). 
 
Worldwide incidence statistics for 2012 estimate that oesophageal and GOJ/gastric cancers 
were the 8th and 5th most common cancers, making up 3% and 7% of all cancers respectively. 
Similarly, oesophageal and GOJ/gastric cancers were the 8th and 5th most common cause of 
mortality in this year (International Agency for Research in Cancer 2014). In the UK in 2011, 
there were 8,332 new cases of oesophageal cancer and 7,089 new cases of GOJ/gastric 
cancer (Cancer Research UK 2014). In addition, oesophageal and GOJ/gastric cancers were 
the 8th and 11th most common types respectively for males and the 13th and 14th most common 
types for females.  
 
Overall OG cancer is twice as common in males as in females but this male predominance is 
particularly strong for GOJ/gastric cancer at 7:1 (Devesa et al. 1998; Parkin 2001; The Royal 
College of Surgeons of England 2013). The median age at time of diagnosis of OG cancer is 74 
years for all types combined, with 45% of cases being detected in those aged 55-74 years 
(Coupland, Allum, et al. 2012a).  
 
The incidence rates of these cancers in broad ethnic groups have been studied.	  White males 
and Bangladeshi females have the highest incidence of oesophageal cancer, while Pakistani 
males and females have the lowest incidence. For GOJ/gastric cancer, Black Caribbean males 
and females have the highest incidence and Indian males and females have the lowest 
incidence compared with their White counterparts (Coupland, Lagergren, et al. 2012b). 
 
There are guidelines for the referral of patients with suspected upper-gastrointestinal (GI) 
cancer (National Institute for Health and Clinical Excellence, Great Britain 2005). These 
guidelines recommend that an urgent referral for endoscopy assessment or to a specialist with 
expertise in upper-GI cancer should be made for patients aged 55 years and older with 
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unexplained and persistent recent-onset dyspepsia. An urgent referral should also be made for 
patients of any age with dyspepsia who present with any of the following ‘alarm features’: 
chronic GI bleeding, dysphagia, progressive unintentional weight loss, persistent vomiting, iron 
deficiency anaemia, epigastric mass or suspicious barium meal result.  
 
However, it has been demonstrated that use of ‘alarm features’ alone to prompt the referral of 
patients under 55 years causes patients with early disease to be overlooked (Bowrey et al. 
2006). For this reason, the diagnosis of upper-GI cancer as a result of an emergency admission 
still accounts for 15% of cases. The proportion diagnosed during emergency admission is 
higher for GOJ/gastric cancer than oesophageal cancer and the difference may be due to the 
fact that early symptoms of oesophageal cancer are easier to recognise (e.g. dysphagia and 
odynophagia), while GOJ/gastric cancer tends to present later with less specific signs and 
symptoms (e.g. early satiety, anaemia and weight loss), many of which are present in large 
numbers of individuals without cancer (The Royal College of Surgeons of England 2013). 
 
Staging investigations for OG cancer should be coordinated within an agreed pathway led by an 
OG specialist multidisciplinary team (MDT) at a specialist centre. The core team specific to this 
MDT should include: two or more surgeons, a physician gastroenterologist, a clinical oncologist, 
a medical oncologist, a histopathologist, an imaging specialist, an OG nurse specialist, a core 
member of the specialist palliative care team, a dietitian specialising in OG cancer, an oncology 
specialist physiotherapist and a MDT coordinator/secretary (London Cancer Alliance 2014). 
Treatment recommendations should be undertaken in the context of this OG specialist MDT, 
taking into account patient co-morbidities, nutritional status, performance status, patient 
preferences and TNM staging information as per grade C evidence (Allum et al. 2011). 
Recommendations for the radical treatment (treatment with curative intent) of OG cancer are 
shown in Table 1-1. Patients considered for radical therapy are generally younger at diagnosis, 
have a better performance status and have fewer than two comorbidities compared with those 
treated palliatively with T4 disease (The Royal College of Surgeons of England 2013).   
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The surgical resection of the tumour remains the cornerstone of radical treatment for most OG 
cancers, consisting of oeophagectomy, oesophagogastrectomy or gastrectomy, as appropriate. 
For tumours of the oesophagus, an oesophagectomy is performed. In the UK, 97% of 
oesophagectomies are performed via the transthoracic approach and the remaining 3% are 
done via the transhiatal approach. The three transthoracic approaches are the two-phase Ivor 
Lewis, the three-phase McKeown and the left thoraco-abdominal approach. Gastrointestinal 
continuity is usually achieved by using the stomach remnant as a conduit with an end-to-side 
anastomosis. For tumours of the GOJ, a transhiatal extended total gastrectomy 
(oesophagogastrectomy) is the procedure used, often with the two-phase Ivor Lewis method 
and with GI continuity achieved as for oesophagectomy. For gastric resections, 87% of 
procedures are total or distal subtotal gastrectomies (The Royal College of Surgeons of England 
2013).  
 
Table 1-1 Expert recommendations for the radical treatment of oesophagogastric cancers 
in the United Kingdom 
 
 
Cancer site Histology Conditions Definitive treatment modalities 
Upper 
oesophagus 





SCC T1, T2 or T3 disease, 
good performance status and 
good exercise tolerance    
(if for surgery) 
 





I, II or III 
AC T1, T2 or T3 disease,  
good performance status and 
good exercise tolerance 
Combined perioperative 
chemotherapy (pre- and 
postoperative) and surgery 
or 
Preoperative chemotherapy/ 
chemoradiation and surgery 
Stomach AC 
 
T1, T2 or T3 disease, 
 good performance status and 
good exercise tolerance 
 
Did not receive preoperative 
chemotherapy and at high risk 
of recurrence 
Combined perioperative 
chemotherapy (pre- and 
postoperative) and surgery 
 
Surgery and postoperative 
chemoradiation 
Table adapted from ‘Guidelines for the management of oesophageal and gastric cancer’ 
(Allum et al. 2011). 
Abbreviations: SCC, squamous cell carcinoma; AC, adenocarcinoma. 
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Partial gastrectomy is considered adequate when 5 cm clearance of the tumour is possible and 
this is usually the case for cancers of the antrum, but a total gastrectomy is usually necessary 
for cancers of the body and cardia. After a distal subtotal gastrectomy, reconstruction involves a 
Polya or Bilroth I procedure. Reconstruction after a total gastrectomy is generally performed 
using a Roux-en-Y loop with a retro-colic jejunal roux loop. 
 
Resection may be combined with perioperative chemotherapy and/or radiotherapy. Definitive 
treatment for squamous cell carcinoma of the oesophagus is chemoradiation, usually with a 
radiation dose of 50.4 Gray in 28 fractions (London Cancer Alliance 2014). At present, the 
recommended chemotherapy regimens for oesophageal and GOJ tumours are: ECF (epirubicin, 
cisplatin and fluorouracil); or ECX (epirubicin, cisplatin and capecitabine). Tumours of the 
stomach are treated with cisplatin and fluorouracil or capecitabine (London Cancer Alliance 
2014). By adding radiotherapy to chemotherapy there is a beneficial synergistic effect.  
 
1.1.2 Survival and Quality of Life in Patients with Oesophagogastric Cancer  
Following an oesophagectomy or gastrectomy, the median length of stay in hospital is 13 and 
11 days respectively (The Royal College of Surgeons of England 2013). In the UK, the 90-day 
mortality rates for oesophagectomy and gastrectomy are 1.4% and 3.1% respectively and the 
expected recovery period is at least one year (Olsson et al. 2007; The Royal College of 
Surgeons of England 2013). The most recent Cancer Research UK statistics indicate that the 
one-year survival for oesophageal and GOJ/gastric cancers is 40% and 42% respectively. Long-
term survival is mostly stage dependent (King et al. 1987; Vigneswaran et al. 1993). Overall 
five-year survival has gradually improved, although it remains low at 13% and 18% for 
oesophageal and GOJ/gastric cancers respectively, when all treatment modalities are combined 
(Cancer Research UK 2014). Specifically, for surgical patients, the five-year survival rates are 
higher at 27% and 28% respectively (Anderson et al. 2011).  
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Surgery, chemotherapy and radiotherapy are used to cure, prolong life and relieve symptoms in 
patients with OG cancer. However, these treatments often have both short- and long-term 
adverse effects that result in a deterioration in quality of life (QoL). To be able to distinguish 
between QoL in the broader sense and QoL connected with a patient’s health, the concept of 
health-related QoL has been developed. This refers to the ‘subjective evaluation of one’s ability 
to perform usual tasks and their impact on one’s everyday physical, emotional and social well-
being’. In this thesis, the term QoL is used when referring to health-related QoL (Fayers & 
Machin 2007).  
 
Up until the late 1990’s, morbidity and mortality were the main (and often the only) outcome 
measures used to evaluate the success of treatment for OG cancer. High morbidity and low 
survival rates associated with these cancers, especially oesophageal cancer, resulted in little 
interest in the measurement of QoL in research. However, in the past 15 years, there has been 
an improvement in treatment options and increasing numbers of long-term survivors. Also, QoL 
has been shown to be an independent predictor of survival after treatment for upper-GI cancer 
(Blazeby et al. 2001; Fang et al. 2004). Therefore, QoL has become increasingly accepted as 
an important outcome measure in trials. As such, a number of tools have been developed to 
measure QoL and can be classified into three main categories: generic tools, symptom-focused 
questionnaires and cancer-specific tools (Conroy et al. 2006).  
 
The use of cancer-specific tools has become increasingly popular e.g. the Functional 
Assessment of Cancer Therapy-General (FACT-G) tool and the European Organisation for the 
Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30). 
The EORTC QLQ-C30 is a valid and reliable tool that has 30 items with five functional scales, 
three symptom scales and one global scale (Aaronson et al. 1993). It is applicable to all patients 
with cancer. In addition, site-specific modules have been developed: they include specific 
symptoms relevant to a cancer site and this increases the tool’s sensitivity to detect small, but 
clinically important differences in QoL. It also allows the contribution of symptoms to overall QoL 
to be determined. For EORTC QLQ-C30, the oesophageal-specific module is QLQ-OES18 (18 
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additional items), the gastric-specific module is QLQ-STO22 (22 additional items) and the 
module for the oesophagus, GOJ and stomach combined is QLQ-OG25 (25 additional items) 
(Blazeby et al. 2003; Blazeby et al. 2004; Lagergren, Fayers, et al. 2007b).  
 
It has been demonstrated that patients with newly diagnosed oesophageal cancer waiting for 
surgery have compromised QoL (Visser et al. 2006). This impairment in QoL continues, as 
patients who have undergone chemoradiation or surgery for OG cancer have reduced QoL 
during and after treatment (Blazeby et al. 2000; Carey et al. 2011; McLarty et al. 1997; Gillham 
et al. 2008). A prospective study of 56 patients undergoing definitive chemoradiation to the 
oesophagus found that QoL scores (using the EORTC tools) did not improve significantly one 
year after the end of treatment, though there was a slow improvement in emotional, cognitive 
and social scales over time (Gillham et al. 2008). Similarly, longitudinal and population-based 
studies have shown that oesophagectomy has an immediate negative impact on all aspects of 
QoL and there is a limited and slow recovery (Blazeby et al. 2000; Viklund et al. 2006).  
 
Indeed, following oesophagectomy, those patients still alive at three years reported persistent 
impairment in QoL and those not living beyond 12 months did not regain preoperative QoL 
levels before their death, as measured by EORTC QLQ-C30 and QLQ-OES18 (Djärv et al. 
2008; Lagergren, Avery, et al. 2007a). Interestingly, in their non-randomised study, using the 
same QoL tools, Ariga et al. directly compared the outcomes after treatment in patients with 
oesophageal cancer who had chosen to receive definitive chemoradiation (with salvage surgery 
if disease progressed) and those who had chosen to undergone surgery alone (Ariga et al. 
2009). Quality of life was assessed by a cross-sectional survey in those patients who had 
survived at least two years. Results indicated that QoL was similarly compromised in both 
groups of patients except for symptoms such as diarrhoea, appetite loss, and eating problems, 
which were not as bothersome in the chemoradiation group compared with the surgical group 
(Ariga et al. 2009).  
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There are very few studies that have prospectively and critically assessed the QoL of gastric 
cancer patients, with the monitoring of change over time. However, the available literature 
suggests that for patients undergoing gastrectomy, QoL is impaired immediately postoperatively 
but appears to improve over time (Avery et al. 2010; Karanicolas et al. 2013; Conroy et al. 
2006). In the study undertaken by Karanicolas et al., most patients returned to baseline QoL by 
approximately six months post-gastrectomy, although about one third continued to have 
important QoL impairment (Karanicolas et al. 2013). A limitation of this study is the large 
amount of missing data: 14% of patients were excluded because of this issue. In Avery’s cohort, 
patients surviving two years generally recovered most aspects of QoL within six months of 
surgery and thereafter only reported problems with a few specific symptoms (Avery et al. 2010). 
However, 20% of patients died within six months of surgery during which QoL recovery was not 
achieved. Although this was a prospective and longitudinal study, the sample size was small (n= 
58) which limits the interpretation of the data. 
 
A prospective longitudinal Korean study that consecutively followed 465 newly diagnosed 
gastric cancer patients planned for radical resection is one of just a few large-scale studies 
designed to measure differences in QoL scores between surgical techniques (Kim A. R et al. 
2012a). Quality of life was measured using EORTC QLQ-C30 and QLQ-STO22. The number of 
patients undergoing subtotal gastrectomy and total gastrectomy were 377 and 88, respectively. 
There was 119 also receiving chemotherapy and 39 receiving radiotherapy. Global QoL and 
emotional functioning was found to improve over time for the 12-month study period regardless 
of surgical technique. Patients in the subtotal gastrectomy group were more likely to report 
better QoL than those in the total gastrectomy group. Of note, fatigue, body image disturbance, 
impaired cognitive function and GI symptoms (such as diarrhoea, dysphagia and eating 
restrictions) were the unrecovered problems in both surgical groups. Patients in the total 
gastrectomy group were more likely to be diagnosed with T2 and T3 cancer and to receive 
chemotherapy and radiotherapy than those in the subtotal gastrectomy group. Even after 
adjusting for this, the QoL of the former was still worse than the latter (Kim A. R et al. 2012a). 
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The study has strengths with regard to the high numbers of patients followed up (85% at 3 
months and 88% as 12 months) and the use of the standardised and valid EORTC tools.  
 
An earlier study undertaken by a Swedish group supports the findings of this study. Svedlund 
and colleagues used the Gastrointestinal Symptom Rating Scale (GSRS) to assess GI 
symptoms in patients following total gastrectomy and subtotal gastrectomy for up to five years 
after surgery (n= 64) (Svedlund et al. 1999). They reported that patients who underwent total 
gastrectomy continued to suffer from a persistent decrease in QoL due to the presence of GI 
symptoms, especially indigestion and diarrhoea, whereas those who underwent subtotal 
gastrectomy experienced improvement in the same symptoms.  
 
It is apparent, therefore, that regardless of tumour type or the treatment modalities received, OG 
cancer patients suffer impairment in their QoL, which does not always improve even months or 
years after the completion of treatment.  
 
1.1.3 Gastrointestinal Function in Patients with Oesophagogastric Cancer  
Gastrointestinal function in patients with OG cancer can be acutely and chronically affected by 
both the cancer itself and the oncological treatments received (Andreyev et al. 2011). With 
regard to the former, the tumour, especially when bulky, may cause a physical obstruction in the 
lumen of the GI tract, leading to symptoms directly. A tumour in the oesophagus can prevent the 
normal passage of food and fluid into the stomach causing dysphagia and/or odynophagia; a 
tumour at the cardiac sphincter muscle can stop the sphincter from working and lead to acid 
reflux/indigestion; a tumour in the pyloric region of the stomach can cause gastric outflow 
obstruction and result in nausea, vomiting, abdominal bloating/discomfort and constipation. In 
advanced disease, peritoneal spread may cause ascites or intestinal dysmotility, which can lead 




Symptoms may also arise because of changes in GI physiological processes following 
oncological treatment. Cytotoxic cancer chemotherapy affects cellular cycles and proves 
particularly detrimental to rapidly proliferating cells such as enterocytes leading to inflammation, 
oedema, ulceration and atrophy (Beck et al. 2006). The GI mucosa is highly vulnerable to 
radiation therapy as it induces death in cells undergoing mitosis. As such, for those patients 
who undergo radiotherapy to OG tumours, there is a risk of complications to normal tissues 
around the tumour. In addition, the development of functional disorders after oesophagectomy 
or gastrectomy is related to the new anatomic and functional configuration of the upper-GI tract 
following surgery. 
 
When radiotherapy is concomitant with chemotherapy, it is likely that the GI toxicity intensifies. 
However, randomised controlled trials in OG cancer comparing chemoradiation with 
chemotherapy alone focus on overall survival and disease-free survival, not on the prevalence 
and severity of GI symptoms, and so firm conclusions on this cannot be drawn (Stahl et al. 
2009; Burmeister et al. 2011). There is an array of GI symptoms that can result from the 
anatomical changes and/or enterocyte damage caused by OG cancer treatment. 
 
1.1.3.1 Gastrointestinal Symptoms in Patients with Oesophagogastric Cancer  
The acute and chronic GI side effects of chemotherapy and radiotherapy in OG cancer have not 
been studied systematically or prospectively. There have been few studies assessing GI 
function following chemoradiation in patients with oesophageal cancer. In the few studies that 
have, most measured just a few GI symptoms or just those related to swallowing function.  
 
For example, a study was undertaken in the United States (US) in the 1980’s and early 1990’s 
to determined the impact of chemoradiation on swallowing function in patients with oesophageal 
cancer (Coia et al. 1993). Pre-treatment and on-treatment swallowing was measured 
retrospectively using clinical notes, where the O’Rourke scale was used to determine the 
prevalence and severity of dysphagia (O'Rourke et al. 1988). The pre-treatment swallowing 
function of 120 patients was reported and 93% of them reported dysphagia: eating solids with 
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some dysphagia in 48 (40%); eating soft or pureed food in 50 (42%); drinking liquids only in 8 
(7%); and no swallowing at all in 5 (4%). Sufficient information was present in the charts to 
determine the initial improvement in dysphagia in 102 patients and 90 (88%) of these 
experienced some degree of improvement in their dysphagia during treatment. After two weeks 
of treatment, 41 (45%) experienced improved swallowing, and at treatment completion (six 
weeks), 75 (83%) had improved. For those who had improvement, the median time to initial 
improvement was two weeks, and by four weeks, improvement was noted in 86% of patients. 
The range of time for patient improvement was 1-21 weeks. Although dysphagia was the only 
symptom measured in this study, it does provide interesting data for an oesophageal cancer 
cohort: a high prevalence of dysphagia at baseline and a rapid and considerable initial 
improvement in nearly 90% of those treated with chemoradiation. 
 
Other trials recorded some GI symptoms in chemotherapy/chemoradiation treated patients 
using a QoL tool. For instance, the study undertaken by Blazeby et al., which examined QoL 
during neoadjuvant chemotherapy/chemoradiation for oesophageal carcinoma (Blazeby, 
Sanford, et al. 2005b). Quality of life was measured by EORTC QLQ-C30 and QLQ-OES18 and 
these tools provided information on GI symptoms experienced pre-treatment, seven weeks after 
the start of chemotherapy and five weeks later for patients undergoing chemoradiation. Thirty-
four patients underwent chemoradiation and 48 received chemotherapy alone. With reference to 
specific GI symptoms, both the chemoradiation group and the chemotherapy group reported 
worsening of the following symptoms at seven weeks compared with baseline: nausea and 
vomiting (p< 0.01, p= 0.05), anorexia (p< 0.01, p= 0.01), diarrhoea (p< 0.01, p= 0.01) and taste 
changes (p< 0.01, p< 0.01). For chemoradiation patients, the symptoms of dysphagia, eating 
problems, and reflux that had relieved or been unchanged at week seven, had deteriorated by 
week 12 (p= 0.03, p= 0.03 and p< 0.01) compared with baseline. Also at 12 weeks, anorexia 
(p= 0.03) and diarrhoea (p= 0.02) continued to be significantly worse than baseline levels.  
 
A similar study showed that the presence of GI symptoms resulted in a reduction in QoL 
following chemoradiation for oesophageal cancer (Avery et al. 2007). The aim of this 132-
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patient study was to evaluate QoL during potentially curative chemoradiation (n= 51) and to 
compare this with QoL during combination treatment including surgery (n= 81). The same 
EORTC QoL measures were used as in Blazeby’s study, with the following time points: pre-
treatment, after induction chemotherapy (six weeks), at 12 weeks, and at six and nine months, 
when recovery was anticipated. Patients who had chemoradiation experienced a moderate 
reduction in QoL during treatment, with worsening of anorexia, taste problems, dry mouth, 
diarrhoea, nausea and vomiting (p-values not reported), although dysphagia significantly 
improved (p= 0.003). By nine months, their QoL levels had recovered and GI symptom severity 
had returned to pre-treatment levels, or had improved.  
 
Although research into GI symptoms before and during chemotherapy or chemoradiation is 
limited, those available data indicate that symptoms may be common, certainty in the acute 
setting. There has been a much greater interest in measuring GI symptoms related to surgery in 
OG cancer. A seminal paper by Visick in 1948 outlined symptoms among 500 patients who had 
undergone gastrectomy for peptic ulcer disease (Visick 1948). Reported symptoms six months 
after surgery included pain, fullness, vomiting and diarrhoea. Although, the patients did not have 
cancer, this study was one of the first to highlight the burden of symptoms after radical upper-GI 
surgery.  
 
In a cross-sectional study of 30 patients (at least six months) following major upper-GI surgery, 
Carey et al. used a stepwise backward linear regression model to assess which features 
(including nutritional status, dietary intake and GI symptoms) might explain QoL scores (Carey 
et al. 2011). All participants with the exception of one had surgery for a malignant tumour. 
Gastrointestinal symptoms were assessed using the GSRS tool. Quality of life was measured 
using the EORTC QLQ-C30. Total GSRS scores indicated that patients experienced mild 
symptoms, although the prevalence of individual symptoms was not reported. In the final model, 
only GSRS scores and nutritional status category were significant in explaining 50.3% of 
variance in QoL, (F= 13.646; p< 0.001). The GSRS measure recorded a high beta value of -
0.441 (p= 0.004). This study is one of few to measure the association between GI symptoms 
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and QoL (Carey et al. 2011). Although, the sample size was small, these data highlight the 
detrimental effect that ongoing GI symptoms can have on QoL in this group. Further aspects of 
this study will be discussed in due course.  
 
Many of the large prospective studies in OG cancer patients do not measure GI symptoms in 
isolation but rather use a QoL tool with one or multiple symptom scales within it, which can 
capture the influence of symptoms on overall QoL. For example, a Swedish research group 
carried out a prospective nationwide population-based study with the aim of assessing QoL six 
months after radical surgery for oesophageal cancer (Viklund et al. 2006). Two hundred and 
eighty-two postoperative patients and 3,069 Swedish natives completed the EORTC QLQ-C30 
(includes five GI symptom measures) and QLQ-OES18 (includes 18 oesophageal-specific 
symptoms, 14 are GI in nature). With particular reference to the GI symptom results from this 
study, nausea and vomiting were significantly more common in people following 
oesophagectomy than in the general reference population (p< 0.001). Among the general 
symptom items, appetite loss and diarrhoea were dominating problems that were considerably 
more prevalent in OG cancer patients, particularly appetite loss (p< 0.001). For the 
oesophageal-specific symptoms, eating problems was the single worst symptom. Oesophageal 
pain, dysphagia and taste issues were also reported very frequently by the OG cancer patients 
(Viklund et al. 2006). With regard to the methodological aspects of this study, the population-
based design reduced the risk of selection bias, while the large sample size diminished the risk 
of chance errors. Moreover, the use of QoL questionnaires with documented good reliability and 
validity was another one of its strengths. 
 
A prospective study evaluated GI symptoms at two weeks, six months and 12 months post-
oesophagectomy in 48 patients (Ludwig et al. 2001). A sub-group of these patients (n= 10) had 
also received chemoradiation. Periodic dysphagia was present in 52% of patients in the early 
postoperative period and at 12 months this symptom was reported by 38%. At the latter follow-
up, 19% of patients still reported periodic nausea associated with food consumption, 15% had 
increased stool frequency and 17% had intolerance to dairy products. After 12 months, 
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occasional episodes of regurgitation were still reported by 25% and a small number of patients 
(n= 4) reported nausea and diarrhoea (Ludwig et al. 2001). In other studies assessing patients 
after oesophagectomy, between 10% and 50% of patients complained of diarrhoea, nausea, 
reflux, bloating and abdominal pain (McLarty et al. 1997; Banki et al. 2002; De Leyn et al. 1992; 
Ginex et al. 2013). Similarly, in patients at least six months after gastrectomy, large-scale cross-
sectional data (n= 1,153) demonstrated that abdominal pain, diarrhoea and nausea/vomiting 
were reported by 47%, 35% and 20% respectively (Mine et al. 2010).  
 
Another Swedish study explored 24 patients’ QoL and symptoms preoperatively and at three 
and 12 months following upper-GI surgery for malignancy (tumour site not described) (Olsson et 
al. 2007). With respect to GI symptoms, there was a significant worsening of reflux symptoms 
between the three- and 12 month time points (p= 0.008). Patients’ experiences of abdominal 
pain were approximately the same both pre- and postoperatively. Indigestion was reported as 
the most discomforting of all the symptoms recorded and it had not improved by 12 months. 
Diarrhoea increased in the period up to three months (p< 0.01) and at 12 months was nearly at 
the same level as before surgery. There were no significant differences noted in constipation 
symptoms between the pre- and postoperative periods. Overall, this study demonstrated that 
patients at 12 months had the same GI symptoms as they had before surgery, although some 
were more severe (Olsson et al. 2007).  
 
Symptoms related to acid or biliopancreatic reflux have also been described in OG cancer 
patients, particularly surgical patients. Commonly reported symptoms include nausea, 
heartburn, regurgitation, dysphagia, odynophagia and vomiting (Lerut & van Lanschot 2004). Up 
to 72% and 26% of patients report reflux symptoms after oesophagectomy and gastrectomy 
respectively (Shibuya et al. 2003; Fukuhara et al. 2002; Gutschow et al. 2001). In their 
retrospective study of 80 patients post-oesophagectomy, De Leyn et al. reported that 15% of 
patients had heartburn and regurgitation at three months and this increased to 21% after 12 
months (De Leyn et al. 1992). Gutschow et al. measured reflux symptoms in 91 subtotal 
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oesophagectomy patients at three years or more after surgery and found that 36% of patients 
reported reflux in the remnant oesophagus at this time (Gutschow et al. 2001). 
 
Qualitative interviews also provide insight into the impact that GI symptoms have on patients. A 
study of 17 post-oesophagectomy patients participating in focus-groups identified a theme of 
‘losing control of elimination’ from the patient interviews (Malmström et al. 2013). Diarrhoea and 
constipation were symptoms described as difficult. Problems with excessive gas and 
borborygmi were also described, which were said to affect their everyday lives. Interestingly, 
neither of these symptoms is captured in the GI symptom tools and QoL symptom scales used 
in the quantitative studies previously discussed.   
 
Table 1-2 summaries the data from the key studies reported in this section with regard to the 
prevalence of GI symptoms in patients following surgery for OG cancer. Only studies including 
surgical patients were added, as there are few symptom data available for those receiving 
chemoradiation alone. As demonstrated by the table, data are not available for many studies for 
both the acute and chronic postoperative periods. Also, there are a limited number of GI 
symptoms included in some studies and there are no data on symptoms of belching, abdominal 
gurgling, flatulence, faecal urgency, incomplete evacuation and faecal incontinence. As such, it 
is likely that GI symptoms important to patients have been underestimated in the literature. In 
addition, only one study included a preoperative time point to assess the trajectory of symptoms 
following surgery, allowing the determination of the cause for new-onset symptoms. It is 
apparent that there is a need for a comprehensive assessment of all GI symptoms relevant to 
OG cancer at the following time points: before the commencement of treatment, during 
treatment and after completion of treatment.       
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Table 1-2 Key studies reporting the prevalence of gastrointestinal symptoms in patients following surgery for oesophagogastric cancer 
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Gutschow et al. 2001 
 
 
Shibuya et al. 2003 
 
Ginex et al. 2013 
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Oesophagectomy - 25% - Ludwig et al. 2001 
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Visick 1948 
 
Viklund et al. 2006 
 
 
Olsson et al. 2007 
 
 




  Symptom prevalence (%) where available  
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6-66 months: 38% 
Ludwig et al. 2001 
 
Olsson et al. 2007 
 
 




Oesophagectomy - 15% - Ludwig et al. 2001 
Constipation n/a Same mean score as 
preop 
Same mean score as 
preop 
- Olsson et al. 2007 
Abbreviations: Postop, postoperative; Preop, preoperative; n/a, not available. 
Notes: One study assessed preoperative symptoms (Olsson et al. 2007) and in another, 21% of the patients had perioperative chemotherapy 
and/or radiotherapy (Ludwig et al. 2001) 
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1.1.3.2 Causes of Gastrointestinal Dysfunction in Patients with Oesophagogastric 
Cancer  
1.1.3.2.1 Motility Irregularities  
Normal peristalsis results from an integrated interaction between neural, myogenic and 
hormonal control mechanisms. There is evidence to suggest that there is a high incidence of 
motility irregularities in patients with OG cancer even at the time of diagnosis (Tormey et al. 
2003). The mechanisms for such irregularities have been studied in much greater detail in 
patients during treatment or following its completion rather than at the time of diagnosis.   
 
It has been suggested that GI symptoms following surgery for OG cancer may be due to 
irregularities that interfere with normal processes of GI motility, gastric reservoir function or 
gastric emptying. The physiological causes are complex and although divergent in origin, both 
rapid and delayed emptying can produce remarkably similar GI symptoms: nausea, vomiting 
and abdominal pain tend to be the predominant symptoms in both cases, though diarrhoea is 
usually only seen in rapid emptying (Rostas et al. 2011).   
 
Gastroparesis occurs when gastric (or gastric remnant, if applicable) transit is abnormally slow 
in the absence of a physical obstruction. It can be referred to as ‘delayed emptying’ and often 
presents with one or more of the following symptoms: nausea, vomiting, abdominal pain, early 
satiety, postprandial fullness, heartburn, reflux and dysphagia. Abdominal surgery is thought to 
be the third most common cause of gastroparesis in clinical practice (after medications/drugs 
and diabetes) (Patrick & Epstein 2008). The vagus nerve normally provides extrinsic 
parasympathetic regulation to the stomach by modulating fundal accommodation and phasic 
antral peristalsis. This nerve will be cut during an antrectomy, a Roux-en-Y gastrojejunostomy 
or a vagotomy. The vagal denervation eliminates a critical postprandial stimulus to the enteric 
nervous system, leading to reduced peristalsis, a reduced ability to empty solids and a profound 
delayed emptying from the gastric remnant and efferent limb (Patrick & Epstein 2008; Rostas et 
al. 2011).  
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Aside from this neural disorder, it is believed that hormonal, muscular and rhythm disorders may 
also have a role to play in gastroparesis. With regard to hormones, cholecystokinin (CCK) and 
somatostatin are of interest in this context. Cholecystokinin potentiates gastric relaxation, 
stimulates mechanoreceptors sensitive to gastric stretch and slows gastric emptying (Luttikhold 
et al. 2013). Levels of CCK have been shown to be increased following gastrectomy, which is 
likely related to inhibition of antral motor activity and slowing of gastric emptying (Yamashita et 
al. 2000). Somatostatin has an anti-secretory function but also reduces intestinal motility, 
decreases splanchnic blood flow, and prolongs gastric emptying (Luttikhold et al. 2013). Levels 
of this hormone are also raised following surgery, suggesting a role in delayed gastric emptying. 
 
The reported incidence of delayed emptying after oesophagectomy and gastrectomy ranges 
from 2-47% and 3-30% respectively (Kim K. H et al. 2012b; Cohen & Ottinger 1976; Jordon & 
Walker 1973; Bar-Natan et al. 1996; Arya et al. 2014). A systematic review of the literature with 
regard to the outcomes of pyloric management following oesophageal reconstruction was 
recently performed (Arya et al. 2014). The authors demonstrated that there was a trend 
favouring drainage procedures, with pyloroplasty (procedure to widen the opening in the pylorus 
so that gastric/gastric remnant contents can empty into the duodenum) and pyloromyotomy 
(procedure in which an incision is made in the longitudinal and circular muscles of the pylorus) 
being the most popular, which reduced the incidence of delayed emptying, although significance 
was not reached.  
 
Hayami et al. were interested in measuring gastric emptying following surgery. They performed 
the 13C-octanoic breath test in patients after gastrectomy and examined the residual stomach’s 
emptying ability (Hayami et al. 2011). This is an easy, non-invasive and reliable method to 
clinically assess the emptying function (Viramontes et al. 2001). Results showed that increased 
gastric emptying correlated significantly with abdominal pain, indigestion and symptom score, 
using the GSRS tool. The more rapid the emptying was, the worse the symptoms were. A 
similar trend was seen for diarrhoea, indicating a role for rapid gastric emptying in the 
generation of these symptoms.  
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In addition to the motility irregularities caused by surgery, there is some evidence to suggest 
that chemotherapy and radiotherapy can induce similar effects (Coia et al. 1995; Sung et al. 
2012; Di Fiore & van Cutsem 2009). Following chemotherapy, delayed emptying may be 
responsible, in part, for anorexia, early satiety and delayed nausea and vomiting (i.e. 24 hours 
to five days after the start of chemotherapy) (Nelson et al. 1993; Nelson & Walsh 1993). The 
gastric stasis may be secondary to autonomic nervous system dysfunction, though it is likely to 
be multifactorial in nature (Nelson et al. 2002). It is believed that chemotherapy can induce 
diarrhoea by decreasing whole gut transit time, thereby reducing water absorption in the colon 
(i.e. osmotic diarrhoea) (Gibson & Keefe 2006; Richardson & Dobish 2007). However, transit 
time has not been directly measured after the administration of chemotherapy. Following 
radiotherapy, delayed symptoms of oesophageal injury can manifest after several months and 
include chronic dysphagia secondary to a motility disorder induced by muscular or nerve injury 
(Shadad 2013).   
 
1.1.3.2.2 Dumping Syndrome 
Dumping syndrome after surgery is the spectrum of symptoms resulting in the transit of poorly 
processed hyperosmolar gastric contents into the duodenum (Rostas et al. 2011). Dumping 
syndrome can include the following postprandial symptoms: nausea, flushing, dizziness, 
sweating, hypotension, abdominal cramps and diarrhoea. These symptoms can occur in two 
phases, (1) soon after meals (‘early dumping’) or (2) delayed for up to several hours (‘late 
dumping’).  
 
Early dumping occurs 15 to 30 minutes after eating. When hyperosmolar diet contents swiftly 
enter the duodenum, this leads to a sudden osmotic fluid shift into the small bowel, resulting in 
nausea, vomiting, diarrhoea and hypotension (Rostas et al. 2011). Late dumping, on the other 
hand, typically occurs 45 to 60 minutes (but sometimes up to three hours) after eating and is 
likely to occur secondary to reactive hypoglycaemia. Rapid stomach (or gastric remnant, if 
applicable) emptying induces a high glucose (and other sugar) concentration in the small bowel 
lumen, followed by rapid uptake by the enterocytes causing hyperglycaemia, which stimulates 
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the release of insulin and leads to rebound hypoglycaemia (Lerut & van Lanschot 2004). The 
characteristic symptoms of late dumping syndrome include faintness, hunger, dizziness, and 
cold sweat (i.e. the symptoms of hypoglycaemia). 
 
1.1.3.2.3 Surgical Technique  
As discussed in Section 1.1.3.2.1, vagal denervation can reduce peristalsis and cause profound 
delayed emptying from the gastric remnant and (denervated) efferent limb. There are also 
indications that damage or removal of the vagus nerve during surgery for OG cancer alters acid 
secretion. It was once believed that patients following oesophagectomy had reduced acid output 
of the denervated stomach (used as an oesophageal substitute) (Hölscher et al. 1988). 
However, researchers have recently shown that the oesophageal substitute recovers a normal 
intraluminal acidity with time, so that more than three years after surgery, the 24-hour pH profile 
in the gastric cavity of almost all patients is similar to that in healthy subjects. Similarly, 
Hashimoto and colleagues described that gastric acidity did not decrease after 
oesophagectomy in 55 patients, but rather postoperative acidity in the gastric tube was high, 
especially in patients with high preoperative acidity (Hashimoto et al. 1995). This can result in 
symptoms of reflux, though there are other causes for reflux too e.g. overweight/obesity, 
defective cardiac sphincter muscle and hiatus hernia. 
 
In recent years, the use of potent anti-acid medication (usually proton pump inhibitors) 
postoperatively appears to have reduced the prevalence of reflux symptoms in patients with OG 
cancer. The beneficial effect of these drugs has been demonstrated in a randomised trial 
involving 79 patients following oesophagectomy (Johansson et al. 2009). Those patients 
receiving the medication at the dose recommended for the treatment of erosive oesophagitis 
had significantly less gastric acid secretion postprandially (p= 0.008), less exposure of the 
remnant oesophagus to gastric acid (p= 0.034), a lower rate of esophagitis (p= 0.002), and less 
dysphagia (p= 0.032) than control patients.  
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Surgical technique appears to have a role in determining the development of reflux symptoms. 
In De Leyn et al.’s study, at 12 months following oesophagectomy, there was a statistically 
significant difference between patients with cervical anastomosis and those with intrathoracic 
anastomosis when comparing reflux symptoms (4% versus (vs.) 50%; p= 0.0001) and remnant 
oesophagitis (8% vs. 53%; p= 0.001) (De Leyn et al. 1992). These findings were subsequently 
supported by the study undertaken by Shibuya et al. In their group of 80 oesophagectomy 
patients, the incidence of reflux esophagitis in the cervical anastomosis group and the 
intrathoracic anastomosis group was 56.4% and 88.6% respectively, with a significant 
difference between them (p= 0.004).  
 
For gastric cancer, the surgical reconstruction technique is also an important factor to consider. 
Bile reflux resulting in remnant gastritis and gastro-oesophageal reflux disease has been noted 
as a problem associated with Billroth I reconstruction after distal gastrectomy (Fujiwara et al. 
1998). This finding was reinforced by other reports, which indicate that Roux-en-Y 
reconstruction following distal gastrectomy is superior to Billroth I in terms of preventing 
remnant gastritis and reflux oesophagitis because this procedure reduces duodenogastric and 
gastro-oesophageal reflux (Fukuhara et al. 2002; Ishikawa et al. 2005).  
 
1.1.3.2.4 Gastrointestinal Hormone Abnormalities  
The removal of some or the entire hormone producing mucosa of the stomach and rearranging 
the route for the passage of food will inevitably alter GI hormone production. Hormones that 
have been studied in this regard include gastrin, CCK, neurotensin, pancreatic polypeptide, 
serotonin and glucagon. The hormonal involvement in gastroparesis has previously been 
described in Section 1.1.3.2.1.  
 
Serum concentrations of gastrin, pancreatic polypeptide, neurotensin and CCK were measured 
in 16 patients before and after partial gastrectomy for gastric cancer (with reconstruction by 
Bilroth methods) (Yamashita et al. 2000). Compared with a control group, fasting levels of CCK 
and neurotensin were significantly increased in the patients who had a gastrectomy. In addition, 
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gastrin and pancreatic polypeptide were completely abolished in these patients. The effect of 
these hormonal alterations is thought to result in reduced contraction of the lower oesophageal 
sphincter and may lead to symptoms of reflux.  
 
Kalmar and colleagues measured plasma concentrations of insulin, CCK and somatostatin in 
patients with three different reconstruction types following gastrectomy (Kalmar et al. 2006). 
Their results supports a diabetoid blood glucose profile in the first postprandial hour in patients 
after gastrectomy and Roux-en-Y reconstruction, with higher insulin and CCK concentrations, 
and an increasing somatostatin release 15 to 30 minutes postprandially. This picture indicates 
that the pathophysiology of early dumping syndrome may include a hormonal imbalance. This is 
supported by findings that the hyperosmolar luminal contents seen in dumping syndrome cause 
the release of vasoactive neurotransmitters (e.g. serotonin, neurotensin, peptide YY, glucagon). 
Serotonin exacerbates the situation by causing peripheral and mesenteric vasodilation, adding 
to the hypotension-inducing fluid shifts (Rostas et al. 2011). 
 
1.1.3.2.5 Small Intestinal Bacterial Overgrowth  
Small intestinal bacterial overgrowth (SIBO) is a condition that implies abnormal bacterial 
colonisation of the proximal small bowel (Gasbarrini et al. 2007; Rana & Bhardwaj 2008; 
Dukowicz et al. 2007). In health, the acidity of the stomach and the relatively swift peristalsis 
through the stomach and small bowel means that the stomach, duodenum and jejunum contain 
only low levels of microbiota, which range from 103 to 105 colony-forming units per millilitre 
(CFU/ml) of luminal contents. This is made up mainly of acid-resistant Lactobacilli and 
Streptococci (Hao & Lee 2004). The duodenum and jejunum act as a transition zone leading to 
the ileum where the microbiota begin to resemble those of the colon, with around 107-108 
CFU/ml. The colon is the primary site of microbial colonisation in humans with approximately 
1011-1012 CFU/ml of contents (Power et al. 2013). The main types of colonic microbiota are 
obligate anaerobes, with the most abundant being members of the genus Bacteroides, 
anaerobic Gram-positive cocci such as Peptostreptococcus species (sp.), Eubacterium sp., and 
Clostridium sp. 
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Small intestinal bacterial overgrowth results from the failure of intrinsic defence mechanisms 
that restrict bacterial proliferation. Under normal physiological conditions, low microbial numbers 
in the small bowel is maintained by the following mechanisms: normal interdigestive migrating 
motor complex activities propel intraluminal contents towards the colon; actions of gastric, 
biliary and pancreatic enzymes limit bacterial growth; the mucosa’s protective mucous layer 
traps bacteria; and the ileo-caecal valve inhibits retrograde translocation of bacteria from the 
colon into the ileum (Trespi & Ferrieri 1999; Lombardo et al. 2010; Deloose et al. 2012; Miller et 
al. 2012; George et al. 2012; Rana et al. 2011; Faria et al. 2013). The pathophysiology of SIBO 
is pictorially described in Figure 1-1.  
 
There is no agreed definition for SIBO, but the most commonly cited definition is quantitative: 
105 or more CFU/ml of bacteria grown from a small bowel aspirate collected during an 
oesophago-gastroduodenoscopy (OGD) (Khoshini et al. 2008). The validity of this cut-off level 
has not been confirmed, despite its widespread use (Khoshini et al. 2008). Similarly, there is no 
gold-standard test for its diagnosis. The ongoing debate over its diagnosis will be discussed in 
Section 1.3.1. 
 
Patients with SIBO may be clinically asymptomatic or have symptoms that fulfill the diagnostic 
criteria of irritable bowel syndrome (IBS): Rome III criteria define IBS as pain associated with 
change in bowel habit (Drossman 2006). In addition, research in IBS suggests that bloating, 
diarrhoea and flatulence are important symptoms, which are believed to be common in SIBO 
too (Yamini & Pimentel 2010; Pimentel et al. 2000; Reddymasu et al. 2010). However, there are 
few studies, which have focused on identifying the predominant clinical symptoms in patients 
with SIBO. Those that have, suggest that the most common GI symptom caused by SIBO is 
diarrhoea, followed by abdominal pain, and then bloating (Grace et al. 2013). Other 
troublesome symptoms reported in the literature include flatulence, abdominal tenderness, 
constipation, gastric stasis, steatorrhoea, increased stool frequency, nausea and weight loss 
(Lombardo et al. 2010; Tursi et al. 2003; Marie et al. 2009; Klaus et al. 2009; Compare et al. 
2010; Pimentel et al. 2000; Roberts et al. 1977; Davidson et al. 1984; Choung et al. 2012).  
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Classically, the recognised causes for SIBO were blind intestinal loops, which occur when part 
of the bowel is by-passed (Hamilton et al. 1970). The five types of blind loop include those 
caused by (a) anastomosis with formation of self-filling loop, (b) jejunal diverticulosis, (c) 
intestinal stricture, (d) enterostomy or fistula, and (e) gastric surgery. In fact, SIBO was once 
known as the ‘blind loop syndrome’ or the ‘stagnant loop syndrome’. In recent years, there has 
been renewed interest in SIBO as it has been implicated in the pathophysiology of conditions 
previously not classically associated with it. These clinical conditions and their reported 
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Figure 1-1 Pathophysiology of small intestinal bacterial overgrowth  
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Table 1-3 Reported prevalence of small intestinal bacterial overgrowth in normal populations and disease states 
 
 Reported prevalence References 
Healthy study controls 0-20% 
Lombardo et al. 2010; Sabaté et al. 2008; Posserud et al. 2007; Teo et al. 2004; Lewis et 
al. 1999; Pimentel et al. 2003; Rana et al. 2011; Bratten et al. 2008; Scarpellini et al. 2009 
Dysmotility/Gut wall injury 
Coeliac disease 9-67% Rana et al. 2007; Rubio-Tapia et al. 2009; Tursi et al. 2003 
Connective tissue diseases  43-55% Marie et al. 2009; Parodi, Sessarego, et al. 2008b 
Diabetes mellitus 8-44% Rana et al. 2011; Lin & Pimentel 2012 
Hypothyroidism 54% Lauritano et al. 2007 
Inflammatory bowel disease 25-88% Funayama et al. 1999; Klaus et al. 2009; Lin & Pimentel 2012; Ibanez et al. 2008 
Nonspecific dysmotility 76% Jacobs et al. 2013 
Radiation enteropathy 26% Wedlake et al. 2008 
Neuromuscular Diseases 
Muscular dystrophy 65% Tarnopolsky et al. 2010 
Parkinson’s disease 54% Gabrielli et al. 2011 
Surgery 
Abdominal Surgery  82% Petrone et al. 2011 
Bilateral truncal vagotomy 93% Browning et al. 1974 
Gastrectomy 
37-100% 
Brägelmann et al. 1997; Paik et al. 2011; Bjorneklett et al. 1983; Iivonen et al. 1998; Lock 
et al. 1995 
Ileo-caecal valve resection 32% Klaus et al. 2009 
Roux-en-Y reconstruction 86% Iivonen et al. 1998 
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 Reported prevalence References 
Miscellaneous 
Chronic fatigue syndrome 81% Lin & Pimentel 2012 




Lombardo et al. 2010; Jacobs et al. 2013; Compare et al. 2010 
End-stage renal failure 36% Strid et al. 2003 
Fibromyalgia 93% Lin & Pimentel 2012 
Irritable bowel syndrome  4-78% 
Posserud et al. 2007; Bratten et al. 2008; Pimentel et al. 2000; Nucera et al. 2005; 
Lupascu et al. 2012; Grover et al. 2008 
Immunodeficiency syndromes  30-50% Smith et al. 1990 
Liver cirrhosis 17-36% Yang et al. 1998; Gunnarsdottir 2003 
Obesity 17-41% Sabaté et al. 2008; Madrid et al. 2011 
Parenteral nutrition 70% Gutierrez et al. 2012 
Rosacea 46% Parodi, Paolino, et al. 2008a 
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There are published data indicating that oncology patients may be at increased risk of 
developing SIBO. For example, there are case reports in pancreatic cancer, ovarian cancer, 
small bowel lymphoma and small bowel leiomyosarcoma (Bustillo et al. 2009; Russell et al. 
1977; Takagi et al. 2002; Swan 1974), as well as small hypothesis-generating studies in chronic 
lymphocytic leukaemia patients and a mixed cohort of GI, gynaecological and urological cancer 
patients (Wedlake et al. 2008; Smith et al. 1990).  
 
Also, clinical experience at The Royal Marsden (RM) informs us that SIBO is a condition of 
relevance in patients attending gastroenterology clinics for new onset GI symptoms related to 
their cancer treatment (any primary diagnosis). A retrospective review of the records of 435 
patients referred for investigation of GI symptoms potentially caused by SIBO was performed 
(unpublished data). Each patient underwent at least one of two commonly used diagnostic tests: 
the glucose hydrogen methane breath test (GHMBT) and endoscopic aspiration and culture 
technique (test details in Section 2.4). Of those included, 49 (11%) patients had been treated for 
a primary cancer occurring in the upper-GI tract. In total, 46 patients (10.6%) had a diagnosis of 
Definite SIBO, 74 patients (17.1%) had Possible SIBO, 115 (26.4%) did not have SIBO and 200 
(45.9%) were not assessable due to missing data. Of those with Definite- or Possible SIBO, 
almost a quarter had an upper-GI cancer diagnosis, compared with 1% in the No SIBO group. 
The retrospective nature of this study means that there is a limit to how far the data can be 
reliably interrogated. In addition, not every patient had a complete GHMBT or available aspirate 
culture results and some were not followed-up. In total, this represented 30% of the study 
population and may have resulted in some missed cases of SIBO. 
 
Another study undertaken at RM suggests that SIBO is a condition of importance in the 
oncology setting. In this study, 38 consecutive patients with GI, gynaecological and urological 
cancers were recruited (Wedlake et al. 2008). All patients were planned for radical or adjuvant 
pelvic radiotherapy. To define the development of new SIBO, glucose-H2 breath tests were 
performed at baseline and at four-five weeks after the commencement of treatment, irrespective 
of the presence of GI symptoms. Ten patients (26%) with a negative test at baseline, tested 
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positive for SIBO at four-five weeks. Of these patients, two (20%) had normal bowel movements 
at baseline and at follow-up and six (60%) developed new-onset increase in bowel frequency or 
a change in the quality of bowel habit. The remaining two patients had existing bowel problems 
at baseline, which either remained stable or improved. The authors suggested that pelvic 
radiotherapy was the cause for SIBO in this cohort (Wedlake et al. 2008; Swan 1974). Other 
data from patients with chronic GI symptoms following gynaecological cancer indicates that 
radiotherapy was the main cause for SIBO (Husebye et al. 1994). The potential mechanism for 
its development following radiotherapy may be multifactorial, with previous intestinal resections, 
intestinal strictures, epithelial dysfunction, intestinal dysmotility and hypochlorhydria potentially 
involved. 
 
Chemotherapy can cause extensive damage to the GI tract, leading to functional and structural 
changes (Cunningham et al. 1985). In fact, histological evidence of damage can be seen in the 
jejunum as early as 30 minutes after treatment, with greatest damage seen 24 hours later 
(Stringer, Gibson, Logan, et al. 2009a). Some recent studies have implicated the intestinal 
microbiota, though not specifically SIBO, in the adverse side-effects of chemotherapy, but this is 
a relatively new area of research and very little exists in the literature (Stringer, Gibson, Bowen, 
et al. 2009b).  
 
Stringer et al. undertook a study in rats investigating changes in mucin secretion and microbiota 
following treatment with 5-fluorouracil chemotherapy (Stringer, Gibson, Logan, et al. 2009a). 
Mucins are large glycoproteins produced by goblet cells, which provide attachment sites for 
resident bacteria and pathogenic bacteria, as well as simultaneously protecting the mucosa 
from SIBO and/or penetration (Robbe et al. 2004; Specian & Oliver 1991). Results from 
Stringer’s study clearly demonstrated changes in the microbiota of the jejunum. There were 
decreases in Clostridium sp. and Lactobacillus sp., with an increase in Escherichia sp. 48-72 
hours after treatment. Organisms involved in maintaining balance in the intestine were 
susceptible to 5-fluorouracil, while Pseudomonas aeruginosa and Escherichia coli were not. 
This may allow the proliferation of these non-susceptible opportunistic bacteria, potentially 
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causing SIBO. In addition, goblet cells in the jejunum decreased after treatment with the 
chemotherapy, with crypt goblet cells being affected the most, decreasing significantly from 24-
72 hours after treatment. Alterations in the protective capacity of the mucus barrier could also 
lead to the development of SIBO (Stringer, Gibson, Logan, et al. 2009a). There are some other 
animal studies that have implicated altered microbiota or goblet cell functioning as the causes 
for chemotherapy induced side-effects (Stringer, Gibson, Bowen, et al. 2009b; Verburg et al. 
2000). However, further studies are warranted to fully elucidate these relationships, particularly 
with regard to the pathophysiology of SIBO.  
 
To date, the greatest body of evidence linking oncological treatments to SIBO exists for surgical 
procedures. The creation of self-filling blind loops in animal experiments were frequently used in 
the 1970’s and 1980’s in order to investigate the pathophysiology of SIBO (Sherman & 
Lichtman 1987; Schjönsby & Hofstad 1972; Giannella & Toskes 1976). Today, this experimental 
model is still relevant as the structural conditions necessary for the blind loop are present after 
Roux-en-Y gastric by-pass and gastrectomy with Roux-en-Y reconstruction (Di Stefano et al. 
2005).   
 
Data regarding the frequency of SIBO after gastric surgery strongly suggests an association. 
For example, Lock et al. found SIBO in 35 of 38 (92%) patients after gastric surgery of varying 
types (1995). However, this study recruited patients referred for a gastroscopy and so a 
selection bias needs to be considered. Another group studied 22 patients after a Billroth II 
resection, all of whom had SIBO (Bjorneklett et al. 1983). Larger studies also reported high 
prevalence rates e.g. in a study of 127 patients after total gastrectomy, SIBO was diagnosed in 
37% (Brägelmann et al. 1997). Another study of 46 total gastrectomy patients found that most 
(88%) had SIBO (Iivonen et al. 1998). While Paik et al. reported that 78% of their 76 
gastrectomy patients had SIBO, which appeared to be the cause for their postprandial GI 
symptoms (Paik et al. 2011). In addition, in a study of older patients (n= 168) with symptoms 
suggestive of SIBO, previous partial gastrectomy was shown to be one of the characteristics 
  56 
predictive of SIBO (p< 0.01) (Elphick et al. 2005). There does not appear to be any data in the 
literature on SIBO prevalence following oesophagectomy.  
 
The underlying mechanism for SIBO development is likely to be multifactorial including both 
anatomical and functional conditions as shown in Table 1-4. Achlorhydria and impaired motility, 
are likely to be the primary factors responsible for controlling the number of bacteria in the small 
bowel (Henderson & Wilson 1996). In more severe cases of SIBO, there may be signs of 
malabsorption (e.g. weight loss and steatorrhoea). The mechanisms causing malabsorption of 
different macro- and micronutrients in SIBO are outlined in Table 1-5.  
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Table 1-4 Mechanisms for the development of small intestinal bacterial overgrowth (SIBO) in oesophagogastric cancer  
 
Mechanism Description of mechanism Reference (s) 
Dysmotility Cleansing action of propulsive forces, and especially, phase III of the interdigestive migratory motor 
complex, limits the ability of the bacteria to colonise the small bowel by sweeping its contents towards the 
colon. Lack of phase III predisposes to SIBO. Delayed orocaecal transit time has been shown to be 
associated with the presence of SIBO. 
Tomita et al. 2006; 
Vantrappen et al. 1977; 
George et al. 2012; Kaur 
et al. 2014 
Hypochlor-
hydria  
The use of proton pump inhibitors causes suppression of gastric acid secretion, which increases the gastric 
pH and facilitates the survival and colonisation of bacteria including viable swallowed bacteria. 
Hypochlorhydria has been shown to contribute to proximal migration of more distally located bacteria in the 
gastrointestinal tract.  
Jacobs et al. 2013; 
Lombardo et al. 2010; 
Compare et al. 2010 
Enterocyte 
dysfunction 
Villus and crypt hypertrophy and a decreased villus to crypt ratio have been seen in experimental models of 
SIBO. Bacterial production of short-chain fatty acids and a decreased intraluminal pH can lead to direct or 
indirect damage to enterocytes. Mucosal breaks (erosions and ulcerations) have been described in SIBO. 
SIBO may also induce an inflammatory response in the intestinal mucosa. It may result in microscopic 
mucosal inflammation and has been associated with increased serum endotoxin and bacterial compounds 
stimulating production of pro-inflammatory cytokines. Pro-inflammatory cytokines (interleukin (IL)-6, IL-8 and 
tumour necrosis factor alpha), and lipid peroxidation (marker of oxidative stress) have been shown to be 
significantly higher in the plasma of patients with SIBO compared with those without it.  
Toskes et al. 1975; 
Gilroy et al. 2003; Hoog 
et al. 2007; Saltzman et 
al. 1994; Wanitschke & 
Ammon 1978; Saltzman 
& Russell 1994 
Altered 
anatomy 
A change to the normal anatomy of the GI tract may cause stagnation of intraluminal flow and cause 
bacterial stasis in the small bowel. It may also lead to abnormal motility and ineffective clearance of retained 
food and secretions.  
Brägelmann et al. 1997; 




The integrity of the normal intestinal microbiota is maintained by the structure of mucins. In SIBO there is a 
significant increase in luminal mucins and a fall in mucosal mucins. The luminal mucins should act to protect 
the mucosa from SIBO, but in fact, they do not completely preserve mucosal enterocyte structure and 
function. Anaerobic bacteria produce proteases that are capable of destroying brush border disaccharidase 
activity.  
Stringer, Gibson, Logan, 





A functioning valve inhibits retrograde translocation of bacteria from the colon into the ileum. Individuals with 
SIBO are more likely to have a defective ileo-caecal valve (with low ileo-caecal junction pressures) than 
individuals without SIBO. 
Miller et al. 2012; 




Individuals with SIBO are more likely to have abnormalities in intestinal mucosal immunity as evidenced by 
increased luminal immunoglobulin A concentrations and lamina propria immunoglobulin A plasma cell 
counts. 
Riordan et al. 1999; 
Riordan, McIver, 
Wakefield, et al. 1997b 
Pancreatic 
insufficiency 
Pancreatic enzymes have an important influence on small bowel microbiota. Proteolytic enzymes have anti-




Table 1-5 Mechanisms for macronutrient and micronutrient malabsorption in small intestinal bacterial overgrowth (SIBO) 
 
Nutrient Description of malabsorption Reference(s) 
Fat Fat malabsorption may result from SIBO and is principally due to bacterial deconjugation of bile acids and 
subsequent deficiency of intraluminal conjugated bile acids. In health, water-soluble conjugated bile salts are 
secreted to form mixed micelles consisting of partially digested dietary lipids. Such bile salts are not readily 
reabsorbed until they reach the ileum. In SIBO, the microbiota deconjugate bile acids resulting in free bile acids, 
which are readily absorbed by the jejunum. This process can lead to impaired formation of the bile-salt-lipid 
micelle complex and resultant dietary fat malabsorption. Free bile acids formed may also be toxic to the mucosa. 
Kim et al. 1966; 
Singh & Toskes 
2004; Wanitschke 
& Ammon 1978 
Carbohydrate The presence of a blind loop causes a progressive loss of brush border disaccharidase function beginning with 
the loss of lactase activity. The exact reason for the disaccharidase deficiencies remains unknown. Small bowel 
bacteria can ferment the malabsorbed carbohydrates to form short-chain fatty acids, leading to concentrations in 
jejunal aspirates four times higher than those in healthy subjects. These short-chain fatty acids can cause direct 
damage to enterocytes, which leads to further loss of activity of brush border disaccharidases. 
Sherman et al. 
1985; Hoverstad 
et al. 1985 
Protein There are numerous factors that can contribute to protein malabsorption in SIBO. The bacteria may be 
responsible for deaminating dietary protein in the gut lumen. Thus, there is a diversion of dietary nitrogen into 
urea formation and it becomes unavailable for protein anabolism by the human host. Also, direct or indirect 
damage to enterocytes can lead to altered permeability, which allows for protein leakage from the blood into the 
gut lumen (protein-losing enteropathy). If the enterocytes are damaged, amino acids absorption is impaired.  
Jones et al. 1968; 
King & Toskes 
1981; Giannella et 
al. 1974; 




Malabsorption of vitamins A, D or E may occur in association with general fat malabsorption and is caused by 
similar mechanisms. In vitamin D deficiency, hypocalcaemia, osteomalacia or osteoporosis can be complications 
of SIBO. In severe cases, hypocalcaemia tetany has been reported. There are only case reports of deficiencies 
of vitamins A and E. Levels of vitamin K are usually normal or raised due to bacterial synthesis of menaquinone. 
Stotzer et al. 
2003; Saltzman et 
al. 1994; Kowdley 
et al. 1992 
Vitamin B12 Megaloblastic, macrocytic anaemia can occur in SIBO due to a vitamin B12 deficiency. In the duodenum and 
jejunum, vitamin B12 binds to intrinsic factor enabling its absorption in the distal ileum. However, in SIBO, Gram-
negative bacteria are capable of competitively utilising vitamin B12 i.e. bacteria use the vitamin to produce 
inactive cobamides, which compete with dietary vitamin B12 for ileal binding sites. Paradoxically, the cobalamin 
synthesised by bacteria is retained by them, and thus it remains mostly unavailable for host absorption.  
Saltzman & R. 
Russell 1994; 
Welkos et al. 
1981; Giannella et 
al. 1972 
Folic acid Bacteria in the small bowel may utilise folic acid. Ironically these bacteria also produce the vitamin, which is 
available to the host. Therefore, serum folate concentrations are typically normal or even elevated in SIBO. 
Russell et al. 
1986 
Iron  Iron deficiency anaemia can occur, though the exact mechanism is unknown: it is likely that iron deficiency is due 
to abnormal intestinal conditions (e.g. a blind loop), where ulceration leads to blood loss causing detectable 
faecal occult blood. Damage to the mucosa by bacterial toxins, short-chain fatty acids or unconjugated bile acids 
may inhibit iron absorption. A mixed anaemia will result if the patient has both iron and vitamin B12 deficiencies. 
Giannella & 
Toskes 1976; 
Iivonen et al. 
1998 
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Weight loss has been described as a feature of SIBO. In a study of 150 patients with Crohn’s 
disease, those who tested positive for SIBO showed a significantly lower body weight than did 
patients without SIBO (63.6 kg vs. 70.4 kg, p= 0.014) (Klaus et al. 2009). Haboubi and 
Montgomery described 16 elderly patients with SIBO (1992). Following treatment for it, 13 
gained weight: there were highly significant increases in body weight, mid-arm muscle 
circumference and triceps skin-fold thickness. Similarly, in a larger study of 168 symptomatic 
elderly patients, those with SIBO were more likely to have lost weight than those without SIBO 
(44.9% vs. 27.7%, p= 0.05) (Elphick et al. 2005). The period over which weight was lost was not 
reported. There has been one study, which suggests that the weight loss seen in OG cancer 
may be associated with SIBO. Paik et al.’s study of patients following total gastrectomy (n= 78) 
found there to be a negative correlation between the presence of SIBO and postoperative 
weight loss (2011). This suggests the importance of SIBO in the postoperative nutrition of OG 
cancer patients.  
 
The primary goal of therapy in SIBO should be the treatment of any underlying disease or 
structural defect, although for many conditions this cannot be achieved. The management 
should include the correction of any nutritional deficiencies, where present. The cornerstone of 
treatment of SIBO is the use of antibiotics to modify the GI microbiota and improve symptoms. 
Effective treatment generally involves one or more antibiotic regimens with activity against 
aerobic and anaerobic organisms. Many different regimens have been advocated, including 
ciprofloxacin, metronidazole, neomycin, norfloxacin and doxycycline. There is no consensus on 
the most efficacious dose of antibiotics or duration of treatment. Recently, there has been a 
growing interest in the use of rifaximin (a non-absorbable rifamycin analogue) in the treatment 
of SIBO, especially in patients with IBS (Di Stefano et al. 2005; Lauritano et al. 2005; Chang & 
Green 2012; Pimentel et al. 2006). It has been shown to be efficacious and has good short-term 
safety in this setting (Menees et al. 2012; Pimentel et al. 2014; Zhao et al. 2014), but similar 
studies have not been undertaken specifically in SIBO. 
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Recently, a systematic review and meta-analysis was performed that compared the clinical 
effectiveness of antibiotics in the treatment of symptomatic IBS patients with documented SIBO 
(Shah et al. 2010). Of the ten studies that met the inclusion criteria, rifaximin was the most 
studied antibiotic (eight studies). Meta-analysis of four studies favoured antibiotics over placebo 
for successful treatment of SIBO with an odds ratio (OR) of 2.55 (95% confidence interval (CI) 
1.29–5.04). However, trials involving larger patient populations, comparing a greater diversity of 
antibiotics with one another and with placebo are needed to determine an optimal treatment 
strategy. Importantly, large prospective studies of SIBO in patients with cancer have not been 
undertaken, despite the SIBO-like GI symptoms that they experience and the risk factors that 
they may have.  
 
1.1.4 Nutritional Status in Patients with Oesophagogastric Cancer  
1.1.4.1 Defining Malnutrition in Oncology  
Malnutrition can be defined as a ‘state of nutrition in which a deficiency, excess or imbalance of 
energy, protein, and other nutrients causes measurable effects on tissue (shape, size, 
composition), function and clinical outcomes’ (Stratton et al. 2003). Although, this term 
encompasses overnutrition, for the purpose of this thesis the term malnutrition shall be 
synonymous with undernutrition. The cause of malnutrition in cancer is multifactorial in nature, 
resulting from inadequate dietary intake, increased requirements, impaired nutrient absorption 
and transport and/or altered nutrient utilisation, as well as, the effect of antineoplastic 
treatments (White et al. 2012).  
 
Until recently, there has been no single, universally accepted approach to the diagnosis and 
documentation of adult malnutrition. This may explain a survey in the UK demonstrating that 
80% of specialist oncological trainees expressed uncertainty or a lack of confidence in their 
ability to identify malnutrition (Spiro et al. 2006). This is a widespread problem with a similar 
study in the US demonstrating that 88% of radiology oncologists measured only body weight in 
order to determine malnutrition, while just 9% of them used body weight plus other assessment 
approaches (DeCicco et al. 2010). As such, despite the recommendations that standardised 
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and validated nutrition assessment approaches be used for patients with cancer, nutritional 
status is often not systematically evaluated in clinical practice (Elia 2003; Kondrup, Allison, et al. 
2003b). 
 
In 2009, an international guideline committee of nutrition experts from the American Society for 
Parenteral and Enteral Nutrition (ASPEN) and the European Society for Clinical Nutrition and 
Metabolism (ESPEN) was convened. Their aim was to develop a consensus approach to 
defining malnutrition for adults in the clinical setting. The committee produced three aetiology-
based definitions for diagnosing malnutrition, which highlight (a) the depletion of body cell mass 
due to reduced intake or assimilation of energy/protein and (b) the inflammation which promotes 
catabolism of skeletal muscle (Jensen et al. 2010). With regard to the latter, the contribution of 
inflammation to malnutrition is important to consider as nutrient requirements are altered by the 
inflammatory response (Zoico & Roubenoff 2002). If the catabolism of muscle tissue results in 
skeletal muscle mass greater than two standard deviations (SD) below that typical of healthy 
adults, the individual has sarcopenia (Baumgartner et al. 1998). The three aetiology-based 
definitions proposed by the committee are as follows: 
• Starvation-related malnutrition which is pure chronic starvation (e.g. anorexia nervosa) 
• Chronic disease-related malnutrition related to chronic inflammation of a mild-moderate 
degree (e.g. organ failure, pancreatic cancer, rheumatoid arthritis) 
• Acute disease or injury-related malnutrition related to acute inflammation of a severe 
degree (e.g. major infections, burns, trauma or closed head injury) 
 
The malnutrition experienced by patients with cancer is most likely to be chronic disease-related 
malnutrition, whereby they experience a chronic weight loss associated with an imbalance 
between pro- and anti-inflammatory cytokines. Though, cancer patients may also experience 
acute disease or injury-related malnutrition following an acute episode e.g. following surgery or 
a serious infection. Once these aetiology-based definitions were agreed upon, the Academy of 
Nutrition and Dietetics and ASPEN developed a list of metrics to detect and diagnose 
malnutrition (White et al. 2012). The group agreed that there was no single parameter that was 
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definitive for diagnosing adult malnutrition. The identification of two or more of six characteristics 
was recommended for diagnosis of malnutrition (Table 1-6). Criteria are available that delineate 
how to measure each of the characteristics for the accurate diagnosis of malnutrition (Appendix 
8.2) (White et al. 2012). At present, there is insufficient evidence to allow for distinction to be 
made between mild and moderate forms of malnutrition using these characteristics. Of note, the 
National Institute for Health and Care Excellence describe a different definition for malnutrition 
compared with the Academy of Nutrition and Dietetics and ASPEN as follows: the presence of 
(a) a body mass index (BMI) of less than 18.5 kg/m2, (b) unintentional weight loss greater than 
10% within the last three-six months, or (c) a BMI of less than 20 kg/m2 and unintentional weight 
loss greater than 5% within the last three-six months (National Institute for Health and Care 
Excellence 2006). 
 
Some malnourished patients may develop cachexia. The term cachexia originates from the 
Greek words kakos (‘bad’) and hexis (‘condition’). Cachexia may develop in different diseases, 
for example cancer, congestive heart failure and human immunodeficiency virus 
infection/acquired immunodeficiency syndrome. For simplicity purposes it describes severe 
wasting from any cause including starvation and disease (Lochs et al. 2006).  
 
Over the past decade, our understanding of cancer cachexia has progressed but until recently 
there lacked a definition for it and there were no diagnostic criteria nor classification system for 
it. However, in 2011, an international consensus panel (with members from Europe, Canada 
and the US) developed a definition, diagnostic criteria and a classification system specific to 
cancer cachexia (Fearon et al. 2011). They defined it as ‘a multifactorial syndrome 
characterised by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that 
cannot be fully reversed by conventional nutritional support and leads to progressive functional 
impairment’ (Fearon et al. 2011).  
 
Cancer cachexia is a spectrum with three stages of clinical relevance: pre-cachexia, cachexia, 
and refractory cachexia. Not all patients traverse the entire spectrum and this will depend on the 
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cancer type and stage of disease, the presence of systemic inflammation, low food intake, and 
lack of response to anticancer therapy. Refractory cachexia is associated with active 
catabolism, or the presence of factors that render active management of weight-loss no longer 
possible or appropriate (Fearon et al. 2011). The diagnostic criteria developed by the panel for 
patients who have not entered the refractory period are shown in Table 1-6 (Fearon et al. 2011). 
Malnutrition (in the context of cancer) and cancer cachexia are not synonymous with one 
another. There are many features of malnutrition that are also features of cancer cachexia. 
However, other features are believed to be unique to cancer cachexia and as such it is 
considered to be a more multidimensional and complex syndrome (Fearon et al. 2011). 
Therefore, while not all malnourished patients are cachectic, all cachectic patients are invariably 
malnourished (Muscaritoli et al. 2010). The content of Table 1-6 facilitates discrimination 
between the two terms.  
 
The features of malnutrition in cancer and cancer cachexia are described in detail in Table 1-7. 
Given that there is no validated tool to identify when a malnourished patient is also cachectic, 
most studies do not distinguish between the two entities. As such, when malnutrition prevalence 
data are reported, within the group deemed to be malnourished, there will inevitably be a sub-
group of cachectic patients, though these data will rarely be reported. Therefore, for the purpose 
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Table 1-6 Discrimination between malnutrition in cancer and cancer cachexia   
 
 Malnutrition in cancer Cancer cachexia 
Definition State of nutrition in which a 
deficiency of energy, protein, 
and other nutrients causes 
measurable effects on tissue 
(shape, size, composition), 
function and clinical outcomes 
A multifactorial syndrome characterised by 
an ongoing loss of skeletal muscle mass 
(with or without loss of fat mass) that 
cannot be fully reversed by conventional 






Any 2 or more of 6 features 
 
(a) Insufficient energy intake 
(b) Weight loss 
(c) Loss of muscle mass 
(d) Loss of subcutaneous fat 
(e) Localised or generalised 
fluid accumulation that may 
sometimes mask weight loss 
(f) Diminished functional status 
as measured by hand-grip 
strength 
Any 1 of 3 features 
 
(a) Weight loss > 5% over the past six 
months (in the absence of simple 
starvation)  
(b) A BMI < 20 kg/m2 with weight loss > 2% 
(c) Appendicular skeletal muscle index 
consistent with sarcopenia (males  
< 7.26 kg/m2; females < 5.45 kg/m2) and 







Subjective Global Assessment 
and Patient Generated 
Subjective Global Assessment 
None. A comprehensive, yet simple, 
framework for the clinical assessment of 





Reduced availability of nutrients 
Weight loss 
Loss of muscle mass and strength 
Loss of fat mass 
Fluid accumulation 
Increased metabolism 
Inflammatory factors  
Catabolic factors 
Negative functional effects 
Psychosocial effects 
Treatment  Nutritional support as a 
unimodal therapy is likely to be 
effective 
As the majority of cachectic patients 
probably have more than one component to 
their cachexia, nutrition as a unimodal 
therapy is unlikely to be effective in 
reversing cachexia. Other therapies if 
indicated are: physical activity prescription, 
anti-inflammatory drugs or nutrients, other 
drugs e.g. appetite stimulants, substrate 
normalisation approaches and 
psychotherapeutic therapy.  
Abbreviations: BMI, body mass index 
References: Jensen et al. 2010; Aapro et al. 2014; Fearon et al. 2011; Muscaritoli et al. 2010  
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Table 1-7 Features of malnutrition in cancer and cancer cachexia 
 







Loss of desire to 
eat in cancer 
can be 





Anorexia has been related to weight loss in the majority (40%), 
but not in all malnourished cancer patients (Blum et al. 2011). 
Energy intake relates unreliably to weight loss in studies where 
prospectively collected dietary assessment methods are used 
(Blum et al. 2011). 
Impaired absorption, altered transport, and altered nutrient 
utilisation can reduce the availability of nutrients (White et al. 
2012).  
Decreased food intake alone cannot explain 
the progressive weight loss seen in cancer 
(Heber et al. 1992). Malnutrition and 
cachexia appear to be explained by 
uncoupling of food intake to energy 
expenditure rather than by primary 





factors and a 




The incidence of sarcopenia increases following treatment with 
chemotherapy (Awad et al. 2012). 
Loss of lean body mass leads to a reduced capacity to exercise 
(Moses et al. 2004). 
 
 
Sarcopenia is a significant indicator of 
chemotherapy toxicity and efficacy. Dose 
reductions and treatment delays are 
common in these patients (Prado et al. 
2009; Prado et al. 2007).  
Low muscle mass has been shown to be an 
independent predictor of immobility and 
mortality (Prado et al. 2008).  
Reduced muscle function is associated with 









of body fat.  
Increased rates of fat oxidation and decreased lipogenesis have 
been demonstrated in cancer patients (Cao et al. 2010; 
Jeevanandam et al. 1986).  
Lipid-mobilising factor has been detected in the urine of patients 
with cancer and may be responsible for progressive lipid 
depletion (Russell & Tisdale 2002).  
Significant reductions in fat mass have been reported in patients 
with cancer following chemotherapy (Awad et al. 2012; Yip et al. 
2014). 
Increased mobilisation of peripheral fat and 
excessive oxidation of fatty acids can lead 
to depletion of fat stores and indirectly to 
weight loss (McAndrew 1986). 
Changes in fat composition (i.e. lower 
visceral to subcutaneous fat ratio) could be 
related to positive circumferential resection 






lead to weight 
loss.  
Tumour progression, comorbidities, old age, physical 
deconditioning, nutritional deficiency and drugs contribute to 
hypermetabolism in cancer (Dodson et al. 2011). Liver 
metastasis appears not to influence it (Cao et al. 2010). 
Elevated resting energy expenditure shows 
a much stronger association to weight loss 
than energy intake does indicating that an 
expected up-regulation of dietary intake in 
  
66 
Component Description Research Findings Effect 
Although inconsistent findings have been reported,  
cancer patients, in general, are at a higher energy consumption 
condition compared with healthy controls (Cao et al. 2010). 
response to elevated energy expenditure is 












Pro-inflammatory cytokines such as IL-1, IL-6, TNF-α and IFN-γ 
have all been associated with cachexia (Espat et al. 1995; Espat 
et al. 1994; Strassmann & Kambayashi 1995; Staal-van den 
Brekel et al. 1995). 
Levels of IL-12 are significantly lower in cachectic patients 
compared with controls (Shibata et al. 2002). 
C-reactive protein has been associated with anorexia and 
hypermetabolism (Wigmore et al. 1997).   
There is no clear, reproducible pattern whereby the plasma 
concentration of any one cytokine or acute phase reactant can 
be directly related to cachexia (Blum et al. 2011).  
These cytokines initiate a cascade of 
events, including direct effects on 
metabolism and appetite suppression and 
indirect effects on the acute phase protein 
response. This response has been 
associated with the increase in the resting 
metabolic rate and loss of muscle mass 











Gluconeogenesis is known to be increased in patients with 
cancer (van Cutsem & Arends 2005). Due to insulin resistance 
and glucose intolerance, this extra glucose is poorly used by 
peripheral tissues (Rofe et al. 1994; Mutlu & Mobarhan 2000).  
Patients with cancer have high rates of glycerol, free fatty acid 
and amino acid turnover (McAndrew 1986; Shaw & Wolfe 1987).  
Such futile substrate cycling leads to an 
increase in energy requirements and 
consequently there is a noticeable depletion 
of body fat and protein stores (Smith & 




High levels of 
fatigue may 
negatively affect 
physical state.  
More severe weight loss has been associated with a higher level 
of fatigue, which diminishes concentration and alertness (Fearon 
et al. 2006; Stewart et al. 2006). 
Cachectic patients have a marked reduction in physical activity 
levels (Dahele et al. 2007; Moses et al. 2004).  
Increased fatigue coupled with reduced 
appetite can lead to a reduction in 
performance status in cachexia (Argilés et 
al. 2007).  
Psychosocial 
effects 





Eating-related anxiety, frustration, helplessness and fear are 
common in patients with cachexia (Reid et al. 2009). 
Depression has been shown to be significantly linked to 
cachexia (Westin et al. 1988). 
Malnutrition has been found to have a 
detrimental effect on patient QoL due to 
poorer general health, reduced social 
functioning and a more negative outlook 
(Fouladiun et al. 2007; Ovesen et al. 1993; 
Andreyev et al. 1998). 
Abbreviations: IFN-γ, interferon gamma; IL-, interleukin; QoL, quality of life; TNF-α, tumour necrosis factor alpha 
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1.1.4.2 Prevalence of Malnutrition in Oncology 
Researchers have been interested in assessing malnutrition in cancer patients for many 
decades. However, the research performed to date has generally not defined malnutrition using 
the international consensus approach outlined in Section 1.1.4.1. Nevertheless, using a range 
of different diagnostic criteria, it is reported that patients with cancer have the highest 
prevalence of malnutrition among hospitalised in-patients, ranging from 40-80% (Ollenschläger 
et al. 1991; Shike 1996; Delmore 1997).  
 
Large studies of malnutrition prevalence have been undertaken in the UK, albeit not specifically 
in the oncology setting. In hospitals, care homes and mental health units, four Nutrition 
Screening Week Surveys were undertaken by the British Association of Parenteral and Enteral 
Nutrition (BAPEN) between 2007 and 2011 (Russell & Elia 2014). The surveys aimed to 
establish the prevalence of malnutrition using the Malnutrition Universal Screening Tool (MUST) 
in different care settings. This tool involves the addition of three scores: a BMI score, an 
unintentional weight loss score and an acute disease effect score. There were a total of 661 
hospital centres and 34,699 patients involved in the surveys. Overall the prevalence of 
malnutrition in patients newly admitted to UK hospitals was 29% (Russell & Elia 2014). The 
prevalence of malnutrition was found to be higher in those with cancer (39%) compared with 
those without it (28%) and those patients with GI disease had a consistently higher prevalence 
(43%) when compared with the other diagnostic categories. A pitfall of this research, is that 
MUST is a screening tool rather than an in-depth nutritional assessment tool, and thus, cannot 
diagnose malnutrition. 
 
Specifically in oncology, malnutrition prevalence can vary depending upon the setting. Dewys 
and colleagues demonstrated that the prevalence of malnutrition was high in the US out-patient 
setting. Patients (n= 3,047) reported unplanned weight loss in the preceding six months and this 
was recorded within the following ranges: 5-10% or > 10% (Dewys et al. 1980). Depending on 
the primary tumour site, 8-32% had lost 5-10%, while 4-38% had lost > 10% of their weight. In a 
more recent observational, cross-sectional study undertaken at an Australian public tertiary 
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hospital, the prevalence of malnutrition was measured using the valid and reliable Patient 
Generated Subjective Global Assessment (PG-SGA). The rates of malnutrition ranged from 
26% (13/50) in the out-patient chemotherapy unit, 56% (71/126) in the cancer clinic, and 67% 
(10/15) in the oncology ward (Isenring et al. 2010). 
 
By far one of the largest studies of malnutrition prevalence in cancer is the one-day prospective 
French prevalence survey, results of which were recently published (Hebuterne et al. 2014). 
Information on nutrition status was collected on 1903 cancer in- and out-patients (mixed tumour 
sites) in 24 cities. Malnutrition was defined as (a) BMI < 18.5 kg/m2 in those aged < 75 years or 
< 21 kg/m2 in those ≥ 75 years and/or (b) weight loss > 10% since disease onset. The nutrition 
risk index (NRI) screening tool was used in a sub-group of patients to identify malnutrition and 
risk thereof. Serum albumin is a component of the NRI equation. Overall, 39% of patients were 
considered malnourished using the BMI and weight loss definitions. Since disease onset, 84% 
of the patients had experienced weight loss, and 51% had lost more than 5% of their body 
weight. Of the 103 with oesophageal or gastric cancer, 60% were found to be malnourished. In 
the subgroup of patients (n= 368) for whom a recent serum albumin result was available, NRI 
was calculated and the prevalence of malnutrition was 59% (37% were moderately 
malnourished and 22% were severely malnourished).  
 
Although the findings of this study highlight the high prevalence of malnutrition in the oncology 
setting, they must be interpreted with caution. Body mass index used as a measure of 
nutritional status alone is often criticised as it does not provide information on body fat 
distribution and body composition and is prone to error e.g. underestimation of malnutrition in 
obese individuals. Also, it does not take into consideration non-nutrition influences on BMI such 
as oedema, ascites, or a low but stable index. The use of the NRI screening tool (with serum 
albumin as a component) is also noteworthy (Hebuterne et al. 2014). Following a review of the 
literature, the Academy of Nutrition and Dietetics confirmed that serum albumin does not 
consistently or predictable change with weight loss, energy restriction or nitrogen balance 
(American Dietetic Association Evidence Library 2014). They suggest that hypoalbuminaemia 
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reflects the severity of the inflammatory response rather than poor nutritional status and as such 
is not a valid surrogate marker. However, referring back to the aetiology-based definitions 
discussed in Section 1.1.4.1, both the acute disease/injury-related malnutrition and the chronic-
disease related malnutrition relate to inflammation. Therefore, malnutrition and inflammation can 
co-exist i.e. a malnourished patient is likely to have a low serum albumin. The presence of 
inflammation can contribute to malnutrition and can blunt a favourable response to nutritional 
intervention. Conversely, if inflammation is absent then even advanced malnutrition due to 
starvation can be reversed with appropriate nutritional support (Jensen et al. 2009; Jensen et al. 
2010). Therefore, though serum albumin is not an ideal surrogate marker of nutritional status, it 
can provide insight into the pathophysiology of malnutrition.  
 
Another malnutrition prevalence study involving 1,000 patients was recently published. The 
cohort consisted of head and neck, lung and GI cancer patients, all of whom were receiving 
radiotherapy. Nutritional status was measured using the validated Subjective Global 
Assessment (SGA) (Koom et al. 2012). In total, the mean (SD) weight loss over the previous six 
months was 2.1 (3.9) kg and 275 (27.5%) patients had lost some weight in the previous one 
month. The prevalence of malnutrition was high in the cohort at 42.6%. Of those with GI cancer 
(n= 444, 44.4%), 169 (43.1%) were malnourished. This value was much higher than that for the 
head and neck and lung cancer patients, at 29.1% and 27.8% respectively.  
 
A number of studies have investigated nutritional risk specifically in GI cancer. In a Chinese 
study of advanced GI cancer patients (n= 498), the need for nutritional intervention was 
calculated using PG-SGA (Zhang et al. 2014). The mean (SD) PG-SGA total score was higher 
for oesophageal cancer patients (11.07 (4.03)) than other GI cancer groups and significantly 
higher than that of colon cancer (9.54 (3.50)), indicating a more critical need for improved 
symptom management and nutritional intervention. Nutritional status results were not reported 
for the cohort.  
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High prevalence rates for malnutrition in patients with OG cancer were found in an Italian study. 
The study involved almost 1,500 cancer out-patients, most of who were having ongoing 
oncology treatment (Bozzetti et al. 2012). One-fifth of the cohort had OG cancer. The Nutrition 
Risk Screening (NRS) 2002 tool was used to determine nutritional risk, where a score of 3-4 
indicates that the individual is at medium risk and a score of > 5 indicates a high risk of 
malnutrition. The results were presented as the percentage of patients at medium risk of 
malnutrition: of those with oesophageal and gastric cancer, 62.5% and 43.7% respectively were 
at medium risk. Compared with all other cancer groups, those with oesophageal cancer had 
more weight loss and were at a higher nutritional risk.  
 
In a local in-patient study at RM, the nutritional status of 128 patients was assessed using PG-
SGA (Shaw et al. 2014). There were 26 (21%) GI cancer patients in the study. The PG-SGA 
categorised 36 (29%) as well-nourished and 90 (71%) as malnourished of which 63 (50%) were 
moderately/suspected malnourished and 27 (21%) were severely malnourished. Another RM 
prospective study added to the evidence of increased nutritional risk for patients with OG 
cancer. Consecutive patients (n= 920) referred for consideration of treatment of their newly 
diagnosed GI cancer at RM were recruited (Baldwin et al. 2006). Reported unplanned weight 
loss in the preceding three-six months was recorded and if the weight loss was 5-10% or > 
10%, the patient was considered to be at medium or high risk of malnutrition respectively. 
Overall 223 (24%) patients had lost 5-10% of their body weight, while 294 (32%) had lost > 
10%. In the combined gastric and oesophageal cancer group (n= 238), 24% had 5-10% weight 
loss, while 37% had weight loss of > 10%.  
 
There are numerous causes for malnutrition and it is certainly prevalent in cancer with many 
data suggesting an increased risk of malnutrition in patients with OG cancer. However, there 
are few studies that have investigated its prevalence exclusively in patients with OG cancer by 
means of a nutritional screening or assessment tool.   
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1.1.4.3 Consequences of Malnutrition in Oncology 
Malnutrition has been shown to have measurable and important adverse effects on clinical 
outcome. In patients with cancer, malnutrition has been associated with increased toxicity to 
oncological treatments (van Cutsem & Arends 2005; Andreyev et al. 1998), lower response to 
treatment (van Cutsem & Arends 2005) and lower overall survival (Dewys et al. 1980; Clavier et 
al. 2014). These poorer outcomes may be explained by the finding that individuals who present 
with weight loss receive less chemotherapy than those without weight loss because the 
treatment dose is calculated according to body surface area, which takes weight into account 
(Ross et al. 2004; Andreyev et al. 1998). Stabilisation of body weight is associated with a 
significantly increased survival compared with those who continue to lose weight (Andreyev et 
al. 1998). Malnutrition has also been shown to be strongly associated with deteriorating 
performance status (Hebuterne et al. 2014), it impairs immune status and reduces the body’s 
defence against infectious diseases (Alexandre et al. 2003) and results in higher overall 
treatment costs by causing longer length of stay in hospital (Kyle et al. 2005).  
 
In a systematic review assessing the role of nutritional status in predicting QoL in cancer, it was 
concluded that better nutritional status was positively associated with better QoL in GI cancer 
patients (eight studies) (Lis et al. 2012). In Carey et al.’s cross-sectional study of upper-GI 
cancer patients following surgery (n= 30) (refer to 1.1.3.1), nutritional status was assessed to 
determine if it might help to explain QoL scores (Carey et al. 2011). Mean (SD) weight loss 
since surgery was 9.8 (10.5) kg and those patients with malnutrition had poorer QoL; QoL was 
correlated with BMI (r= 0.524; p= 0.004) and percentage weight change (r= 0.494; p= 0.006) 
after adjustment for age. Fourteen patients (47%) displayed some degree of malnutrition using 
SGA. Along with GSRS this score was significant in explaining 50.3% of variance in QoL, with a 
high beta value of -0.458 (p= 0.003). 
 
Although many studies have focused on assessing the relationship between malnutrition and 
other variables, this does not by any means imply causation. There are many confounding 
factors that need to be considered e.g. patients with weight loss have poorer survival, but this 
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may be because they have more advanced cancer or poorer performance status, and as such, 
it cannot be concluded that weight loss was the sole cause for reduced survival. 
 
1.1.4.4 Oral Intake in Patients with Oesophagogastric Cancer  
Inadequate oral intake can contribute to malnutrition in cancer. Oral intake might be 
compromised following surgery due to absence or reduction in the reservoir of the stomach. 
However, research in OG cancer patients with regard to this is limited and conflicting.  
 
A prospective evaluation of dietary intake after near-total oesophagectomy (with or without 
perioperative chemotherapy) (n= 32) indicated that most patients appeared to be meeting their 
energy needs at a mean (SD) of 2.8 (1.8) years post-surgery (Ludwig et al. 2001). It was found 
that the mean (SD) energy intake was 2,179 (502) kcal/day, which was, as a group, 98% of the 
recommended energy intake (based on ideal body weight). Overall, 78% (25 of 32) were able to 
meet or exceed daily energy intake recommendations based on ideal body weight. However, it 
was not reported whether patients were weight stable at the point of dietary assessment, thus it 
is not possible to conclude that dietary adequacy prevented the development of malnutrition.   
 
A Korean study of 20 patients suggested that dietary intake was not sufficient to maintain body 
weight. In this study, patients underwent a total gastrectomy and adjuvant chemotherapy and 
oral intake was assessed at a mean (SD) of 2.8 (2) years following the end of treatment (Bae et 
al. 1998). Weighed food diaries were used, although the number of assessment days was not 
clearly stated. The mean (SD) energy intake was 1,586 (129) kcal/day (range 883-3139 
kcal/day), which was 31.8 (10.9) kcal/kg body weight (range 16.7-57.1 kcal/kg). This intake was 
somewhat lower than the average daily energy intake of Korean adults, which is 1,838 kcal/day. 
There was also a mean 15% loss of preoperative weight and fat mass (measured by triceps 
skinfold thickness) was significantly less than that of the normal Korean population. Although, 
the sample size was small, and no estimations of energy requirements were made, these 
results indicated that insufficient energy intake might be a cause for the weight loss and 
malnutrition seen in OG cancer. 
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In Carey et al.’s cross-sectional study of weight-losing upper-GI cancer patients six months or 
more after surgery (n= 30), patients completed 3-day weighed food diaries (Carey et al. 2011). 
The mean (SD) time since surgery was 1.3 (2.2) years. Nutritional requirements for energy were 
estimated using the Schofield equation, where basal requirements were multiplied by a 1.5-1.8 
activity factor, depending on the reported level of activity. Protein requirements were based on 
standard requirements for free living individuals, with a range of 0.8-1 g/kg per day. Their data 
agrees with that of the Korean study: mean (SD) energy intake as a percentage of estimated 
daily requirements was 79 (20.6)%. However, mean (SD) protein intake appeared adequate at 
118.2 (32.9)% of estimated requirements. A limitation of this study lies in the use of the 
Schofield equation to estimate energy requirements, which has been shown to overestimate 
resting energy expenditure in patients with pancreatic cancer (Bauer et al. 2004). Still, there are 
no prediction equations that have been specifically developed for use in cancer and although 
indirect calorimetry is the most accurate method for determining energy requirements, it is 
impractical, time-consuming and expensive in the clinical setting. In addition the small sample 
size limits the ability to draw firm conclusions on dietary intake.   
 
Similarly, data from a study involving just six post-gastrectomy patients agreed with these 
findings for protein, although not for energy. The median (range) time of assessment in this 
study was somewhat longer at 3.8 (2.1-5) years (Curran & Hill 1990). Dietary intake was 
assessed using a 24-hour recall and a 3- or 4-day dietary diary. The patients had a mean (SD) 
daily protein intake of 81 (15) g/day, which was not significantly different from their estimated 
daily requirements of 85.7 (3.5) g/day (based on individual estimated requirements of 1.5 
g/kg/day). The mean (SD) energy intake was not significantly different from their estimated 
requirement, 2,224 (381) kcal and 2,284 (93) kcal respectively (based on individual estimated 
requirements of 40 kcal/kg/day). However, pre-diagnosis weight was significantly lower than 
post-surgery weight (p< 0.02) suggesting that oral intake at diagnosis/during and after treatment 
(i.e. before the study assessment) was inadequate.   
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There are no large studies assessing dietary intake patterns in the OG cancer setting. The 
studies discussed above are very heterogeneous, with different methods used for assessing 
dietary intake and estimating energy and protein requirements. As such, one cannot be certain 
that inadequate oral intake is contributing to malnutrition in all weight-losing OG cancer patients.  
 
1.1.4.5 Nutritional Psychosocial Factors in Patients with Oesophagogastric Cancer  
Beyond the physical difficulties with eating and the metabolic implications of severe weight loss, 
the psychosocial impact of adapting to a new way of eating appears to be substantial. This has 
been mentioned previously in Table 1-7. 
 
Many qualitative studies focused on patients’ own experiences of changes in their appetite, food 
intake and weight loss. They provide us with a deep understanding of the patients’ experience. 
In one such study, qualitative interviews were performed with 15 participants. Patients were 
asked to recount their experiences concerning appetite and hunger, smell and taste, changes in 
weight, and type of nutritional intake three months following gastrectomy (Olsson et al. 2002). 
Three themes were identified: the struggle to eat and drink, bodily estrangement and nutritional 
treatment regimens.  
 
With reference to the first theme, the majority (proportion not known) of patients indicated that 
they did not have any appetite after their operation, that they did not feel hungry and that 
nausea was common. One patient said that he had to force himself to eat and in some cases, 
spouses or relatives tried to force the patients to eat more frequently, despite their lack of 
appetite or feelings of hunger. Regarding the second theme (bodily estrangement), the patients 
in this study experienced a range of variations in their weight following surgery. This affected 
their bodily perception and lead to feelings of alienation with their own bodies. For the third 
theme (nutritional treatment regimens), individuals receiving enteral nutrition (EN) felt irritated 
and uncomfortable because of it. They had feelings of isolation, because they could not meet 
their friends during the evenings and it limited their freedom (Olsson et al. 2002). 
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Similarly, in another qualitative study by Olsson et al. 15 patients (n= 13 had cancer) were 
assessed one year after upper-GI surgery. The patients related feelings of caution with regard 
to their diet (2010). If they ate too much at any one time or ate too quickly, it could lead to 
overload and vomiting. Many patients felt they could no longer eat foods high in fat. During the 
year they reported learning to be aware of any foods that did not agree with them and that could 
cause negative physical reactions. For example, some patients could not consume any meat, 
dairy products, or fresh vegetables. For these individuals, having the ability and desire to share 
a meal with others, appreciate good food, and regaining their appetite were seen as a positive 
recovery sign (Olsson et al. 2010).  
 
Feelings of embarrassment about eating in public and/or being unable to control how their body 
would react when eating (e.g. nausea, vomiting) has been described in another focus-group 
study (Malmström et al. 2013). Bodily perception was also subject to change in this group. 
Participants reported feeling as though they had become shorter, more compact, or shrunken 
and thus, had become alienated from their body (Malmström et al. 2013).  
 
The effects of nutrition-related problems are far-reaching: malnutrition is the obvious factor to 
consider but the psychosocial effects should not be overlooked in an effort to prevent QoL 
decline.   
 
1.1.5 Research Needs in Patients with Oesophagogastric Cancer: Gastrointestinal 
Symptoms and Nutritional Status 
Acute and chronic GI symptoms have not been studied systematically or prospectively in OG 
cancer patients undergoing radical treatment and, as such, the symptom burden is not fully 
understood. Also, these patients represent a high-risk group for malnutrition, yet there is still 
only a relatively small body of research concerned with measuring their nutritional status. 
Furthermore, although GI symptoms and nutritional status are theoretically likely to be 
associated with each other, this has only been investigated by a few studies, as described in 
Table 1-8. Of these studies, none have incorporated the use of an oncology-specific nutritional 
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assessment tool and the number of GI symptoms measured is generally small. Of note, just one 
pilot study looked at this relationship in upper-GI cancer patients and there is no data for OG 
cancer specifically (Chate 2006).  
 
There has also been limited research to assess the prevalence of SIBO in an OG cancer 
population. The few studies that have focused on this have involved patients following 
gastrectomy and high prevalence rates (37-100%) were reported (Paik et al. 2011; Iivonen et al. 
1998; Brägelmann et al. 1997). To date, no researchers have tested for SIBO before the 
commencement of treatment and then re-tested during and after treatment to determine the 
incidence of the condition at these points. Therefore, a gap in the literature remains, which, if 
filled, could potentially change the management of GI symptoms in OG cancer patients. 
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Table 1-8 Studies investigating the relationship between gastrointestinal symptoms and nutritional status in patients with cancer  
 
Reference Study design, 
cohort 
n= Gastrointestinal symptom and 
nutritional status assessment 
Findings 
Sánchez-









191 5 symptoms: anorexia, nausea, 
vomiting, diarrhoea, constipation 
 
6 month unintentional weight loss 
 
Most commonly reported symptoms were nausea (60%) 
and anorexia (46%) 
 
39% had ≥ 5% weight loss, 25% had ≥ 10 % weight loss 
 
In patients with ≥ 5% weight loss, there was a significant 
associated with nausea (p= 0.03), vomiting (p= 0.017) 
and anorexia (p= 0.003). In those with ≥ 10% weight 
loss, there was a significant associated with vomiting (p= 
0.05) and anorexia (p< 0.001) 
 





study, mixture of 
cancers, advanced 
disease, no active 
treatment  
143 10 symptoms: anorexia, dry mouth, 
dysphagia to solids, dysphagia to 
liquids, decreased taste, taste changes, 
chewing problems, nausea, vomiting, 
hiccup 
 
6 month unintentional weight loss, 
triceps skinfold thickness, mid-arm 
muscle circumference and BMI 
  
Most commonly reported symptoms were dry mouth 
(73%), anorexia (50%), chewing problems (40%), hiccup 
(20%) and nausea and vomiting (31%) 
 
54% had > 10% weight loss  
 
Weight loss was significantly associated with anorexia 
(p= 0.03), dysphagia to solids (p= 0.04) and liquids (p< 
0.001) and nausea (p= 0.025). Those with > 10% weight 
loss had a relative risk for developing dysphagia to 




al. 2007  
 
Cross-sectional 
study, GI and lung 
cancer, any disease 
stage, out-patients, 
recent surgery in 
18%  
151 12 symptoms: anorexia, dry mouth, 
mouth sores, dysphagia, taste changes, 
bothersome smells, early satiety, 
nausea, vomiting, pain, diarrhoea, 
constipation 
 
PG-SGA (only first part of tool used), 
62% had symptoms: most commonly reported 
symptoms were anorexia (38%), early satiety (27%), 
pain (23%), taste changes (20%) and nausea (18%) 
 





Reference Study design, 
cohort 
n= Gastrointestinal symptom and 
nutritional status assessment 
Findings 
including weight loss over past 1-6 
months 
 
Those with 5% or more weight loss had more symptoms 
than patients with no weight loss (p< 0.0001). Those 
with any weight loss were significantly more likely to 
report anorexia and dysphagia than those without weight 













40 10 symptoms: anorexia, dry/sore mouth, 
dysphagia, taste changes, early satiety, 
heartburn, nausea, abdominal pain, 
diarrhoea, constipation 
 
3 month unintentional weight loss, BMI 
 
 
Most commonly reported symptoms were anorexia 
(45%), early satiety (35%), abdominal pain (33%), 
dysphagia (30%) and nausea (30%) 
 
65% had lost some weight 
 
The weight loss group reported a greater number of 
symptoms especially anorexia (54%) and early satiety 
(42%). Nausea (46%) and dysphagia (42%) in the 
weight loss group was significantly different compared 







study, head and neck 
cancer, any disease 
stage, out-patients, 
multimodality 
treatment in 81% 
 
49 8 symptoms: anorexia, dry mouth, sticky 
saliva, dysphagia, nausea, vomiting, 
diarrhoea, constipation 
 
6 month unintentional weight loss 
 
41% had lost ≥ 10% body weight and 59% had lost < 
10% 
 
In those with ≥ 10% weight loss compared with those 
with less weight loss, symptoms were significantly worse 
at: 
(a) Diagnosis: anorexia (p< 0.01), dysphagia (p< 0.01), 
dry mouth    
      (p< 0.05), sticky saliva (p< 0.001) 
(b) 1 year: sticky saliva (p< 0.05) 




Reference Study design, 
cohort 
n= Gastrointestinal symptom and 







study, mixture of 
cancers, metastatic 
disease, in- and out-
patients, recent 
chemotherapy in 
24%, radiotherapy in 
28%  
352 15 symptoms: anorexia, dry mouth, sore 
mouth/throat, odynophagia, decreased 
taste, early satiety, belching, hiccup, 
nausea, bloating, vomiting, abdominal 
pain, dyspepsia, diarrhoea, constipation 
 
6 month weight loss, triceps skinfold 
thickness, mid-arm muscle 
circumference and BMI 
Most commonly reported symptoms were anorexia 
(81%), early satiety (69%), dry mouth (69%), 
constipation (59%) and nausea (49%) 
 
87% had lost some weight, and most (71%) lost ≥ 10% 
of pre-illness weight 
 
The absolute number of GI symptoms correlated (r= 0.8) 
with severity of weight loss (p= 0.01) 
 
Grosvenor 










radiotherapy in 54% 
254 12 symptoms: dry mouth, sore mouth, 
difficulty chewing, taste changes, 
dysphagia, nausea, abdominal fullness, 
abdominal pain, milk product 
intolerance, vomiting, diarrhoea, 
constipation  
 
Weight loss compared with usual weight 
(no time frame), triceps skinfold 
thickness, mid-arm muscle 
circumference 
Most commonly reported symptoms were abdominal 
fullness (61%), taste change (46%), constipation (41%), 
dry mouth (41%) and nausea (39%) 
 
Mean weight loss of 12% from their usual body weight, 
67% had lost > 5% 
 
Symptoms significantly more common in the group with 
> 5% weight loss included abdominal fullness (p< 
0.001), taste change (p< 0.003), vomiting (p< 0.005), 
and dry mouth (p< 0.02) 
 
Abbreviations: BMI, body mass index; GI, gastrointestinal; PG-SGA, Patient-Generated Subjective Global Assessment 
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1.2 Nutritional Screening, Assessment and Intervention in 
Patients with Oesophagogastric Cancer  
Malnutrition is a common phenomenon in patients with OG cancer. It can occur at diagnosis, 
during treatment and/or after the completion of treatment. The optimisation of nutritional status 
can be achieved when three essential components of a nutrition support programme are 
effectively implemented: screening, assessment and intervention. The aim of screening is to 
quickly identify individuals at nutritional risk so that they may undergo a more formal and 
extensive nutrition assessment. If a patient is found to be malnourished on assessment, an 
appropriate nutritional intervention should be started with the aim of improving nutritional status, 
clinical outcomes and QoL. 
 
1.2.1 Nutritional Screening in Patients with Oesophagogastric Cancer  
The 2003 ESPEN guidelines state that the purpose of nutrition screening is to predict the 
probability of a better or worse outcome due to nutrition factors and whether nutrition treatment 
is likely to influence this (Kondrup, Allison, et al. 2003b). Routine nutrition screening has been 
endorsed by many national, international and specialist organisations including the National 
Institute for Health and Care Excellence (National Institute for Health and Care Excellence 
2006), the British Dietetic Association (BDA) (The British Dietetic Association 1997), BAPEN 
(Elia 2003), ESPEN (Kondrup, Allison, et al. 2003b), the Council of Europe (Beck 2001) and the 
Royal College of Physicians (The Royal College of Physicians London 2002) .  
 
Screening is often performed by a non-expert in nutrition, such as a nurse or healthcare 
assistant (Green & Watson 2005). More recently, researchers have investigated patient self-
screening, including electronic self-screening, to good effect (Cawood et al. 2012; McGurk et al. 
2013). Screening should be a non-invasive, quick and simple process. To efficiently screen a 
patient’s nutrition status, readily available objective and subjective data are reviewed. Height, 
weight, weight change, primary diagnosis, illness severity, change in food intake and the 
presence of symptoms are objective measures commonly included in nutritional screening tools 
(Huhmann & August 2008). For patients with cancer, it has been proposed that nutritional 
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screening should be performed at diagnosis, initiation of treatment and at scheduled intervals 
throughout treatment to monitor changes in nutritional status (Huhmann & Cunningham 2005). 
There are a variety of nutritional screening tools, of which the NRI, NRS 2002, Malnutrition 
Screening Tool (MST), MUST, Malnutrition Screening Tool for Cancer (MSTC) and Mini 
Nutritional Assessment (MNA) are frequently used and investigated (Green & Watson 2005). A 
brief description of these tools is described in Table 1-9.  
 
Table 1-9 Overview of commonly used nutritional screening tools 
 
Tool Components Validation cohort(s) 
Nutrition Risk 
Index 
Equation: NRI= 1.519 (serum 




Screening 2002  
4 items: BMI, weight loss, dietary 
intake, illness severity 
General hospital in-patients, acute 
hospitalised patients 
Malnutrition 
Screening Tool  
3 items: weight, percentage weight 
loss, appetite 
 
Acute hospitalised patients, elderly 
care home residents, cancer 
patients receiving radiotherapy, 




Screening Tool  
3 items: BMI, percentage weight loss, 
acute disease effect 
General hospital in-patients, out-
patients and community dwellers 
Malnutrition 
Screening Tool 
for Cancer  
Equation: MSTC= -0.116 + (1.777 × 
intake change) + (1.304 × ECOG 
performance status) + (1.568 × weight 




6 items: dietary intake, weight loss, 
mobility, psychological stress/acute 
disease, neuropsychological 
problems, BMI  
Elderly in-patients, out-patients 
and elderly community dwellers 
Abbreviations: BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; MSTC, 
Malnutrition Screening Tool for Cancer; NRI, Nutrition Risk Index 
References: Kondrup, Rasmussen, et al. 2003a; Ferguson, Capra, et al. 1999a; Stratton et al. 
2004; Kim et al. 2011; Guigoz & Vellas 1999; The Veterans Affairs Total Parenteral Nutrition 
Cooperative Study Group 1991; Bauer et al. 2005; Ferguson, Bauer, et al. 1999b; Isenring et 
al. 2006; Isenring et al. 2009 
 
The majority of these screening tools were developed for general hospitalised or community 
patients, with MSTC being the only one designed specifically for cancer in-patients. As such, 
few tools have been validated in cancer patients. To date, seven well-conducted studies have 
aimed to validate a nutritional screening tool in adult oncology against an acceptable reference 
standard (i.e. SGA or PG-SGA) with five studies indicating suitability of four screening tools 
tested (Table 1-10). 
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Table 1-10 Studies measuring the validity of nutritional screening tools in adult patients with cancer against Subjective Global Assessment 
(SGA) or Patient Generated Subjective Global Assessment (PG-SGA) 
 









of tool  
Specificity (%) 
of tool  
Suitability 
of tool * 
Read et al. 
2005 
Out-patients, mixture of cancers, 
prior treatment in the majority  







Bauer, et al. 
1999b 
Out-patients, mixture of cancers, 
receiving radiotherapy 







Out-patients, mixture of cancers, 
receiving chemotherapy 





Wolf et al. 
2002 
In-patients, gynecological 
cancers, treatment not described 






Kim et al. 
2011 
In-patients, mixture of cancers, 
treatment not described 






et al. 2011 
Out-patients, mixture of cancers, 
receiving radiotherapy 







In-patients, cancer site and 
treatment not described 






Shaw et al. 
2014 
In-patients, mixture of cancers, 





















* Suitability of the tool: as determined by the study investigators. Abbreviations: MAG, Malnutrition Advisory Group tool; MNA, Mini Nutritional 
Assessment; MST, Malnutrition Screening Tool; MSTC, Malnutrition Screening Tool for Cancer; MUST, Malnutrition Universal Screening Tool; n/a, 
not available; NPV, negative predictive value; PPV, positive predictive value; RMNST, Royal Marsden Nutrition Screening Tool 
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1.2.2 Nutritional Assessment in Patients with Oesophagogastric Cancer  
Nutritional screening allows identification of patients at risk of malnutrition. For those at risk, a 
comprehensive nutritional assessment should be performed by an expert in clinical nutrition 
(e.g. a dietitian or nutrition-trained doctor). Nutritional assessment incorporates medical and 
weight history, a detailed dietary history, physical examination, anthropometric measurements 
and laboratory data (American Dietetic Association Council on Practice Quality Management 
Committee 1994). An assessment of body compartments as well as an analysis of structure and 
function of organ systems and metabolic status is included (Huhmann & August 2008). The 
purpose of nutritional assessment is to collect the information necessary to establish nutrition-
related diagnoses and to formulate nutrition, metabolic, dietary, pharmacologic, and functional 
interventions in the form of a nutrition care plan (Huhmann & August 2008).  
 
Many nutritional assessment tools have been developed that combine the aspects of nutritional 
assessment into an algorithm or score, although few have been validated in cancer patients. 
Two tools that have been evaluated in prospective trials of cancer patients and have been 
shown to have adequate sensitivity and specificity: SGA and PG-SGA (Detsky et al. 1987; 
Bauer et al. 2002; Ottery 2000).  
 
The SGA was originally developed in the 1980’s for GI surgical patients and is comprised of 
history (weight loss, dietary intake, GI symptoms and functional capacity), metabolic demands 
of the underlying disease and a nutrition-related physical examination (Detsky et al. 1987). The 
rating of nutritional status as (a) SGA-A, well-nourished, (b) SGA-B, moderately/suspected 
malnourished or (c) SGA-C, severely malnourished is subjective. The SGA tool was 
subsequently modified by Ottery and Bauer and PG-SGA has evolved. Ottery modified the SGA 
making it specific for an oncology population (Ottery 1994). The history section of the tool 
became ‘patient-generated’ to simplify the process and to involve the patient more. Also, the 
number of GI symptoms in this section was increased to include nutrition-impact symptoms 
relevant to cancer patients (Ottery 1994). Then, Bauer added a scoring and triage component 
producing the tool in use today (Bauer et al. 2002; Ottery 2000)  (Appendix 8.3). The PG-SGA 
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tool is often referred to as the gold-standard method for nutritional assessment and is the most 
commonly used technique to diagnose malnutrition in practice and research. In Table 1-6, the 
six diagnostic criteria for malnutrition in cancer were listed and all of these items are measured 
by the PG-SGA. 
 
A study of 71 cancer in-patients compared the performance of the PG-SGA with SGA and found 
that there was a significant difference in the median PG-SGA total scores for each of the SGA 
classifications (p< 0.001), with the severely malnourished patients (SGA-C) having the highest 
scores, as would be expected (Bauer et al. 2002). These findings are consistent with other 
studies that have shown a linear association between PG-SGA total score and SGA global 
category (Desbrow et al. 2005; Isenring et al. 2003). To move one SGA category (i.e. 
improvement or deterioration), a mean change in PG-SGA total score of ± 9.0 (95% CI= 7.2-
10.9) was required (Isenring et al. 2003). In addition, the PG-SGA total score has been shown 
to be significantly correlated with percentage weight loss in the previous six months (r= 0.31, p= 
0.012) (Bauer et al. 2002). This correlation between SGA category and PG-SGA total scores 
reassures that PG-SGA total score can be used as a valid measure of nutritional status. 
 
1.2.3 Nutritional Intervention in Patients with Oesophagogastric Cancer 
Formal nutrition assessment in at-risk patients identifies opportunities for dietary interventions. 
By providing early nutrition intervention, it may be possible to prevent or delay deterioration in 
patients’ nutritional status (Marín Caro et al. 2007; Ravasco, Monteiro-Grillo, Vidal & Camilo 
2005a; Ravasco, Monteiro-Grillo, Vidal & Camilo 2005b). A systematic review of the literature 
performed reported that dietary advice for adults with disease-related malnutrition (including 
cancer) had positive effects on weight, body composition, and hand grip strength (Baldwin & 
Weekes 2011). However, the effect of dietary intervention on patients with OG cancer has been 
researched much less than other cancer sites. Therefore, data available for this group is limited.  
 
A two-year prospective Swedish study assessed 133 patients with colorectal and gastric cancer. 
Newly diagnosed patients were randomised in a 2 × 2 design between (a) nutritional support 
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only, (b) group rehabilitation only, (c) nutritional support and group rehabilitation or, (d) standard 
care (Persson et al. 2002). The individually designed nutritional support consisted of intensified 
primary care from nurses, psychological support from psychologists and nutritional support from 
dietitians. Patients who received nutritional support managed to gain weight more rapidly and to 
a greater extent than patients who received no nutritional support (exact data not given) 
(Persson et al. 2002).  
 
The effects of a patient participation based dietary intervention on patients’ nutritional and 
functional status following gastrectomy were determined in a 12-week randomised controlled 
trial (n= 48) (Kim et al. 2014). Patients were randomised to either the experimental arm 
(coaching through education by research nurses) or the control arm (standard care). In the 
experimental group, the patients received individualised dietary plans, which were approved by 
dietitians. At the end of the intervention, using the results from a 3-day food diary and a dietary 
history, participants in the experimental group consumed significantly more energy than those in 
the standard care group (p= 0.001). Body weight and BMI were falling trends in the control 
group, unlike in the intervention group. However, the differences were not statistically significant 
over time. Similarly, for nutritional status, scores from the PG-SGA only differed significantly 
across group over time, without any of the interaction effect (Kim et al. 2014). Of note, there 
was a significant difference between the groups with regard to socioeconomic background, with 
those in the control group tending to be socioeconomically working class (p= 0.015). In the 
intervention group, most participants were socioeconomically middle class and above, and as 
such, these patients may have had a good pre-intervention knowledge of nutrition and high 
motivation to adhere to their individual dietary plan. This is a confounding factor to consider 
when interpreting the positive dietary outcomes of the intervention.     
 
Research conducted to date generally demonstrates the benefit of nutritional support in cancer 
with regard to macronutrient intake and weight gain. Also, as well as evidence that early 
nutritional intervention (when tumour burden is still limited) is able to achieve a clinical benefit 
with regard to nutritional status, there are also indications that it leads to improved functional 
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status, symptom-induced morbidity and QoL (Isenring et al. 2004; Ravasco, Monteiro-Grillo, 
Vidal & Camilo 2005b; Ravasco, Monteiro-Grillo, Vidal & Camilo 2005a). Given this evidence, it 
is of paramount importance that appropriate nutritional screening tools are used, so that those 
who are actually malnourished can be identified and dietetic support provided in a timely 
manner. 
 
1.2.4 Research Needs for Nutritional Screening in Patients with Oesophagogastric 
Cancer  
There is a need to ensure that nutritional screening tools used in patients with OG cancer are 
sensitive and specific in this setting. The MUST tool is the most commonly used screening tool 
in the UK but has only been validated in one cancer study (Table 1-10). In this study, Bolé-
Tomé’s cohort included non-selected cancer patients receiving radiotherapy and so the results 
should not be generalised to OG cancer patients who are treatment naïve. As such, there is no 
tool that can accurately indicate which patients with OG cancer need to undergo nutritional 
assessment. This means that there can be either (a) an overestimation of those at risk, resulting 
in an unnecessary strain on dietetic resources following excessive referrals or (b) an 
underestimation of those at risk, resulting in a lack of nutritional intervention in vulnerable 
patients.  
 
1.3 Exploring the Potential of Metabolomics Technology in Small 
Intestinal Bacterial Overgrowth Diagnosis 
1.3.1 Current Diagnostic Tests for Small Intestinal Bacterial Overgrowth  
As mentioned in Section 1.1.3.2.5, there is no gold-standard test for the diagnosis of SIBO. 
There are three common approaches towards diagnosing the condition: the first is the traditional 
approach of classifying it in quantitative terms in a microbiological context; the second is the 
breath testing technique using carbohydrates; the third uses the symptomatic response to a trial 
of antibiotics.  
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Bacteriological analysis of small bowel secretions is a direct method of assessing the microbial 
populations therein. The patient undergoes an OGD during which fluid (usually 2-5 ml) is 
aspirated from the lumen of either the duodenum or the jejunum (usually at only one site) and 
then undergoes quantification in a microbiology laboratory. Traditionally, many authors have 
regarded this direct aspiration and culture technique as the gold-standard approach for 
diagnosing SIBO (Kerlin & Wong 1988; Corazza et al. 1990). However, in their systematic 
review, Khoshini et al. determined that it was not a gold-standard after applying the criteria of 
Reid et al. for the development and application of a diagnostic test (Khoshini et al. 2008; Reid et 
al. 1995). Of Reid’s seven methodological standards, the standards that were not met by any of 
the studies were (a) reporting frequency and management of indeterminate results when 
calculating test indexes and (b) specifying test reproducibility. In addition, three of the standards 
infrequently met were (a) specifying spectrum of evaluated patients, (b) avoiding review bias 
and (c) having an adequate sample size to calculate sensitivity and specificity or likelihood 
ratios (Khoshini et al. 2008).  
 
In recent years, owing to the invasive nature of the direct aspiration and culture technique, 
indirect tests have been developed and are now commonly used alternatives. Breath testing is 
the most common indirect method for evaluating SIBO (Khoshini et al. 2008). Breath tests have 
advantages over the direct culture method, in that they are simple to use, cheap and non-
invasive. Hydrogen-based breath tests are currently the most popular and work on the 
assumption that the only source of H2 production in the body is from fermentation of 
carbohydrates by GI microbiota.  
 
The most frequently used substrates in breath tests are glucose and lactulose, with the former 
suggested to have a greater diagnostic accuracy than the latter. When compared with the direct 
aspiration method (i.e. taking it to be a gold-standard, although it is not), the glucose-H2 breath 
test has a sensitivity of 62.5% and a specificity of 81.7% (Gasbarrini et al. 2009). The lactulose-
H2 breath test has a sensitivity of 52.4% and a specificity of 85.7% when compared with the 
direct aspiration method (Gasbarrini et al. 2009). Due to the high variability in oro-caecal transit 
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time in health and disease, combining the lactulose-H2 breath test with scintigraphic 
measurement of oro-caecal transit is likely to provide a more accurate and reproducible test for 
SIBO (Zhao et al. 2014). However, with culture being a poor gold-standard, the validation of any 
breath test against it cannot be acceptably performed. Nevertheless, Grade IIA evidence 
suggests that the glucose-H2 breath test is the most accurate H2-breath test for non-invasive 
diagnosis of SIBO (Gasbarrini et al. 2009).  
 
The third approach towards SIBO diagnosis is to treat it when symptoms and/or non-invasive 
surrogate markers (e.g. serum folate, vitamin B12, haemoglobin and weight) are clinically 
suggestive of SIBO and to use the clinical response to antibiotics as an affirmation of SIBO 
being the cause of the patient’s complaints- the so-called ‘therapeutic trial’ (Pimentel et al. 
2000). With the problems associated with culture and breath testing methods (Table 1-11) it is 
unsurprising that Khoshini et al. found that almost one third of studies used this therapeutic trial 
approach for diagnostic purposes. There is, however, no standardised approach towards the 
type, dose or duration of the antibiotics and reported clinical response rates range from 35% to 
100% (Khoshini et al. 2008).  
 
All of the commonly used methods of diagnosing SIBO have inherent limitations as outlined in 
Table 1-11. As such, clinicians should be cautious when interpreting the results of such tests. 
Often two or three of these techniques are combined for a more robust approach, which aids 
clinical decision-making. For example, a therapeutic trial can be used in association with other 
diagnostic tests, i.e. all of the following could be taken into consideration, so as to confirm the 
presence of SIBO: abnormal GI symptoms/non-invasive surrogate markers, abnormal test(s) 
(breath test and/or aspirate and culture) and clinical response to antibiotics. Measuring 
response necessitates assessing symptom change systematically, as well as the resolution of 
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Table 1-11 Limitations associated with the three common diagnostic techniques for small 
intestinal bacterial overgrowth 
 
Small bowel aspiration and culture technique 
• Invasive and cumbersome 
• Time-consuming and expensive 
• Technical difficulties with transport and culture of the aspirate 
• No consensus on sample handling and microbiological techniques 
• Appropriate use of anaerobic techniques is necessary 
• Representation of the sample is unknown 
• Oral bacteria may contaminate the aspirate 
• No consensus for defining SIBO in quantitative terms 
• SIBO occurring more distally in the small intestine may be missed 
• False negative results may occur where SIBO is caused by obligate anaerobes  
• Location of sampling and the amount of fluid recovered can be variable 
Breath testing technique 
• Low fibre diet required for 24 hours before the test 
• Smoking, sleep and exercise can affect test accuracy 
• Antibiotics and laxatives need to be avoided before the test 
• No consensus on a definition for a positive test (regardless of the substrate used) 
• Breath sampling frequency is highly variable 
• Both H2 and CH4 gases should be measured 
• Luminal pH differences affects carbohydrate metabolism 
• Carbohydrate malabsorption may lead to false positive result 
• Consideration of oropharyngeal bacteria 
• Rapid transit can give a false positive, slow transit can give a false negative 
• Inconsistencies in the definition of an ‘early peak’ in lactulose breath testing 
Therapeutic trial approach 
• Follow-up may be difficult 
• No standardised approach towards the type, dose or duration of the antibiotic 
regimen 
• No consensus on the meaning of a clinical response to antibiotics 
• Over-prescribing of antibiotics 
• Risk of serious side-effects from antibiotic treatment 
• Difficulty in identifying patients without SIBO versus those with SIBO caused by an 
antibiotic resistant organism  
Abbreviations: CH4, methane; SIBO, small intestinal bacterial overgrowth 
 
The dysbiosis of GI microbiota in SIBO are evidently difficult to characterise in clinical practice. 
Although advances in genomic technology allow for phylogenetic analysis and typing in the 
research setting, such methods are labourious, expensive and not suitable for routine clinical 
application. More accessible means of gaining insight into the dysbiosis associated with SIBO 
include metabolic profiling of biofluids using Metabolomics technology. 
 
1.3.1.1 Metabolomics Technology  
Metabolomics is the comprehensive assessment of all the small-molecules (metabolites) within 
a biological sample and attempts to systematically identify and quantify them. A metabolite is a 
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substance made or used when an organism breaks down food, drugs or chemicals, or its own 
tissue (e.g. fat or muscle tissue). Metabolomics technology enables the simultaneous 
identification and monitoring of a wide range of low molecular weight compounds and thus 
provides a biochemical fingerprint of an organism. It offers the potential for a holistic approach 
to clinical medicine and improving disease diagnosis, as well as, understanding disease 
mechanisms (Nicholson et al. 1999; Nicholson & Lindon 2008). Metabolomic studies generally 
use biological fluid (biofluid), cells or tissue extracts as the source of biochemical fingerprint 
data. The biofluids are usually relatively easy to obtain, which is an advantage in human 
studies. In these fluids, metabolites are in dynamic equilibrium with those inside cells and 
tissues and if there is an abnormal cellular process occurring in tissues of the whole organism, 
this will be reflected in altered biofluid compositions (Nicholson et al. 1999). 
 
Urine and plasma are the most commonly used biofluids, but others have been studied in this 
context including amniotic fluid, dialysis fluids, lung aspirates, seminal fluid, synovial fluid, saliva 
and other digestive fluids. Of note, the largest and most complex microbiome (microbiota 
associated with a host) resides in the gut and interacts with the human genotype and 
environment to maintain body homeostasis (Qin et al. 2010). This homeostasis is hugely 
important, as the microbiota directly communicate with the human host e.g. controlling intestinal 
epithelial proliferation through toll-like receptors, enteric nerve system signalling and initiating fat 
storage (Tilg 2010; Abreu 2010; Sharkey & Savidge 2014). Therefore, measuring the 
metabolites from the host and gut microbiome together may provide an insight into any 
perturbations in this homeostasis. 
 
A variety of analytical technologies have been applied to metabolomics but the most popular are 
nuclear magnetic resonance (NMR) spectroscopy and mass spectroscopy. These techniques 
have different strengths and weaknesses and can give complementary information. Nuclear 
magnetic resonance spectroscopy is suitable for metabolomics as it requires little physical or 
chemical treatment preparation, is rapid and requires only small amounts of sample/specimen. 
Mass spectroscopy studies, on the other hand, usually require larger amounts of the sample, 
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with pre-separation of the metabolites from the biological fluid needed before analysis, typically 
by using high-performance liquid chromatography. Liquid chromatography greatly improves the 
resolution characteristics and capabilities of this approach (Nicholson et al. 2005). Alternatively, 
the metabolites can be chemically modified to make them more volatile and so gas 
chromatography-mass spectroscopy can be used (Nicholson & Lindon 2008). The inherent 
sensitivity of this approach is useful in the detection of low concentrations of metabolites. 
 
1.3.1.1.1 Nuclear Magnetic Resonance Spectroscopy-Based Metabolomics 
Nuclear magnetic resonance-based metabolomics is a quantitative nondestructive technique 
that provides detailed information based on atom-centred nuclear interactions and properties 
(Beckonert et al. 2007). It is generally used to detect H1 or carbon atoms in metabolites, but 
other atoms can also be used e.g. phosphorus, sodium, boron or lithium. Taking H1 as an 
example i.e. hydrogen nuclear magnetic resonance (1H NMR) spectroscopy: in a typical biofluid 
sample, all H1-containing molecules in the sample without prejudice (including nearly all 
metabolites) will give a 1H NMR signal, assuming they are present in concentrations above the 
detection limit. As such, the 1H NMR spectrum of a biological fluid is the superposition of the 
spectra of all of the metabolites in the sample (Nicholson & Lindon 2008). Hydrogen nuclear 
magnetic resonance spectroscopy-based metabolomics using biofluids has shown high 
reproducibility and so, generally it is sufficient to have one sample per study time point (Keun et 
al. 2002; Dumas et al. 2006).  
 
A typical 1H NMR spectrum is extremely complex, consisting of thousands of peaks. The peak 
integrals relate directly to the number of protons giving rise to the peak, and hence to the 
relative concentrations of the predominantly low molecular weight metabolites in the sample 
(Beckonert et al. 2007). Given the complexity of the raw data, all metabolomic studies result in 
complicated multivariate data sets, which require visualisation software and bioinformatics 
methods for interpretation. Then, the complex set of biomarkers that define the biological or 
clinical context and help to explain the disease or tissue damage can be identified (Beckonert et 
al. 2007).  
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Multivariate statistical techniques coupled with NMR have been incorporated into the 
metabolomics approach to enable exploration by separation, detection, characterisation, and 
quantification of small molecules and related metabolic pathways of the onset and progression 
of human diseases. One of the most frequently used techniques in multivariate analysis is a 
technique called Pattern Recognition. This is a term applied to methods of data analysis that 
can reduce the many parameters (Nicholson et al. 1999). One of the most useful and easily 
applied pattern recognition techniques is principal components analysis (PCA).  
 
Principal component analysis is an unsupervised data analysis (dimension reducing) method 
that can deal with large volumes and is often performed as a part of an exploratory data 
analysis. Principal components (PC) are new variables created from linear combinations of the 
starting variables with suitably weighted coefficients. The properties of these PCs are such that 
(a) each PC is uncorrelated with all other PCs and (b) the first PC contains the largest part of 
the variance of the dataset with subsequent PCs containing consistently smaller amounts of 
variance. Principal component analysis refers to the process by which PCs are computed, and 
the subsequent use of these PCs in understanding the data (James et al. 2013). It converts the 
multidimensional data space into a low-dimensional model plane resulting in two matrices, 
where the first two or three PCs give the ‘best’ representation in terms of biochemical variation 
in the data set. Such PC maps can also serve as a tool for data visualisation i.e. visualisation of 
the observations or visualisation of the variables to assess for clustering. Hierarchical cluster 
analysis is another unsupervised method that is widely used in metabolomics data analysis, and 
this method has the ability to group samples according to their similarity.  
 
The workflow for many clinical metabolomics studies using NMR spectroscopy is as follows 
(Zhang et al. 2013) (Figure 1-2): 
 
• Samples are collected in a uniform way to minimise variability 
• Samples are analysed by NMR to collect data on all metabolites potentially present in 
the sample 
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• Pattern recognition approaches include PCA, partial least squares discriminant analysis 
(PLSDA), heat map, orthogonal projections to latent structures, support vector 
machines, random forests method, and other methods aiming to highlight underlying 
trends and visualisation tools are utilised 
• Trend and box plots are used to further evaluate the techniques above 
• Receiver operating characteristic (ROC) curves are usually considered the method of 
choice for evaluating the performance of potential biomarkers  
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Figure 1-2 Workflow for clinical metabolomics studies using nuclear magnetic resonance 
spectroscopy 
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1.3.1.1.2 Application of Nuclear Magnetic Resonance Spectroscopy Technology 
Nuclear magnetic resonance based metabolomics is becoming a useful tool in the study of 
biofluids and has a strong potential to contribute to disease diagnosis. The research conducted 
so far provides compelling evidence that this analytical platform offers great promise for the 
minimally invasive screening of disease-related perturbations. Metabolomics has found 
application not only in the study of many diseases (Brindle et al. 2002; Moolenaar et al. 2003) 
but also of factors such as nutrition and gut microbiota (Nicholls et al. 2003; Nicholson et al. 
2005).  
 
In a Danish study, 1H NMR was used to profile the serum of patients with metastatic colorectal 
cancer and to determine whether a disease signature may exist that is strong enough to predict 
overall survival (Bertini et al. 2012). One hundred and fifty three cancer patients and 139 
healthy controls were recruited. A clear metabolic signature of the disease was found to exist in 
the serum of the cancer patients; in the validation set, 96.7% of subjects were correctly 
classified. A number of metabolites were identified from the spectra, whose concentrations 
differed in the cancer patients and the healthy subjects; cancer patients had lower serum levels 
(p< 0.05) of alanine, citrate, creatine, glutamine, lactate, leucine, pyruvate, tyrosine and valine 
and higher serum levels (p< 0.05) of 3-hydroxybutyrate, acetate, formate, glycerol, lipid (-CH2-
OCOR), N-acetyl signal of glycoproteins, phenylalanine, and proline. In addition, the results 
demonstrated the capability of 1H NMR profiling to predict overall survival in these patients. 
There was a clear signature in serum in those patients with a good performance (i.e. Eastern 
Cooperative Oncology Group (ECOG) performance status= 0). 
 
Another metabolomics study investigating the content of upper-small bowel (location not 
defined) aspirates in patients with malabsorption syndrome found that individuals with the 
syndrome had significantly higher median quantities of bile acids/cholesterol, acetate, formate 
and lactate than controls (Bala et al. 2006). In those who had both the syndrome and SIBO, 
significantly greater quantities of acetate, formate, lactate and unconjugated bile acids were 
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found compared with the controls (p< 0.01 for all), implying that SIBO itself might elicit a 
specific, potentially diagnostic metabolomic signature.  
 
A different study using faecal samples from patients with inflammatory bowel disease (n= 10 
Crohn’s disease and n= 10 ulcerative colitis) and healthy controls (n= 13), also employed the 
metabolomics approach to aid with diagnosis (Marchesi et al. 2007). Marchesi and co-workers 
reported that the faecal samples obtained from the patients with Crohn’s disease and ulcerative 
colitis manifested similar global differences in metabolic profiles compared with the healthy 
subjects. A depletion of short-chain fatty acids, including acetate and butyrate, was a prominent 
feature of Crohn’s disease patients when compared with healthy subjects. In addition, a high 
concentration of glycerol was found in the faeces of Crohn’s disease patients in comparison to 
ulcerative colitis patients. Higher concentrations of amino acids were also found in the faeces of 
patients with both Crohn’s disease and ulcerative colitis as compared with the controls. A 
potential explanation for the identified metabolites is that they were a consequence of 
malabsorption caused by the inflammation. 
 
As SIBO has been shown to result in microscopic mucosal inflammation, it is plausible to 
consider that overall differences in the metabolic profiles of SIBO patients and controls are likely 
to be found (Riordan et al. 2012; Riordan, McIver, Thomas, et al. 1997a; Haboubi et al. 1991). 
Also, as it is increasingly believed that a dysbiosis of the gut microbiota is involved in 
inflammatory bowel disease, either in initiating it or in maintaining it, and as SIBO is also related 
to dysbiosis, it may be that following the successful application of metabolomics in inflammatory 
bowel disease, it will also prove relevant in SIBO (Marchesi et al. 2007; Sartor 1997).  
 
Characterisation of the microbial content of the small bowel is a concept that may prove useful 
in the identification of biomarkers and prognostic factors for SIBO, which might enhance the 
clinical diagnosis of it. The advantages of these techniques are manifold: rapid, non-invasive 
and requiring minimal pre-analysis sample preparation.  
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1.3.2 Research Needs for Small Intestinal Bacterial Overgrowth  
Small intestinal bacterial overgrowth is a significant clinical problem, not just in oncology, but 
also across the field of gastroenterology. It is difficult to diagnose it accurately and there are no 
optimal therapeutic options. Given the lack of a gold-standard test for SIBO, the concept of 
discovering novel biomarkers in biofluids using metabolomics technology is attractive. Although, 
metabolomics technology in the setting of SIBO detection has not yet been investigated, it has 
the potential to be superior to the currently available diagnostic methods for SIBO and so 
warrants investigation in this setting.  
 
1.4 Thesis Statement and Research Hypotheses 
1.4.1 Research Statement 
The nature of OG cancer and the multimodal approach used in its radical treatment puts 
patients at an increased risk of developing persistent GI symptoms and/or malnutrition. This 
thesis proposes to establish if there is a persistence of symptoms and malnutrition one year 
following diagnosis. It is also likely that GI symptoms co-exist with malnutrition rather than 
occurring in isolation. However, to date the relationship between these two variables has not 
been elucidated in this patient group. This thesis aims to provide an insight into this relationship. 
With regard to nutritional screening, there is a need to ensure that the screening tools used in 
patients with OG cancer are sensitive and specific. The MUST is the most commonly used 
screening tool in the UK, but has not yet been validated in the OG cancer setting. This thesis 
aims to validate the tool against an accepted standard (PG-SGA). Finally, due to the poor 
performance of available diagnostic tests for SIBO, there is a need to pursue new technologies 
that will improve the ability to detect SIBO reliably. This thesis purposes to investigate the 
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1.4.2 Research Hypotheses  
1. Disease processes and/or radical treatment result in the persistence or development of 
moderate-severe GI symptoms at 12 months in OG cancer patients 
 
2. Disease processes and/or radical treatment result in the persistence or development of 
malnutrition at 12 months in OG cancer patients 
 
3. There is a positive association between GI symptom scores (higher score equals worse GI 
symptoms) and nutritional status scores (higher score equals worse nutritional status) at 
diagnosis, during the acute phase of management (3 months) and chronically (12 months) 
in OG cancer patients 
 
4. The MUST has an acceptable sensitivity and specificity (≥ 70% for both) in the OG oncology 
setting, by comparison with PG-SGA 
 
5. In patients previously or currently being treated for cancer, qualitative and quantitative 
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This chapter provides an analysis of the key methods used in this thesis, in the GI and 
nutritional status study (Chapter 3), MUST validation study (Chapter 4) and the SIBO study 
(Chapter 5). It provides a rationale for the selection of the methods, including a critical 
discussion of the literature in the area, as well as a detailed description of the actual method 
used. The methods include the assessment of GI symptoms, nutritional status, dietary intake 
and SIBO. 
 
2.1 Gastrointestinal Symptom Assessment  
For Chapters 3 and 5, a GI symptom assessment tool was needed. The literature on GI 
symptom tools was searched, with numerous tools identified that measure GI symptoms in 
patients with cancer and disorders of the GI tract. 
 
Many scales have been used to measure GI symptoms in the oncology setting, most of which 
are toxicity scales developed to assess acute symptoms in clinical practice. A number of 
measures have been based on the graded toxicity scales developed by the World Health 
Organisation, the National Cancer Institute and US oncology groups (e.g. Radiation Therapy 
Oncology Group, ECOG, Southwest Oncology Group) (McNulty 1999). These scales adopt the 
traditional use of clinician ratings of the presence of changes in tissues on the grounds that this 
is more objective than assessments based on patient reports. The tools refer to toxicity of the 
following systems/processes: immunology, blood/bone marrow, coagulation, dermatology, 
haematology, hepatic, auditory, cardiovascular, endocrine, GI, musculoskeletal, lymphatic, 
metabolic, neurology, visual, pain, pulmonary, renal and reproductive. With regard to the GI 
system, symptoms assessed by the scales include anorexia, nausea, vomiting, diarrhoea, 
constipation and mucositis. They do not, however, include any measure of symptom burden; 
that is, the patient’s experience of symptoms and the ways in which these impact on everyday 
functioning and QoL.  
 
There are accurate and valid tools to assess QoL in oncology, including the FACT-G and the 
EORTC QLQ-C30. Although the QoL tools in oncology have supplementary site-specific 
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modules that can focus on specific regions of the GI tract (e.g. oesophagus or stomach), these 
only include a limited assessment of actual GI symptoms (Darling et al. 2006; Eremenco et al. 
2004; Blazeby et al. 2004; Blazeby et al. 2003).  
 
In addition, there are some dysphagia only scores including a five-point swallow score 
developed in the 1980’s by O’Rourke et al. to assess swallowing performance after radiation 
therapy for carcinoma of the oesophagus (O'Rourke et al. 1988). This tool has since been used 
in other oesophageal cancer research protocols (Kassam et al. 2008; Coia et al. 1993). Another 
five-point dysphagia grading scale was developed and used for assessment of the swallow 
function in OG cancer patients (Ogilvie et al. 1982; Homs et al. 2004). However, these systems 
only capture the severity of dysphagia, which has been shown to be absent in 70% of patients 
with early gastric cancers (Allum et al. 2011). Thus, it would not be appropriate to use a 
dysphagia-only tool, as it would not provide a complete picture of the range of troublesome GI 
symptoms experienced by patients with OG cancer. Comparably, the four-point Visick scale has 
historically been used in patients following gastrectomy to record the degree of GI dumping 
(Visick 1948). Non-surgical patients are unlikely to be affected by dumping syndrome and so 
this tool is not ideal for patients undergoing chemoradiation without surgery. Also, this tool does 
not detect other types of GI symptoms experienced and has never been validated.  
 
The Eating Dysfunction Scale was developed by Svedlund et al. in the late-1990’s (Svedlund et 
al. 1999). It is a specific single-site scale including symptoms associated with eating in patients 
who have had a gastrectomy. However, as with the dysphagia and dumping scales, it would be 
inappropriate to use a tool that was designed to assess dysfunction in only a sub-group of the 
overall OG cancer cohort being studied (i.e. the gastrectomy patients).  
 
There are no validated questionnaires specifically designed to measure the frequency, severity 
and burden of GI symptoms in (a) OG cancer patients acutely and chronically and (b) a mixed 
group of oncology patients with GI effects of treatment. In view of the absence of oncology-
  102 
specific tools that allow the measurement of a broad range of upper- and lower-GI symptoms, 
the most widely used GI symptom tool in the literature was employed- the GSRS.      
 
2.1.1 Gastrointestinal Symptom Rating Scale 
The GSRS is a questionnaire developed in Sweden in 1984 to measure GI symptoms important 
to patients with general GI complaints and has been validated in previous studies (Svedlund et 
al. 1988; Kulich et al. 1998; Dimenäs et al. 1993). The results of the GSRS have been shown to 
correlate with QoL, though the GSRS is not a QoL instrument (Dimenäs et al. 1995; Dimenäs et 
al. 1993; Wiklund 1995). The instrument has been used in many areas of GI research, for 
instance in gastro-oesophageal reflux disease, peptic ulcer disease, GI surgery (e.g. 
pancreatectomy), coeliac disease, chronic intestinal pseudoobstruction, chronic non-specific 
abdominal complaints and IBS (Kulich et al. 1998; Dimenäs et al. 1995; Dimenäs et al. 1993; 
Wiklund 1995; Rashid & Velanovich 2011; Iwarzon et al. 2009; Lohiniemi et al. 2000; van den 
Heuvel-Janssen et al. 2006; Lönroth 2000). It has also shown promise in the GI symptom 
assessment of patients with GI and extra-GI cancers (Liedman et al. 2001; Namikawa et al. 
2011; Russo et al. 2013; Olsson et al. 2007). In a cross-sectional study assessing long term (> 
six months) nutritional status and QoL following upper-GI surgery for cancer, Carey et al used 
the GSRS tool to assess GI symptoms (2011). Similarly, Kono et al. used the tool to assess 
QoL in patients with jejunal pouch reconstruction following total gastrectomy (2003).  
 
It assesses five domains (15 symptoms in total) that have been identified as important to GI 
function: reflux syndrome (heartburn and acid regurgitation); acute pain syndrome (abdominal 
pain, hunger pains and nausea); indigestion syndrome (borborygmus, abdominal distension, 
eructation and increased flatus); diarrhoea syndrome (diarrhoea, loose stools and urgent need 
to defaecate); constipation syndrome (constipation, hard stools and feeling of incomplete 
evacuation). The tool requires the patient to rate the severity of their symptoms over the past 
one or two weeks. 
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A score of zero indicates the symptom is absent or negligible and that negative social effects 
are absent. A score of one (mild) indicates that the symptom is noticeable but that negative 
social effects are absent. A score of two (moderate) indicates that the symptom has a negative 
physiological impact and a noticeable impact on their social performance. A score of three 
(severe) indicates that the patient experiences great social and activity-related impairment as a 
result of negative physiological symptoms. The questionnaire can be administered in either self-
report or interview format. 
 
The GSRS was chosen for use as a template in this thesis for a number of reasons. Firstly, its 
reliability and validity are well-documented (Dimenäs et al. 1995) and normal values for a 
general population are available (Dimenäs et al. 1996). The internal consistency reliabilities of 
the five dimensions of the tool (i.e. the extent to which the items within each dimension are 
interrelated) ranged from 0.6 to 0.85 in patients with duodenal ulcer and from 0.61 to 0.83 in 
patients with gastro-oesophageal reflux disease (Kulich et al. 1998; Dimenäs et al. 1995). In 
patients with reflux and dyspepsia, the test-retest reliability of the GSRS dimensions ranged 
from 0.36-0.75 with a generally low test-retest reliability in the abdominal pain domain (Kulich et 
al. 1998). This is likely due to the domain containing only two items, as well as the complexity of 
measuring this symptom. In European patient populations, the GSRS has acceptable construct 
validity and responsiveness (Dimenäs et al. 1993; Dimenäs et al. 1995; Glise et al. 1995). 
 
Although, the tool has not been validated in oncology, it assesses a broad range of both upper-
and lower-GI symptoms likely to be of significance in the oncology setting and the questionnaire 
has been used to good effect when measuring the presence of symptoms in cancer patients 
following gastrectomy (Svedlund et al. 1999; Hayami et al. 2011; Ichikawa et al. 2012). 
However, it does not include items to capture postoperative dysfunction after surgery for OG 
cancer, for example symptoms of dumping syndrome, early satiety and dysphagia. Also, as with 
any retrospective questionnaire, the systematic error that is recall bias (i.e. the differences in the 
accuracy or completeness of the recollections retrieved by study participants regarding events 
or experience from the past) needs to be considered.  
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For the purpose of this research, modifications to the questionnaire were made for use in 
Chapters 3 and 5 following a multi-professional discussion. For both studies, the wording of the 
questionnaire was revised to make the questions more concise and comprehensible to patients. 
For the questionnaire used in Chapter 3, the tool was used to capture symptoms burden over a 
longer time frame (four weeks) than the original tool (one or two week). The rational for this was 
that the longer interval was more likely to reflect the long-term symptomology in the OG cancer 
cohort. Also the tool was made more disease-specific by removing and adding certain 
symptoms. The tool was amended by (a) removing the symptoms of eructation and hunger 
pains as these were not considered to be relevant in this cohort, and (b) adding nine additional 
symptoms to the tool, which from clinical experience, were considered to be relevant to OG 
cancer: dysphagia to solids, dysphagia to fluids, odynophagia to solids, odynophagia to fluids, 
belching, early satiety, regurgitation of fluids, regurgitation of solids and faecal incontinence 
(Appendix 8.4).  
 
The GSRS used in Chapter 5 was different to the tool in Chapter 3. The original tool was 
amended by (a) removing the symptoms of eructation and hunger pains and (b) adding 13 extra 
items relevant to SIBO: dysphagia to solids, dysphagia to fluids, odynophagia to solids, 
odynophagia to fluids, belching, early satiety, regurgitation of fluids, regurgitation of solids and 
faecal incontinence (as per Chapter 3); and vomiting, nocturnal defaecation, steatorrhoea and 
negative change in stool frequency. Of note, the time frame was the same as the original tool 
i.e. two weeks (Appendix 8.5).  
 
A Bristol Stool Form Scale was also added to determine the stool form when the patient was ‘at 
best’ and ‘at worst’ during the four-week and two-week periods captured by the questionnaire in 
Chapters 3 and 5 respectively (Lewis & Heaton 1997) . 
 
A self-report approach to the GSRS has been used for this research, although the study 
dietitian was available to provide assistance with the tool if requested. These modified GSRS 
tools have not been used in other research or clinical situations.  
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2.2 Nutritional Screening and Nutritional Assessment  
2.2.1 Malnutrition Universal Screening Tool 
This tool was used in the MUST validation study (Chapter 4). It was developed by a 
multidisciplinary group, the Malnutrition Advisory Group (MAG), which is a standing committee 
of BAPEN (Elia 2003) (Appendix 8.6). It was developed, using evidence-based criteria, to detect 
protein-energy malnutrition and the risk of developing malnutrition in all adults across all health 
care settings including oncology (Stratton et al. 2004). The current version of the tool is formed 
of three steps as follow: 
 
(1) BMI using cut-offs in line with recommendations made by a range of national and 
international organisations (BMI > 20 kg/m2, score of 0; BMI 18.5-20 kg/m2, score of 1; BMI < 
18.5 kg/m2, score of 2). 
 
(2) Unintentional weight loss in past three-six months, using cut-off points that reflect practical 
and approximate boundaries between normal and abnormal intra-individual changes in weight 
and the likely presence of a treatable underlying condition, which if undetected could produce 
further weight loss and malnutrition (< 5%, score of 0; 5-10%, score of 1; > 10%, score of 2).  
 
(3) Acute disease effect producing or likely to produce no nutritional intake for > five days. This 
allows for the effects of acute conditions that result in no dietary intake, resulting in rapid weight 
loss (if patient meets these criteria, score of 2).  
 
The numbers obtained from the three steps are additive and produce a MUST score, which 
indicates the risk of malnutrition and suggests an appropriate action to be taken (Table 2-1) 
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Table 2-1 Malnutrition Universal Screening Tool: scores, risk of malnutrition and actions 
 
MUST score Overall risk of malnutrition Action 
2 or more High Treat unless detrimental or no benefit from nutritional support expected e.g. imminent death 
1 Medium Observe or treat if approaching high risk or if rapid clinical deterioration anticipated 
0 Low Routine care unless major clinical deterioration expected 
 
Table 2-2 Advantages and disadvantages of the Malnutrition Universal Screening Tool 
 
This screening tool has not been well validated for use in the OG cancer setting, and therefore, 
Chapter 4 will focus on measuring its sensitivity and specificity in OG cancer patients.   
 
2.2.2 Nutritional Assessment: Patient Generated Subjective Global Assessment 
Patient Generated Subjective Global Assessment consists of two sections: a patient-completed 
component and a clinician component (e.g. physician, nurse or dietitian) (Appendix 8.3). The 
Advantages Disadvantages 
• Quick and easy to complete (< 5 minutes)  
• Has content validity (comprehensiveness of the tool) 
• Has face validity (issues which are relevant to the 
purpose of the test)  
• Has internal consistency (the extent to which the three 
steps are interrelated)  
• Has test-retest reliability (the variation in measurements 
taken by a single person or instrument on the same item 
and under the same conditions) 
• Has fair-good to excellent concurrent validity in hospital 
in- and out-patients (this validity is demonstrated when a 
test correlates well with a measure that has previously 
been validated) 
• Has some predictive validity, e.g. predicting length of 
hospital stay, mortality and discharge destination of 
hospital patients 
• Excellent reproducibility when different observers assess 
the same patients 
• Unintentional weight 
loss is a semi-objective 
criterion, that relies on a 
patient’s ability to 
remember their weight 
history 
• Mathematical errors can 
occur during the 
calculation of 
percentage weight loss  
• The acute disease effect 
score is not an objective 
measure and there is no 




• No symptom 
assessment 
• Continued education of 
users required  
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patient-completed component has four parts (weight loss, nutrition impact symptoms, nutritional 
intake and functional capacity) and is completed using a check box format. The clinician is 
required to complete the remainder of the form (diagnosis, age and metabolic stress), conduct a 
physical examination assessing fat and muscle stores and fluid status and perform a global 
assessment of nutritional status. It produces a (a) subjective global rating (i.e. SGA) and (b) PG-
SGA total score and although they are related, they are independent assessment and triage 
systems respectively. The subjective global rating categories are consistent with the three 
categories from the SGA tool: 
 SGA A          Well-nourished 
 SGA B          Moderately/suspected malnourished  
SGA C          Severely malnourished 
 
There are eight domains in the tool that contribute to the score as follows: weight loss; food 
intake; nutrition impact symptoms; activities and function; disease and its relation to nutrition 
requirements; metabolic demand; nutrition-related physical examination and anthropometric 
assessment. Some of the items are additive, whereas others use the highest score attained. 
Typical total scores range from 0-35 (maximum score= 49), with scores enabling subtle 
changes in nutritional status to be identified over a period of two-four weeks. Nutritional triage 
recommendations using the PG-SGA total score are:  
Score 0-1 No intervention required at this time 
Score 2-3 Patient and family education with pharmacological intervention and/or 
laboratory values as appropriate  
Score 4-8 Requires intervention by dietitian in conjunction with nurse or physician 
as appropriate  
Score ≥ 9 Indicates a critical need for improved symptom management and/or 
nutrient intervention options 
 
The PG-SGA was selected for use in this thesis as it has been shown to have a sensitivity of 
98% and a specificity of 82% when compared to the SGA (Bauer et al. 2002). It remains the 
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only validated and specific tool for a thorough nutritional assessment in oncology and as such is 
used to validate screening tools as referred to in Section 1.2.1. In addition, it is suitable for use 
as an outcome measure in clinical practice and is associated with QoL in ambulatory patients 
receiving radiotherapy to the head, neck, abdominal or rectal area and also in a mixed group of 
patients having chemotherapy (Vergara et al. 2013; Lis et al. 2012).  
 
Although PG-SGA is a relatively easy tool to administer, it does require a trained practitioner for 
its use. Inter-observer agreement was found in 90% of cases when both a dietitian and doctor 
performed the assessment using PG-SGA on the same patient (Persson et al. 1999). Some of 
the advantages and disadvantages of the tool are described in Table 2-3. 
 




• Validated in oncology setting 
• Identifies treatable nutrition impact symptoms 
• Parameters are weighted based on their nutritional impact 
• Patient/family participation increases acceptance 
• Simplifies data collection 
• User friendly; tables and worksheets included on reverse 
of form 
• Serial measures can identify subtle changes in nutritional 
status 
• Objective measure to demonstrate the outcome of nutrition 
intervention 
• Inclusion of triage recommendations  
• Gives an indication of quality of life  
• High rate of interobserver reliability between physicians 
and dietitians 
• Requires more training 
than other tools 
• Scoring system can be 
confusing 
• Perception of additional 
workload 
• Patient generated 
component relies on 
patient literacy and recall 
ability 
• Physical examination 
may be resisted by 
patient and/or healthcare 
professional 
• Time intensive 
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2.3 Dietary Assessment Methods 
For the GI and nutritional status study (Chapter 3), a method of assessing habitual dietary 
intake in OG cancer patients was required. Four dietary assessment methods were considered 
for use in the study; weighed food diaries, estimated food diaries, the 24-hour recall and the 
food frequency questionnaire (FFQ). Table 2-4 summarises the general advantages and 
disadvantages associated with these methods.  
 
Table 2-4 Advantages and disadvantages of dietary assessment methods commonly 
used to assess food and nutrient intakes 
 
Weighed Food Diaries (usually 3, 5 or 7 days) 
 
Advantages                                                Disadvantages 
• 7-day diaries considered the gold-
standard dietary assessment method 
• Precision of portion sizes 
• Suitable to capture foods eaten on a 
regular basis 
• Estimates for energy, nutrients, foods and 
food groups have been shown to be 
excellent 
• Food/drink recorded at point of 
consumption and does not rely on 
individual memory and recall 
• Provides a detailed description of all foods 
consumed 
• Open-ended 
• 3-10 days is generally sufficient to 
accurately assess energy and 
macronutrient intakes  
• Costly in staff time and equipment 
• Labour intensive for participants and 
researchers 
• Subjects need to be well-motivated 
• Misreporting is common 
• Compliance can be an issue 
• Subjects might alter actual intake to make 
it easier to record (e.g. less cooking from 
scratch, not eating out) 
• Requires literacy and numeracy skills 
• Unrepresentative of usual intake if only a 
few days assessed  
• Reliability decreases over time due to 
respondent fatigue 
• Inappropriate for assessment of past diet 
• Up to 50 days may be required to assess 
intake of nutrients where inter-diurnal 
variation of intake is large 
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Estimated Food Diaries (usually 3 or 7 days) 
 
Advantages                                                Disadvantages 
• Facilitates collection of information on 
quantities of foods consumed 
• Provide useful information on patterns of 
food used over time, and combinations of 
foods consumed  
• An individual’s daily intake of energy and 
nutrients can be calculated 
• No complex calculations required by 
subjects in order to fit their food intakes 
into pre-ordained categories 
• Lower respondent burden than weighed 
food diaries 
• Relatively high subject burden  
• Requirement to keep food records for long 
periods decreases the reliability 
• Errors can arise in the conversion of 
estimated to actual food weights 
• Estimation of portion sizes  
• Response bias (subject may provide 
incomplete or false information) 
• Observation bias may be an issue 
(respondents may change their intake 
during the diary period) 
• Expensive due to data entry costs 
24-Hour Recall 
Advantages                                                Disadvantages 
• Low respondent burden  
• Suitable for large scale surveys 
• Can be administered by telephone or 
web-based application 
• Interview relatively quick 
• Literacy not required 
• Applicable for a broad population of 
different ethnicities 
• Estimation of portion sizes required 
• Single observation is seldom 
representative of habitual intake 
• Bias in recording ‘good/bad’ foods 
• Memory dependent 
• Possibility of recall bias (individual may 
selectively recall food items)  
• Expensive due to high interview burden 
but telephone recall can reduce cost 
• Repeat 24-hour recalls increase time and 
cost of analysis 
• Under-reporting is common 
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• Reported intakes tend to differ between 
week days and weekend days 
• Difficulty in capturing foods eaten rarely or 
occasionally 
• Results may vary if a typical day’s intake 
is described rather than intake for the 
previous 24 hours  
Food Frequency Questionnaire 
 
Advantages                                                Disadvantages 
• Suitable for large scale surveys  
• Useful for ranking subjects to establish 
low, medium and high consumers  
• May be self-administered, reducing staff 
time and effort 
• Questionnaires may be pre-coded and 
machine readable 
• Low respondent burden, quick to 
complete 
• Can be posted 
• Cheap to use due to rapid data entry 
• Low subject motivation required  
• Good literacy and numeracy skills not 
required 
• Good cooperation from respondents 
reported 
• Good reproducibility 
• Can assess current or past intake 
• Short versions can focus on specific 
nutrients with fewer food sources  
• List of foods/food groups must be adapted 
to local population 
• High level of aggregation of single foods 
into food groups are required to limit the 
length of the questionnaire 
• Relies heavily on memory recall 
• Assuming a standard portion weight for 
each food/food group is likely to introduce 
substantial error 
• Estimation of portion sizes often difficult 
(though use of food atlases, household 
measures etc. may help with this) 
• Possible over-reporting of healthy foods  
• Conceptualisation skills needed to 
estimate frequencies of consumption of 
certain foods 
• Observer bias is possible if it is 
interviewer administered  
• More accurate if regular eating habits 
• Quantification of intakes is not as accurate 
as with recalls or records 
• Little detail of food characteristics e.g. 
cooking method, food combinations 
• Needs to be updated if changes in 
commonly eaten foods by population 
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2.3.1 Food Frequency Method 
Based upon this critique of the dietary assessment methods, it was decided to use a FFQ in the 
current thesis because weighed and estimated food diaries were not a realistic option due to the 
high respondent burden involved, especially in patients with a new diagnosis of OG cancer who 
are already facing considerable emotional and psychological challenges. Also, the original 
intention to recruit a larger number of patients would have meant excessive data entry that was 
not feasible within the scope of this PhD. The FFQ method is the most practical and economical 
method for the collection of comprehensive dietary data. Dietary intakes of individuals 
undergoing cancer treatment can vary greatly from day-to-day and week-to-week, due to an 
altered daily treatment schedule and the GI side-effects of therapies and disease. Therefore, 
capturing habitual dietary intake using a FFQ would appear to be a more rational approach for 
this group.  
 
The majority of validated FFQs have been designed to be used by the general population such 
as that used in the Whitehall II study, which investigated the importance of social class for 
health (Brunner et al. 2001). A smaller number have been specifically designed for use in 
populations with or at risk of a particular disease e.g. osteoporosis, cardiovascular disease and 
prostate cancer (Cade et al. 2004; Patton et al. 1998; Cox et al. 2000; Bairati et al. 1998). There 
are many tools, which have been validated to assess the associations between the intake of 
certain foods and beverages and the incidence of certain cancers including OG cancer (Brown 
et al. 1998; Galanis et al. 1998). However, there are no validated FFQs that assess dietary 
intake in individuals with an existing cancer diagnosis.  
 
The food frequency approach asks respondents to report their usual frequency of consumption 
of each food from a list of foods for a specific period. Only information on frequency (and 
sometimes also quantity) of a list of foods is collected, with little detail on other characteristics of 
the foods as eaten, such as the methods of cooking or the combinations of foods in meals. The 
term ‘semi-quantitative FFQ’ is used to indicate a general FFQ that allows for a limited 
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quantification of serving size. Complete FFQs typically must contain 100 or more food items to 
capture the range of foods contributing to the many different nutrients in the diet.  
 
2.3.2 European Prospective Investigation into Cancer in Norfolk Food Frequency 
Questionnaire  
The dietary assessment tool of choice for Chapter 3 was the European Prospective 
Investigation into Cancer in Norfolk (EPIC-Norfolk) FFQ (version 6, Appendix 8.7). This is a 
semi-quantitative FFQ validated for assessing habitual dietary intake for the previous 12 months 
in the EPIC-Norfolk population (Bingham 1997; McKeown et al. 2001). This FFQ was based on 
that used in the US Nurses’ Health Study (Willett et al. 1985; Willett et al. 1988). The lists of 
foods were altered by changing American food names to their British equivalent and by using 
National Food Survey data to identify additional foods that were important sources of nutrients 
in average British diets. Therefore, its food lists and portion sizes are representative of an adult 
population likely to have established eating habits and following a traditional British diet. 
 
In Part 1, the EPIC-FFQ contains a list of 130 foods items, followed by a multiple response grid 
to record the frequency of consumption over the previous 12 months, using one of nine 
categories ranging from ‘never/less than once a month’ to ‘more than six times per day’. 
Medium servings or units were specified (pints, slices, teaspoons, etc.) for each food item. In 
Part 2, a number of supplementary questions are included regarding the type of breakfast 
cereals and fats most often used and the amount of fat usually eaten on meat. A further 
question on milk is also found in Part 2, requesting information on the type and quantity of milk 
consumed. 
 
There are two studies that have assessed the accuracy of this FFQ (McKeown et al. 2001; 
Bingham 1997), both of which have been validated against independent biomarkers of intake 
and food records. In the study by McKeown et al., the mean reproducibility of the FFQ was 
moderate to high, with correlation coefficients between the FFQ and an estimated 7-day food 
diary of 0.64 in men and 0.74 in women. The most notable discrepancies in the reproducibility of 
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nutrient intake between men and women, as expressed by the crude correlation coefficient, 
were for protein (0.57 and 0.70, respectively), β-carotene (0.48 and 0.78), non-starch 
polysacchariderides (0.58 and 0.82), and potassium (0.60 and 0.76). The superior ability of a 7-
day food diary to document food intake was confirmed in this study. 
 
In the study by Bingham, the reproducibility of the EPIC-FFQ was poorer, with correlation 
coefficients between the FFQ and a 16-day weighed record ranging from 0.39 to 0.57 (1997). 
The FFQ overestimated most nutrients when compared with weighed records e.g. daily milk 
consumption (150 g greater), cheese (15 g greater), and coffee (160 g greater), which largely 
accounted for the significant differences in energy, fat, protein, potassium, calcium and sugars 
found between the two methods. In the individuals who completed four different dietary 
assessment methods, the correlation between urine nitrogen and dietary nitrogen using 
weighed records was 0.83, using the diary was 0.67, using the FFQ was 0.30, and using the 24-
hour recall was 0.12.  
 
In the GI and nutritional status study (Chapter 3), patients were requested to complete the FFQ 
for intake over the past one month (rather than over the past 12 months) so as to fit with the 
study design (three study visits in 12 months). No other aspect of the FFQ was adapted. 
Additional validation studies are recommended when a previously validated instrument is used 
under new conditions as even subtle changes in its design may affect its performance (Willett 
1994). Ideally, this FFQ would have been validated for use over this new time period and in this 
OG cancer patient group. However, such validation was not within the scope of this thesis, and 
therefore the reliability of the tool in an acute OG cancer cohort is unknown. 
 
However, despite the limitations of the EPIC-FFQ dietary assessment approach, the benefits of 
using it in this patient group must be noted. The EPIC-FFQ has a low-respondent burden and is 
quick to complete, which is important in a patient group with high levels of anxiety, depression 
and fatigue. Research has shown that 39% and 17% of newly diagnosed GI cancer patients 
have sub-clinical and clinical anxiety respectively, while 28% and 11% have sub-clinical and 
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clinical depression respectively (Linden et al. 2012). Also, 28% of GI cancer patients are 
severely fatigued at the pre-treatment stage (Goedendorp et al. 2008). Given the reported levels 
of anxiety, depression and fatigue in this group, it was felt that the dietary assessment method 
chosen would need to be quick and easy to complete. Otherwise, patient recruitment into the 
study may have been negatively affected. Likewise, the tool can be completed during a study 
visit (rather than at home), meaning that the patient doesn’t need high levels of motivation to 
complete it and so compliance and acceptability should be improved.  
 
2.4 Diagnostic Tests for Small Intestinal Bacterial Overgrowth 
As discussed in Section 1.3.1, all of the commonly used methods for detecting SIBO have 
inherent limitations. For the purpose of the GI and nutritional status study (Chapter 3), the non-
invasive GHMBT was used. For the SIBO study (Chapter 5), both the GHMBT and endoscopic 
aspiration and culture technique were used. The addition of the direct approach to the GHMBT 
has been shown to identify a further 16% of patients that would otherwise have been missed 
(unpublished local data). 
 
2.4.1 Glucose Hydrogen Methane Breath Testing  
The GHMBT is a simple, non-invasive indirect test to detect H2 and methane (CH4) produced in 
the GI tract. These gases are primarily produced by the bacterial fermentation of carbohydrates 
(in this case glucose), so when either of these gases appear in expired air, it is usually a signal 
that the ingested glucose has been exposed to considerable numbers of bacteria, permitting 
such fermentation to take place (Levitt 1969).  
 
The GHMBT is based on the physiological observation that healthy, fasting humans at rest do 
not produce H2 or CH4 gas. These gases are only generated during the anaerobic metabolism 
of nutrients in the gut by bacteria. Therefore, if one or both gases are excreted in exhaled air, 
they must originate from anaerobic bacteria (Levitt & Ingelfinger 1968; Levitt 1969). If gases are 
generated in the bowel, it is possible to measure them in exhaled air because they enter the 
bloodstream by diffusing across enterocytes and are then transported to the lungs, where they 
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cross the capillary membranes and are excreted during exhalation. Bacteria are ordinarily not 
present in significant numbers in the small bowel. Therefore, in an individual with SIBO, the 
generation of these gases will result in their reabsorption into the blood stream from the site of 
their metabolism by the bacteria.   
 
The measurement of CH4 excretion while testing for SIBO derives from the fact that CH4 
production is critical for intraluminal H2 consumption (Strocchi & Levitt 1992). The production of 
one molecule of CH4 requires two molecules of H2 and so it is possible to reduce the total 
volume of intraluminal H2 if it is being used for CH4 production. Therefore, if H2 is metabolised to 
produce CH4, this reduces the amount excreted, which will reduce the breath H2 peak and could 
lead to false negative results. Therefore, if H2 excretion alone is considered as the marker of 
ongoing small bowel fermentation, any mechanism that reduces H2 excretion may make the test 
less accurate. 
 
Thus, breath CH4 excretion represents an important additional target for an intestinal gas breath 
excretion measurement in the subgroup of H2 non-producers, thus enhancing the test accuracy 
(Corazza et al. 1994). This subgroup could consist of between 2% and 43% of all individuals 
(Cloarec et al. 1990; Saltzberg et al. 1988; Read et al. 1985; Joseph & Rosenberg 1988; Gilat et 
al. 1978; Bjorneklett & Jenssen 1982; Flatz et al. 1985). This is in line with findings from our 
group: a retrospective study (n= 435) demonstrated that the addition of CH4 to the H2 breath test 
identified an additional 20% of patients with SIBO (unpublished data). The predominant 
methanogen in humans is Methanobrevibacter smithii and others include Staphylococcus 
aureus, Streptococcus viridans, Enterococci sp., Serratia sp. and Pseudomonas sp.  
 
The GHMBT test consists of the oral administration of a predetermined dose of glucose, with 
subsequent collection of alveolar breath samples (an air sample that is the last portion of a 
prolonged, uninterrupted exhalation). Small intestinal bacterial overgrowth is diagnosed by 
measuring the early appearance of H2 and/or CH4 gases following the challenge dose, usually 
within two hours (Hamilton 1998). 
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Evidence-based standards concerning the optimal test substrate concentration, the H2 and CH4 
cut-off levels for test positivity, the frequency of breath sample measurement and the period 
over which measurements should be taken are lacking and are the topic of ongoing discussion 
(Romagnuolo et al. 2002; Simren & Stotzer 2006; Ghoshal et al. 2006). However, GHMBT 
validation studies are divided into two main types based on the substrate dose administered 
and the test duration: 50 g for 120 minutes and 75-100 g for 180 minutes (Gasbarrini et al. 
2009). 
 
The baseline (basal) sample typically has 0-10 parts per million (ppm) of H2 and 0-7 ppm of 
CH4. Ordinarily, basal values of H2 over 20 ppm are suspicious of SIBO and values between 10 
and 20 ppm suggest incomplete fasting for the 12-hour period before the test or the ingestion of 
foods containing non-absorbed carbohydrates during the day before the test, with the large 
bowel being the source of the elevated levels (see below) (Hamilton 1998). The samples of 
expired air are generally collected every 15-20 minutes, while the most frequently used cut-off 
values for test positivity are: a rise of 10-12 ppm for H2 and a rise of 6-12 ppm for CH4 
(Gasbarrini et al. 2009). If bacteria are present in the proximal small bowel, H2 and CH4 will 
usually reach the cut-off levels within 20-60 minutes. However, by measuring H2 for at least 
three hours for persistently negative tests assures that delayed gastric emptying did not cause a 
false negative result.  
 
The GHMBT was adopted for use in this thesis because the measurement of CH4 is likely to 
improve the test’s sensitivity and specificity further (Gasbarrini et al. 2009). Besides being 
accurate, the GHMBT has other advantages such as non-invasiveness, lack of toxicity, low cost 
of substrates and easy accessibility in clinical practice.  
 
There are limitations associated with this testing technique including the lack of consensus for a 
definition of a positive test. Also, a diet low in non-absorbed carbohydrates is advised for the 24 
hours prior to the test, increasing the patient burden. It has been shown that a diet low in non-
absorbed carbohydrates gives significantly lower basal breath H2 concentrations, which 
  118 
facilitates the interpretation of the test results, since changes in H2 concentrations following 
glucose challenge can be more easily detected if high ‘background noise’ is avoided (Brummer 
et al. 1985). Breath concentrations of CH4 appear to be less affected by the ingestion of non-
absorbed carbohydrates than are H2 concentrations (Le Marchand et al. 1992). However, CH4 
responds to disaccharides which escape digestion in the small bowel and hence, the avoidance 
of disaccharide-containing foods such as dairy products is encouraged during the 24 hours 
preceding the test (Hamilton 1998). However, as yet there are no published data on the effect of 
breakfast consumption on breath H2 or CH4 levels.  
 
There are other guidelines that patients should adhere to for at least one hour before and for the 
duration of the test, as non-compliance can affect test accuracy. They should not smoke (as 
tobacco interferes with H2 excretion), fall asleep (due to hypoventilation) nor undertake vigorous 
exercise (due to hyperventilation) (Thompson et al. 1985; Perman et al. 1985). In cases of rapid 
intestinal transit, glucose may not be completely absorbed in the proximal small bowel (as 
normal) but rather it quickly reaches the large bowel causing a false positive result (Sellin & Hart 
1992). A false positive test result could also occur if bacterial fermentation by oropharyngeal 
bacteria is not minimised by patients brushing their teeth and/or using mouthwash before the 
test (Thompson et al. 1985).  
 
2.4.1.1 Equipment and Substrate for the Glucose Hydrogen Methane Breath Test  
Glucose hydrogen methane breath tests undertaken as part of Chapters 3 and 5 were 
performed using a Quintron BreathTracker™ DP Microanalyzer. This is a stand-alone analyser 
that measures both H2 and CH4 simultaneously in an alveolar breath sample (Figure 2-1 a). The 
machine was calibrated daily prior to any study measurements being taken, as per instructions 
in the machine manual.  
 
A disposable collection system, the AlveoSampler system is used to collect alveolar air in a 
standard syringe for immediate analysis. The use of this device eliminates the danger of inter-
patient cross-infection and removes the need to clean and sterilise the equipment. Each kit 
  119 
contains all the necessary supplies required for sample collection (a mouthpiece, a vented 
polyethylene bag, a syringe and a stopcock) (Figure 2-1 b and c). The substrate used for the 
test was glucose, a monosaccharide that is completely absorbed in the proximal small bowel. 
The test dose was 50 g for patients weighing < 50 kg and 75 g for those weighing > 50 kg.  
 
For samples that could not be analysed in real-time, Quintron’s Sample Holding Bags were 
used (Figure 2-1 d). These are small foil-laminated bags with a capacity of 250 ml designed to 
safely hold samples until the analyses can be completed. After collection, the alveolar air was 
passed through a drying agent and transferred to a holding bag using the syringe. Each bag 
holds a single breath sample for up to two weeks with minimal loss of sample integrity. A 
stopcock was put into the Luer port on the bag prior to transferring the sample to minimise the 
loss or alteration of the sample. These bags did not come in contact with patients directly and 
were re-used multiple times having been maintained according to the manufacturer’s 
instructions.  
 
The machine uses the basic principles of gas chromatography, which separates the gas 
components. Room air was used as the carrier gas, which is pumped through the system where 
the H2 and CH4 were separated from each other and from all other reducing gases and were 
then carried sequentially past a solid-state sensor. The signals were processed and the sample 
concentrations were displayed in ppm, within a short analytical time of 50 seconds or less.  
 








Figure 2-1 Glucose hydrogen methane breath test equipment: (a) Quintron 
BreathTracker™ DP Microanalyzer, (b) vented polyethylene bag, syringe and stopcock, 
(c) mouthpiece, (d) Sample Holding Bag 
 
 
2.4.1.2 Test Preparation for the Glucose Hydrogen Methane Breath Test  
Patients with insulin-dependent diabetes mellitus were excluded from undergoing a GHMBT. As 
the test involves a 12-hour fasting period, resulting in the risk of hypoglycaemia, it is not an 
appropriate test for these patients. Prior to the GHMBT, all other patients received an 
information booklet, describing the test and providing detailed preparation guidelines for the day 
before and the day of the test (Appendix 8.8). Patients were requested to avoid non-absorbed 
carbohydrates for 24 hours and to fast for 12 hours before the GHMBT, only drinking water 
during this time. Patients were encouraged to brush their teeth and/or use mouthwash on the 
morning of the test.  
 
Testing was performed by the study dietitian at RM’s Endoscopy Unit (Fulham Road, London) 
or at the Department of Rehabilitation at the hospital’s Sutton site. Whenever possible, testing 
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took place in the early morning. For at least one hour before the test (and also during it) patients 
were requested not to undergo vigorous activity, smoke tobacco or fall asleep.  
 
2.4.1.3 Testing Protocol for the Glucose Hydrogen Methane Breath Test 
At the beginning of the test, the study dietitian verified that the patient had adhered to the test 
diet, had fasted for the previous 12 hours, not smoked tobacco, exercised or taken any sugar-
containing medication on the morning of the test and had brushed their teeth/used mouthwash 
before the test. If the patient had incorrectly prepared and the basal H2 was raised, the GHMBT 
was not performed and was re-scheduled. The test was commenced with the collection of an 
initial basal breath sample. Patients were seated for this and all subsequent measurements.  
 
Using the AlveoSampler system, the basal breath sample was collected as follows: the patient 
took a normal breath and, at the end of inspiration, put the mouthpiece into their mouth, sealed 
their mouth and exhaled normally through the mouth into the bag. The polyethylene bag had a 
small vent hole and as it filled with air it was vented allowing exhalation to continue. The patient 
continued the exhalation until all air from the lungs was respired i.e. adequate dead space 
volume had been exhaled. At this point, the patient made a signal (by raising a hand) to the 
study dietitian, who steadily drew into the syringe and retained the 30 ml of end-expiratory air 
blown through the device (Figure 2-2 a). Until the study dietitian had sealed off the stopcock, the 
patient kept their mouth tightly sealed around the mouthpiece. The sample was either analysed 
shortly after collection (Figure 2-2 b), or stored in the syringe for up to four hours. Alternatively 
the sample was passed into a Sample Holding Bag for analysis at a later time, as described in 
Section 2.4.1.1.  
 





Figure 2-2 Glucose hydrogen methane breath test: (a) sample collection, (b) sample 
analysis 
    
Assuming the basal reading did not indicate a positive test, the test substrate was administered 
as a glucose solution (i.e. 50 g or 75 g of glucose dissolved in 150 ml of warm water). The 
solution was consumed orally and the time of ingestion was noted. Breath samples were 
collected (as for basal sample) every 20 minutes after this point until a positive reading was 
noted or if readings remained persistently negative, for a total of 180 minutes. During this time, 
the patient could drink water in moderation but continued to avoid all other beverages, foods 
and smoking. A positive result was recorded if there was: (a) a fasting H2 level ≥ 20 ppm, (b) a 
rise of ≥ 12 ppm H2 above baseline during the test, (c) a fasting CH4 level ≥ 10 ppm and/or (d) a 
rise of ≥ 6 ppm CH4 above baseline during the test, as per those criteria used by Lisowska et al. 
(2009). An example of a typical positive test (for both H2 and CH4) is shown in Figure 2-3. When 
a positive result had been recorded, the test was usually discontinued. If the test was 
persistently negative but was not continued until 180 minutes, it was considered incomplete.  
 























Sampling time (minutes) 
 Hydrogen  Methane 
glucose 
drink 




 basal 20 40 60 80 100 120 140 160 180 
H2, ppm    1 3 8 14 24 42 38 34 30 30 
CH4, ppm     0 2 4 9 14 20 18 13 13 11 
 
Figure 2-3 Typical positive glucose hydrogen methane breath test: the test was first 
positive for hydrogen gas and methane gas at 60 minutes 
 
 
2.4.2 Endoscopic Aspiration and Culture Technique 
For the SIBO study (Chapter 5), a microbiological quantification method was used to detect 
SIBO. There remains a lack of clarity on the cut-offs that define a positive culture. In the 
literature, there is great diversity in defining a positive culture with some definitions including the 
following intestinal bacterial counts: 
• Aerobic bacterial counts of more than 105 CFU/ml (Khoshini et al. 2008; Ford et al. 
2009) 
• Anaerobic bacterial counts of more than 104 CFU/ml (Khoshini et al. 2008; León-Barúa 
et al. 1993) 
• Growth of any Enterobacteriacae sp. or gas-forming organisms (Henriksson et al. 1993) 
  124 
• More than 103 CFU/ml of anaerobes or more than 104 CFU/ml of aerobes excluding 
Streptococcus viridans and Lactobacilli sp. (Farivar et al. 1979) 
• More than 103 CFU/ml of Enterobacteria sp. or Enterococcus sp. or more than 104 
CFU/ml of Bifidobacteria sp., Clostridia sp. and Bacteroides sp. belonging to the B. 
fragilis group (Rumessen et al. 1985) 
 
In a systematic review of the diagnostic tests for SIBO, 50 studies used the results of small 
bowel aspirate culture to determine SIBO. The most commonly cited definition was: 105 or more 
CFU/ml of bacteria or fungi grown from the small bowel aspirate (Khoshini et al. 2008). 
 
This diagnostic approach was used in Chapter 5 in addition to the GHMBT to provide a more 
robust approach to SIBO diagnosis. The OGD also allows the gastroenterologist to assess the 
patient for other causes for their GI symptoms including H. pylori infection, gastritis or 
duodenitis, coeliac disease or recurrent/new oncological disease. For positive results following 
quantification, the microbiology report provides the team with microbial sensitivities, which guide 
antibiotic treatment and avoids the inappropriate use of antibiotics.  
 
With this endoscopic aspiration approach there are a number of limitations to be considered 
including its invasiveness and the low, but measurable risk associated with endoscopic 
intubation (Table 1-11). It is time-consuming and cumbersome, aspirations can be difficult to 
obtain and insufflation of air into the lumen can prevent accurate sampling. Also, the endoscope 
may be contaminated by bacteria proximal to the site of sampling. The location and amount of 
small bowel fluid recovered has been shown to be highly variable (Khoshini et al. 2008). With 
regard to the location, the general consensus is that aspiration should take place beyond the 
ligament of Treitz. However, the distribution of SIBO might be patchy, possibly occurring in the 
distal small bowel or in a difficult-to-access area (e.g. a blind loop) and therefore a single 
sampling site may not always detect SIBO.  
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Aspiration-based approaches also suffer from technical difficulties associated with transporting 
and culturing the aspirate. It places high demands on the quality of laboratory work and has 
several difficulties including low reproducibility, the need for anaerobic techniques and an 
inability to identify cultivation-resistant bacteria. Anaerobic techniques are not always readily 
available in a clinical setting and so false-negative results may occur where overgrowth is 
caused by obligate anaerobes. Furthermore, culturing reveals only a fraction (estimated at 20%) 
of microbiota compared with genomic methods (Eckburg et al. 2005). 
 
2.4.2.1 Testing Protocol for Jejunal Aspiration 
All procedures were carried out at RM’s Endoscopy Unit (Fulham Road site) by one of three 
gastroenterologists, assisted by trained endoscopy nurses. The microbiological culturing and 
analysis of the samples was performed at the hospital’s Sutton site by a team of microbiologists.  
 
The procedure was performed after the patient had fasted for 12 hours. During the endoscopy 
procedure, a sterile endoscope was passed through the stomach and into the small bowel. The 
sample to be cultured was obtained at approximately 25 to 30 cm beyond the pylorus or at the 
ligament of Treitz (i.e. in the first part of the jejunum). When the desired collection site was 
chosen, a sterile catheter was inserted through the washing channel of the endoscope. One 
hundred ml of sterile saline were then vigorously flushed into the jejunum, with care being taken 
to use minimal air-insufflation, so as to maintain the intraluminal anaerobic environment. The 
suction was then turned down and after leaving the jejunal secretions and saline to equilibrate 
for 10-20 seconds, at least 5 ml of jejunal fluid was suctioned through the inner tube and 
collected in the attached sterile Pennine trap. 
 
The trap was immediately sealed to prevent anaerobic contamination by oxygen in the air. The 
appearance of the aspirate was recorded i.e. crystal clear, cloudy or bile stained. This 
information was used to determine how representative the sample was, with bile stained 
samples being more likely to indicate that the sample has been sitting in the upper small bowel 
for some time compared with crystal clear samples. The samples were stored in a dedicated 
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refrigerator maintained between 0 and 4°C before being transferred to the Sutton site for 
microbiological culture and analysis in sealed polyethylene bags (temperature maintained 
between 0 and 4°C) between one and 12 hours after the sample collection.  
 
2.4.2.2 Microbiological Quantification of Jejunal Aspirate 
Following the one-hour trip to the microbiology laboratory, the jejunal samples were analysed 
immediately. Each aspirate sample was cultured on (a) ANE neomycin blood agar anaerobically 
for 48 hours at 37°C (for anaerobic cultures), (b) CPA/CAN bi-plate in air for 24 hours at 37°C 
(for aerobic cultures), and (c) Sabourauds agar in air for 48 hours at 30°C (for aerobic cultures). 
All anaerobic manipulations were performed in an anaerobic glove box in an atmosphere of 
10% CO2, 10% H2 and 80% N2. A quantitative culturing method was employed in the laboratory 
to report the growth of fungi, aerobic and anaerobic bacteria following the culturing process. Any 
bacterial growth > 103 CFU/ml was followed up with full identification and sensitivities. The 
microbiological cut-off values used to determine test positivity in Chapter 5 have previously 
been used by Choung et al. and are shown in Table 2-5 (Choung et al. 2012).  
 
Table 2-5 Microbiological cut-off levels for jejunal aspirate culturing 
 
Result Microbial Growth  
Negative Aspirate Culture 0 CFU/ml for both aerobic and anaerobic bacteria 
Intermediate Aspirate Culture 
0 CFU/ml to 105 CFU/ml of aerobic bacteria   
     or 
0 CFU/ml to 104 CFU/ml of anaerobic bacteria 
Positive Aspirate Culture 
> 105 CFU/ml of aerobic bacteria   
    or 
> 104 CFU/ml of anaerobic bacteria  
Abbreviation: CFU/ml, colony-forming unit per millilitre 

















Chapter 3  
 Gastrointestinal Symptoms and Nutritional Status in 
Patients with Oesophagogastric Cancer:  
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3.1 Introduction 
3.1.1 Rationale 
There are numerous studies in patients with OG cancer who have undergone radical treatments 
with respect to postoperative complications and their disease-free and overall survival at one 
year (Lee et al. 2014; Kubo et al. 2014; Cunningham et al. 2006; Anderson et al. 2011; Gillham 
et al. 2008; Coupland, Allum, et al. 2012a). It is well documented that QoL can be compromised 
during and after treatment for these cancers (Blazeby, C. Metcalfe, et al. 2005a; Scarpa et al. 
2011; Courrech Staal et al. 2010). Interestingly, patients’ well-being and feelings of recovery 
have been shown to be dependent on good GI functioning and them returning to a pre-
diagnosis nutritional state (Olsson et al. 2010). However, quantitative research assessing GI 
function and nutritional status during the first year following diagnosis is limited and in particular, 
there is almost no data on the relationship between these two variables.  
 
Researchers have been interested in assessing the need for artificial nutritional support (i.e. oral 
nutritional supplements (ONS), EN and parenteral nutrition) amongst patients with OG cancer, 
especially following surgery. Still, little is known about the nutrient and food group intake of 
these patients as they progress through radical treatment and following its completion. This 
knowledge, as well as an understanding of their nutritional status and GI symptoms would 
provide a better understanding of their needs from a dietary and symptom control perspective. 
 
The oncological treatments received by patients with OG cancer can alter the anatomy of the GI 
tract, cause dysmotility and hypochlorhydria and impair immune function. As such, these 
patients have predisposing factors for the development of SIBO. Clinical experience suggests 
that the GI symptoms reported by patients with OG cancer in the months following treatment are 
very similar to those described by patients with SIBO. These symptoms include nausea, 
bloating, abdominal pain and grumbling, diarrhoea and flatulence. However, SIBO as a potential 
mechanism for the GI symptoms and/or malnutrition in patients with OG cancer has rarely been 
investigated. If the cause for their ongoing GI symptoms was found to be linked to SIBO, this 
could have important implications for their management during and after treatment.  
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3.1.2 Hypotheses 
1. Disease processes and/or radical treatment result in the persistence or development of 
moderate-severe GI symptoms at 12 months in OG cancer patients 
 
2. Disease processes and/or radical treatment result in the persistence or development of 
malnutrition at 12 months in OG cancer patients 
 
3. There is a positive association between GI symptom scores (higher score equals worse GI 
symptoms) and nutritional status scores (higher score equals worse nutritional status) at 
diagnosis, during the acute phase of management (3 months) and chronically (12 months) 
in OG cancer patients 
 
3.2 Study Objectives and Outcomes 
3.2.1 Study Objectives 
The primary objective was to measure GI symptoms and nutritional status in patients with OG 
cancer at three study time points: baseline (pre-treatment), acutely (3 months) and chronically 
(12 months).  
 
Secondary objectives were as follows:  
• To determine if moderate-severe GI symptoms persist or develop between baseline and 
12 months 
• To describe Bristol Stool Form Scale data at the three study time points 
• To determine if malnutrition persists or develops between baseline and 12 months 
• To determine the association between (a) the presence of individual GI symptoms and 
(b) total score from all GI symptoms combined and nutritional status at the three study 
time points 
• To describe the nutrient and food group intake pattern in patients at the three study time 
points and determine whether estimated requirements are being met 
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• To report the prevalence of SIBO at baseline and its incidence at 3- and 12 months in a 
sub-group of patients tested for it  
 
3.2.2 Study Outcomes  
The primary outcomes included: individual GSRS scores for 22 symptoms (0-3), GSRS total 
scores (0-66), PG-SGA total score (0-49) and PG-SGA categories (SGA A, B, C) at the three 
study time points.  
 
Secondary outcomes included: 
• Percentage weight loss in previous three-six months 
• Stool types when ‘at best’ and ‘at worst’  
• Daily intake of energy, macronutrients, fibre, micronutrients and food groups  
• A positive GHMBT result  
 
3.3 Study Design, Population and Organisation  
3.3.1 Study Design and Population 
This was a prospective, observational, longitudinal cohort study in patients with OG cancer 
undergoing radical treatment. Each patient underwent staging investigations, including an OGD, 
to obtain biopsies for histopathological confirmation of cancer/pre-malignant condition. Patients 
were planned for assessment at three visits during the study: at diagnosis before beginning 
treatment (baseline study visit), three months after commencing treatment (3 month study visit) 
and 12 months after commencing treatment (12 month study visit). 
 
The study’s inclusion criteria were as follows: 
• Newly diagnosed with malignant cancer of the oesophagus, GOJ or stomach or pre-
malignant condition of these regions (e.g. high-grade dysplasia, Barrett’s oesophagus) 
• Planned for radical treatment for their OG cancer 
• Age ≥ 18 years  
• Ability to give written informed consent to participate 
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The study’s exclusion criteria were as follows: 
• Recurrent disease  
• Intended for palliative treatment  
• Patient decision not to undergo radical treatment  
• Radical treatment began more than one week before baseline measurements could be 
performed 
• Inability or unwillingness to give informed consent 
• Incapacity to comply with the demands of the study  
• Inability to adequately understand verbal or written information given in English    
 
For simplicity, from this point onwards the term ‘OG cancer’ will be used to encompass this 
cohort of patients with malignant and pre-malignant diseases of the OG region. Of note, after 
the commencement of the study, a minor amendment to the study protocol was sought (and 
approved), which allowed the expansion of the inclusion criteria to include pre-malignant 
conditions. Therefore, some of the patients screened before this amendment were excluded 
because their tumour was pre-malignant.  
 
3.3.2 Study Organisation and Responsibilities 
The study (CCR 3703) was granted ethical approval by the London-Riverside Research 
Committee (NHS Brighton and Hove) on 31st October 2011 (Appendix 8.9). The study was 
conducted in accordance with the ethical requirements of the Declaration of Helsinki (1996) and 
good clinical practice. The RM’s Committee for Clinical Research authorised the study on 16th 
November 2011. It was approved as a single-centre study, with recruitment taking place at the 
hospital’s Sutton and London sites. The RM’s Charitable Trust funded the study. 
 
Overall responsibility for this study rested with the Principal and Chief Investigator, Dr Jervoise 
Andreyev (Consultant Gastroenterologist in Pelvic Radiation Disease at RM). Co-investigators 
included Dr Clare Shaw (Consultant Dietitian at RM), Prof Kevin Whelan (Professor of Dietetics 
at King’s College London, KCL) and the thesis author, Ms Eva Grace, (Research Dietitian at RM 
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and PhD student at KCL). All four investigators were involved in the study’s design and 
progress, while the day-to-day running of the study and data acquisition was the responsibility 
of Ms Grace. 
 
Mr Amyn Lalji, Database Manager at RM was responsible for the secure protection, 
preservation and integrity of hard copy data records and electronic data. The data were also 
entered into the study database by Mr Lalji. Throughout the study, patient data were handled in 
accordance with the requirements of the Data Protection Act (1998) and in accordance with RM 
data protection and confidentiality arrangements. All data were treated as strictly confidential 
and held in a secure location. There were three study statisticians who assisted with statistical 
work: Ms Karen Thomas and Mr Kjell Pennert at the study design phase and Mr Kabir 
Mohammed at the database development, data extraction and analysis phases. The RM 
employs all of these individuals. Monthly research meetings held at RM took place during the 
course of the study. All co-investigators were invited to attend these meetings, which were a 
forum to discuss study progress including recruitment trends, ethical issues and withdrawals.  
 
3.4 Methodology  
3.4.1 Screening, Inviting and Consenting 
Each patient with a new OG cancer diagnosis was discussed at a weekly OG specialist MDT 
meeting at RM. A treatment plan was established for each individual, which was influenced by 
histopathological results, past medical history, ECOG performance status, fitness for surgery, 
social circumstances and other clinical issues driving their management (as described in 
Section 1.1.1). The decision to proceed with radical treatment was made by this OG specialist 
MDT at these meetings and the study dietitian screened patients to identify those fulfilling the 
study’s inclusion criteria. 
 
Given the vulnerability of the patient group, the study dietitian liaised with other members of the 
MDT (e.g. research nurses and clinical nurse specialists) to determine the most appropriate 
time to approach eligible patients, particularly those who were emotionally fragile. It was hoped 
  133 
that this would minimise stress for the patients and avoid overwhelming them with information, 
especially as many were also eligible for participation in other research studies and drug trials at 
RM. At a suitable time and in a private location, the patient was approached by the study 
dietitian, often at one of their routine out-patient appointments. The study was described in 
detail to the patient and its voluntary nature was emphasised. Patients who expressed an 
interest were provided with written information in the form of a Patient Information Sheet 
(Appendix 8.10). Permission to contact the patient by telephone (or email if favoured) was 
obtained and the patient was provided with contact details should they wish to discuss the study 
further. Each patient was given a minimum of 24 hours to consider participation in the study. 
Only after this time, if they agreed to participate, could written consent be obtained (Appendix 
8.11). After consent was obtained, each patient was registered on the hospital’s ‘Committee for 
Clinical Research Protocols for Patients’ electronic system. Patients were free to withdraw at 
any point, without having to provide a reason and without it affecting their ongoing care or 
treatment. 
 
The first study visit was arranged, allowing sufficient time for the consent process and baseline 
measurements to be undertaken. This and the two future study visits were organised for either 
the London or Sutton site, depending upon the patient’s preference. For out-patients, the study 
visits were set to coincide with their other clinical appointments whenever possible, to avoid 
unnecessary hospital attendances. When a patient was receiving treatment as an in-patient, 
they were seen on the ward.  
 
3.4.2 Data Collection and Entry 
After enrolling a patient, the study dietitian collected information on a case report form (paper 
copy) for the three study visits. The data included on the case report form are described in 
Table 3-1. Details of the questionnaires completed and the GHMBTs performed are discussed 
in Sections 3.4.2.1, 3.4.2.2, 3.4.2.3 and 3.4.2.4. Study data was entered into a secure RM study 
database in a timely manner. This helped to avoid cases of lost or missing data. The study 
dietitian performed checks on 10% of all entered data before statistical analysis was permitted.  
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Table 3-1 CCR 3703: data collected at the three study visits 
  
 
3.4.2.1 Modified Gastrointestinal Symptom Rating Scale  
As described in Section 2.1.1, the modified GSRS was used to measure the prevalence and 
severity of 22 upper- and lower-GI symptoms experienced over the previous four weeks 
(Appendix 8.4). The tool will be referred to as GSRS for the remainder of this chapter.  
 
3.4.2.2 Patient Generated Subjective Global Assessment 
As discussed in Section 2.2.2, the PG-SGA assessment involved a patient component (Boxes 














Demographic and clinical information 
Baseline demographics ✓ ✗ ✗ EPR, patient 
Tumour site and histological stage  ✓ ✗ ✗ EPR 
ECOG performance status ✓ ✗ ✗ EPR 
Other gastrointestinal diagnoses 
and presence of ileostomy/ 
colostomy  
✓ ✗ ✗ EPR, patient 
Conditions and medications that 
may predispose to SIBO ✓ ✓ ✓ EPR, patient 
Nutritional information 
Presence of oesophageal stent ✓ ✓ ✓ Patient, EPR 
Source of nutrition (food, ONS, EN, 
parenteral) ✓ ✓ ✓ EPR, patient 
Modifying texture of food ✓ ✓ ✓ Patient 
Number of consultations with a 
clinical dietitian before/during study ✓ ✓ ✓ EPR 
Treatment information 
Intended oncological treatment  ✓ ✗ ✗ EPR 
Oncological treatment received  ✗ ✓ ✓ EPR, patient 
Treatment completion date ✗ ✓ ✓ EPR, patient 
Questionnaires 
Modified GSRS ✓ ✓ ✓ Patient 
PG-SGA ✓ ✓ ✓ Patient 
Modified EPIC-Norfolk FFQ ✓ ✓ ✓ Patient 
Test for small intestinal bacterial overgrowth  
GHMBT Refer to Section 3.4.2.4 Patient 
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EN, enteral nutrition; EPIC-
Norfolk FFQ, European Prospective Investigation into Cancer-Norfolk food frequency 
questionnaire; EPR, electronic patient record; GHMBT, glucose hydrogen methane breath 
test; GSRS, Gastrointestinal Symptom Rating Scale; ONS, oral nutritional supplements; 
PG-SGA, Patient Generated Subjective Global Assessment; SIBO, small intestinal bacterial 
overgrowth 
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to use the tool by shadowing a PG-SGA trained consultant dietitian (Dr Shaw) as she performed 
assessments on 12 patients and by watching the PG-SGA training video tape (Davis McCallum 
& Polisena 2001). In addition, the consultant dietitian and study dietitian both independently 
performed PG-SGA assessment on six patients and afterwards scorings and categories were 
compared to ensure homogenous results, thereby confirming that the study dietitian was 
sufficiently trained in PG-SGA assessment.  
 
The RM’s Patient Height and Weight Policy and Procedures document was followed for the 
measuring and recording of the patients’ height and weight (The Royal Marsden NHS 
Foundation Trust 2014; Dougherty & Lister 2011). The weighing scales used were the Marsden 
M-120 Column Scales and height was measured using the Marsden HM-200 Telescopic Height 
Measure. In patients who were unable to stand safely or comfortably, weight was measured 
using the Marsden M-210 Chair Scales and height was estimated using ulna length, as 
described in the above RM document. Ulna length is an accurate alternative to measured height 
in older individuals (Reidlinger et al. 2014). Scales and height measures were positioned in 
each ward, day unit and out-patient area. All scales and height measures were serviced and 
calibrated every six months by the equipment manufacturer. 
 
For patients weighed on the standing scales, the calibrated scales were positioned on a level 
surface and connected to the mains electricity. The patient was asked to remove their shoes 
and outdoor garments, so that they were wearing light day clothing only. Items in pockets and/or 
jewellery were removed. It was ensured that the scales recorded zero prior to asking the patient 
to stand on them. Once on the scales, the patient was asked to remain still and it was checked 
that they were not supporting any weight on any object e.g. wall, stick or feet on the floor. The 
study dietitian measured weight to 0.1 kg.  
 
The presence of ascites and/or oedema was noted and where present, an estimated weight 
was recorded using the BDA handbook (Parenteral and Enteral Nutrition Group of the British 
Dietetic Association 2011). Weight loss, if applicable over the past one month (or six months) 
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was determined using the hospital’s electronic patient record (EPR) system, if available, or 
using the patient-reported change in weight.  
 
Standing height was measured with the participants standing barefoot. The patient was asked 
to stand as upright as possible and look directly ahead. It was ensured that the bottom of the 
ear lobe and nose were in a horizontal plane. The height bar was then gently lowered, in a 
horizontal plane, until it touched the top of the patient’s head and height was measured to the 
nearest 0.1 cm.  
 
Patients were requested to wear loose fitting clothes on the day of each study visit to allow the 
physical examination component of the PG-SGA to be performed. Verbal consent was obtained 
before the examination was undertaken. To ensure consistency, the study dietitian used the 
SGA Physical Examination Guidance Sheet developed by Dr Shaw for use in another RM study 
(Appendix 8.12). 
 
Following the completion of all components of the tool, the PG-SGA total score (0-49) and the 
subjective global rating (SGA A, B or C) were determined and recorded. Using the nutritional 
triage recommendations, when a patient had a PG-SGA total score of 2-3 and had not already 
been referred to a clinical dietitian, they were provided with an Eating Well When You Have 
Cancer booklet (The Royal Marsden NHS Foundation Trust 2002). This is a resource designed 
for individuals who are at risk of malnutrition or already malnourished, which is routinely used 
within the Department of Nutrition and Dietetics at RM. In addition, the patient was provided with 
the contact details for this department, should they require an appointment before the next 
study visit. When a patient had a numerical score of ≥ 4 and if there was no previous referral to 
a clinical dietitian, the patient was offered an out-patient dietetic appointment. If this offer was 
declined, the patient was given the booklet and relevant contact details should they change their 
mind. 
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3.4.2.3 Modified European Prospective Investigation into Cancer in Norfolk Food 
Frequency Questionnaire  
The use of the modified EPIC-Norfolk FFQ (Appendix 8.7) has previously been discussed 
(Section 2.3.2) and will be referred to as FFQ for the remainder of the thesis. At each study visit, 
if a patient had received any nutrition from food sources over the previous one month, a FFQ 
was completed. The questionnaire was self-administered but was completed in the presence of 
the study dietitian, who provided clear instructions and assistance to the patient, if requested. 
Each questionnaire took 15-20 minutes to complete. For those patients whose sole nutritional 
source during the previous month was from EN, parenteral nutrition and/or ONS, a FFQ was not 
completed. In these cases, and in instances where a proportion of an individual’s nutritional 
intake came from these sources, the type and volume of formula/supplements taken per day (on 
average) was recorded for the previous one month. These details were acquired using the 
clinical dietetic notes on the EPR system, by liaising with the clinical dietitians and by gathering 
information on volume and frequency from the patient and nursing staff, as appropriate. 
 
Data entry and analysis of the questionnaires was undertaken by the study dietitian using the 
Food Frequency Questionnaire European Prospective Investigation into Cancer and Nutrition 
Tool for Analysis (FETA) software to produce nutrient and food group intake data. Gratitude is 
extended to the EPIC-Norfolk Study team for the use of the FETA EPIC-FFQ software (Mulligan 
et al. 2014). They are supported by programme grants from the Medical Research Council 
United UK (G9502233, G0300128) and Cancer Research UK (C865/A2883).  
 
The software produced nutrient and food group data for the FFQs. Responses to each food item 
were coded 1-9 from ‘never or less than once/month’ (code 1) to ‘6+ per day’ (code 9). If a food 
item had missing frequency data, -9 was entered. Questionnaires were considered incomplete if 
ten or more food items had missing frequency data and were therefore excluded from analysis 
(Welch et al. 2005). Answers to the questions in Part 2 were matched and converted into the 
appropriate nutrient database codes by using milk, cereal and fat reference lists. Daily intake of 
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macronutrients, micronutrients and food groups were produced by the FETA software (Mulligan 
et al. 2014).  
 
One drawback of the FETA software is that it does not include data on nutritional composition of 
ONS or enteral formulas, which are an important source of nutrition in patients with OG cancer. 
In addition, although patients can add commonly eaten food items not covered by the FFQ to 
the questionnaire, the FETA software program is not yet capable of computing them (Mulligan 
et al. 2014). To overcome these issues, the software Dietplan© was used (version 6.70.36, 
Forestfield Software Ltd, UK). The intake of any ONS, enteral formulas and additional non-
standard foodstuffs were entered into the Dietplan software. To allow this analysis to be 
performed, the following food and product tables were downloaded from the Dietplan 6.70 
installation CD: ABT Abbott Nutrition, FRS Fresenius Kabi Ltd, NCC Nutricia Advanced Medical 
Nutrition, NES Nestle Nutrition and NVT Nestle (ex. Novartis) Medical Nutrition. As with the data 
from the FETA software, daily intake of macro- and micronutrients were obtained for ONS, 
enteral formulas and additional non-standard foodstuffs, although Dietplan© does not produce 
food group data.  
 
Finally, the data from FETA (from the EPIC FFQs) and Dietplan©  (from ONS, enteral formulas 
and additional foods) were combined as appropriate, on an individual basis.  
 
3.4.2.4 Glucose Hydrogen Methane Breath Testing  
When the study opened, it was intended that all participants would undergo three GHMBTs- one 
at each study visit. However, following six months of recruitment, it was apparent that this was 
not achievable because many eligible patients were refusing to participate because of the 
requirement to perform the GHMBTs (i.e. ten of the first 25 who declined, declined for this 
reason). Each GHMBT involves a diet change for 24 hours, a 12-hour fast and the test itself can 
take three hours to complete. Given that the patients were already spending considerable time 
undergoing other staging investigations at the hospital (e.g. OGD, laparoscopy, 
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cardiopulmonary exercise test), an additional test was enough to dissuade many from 
participating.  
 
Therefore, the study dietitian decided that all eligible patients would continue to be invited to 
participate with the GHMBT being included as a study measurement. However, if the patient 
refused to take part because of an unwillingness to undergo the GHMBT, then the patient would 
be offered the option of completing the other study components outlined above (GSRS, PG-
SGA, FFQ). The London-Riverside Research Committee approved this substantial amendment 
to the study protocol on 27th July 2012 (Appendix 8.13).  
 
For those patients willing and eligible to undertake the GHMBT, the equipment and substrate, 
the preparation for the test and the test protocol have previously been described in Sections 
2.4.1.1, 2.4.1.2 and 2.4.1.3 respectively. Only those individuals, who performed a GHMBT at 
the baseline visit, were requested to undergo the test at subsequent study visits.   
 
3.4.3 Statistical Methodology 
3.4.3.1 Sample Size Calculation 
This was an observational study with no group comparisons and no reporting of effect size. 
Therefore, it was not necessary to power the study.  
 
3.4.3.2 Statistical Analysis Methods 
Statistical analyses were conducted using the Statistical Package for the Social Sciences 
software (SPSS, version 22.0, IBM, USA). In all statistical testing a 2-sided significance level of 
5% was used to assess significant difference between paired data or between patient groups. 
No missing data was replaced. The Komogorov-Smirnov test was used to visually assess 
GSRS total scores and PG-SGA total scores: both were non-normally distributed. As such, 
median, range and interquartile ranges (IQR) were used to summarise the data and compare 
the paired data using non-parametric tests.  
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For the individual GSRS symptoms, numerical values for each of the 22 symptoms were 
reported (0= none, 1= mild, 2= moderate, 3= severe). The maximum GSRS total score was, 
therefore, 66. Summary statistics were reported at each time point using count (percentage) of 
patients reporting individual symptoms, the median (range) number of symptoms and the 
median (range) GSRS total score. Paired scores comparisons were undertaken using Wilcoxon 
non-parametric tests to establish any change in GSRS total scores between time points. The 
‘persistence’ of a GI symptom occurred when a patient reported the symptom as moderate or 
severe at baseline and also at 12 months, with movement between moderate and severe 
allowed. The ‘development’ of a GI symptom occurred when a patient reported the symptom as 
none or mild at baseline but as moderate or severe at 12 months. To establish if symptoms 
persisted or developed at the 12 month point, the number of individuals with moderate-severe 
symptoms were compared at baseline and 12 months in those patients followed up at the latter 
time point. 
 
For the Bristol Stool Form Scale, the frequency of stool types when ‘at best’ and ‘at worst’ were 
described, with groupings as follows: (a) Types 1 and 2, (b) Types 3, 4 and 5 and (c) Types 6 
and 7. These categories were chosen as Types 3, 4 and 5 are generally considered to be in the 
normal range.  
 
On completion of the PG-SGA, each patient was categorised as follows: well-nourished (SGA 
A), moderately/suspected malnourished (SGA B), or severely malnourished (SGA C). In 
addition, a PG-SGA total score was calculated where the lowest (best) score was 0 and the 
highest (worst) score was 49. Scores for Boxes 1, 2, 3 and 4 (which relate to weight, food 
intake, symptoms, activities and function) and Worksheets 2, 3, and 4 (which relate to relevant 
diagnoses, metabolic demand and physical examination) of the tool were reported separately. 
The median (range and IQR) PG-SGA total score was also reported and paired scores 
comparisons were undertaken using Wilcoxon non-parametric tests to establish any change in 
median PG-SGA total scores between time points. The ‘persistence’ of malnutrition occurred 
when a patient was classed as SGA B or C at baseline and also at 12 months, with movement 
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between SGA B and SGA C allowed. The ‘development’ of malnutrition occurred when a patient 
was classed as SGA A at baseline but SGA B or C at 12 months. To establish if malnutrition 
persisted or developed at the 12 month point, the SGA categories were compared at baseline 
and 12 months in those patients followed up at the latter time point. 
 
To determine if the presence/absence of any one GI symptom was associated with nutritional 
status, 2-sided Pearson chi-square tests were used. For each GI symptom measured at each 
time point, a cross-tabulation was performed to compare those with (i.e. mild, moderate or 
severe) and without (i.e. none) the symptom with respect to SGA category (SGA A and SGA 
B+C) and percentage unintentional weight loss in past three to six months (< 5% and ≥ 5%). 
Percentage unintentional weight loss was used in this association analysis, as it is commonly 
used in clinical practice as a surrogate marker of nutritional status.  
 
To check the relationship between the overall symptom status (GSRS total scores) and 
malnutrition status (PG-SGA total scores), a Spearman’s rank correlation was performed for 
each time point. Notably, although PG-SGA total scores function to triage patients rather than 
determine their nutritional status, the ability of the PG-SGA score to predict SGA category is 
excellent: it has a sensitivity of 98%, a specificity of 82%, a positive predictive value of 95% and 
a negative predictive value of 93% (Bauer et al. 2002). There is a significant difference in the 
median PG-SGA total scores for each of the SGA classifications (p< 0.001), with the severely 
malnourished patients having the highest scores (Bauer et al. 2002). As such, it was felt 
appropriate to use PG-SGA total score as a measure of nutritional status in the correlation 
analysis. Data were visualised using scatter plots and Dancey and Reidy’s categorisations 
aided the determination of the strength of the correlation: where 1 is a perfect correlation; 0.7-
0.9 is a strong correlation; 0.4-0.6 is a moderate correlation; 0.1-0.3 is a weak correlation; 0 is 
no correlation (Dancey & Reidy 2004).  
 
Descriptive analysis was undertaken to report the FFQ and Dietplan© data using mean (SD) 
daily intake of energy, macronutrients, fibre, 24 micronutrients and 14 food groups at each time 
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point. For those with three FFQs, repeated measures analysis of variance (ANOVA) was used 
to compare the intakes at the three time points. Where p< 0.05, a Bonferroni post-hoc test was 
performed to determine which time points differed, if any. At the individual level, the daily intake 
of energy was compared with the appropriate estimated average requirement (EAR), while 
protein, fibre and 18 micronutrients were compared with the appropriate reference nutrient 
intake (RNI) (Scientific Advisory Committee on Nutrition 2012; Committee on Medical Aspects of 
Food Policy 1991). This allowed the determination of the percentage of individuals meeting their 
individualised requirements at each study visit. Those meeting and not meeting their 
requirements for energy and protein were then analysed according to median (range) GSRS 
total score and SGA category (SGA A and B+C) to determine any trends in the data.  
 
The number of cases of SIBO diagnosed during the 12 month study period was calculated as a 
percentage of all patients tested for SIBO, with a 95% CI. If the GHMBT was persistently 
negative but was stopped prematurely, this was considered an incomplete test. 
 
3.4.3.3 Violations and Deviations  
An inclusion criterion for the study was that the patient was planned for radical treatment for OG 
cancer. However, if the patient completed the baseline study components and then decided not 
to proceed with their planned treatment approach, their baseline measurements were still used 
in the analysis. However, the investigator withdrew the patient before the next study visit. For 
any patient who (a) withdrew/was withdrawn (b) was missed or (c) was lost to follow-up after the 
baseline visit, their measurements up until that point were used in the analysis. 
 
3.5 Results 
3.5.1 Data Checking 
There was a high accuracy of data entry into the study’s database, with an error rate of < 1%, 
which was considered acceptable. 
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3.5.2 Screening 
The study opened on 18th November 2011. A total of 334 patients were screened at the weekly 
OG specialist MDT meetings between this date and 17th May 2013. Of these patients, 196 were 
excluded for the reasons shown in the flow diagram (Figure 3-1). The remaining 138 patients 
were eligible to take part, of which 58 (42%) declined.  
 
In the group that declined, there were 38 (65.5%) males and 20 (34.5%) females, whose 
median (range) ages were 65 (40-88) years and 73 (47-83) years respectively. The ECOG 
performance status grading was recorded for the patients who declined to participate, as well as 
those who consented (Oken et al. 1982). Of those who declined, 17 (29.3%) had a performance 
status of 0, 32 (55.2%) had a performance status of 1, 6 (10.3%) of 2, 1 (1.7%) of 3, no patient 
had a performance status of 4 and the performance status was not recorded for 2 (3.5%). The 
ethnicities of the patients who declined to participate were as follows: White, 51 (88%); 
Asian/British Asian, 3 (5.2%); Black/Black British, 2 (3.4%); Other, 2 (3.4%).  
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Figure 3-1 CCR 3703: screening and flow of patients through the study 
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3.5.3 Enrolment and Baseline Patient Characteristics  
In total, the study dietitian recruited 80 patients into the study. The flow of these patients 
through the study is shown in Figure 3-1. There were 61 (76.2%) males and 19 (23.8%) 
females, whose baseline characteristics are described in Table 3-2. Of those who consented, 
68 (85%) and 57 (71.3%) were followed up at 3- and 12 months respectively. There were 52 
(65%) patients who were assessed at all three study visits.  
 
Table 3-2 Baseline characteristics of the recruited cohort with oesophagogastric cancer  
 
 n= 80 
Age (years)                                                                                                 median (range)  
Males  66 (47-89) 
Females 61 (46-80) 
Ethnicity  n (%) 
White 70 (87.5) 
Black/Black British 5 (6.3) 
Asian/British Asian 4 (5) 
Other 1 (1.2) 
Previous gastrointestinal diagnoses                                                              n (%) 
Irritable bowel syndrome 5 (6.3) 
Inflammatory bowel disease 1 (1.3) 
Colorectal cancer (with colostomy) 1 (1.3) 
Eastern Cooperative Oncology Group performance status                          n (%)                                                       
0 35 (43.8) 
1  39 (48.8) 
2 5 (6.2) 
3 1 (1.2) 
4 0 (0) 
Current diagnosis n (%) 
Adenocarcinoma of the upper and middle third of the 
oesophagus  
23 (28.7) 
Adenocarcinoma of the lower third of the oesophagus and 
Siewert type I tumour  
14 (17.5) 
Squamous cell carcinoma of the oesophagus 12 (15.0) 
Siewert type II and III tumour 6 (7.5) 
Adenocarcinoma of the stomach  15 (18.8) 
Gastrointestinal stromal tumour of the stomach 5 (6.2) 
Barrett’s oesophagus  1 (1.3) 
Other malignant/pre-malignant neoplasm 4 (5.0) 
Histopathological tumour (T) staging n (%) 
0-1  6 (7.5) 
2 14 (17.5) 
3 48 (60.0) 
4  5 (6.3) 
Not applicable  7 (8.7) 
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3.5.4 Treatment Modalities 
The intended treatment modalities at baseline (as per MDT decision) and the actual treatment 
received between (a) baseline and 3 months and (b) baseline and 12 months for those followed-
up is described in Figure 3-2. Of those followed up at 3- and 12 months, 64 (94.1%) and 17 
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Actual:       
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Figure 3-2 Treatment modalities intended at baseline, actual treatment received between 
baseline and 3 months and between baseline and 12 months for those followed-up, 
where CT is chemotherapy and RT is radiotherapy 
 
 
At 12 months, of the 57 patients followed up, there were 42 (73.6%) who had undergone 
surgery- the surgery types and reconstruction methods are outlined in Table 3-3. 
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Table 3-3 Surgical procedures and reconstruction methods for the 42 patients who 
underwent a radical resection and were followed up at 12 months 
  
Surgery type and reconstruction method Number (%) 
2 Phase Ivor Lewis Oesophagectomy with gastric conduit  2 (4.8) 
2 Phase Ivor Lewis Oesophagogastrectomy with gastric conduit 20 (47.6) 
3 Phase McKeown Oesophagectomy with gastric conduit 2 (4.8) 
Total gastrectomy with Roux-en-Y anastomosis  8 (19) 
Subtotal gastrectomy with Roux-en-Y anastomosis  5 (11.9) 
Other  5 (11.9) 
 
3.5.5 Gastrointestinal Symptoms 
The proportions of patients reporting the 22 GSRS symptoms as none, mild, moderate and 
severe at the three study time points are displayed in Figure 3-3, Figure 3-4 and Figure 3-5. The 
most commonly reported symptom at each time point was flatulence: 78%, 65% and 70% 
reported it (as either mild, moderate or severe) at baseline, 3- and 12-months respectively. As 
the study progressed, the presence of dysphagia to solids and fluids reduced: at baseline 58% 
had dysphagia to solids and this fell to 37% by 12 months; at baseline 33% had dysphagia to 
fluids and this fell to 18% by 12 months. The opposite was true for diarrhoea and faecal 
incontinence: between baseline and 12 months there were 27% and 13% more patients 
experiencing them respectively.  
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Figure 3-3 The proportion of none, mild, moderate, severe and missing gastrointestinal symptoms at baseline measured using the 




Figure 3-4 The proportion of none, mild, moderate, severe and missing gastrointestinal symptoms at 3 months measured using the 
Gastrointestinal Symptom Rating Scale (n= 68) 
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Figure 3-5 The proportion of none, mild, moderate, severe and missing gastrointestinal symptoms at 12 months measured using the 
Gastrointestinal Symptom Rating Scale (n= 57) 
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For the 80, 68 and 57 patients at baseline, 3- and 12 months, the median (range) number of GI 
symptoms of any severity was 8 (0-22), 8 (0-19) and 8 (0-20) respectively. The median (range) 
GSRS total scores were 12 (0-46), 9.5 (0-39) and 12 (0-46) at the three time points and the 
medians (IQRs) are depicted in Figure 3-6.  
 
 
                         Baseline                        3 months                   12 months  
Figure 3-6 Median (IQR) Gastrointestinal Symptom Rating Scale total scores at baseline 
(n= 80), 3 months (n= 68) and 12 months (n= 57) 
 
Paired score comparisons were performed for those with two or more GSRS questionnaires at 
any of the three time points, as shown in Table 3-4. There was a significant reduction in median 
GSRS total scores between baseline and 3 months.  
 
Table 3-4 Paired score comparisons between study visits for Gastrointestinal Symptom 
Rating Scale total scores  
 
n= Baseline 3 months 12 months p-value 
68 12.5 (0-46) 9.5 (0-39)  0.028  
57 12 (0-39)  12 (0-46) 0.993 
52  9.5 (0-39) 12.5 (0-46) 0.240 
Notes: Data expressed as median (range). Wilcoxon non-parametric tests were performed.  
 
There were 52 patients who completed the three GSRS questionnaires at the relevant study 
time points. Figure 3-7 displays the individual change in GI symptoms over the 12 months, with 












































Figure 3-7 Gastrointestinal Symptom Rating Scale total scores for the 52 patients with complete symptom data: each line on the chart 
represents a patient 
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For the 52 patients with complete GI symptom data, the count (percentage) of those reporting 
moderate or severe individual GI symptoms is displayed in Table 3-5. Of note, at least 20% 
reported early satiety, constipation and incomplete evacuation of a moderate/severe degree at 
all study visits. Also, at least 20% experienced belching, flatulence and abdominal grumbling 
deemed moderate/severe at baseline and 12 months. 
 
Table 3-5 The prevalence of moderate or severe symptoms in the 52 patients with 
complete symptom data 
 
Symptom Baseline 3 months 12 months 
Dysphagia to solids 22 (42.3%) 11 (21.1%) 8 (15.4%) 
Dysphagia to fluids 9 (17.3%) 7 (13.5%) 3 (5.8%) 
Odynophagia to solids 16 (30.8%) 5 (9.6%) 4 (7.7%) 
Odynophagia to fluids 4 (7.7%) 4 (7.7%) 1 (1.9%) 
Regurgitation of solids 12 (23.1%) 3 (5.8%) 4 (7.7%) 
Regurgitation of fluids 8 (15.4%) 5 (9.6%) 5 (9.6%) 
Heartburn, n= 51 9 (17.6%) 3 (5.9%) 7 (13.7%) 
Acid reflux 12 (23%) 6 (11.5%) 10 (19.2%) 
Belching 13 (25%) 8 (15.4%) 14 (26.9%) 
Nausea 6 (11.5%) 9 (17.3%) 5 (9.6%) 
Early satiety 16 (30.8%) 11 (21.1%) 12 (23.1%) 
Bloating 13 (25%) 7 (13.5%) 8 (15.4%) 
Abdominal grumbling 12 (23.1%) 8 (15.4%) 14 (26.9%) 
Abdominal pain 8 (15.4%) 7 (13.5%) 16 (30.8%) 
Flatulence 18 (34.6%) 8 (15.4%) 20 (38.5%) 
Loose stools 4 (7.7%) 8 (15.4%) 8 (15.4%) 
Diarrhoea 2 (3.8%) 6 (11.5%) 7 (13.7%) 
Faecal urgency 10 (19.2%) 7 (13.5%) 14 (26.9%) 
Faecal incontinence 2 (3.8%) 4 (7.7%) 7 (13.5%) 
Hard stools, n= 51 12 (23.5%) 10 (19.6%) 10 (19.6%) 
Constipation 12 (23.1%) 12 (23.1%) 11 (21.1%) 
Incomplete evacuation 11 (21.1%) 11 (21.1%) 11 (21.1%) 
Key:  
Green= < 5% of patients reported the symptom as moderate or severe  
Orange= ≥ 5% - < 20% of patients reported the symptom as moderate or severe 
Red= ≥ 20% of patients reported the symptom as moderate or severe 
 
There were 57 patients with symptom data available at baseline and 12 months, of which 41 
(71.9%) had at least one moderate or severe symptom at 12 months and the median (range) 
number of moderate/severe symptoms was 4 (0-17). To determine which symptoms persisted 
or developed between baseline and 12 months, the individual symptoms of these 57 patients 
were compared at both time points (Table 3-6). There were eight symptoms reported as 
moderate/severe at 12 months in ≥ 20% of patients (red shading). Conversely, there was just 
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one symptom where < 5% of patients reported it as moderate/severe at 12 months- 
odynophagia to fluids (green shading).  
 
Table 3-6 The proportion of patients with persistence or new development of moderate-
severe symptoms at 12 months as compared with baseline (n= 57) 
 
 N (%)  
persistent 
moderate/severe 





symptom at 12 
months 
N (%) 
persistent or newly 
developed 
moderate/severe 
symptom at 12 months 
Dysphagia to solids 6 (10.5) 2 (3.5) 8 (14) 
Dysphagia to fluids 1 (1.8) 2 (3.5) 3 (5.3) 
Odynophagia to solids 4 (7) 0 (0) 4 (7) 
Odynophagia to fluids 1 (1.8) 0 (0) 1 (1.8) 
Regurgitation of solids 3 (5.3) 1 (1.8) 4 (7) 
Regurgitation of fluids 2 (3.5) 3 (5.3) 5 (8.8) 
Heartburn, n= 56 4 (7.1) 4 (7.1) 8 (14.2) 
Acid reflux 5 (8.8) 6 (10.5) 11 (19.3) 
Belching 6 (10.5) 8 (14) 14 (24.5) 
Nausea 0 (0) 6 (10.5) 6 (10.5) 
Early satiety  5 (8.8) 8 (14) 13 (22.8) 
Bloating 3 (5.3) 7 (12.3) 10 (17.6) 
Abdominal grumbling 4 (7) 12 (21.1) 16 (28.1) 
Abdominal pain 4 (7) 14 (24.6) 18 (31.6) 
Flatulence 13 (22.8) 8 (14) 21 (36.8) 
Loose stools 2 (3.5) 8 (14) 10 (17.5) 
Diarrhoea 2 (3.5) 7 (12.3) 9 (15.8) 
Faecal urgency 6 (10.5) 9 (15.8) 15 (26.3) 
Faecal incontinence, n= 56 1 (1.8) 7 (12.5) 8 (14.3) 
Hard stools, n= 56 5 (8.9) 4 (7.1) 9 (16) 
Constipation 6 (10.5) 6 (10.5) 12 (21) 
Incomplete evacuation 6 (10.5) 6 (10.5) 12 (21) 
Key:  
Green= < 5% of patients reported the symptom as moderate/severe at 12 months 
Orange= ≥ 5% - < 20% of patients reported the symptom as moderate/severe at 12 months 
Red= ≥ 20% of patients reported the symptom as moderate/severe at 12 months 
 
Bristol Stool Form Scale results are reported in Figure 3-8. There was a trend towards less hard 
stools (Type 1 or 2) and more loose stools (Type 6 or 7) between the baseline and 12 month 
study visits for both ‘at best’ and ‘at worst’ stool habit.  
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Figure 3-8 Bristol Stool Form Scale stool types reported when ‘at best’ and ‘at worst’ for 
baseline (n= 80), 3 months (n= 68) and 12 months (n= 57)  
 
3.5.5.1 Hypothesis 1: Persistence or Development of Gastrointestinal Symptoms 
Moderate-severe GI symptoms persisted or developed during the 12 month study period in this 
cohort of OG cancer patients. For the 57 who were followed up at 12 months, the comparison 
between baseline and 12 months for GSRS total scores indicates that there was no statistically 
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significant difference between the study visits, p= 0.993 (Table 3-4). The median (range) 
change between the two time points for GSRS total score was -1 (-27: 24). Of these 57 patients, 
71.9% had at least one symptom that was moderate or severe at 12 months. The prevalence of 
persistent or newly developed individual symptoms ranged from 1.8% (odynophagia to fluids) to 
36.8% (flatulence). Based on these results, Hypothesis 1 can be accepted.  
 
3.5.6 Nutritional Status 
The proportion of patients who had a least one clinical dietetic consultation in the 3 months 
before baseline and between study time points is reported in Figure 3-9. In total, 32 (40%) 
patients received an Eating Well When You Have Cancer booklet. The number (percentage) of 
patients who received it before baseline, between baseline and 3 months and between 3- and 







0% 20% 40% 60% 80% 100% 
3-12 months 
Baseline-3 months 
3 months                                                                       
before baseline 
Percentage of patients 
Had consultation(s) No consultation 
               
           Number of Consultations 
 
 n (%) that had 
consultation(s) 
Mean (SD) number of 
consultations 
3 months before baseline 32 (40) 1.6 (0.9) 
Between baseline and 3 months 45 (66) 3.2 (4.3) 
Between 3- and 12 months 42 (74) 7.9 (7.4) 
 
Figure 3-9 The proportion of patients having at least one dietetic consultation in the 3 
month period before baseline (n= 80), in the baseline-3 month period (n= 68) and in the 3-
12 month period (n= 57): for those who had a consultation, the mean (SD) number of 
consultations is reported 
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The mean (SD) weights and BMIs for patients at baseline (n= 80), 3 months (n= 68) and 12 
months (n= 57) were: 76.6 (17.2) kg and 26.7 (4.7) kg/m2; 74.4 (14.8) kg and 25.9 (4.1) kg/m2; 
71.6 (16.7) kg and 25 (4.9) kg/m2 respectively. Paired score comparisons were performed for 
those with data available at two (or more) time points, with significant reductions in weight and 
BMI for all three comparisons (Table 3-7). 
 
Table 3-7 Paired scores comparisons between study visits for weight and body mass 
index 
 
Mean (SD) n= Baseline 3 months 12 months p-value 
Weight, kg 68 76.3 (15.5) 74 (14.8)  
0.003  
BMI, kg/m2 26.5 (4.4) 26 (4.1) 0.006  
Weight, kg 57 77.6 (17.9)  
71.6 (16.7) <0.001  
BMI, kg/m2 27 (5) 25 (4.9) <0.001  
Weight, kg 52  74 (14.4) 70 (13.6) <0.001  BMI, kg/m2 26 (4.1) 24.5 (4.1) <0.001  
Note: Paired t-tests were performed 
 
The scores from all components of PG-SGA, PG-SGA total scores and SGA categories are 
reported in Table 3-8. With reference to Worksheet 4 (nutrition-related physical examination and 
anthropometric assessment), at least 30% of patients obtained a score at all time points, 
meaning that the depletion of fat and muscle stores (and/or the presence of ascites/oedema) 
contributed to malnutrition in these patients. Conversely, there was just one patient (at 3 
months) who was given a metabolic demand score during the study (Worksheet 3). Of those 
assessed at baseline, 3- and 12 months, 61.2%, 61.8% and 59.6% were moderately/severely 
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Table 3-8 Patient Generated Subjective Global Assessment (PG-SGA) total scores and 








PG-SGA total score components n (%) 
Box 1: Weight 
0   (= not changed/increased) 


























Box 2: Food intake 
0   (= same/more than usual) 
1   (= less food than usual) 
2   (= little solid food) 
3   (= supplements only) 



















Box 3: Symptoms 
0-3   (= none/few symptoms) 
4-6   (= several symptoms) 













Box 4: Activities and function 
0   (= no limitations) 
1   (= not normal self) 
2   (= not up to most things) 





































7 (0-24) 4 (0-23) 4 (0-16) 
Worksheet 2: Relevant diagnoses 
0   (= no diagnoses) 
1   (= one diagnosis) 
2   (= two diagnoses) 
















Worksheet 3: Metabolic demand 
0   (= no demand) 










Worksheet 4: Physical examination 
0   (= no deficit) 
1   (= mild deficit) 
2   (= moderate deficit) 
















PG-SGA total score, median (range) 9 (0-28) 6 (2-26) 7 (0-19) 
SGA category  n (%) 
A: Well-nourished 31 (38.8) 26 (38.2) 23 (40.4) 
B: Moderately/suspected malnourished 47 (58.7) 40 (58.8) 32 (56.1) 
C: Severely malnourished 2 (2.5) 2 (3) 2 (3.5) 
 
The higher the % lost in 1- 
or 6 months, the higher 
the score. Add 1 if some 
lost in past 2 weeks.  




                     Baseline                      3 months                     12 months 
Figure 3-10 Median (IQR) Patient Generated Subjective Global Assessment total scores 
at baseline (n= 80), 3 months (n= 68) and 12 months (n= 57) 
 
Paired PG-SGA total scores comparisons were performed for patients with two or more 
complete assessments, with no significant differences noted between any of the study visits 
(Table 3-9).  
 
Table 3-9 Paired scores comparisons between study visits for Patient Generated 
Subjective Global Assessment total scores 
 
Median (range) n= Baseline 3 months 12 months p-value 
PG-SGA total 
score 
68 9 (0-28) 6 (2-26)  0.095 
57 8 (0-23)  7 (0-19) 0.368 
52  5 (2-64) 7 (1-19) 0.730 
Note: Wilcoxon non-parametric tests were performed 
 
To determine whether individuals moved or stayed within an SGA category between time 
points, the SGA category trends are shown in Table 3-10. As can be seen, 16 (23.5%) 
experienced an improvement in their SGA category from baseline to 3 months (shaded green), 
whereas 16 (23.5%) worsened their SGA category (shaded red). From baseline to 12 months, 
14 (24.6%) experienced an improvement in their category (shaded green), while 16 (28%) 
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Table 3-10 Cross-tabulation of Subjective Global Assessment categories at (a) baseline 
and 3 months, (b) baseline and 12 months and (c) 3 months and 12 months  
 
Baseline - 3 months Baseline SGA A SGA B SGA C Total 
3 months 
SGA A 11 14 1 26 
SGA B 14 25 1 40 
SGA C 0 2 0 2 
Missing 6 6 0 12 
Total 31 47 2 80 
 
Baseline - 12 months 
Baseline 
SGA A SGA B SGA C Total 
12 months 
SGA A 10 13 0 23 
SGA B 14 17 1 32 
SGA C 1 1 0 2 
Missing 6 16 1 23 
Total 31 47 2 80 
 
3 months - 12 months 3 months SGA A SGA B SGA C Missing Total 
12 months 
SGA A 8 12 0 3 23 
SGA B 14 14 2 2 32 
SGA C 0 2 0 0 2 
Missing 4 12 0 7 23 
Total 26 40 2 12 80 
Notes: SGA A= well-nourished; SGA B= moderately/suspected malnourished; SGA C= 
severely malnourished. Data expressed as number of patients.  
Key: Green= improved nutritional status; Red= worsened nutritional status 
 
3.5.6.1 Hypothesis 2: Persistence or Development of Malnutrition 
Malnutrition persisted or developed during the 12 month study period in this cohort of OG 
cancer patients. For the 57 patients with baseline and 12 month nutritional status data, the 
paired score comparison for PG-SGA total scores indicates that there was no statistically 
significant difference between the study visits, p= 0.368 (Table 3-9). The median (range) 
change between the time points for this score was 1 (-13: 16). Thirteen (22.8%) patients moved 
from moderately/suspected malnourished at baseline to well-nourished at 12 months, 19 
(33.3%) were moderately/severely malnourished at both time points (malnutrition ‘persisted’) 
and 15 (26.4%) were well-nourished to start but became moderately/ severely malnourished by 
12 months (malnutrition ‘developed’) (Table 3-10). As such, malnutrition either persisted or 
developed during the course of the study in the majority of this group: 34 of 57 patients (59.7%). 
Therefore, Hypothesis 2 can be accepted. 
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3.5.7 Association Between Gastrointestinal Symptoms and Nutritional Status  
As has been reported, moderate-severe GI symptoms (Section 3.5.5) and malnutrition (Section 
3.5.6) persisted or developed in the majority (71.9% and 59.6% respectively) of patients with 
OG cancer at 12 months. The association between each of the 22 GI symptoms and (a) SGA 
category and (b) percentage unintentional weight loss in the previous three-six months at each 
time point are reported in Table 3-11, Table 3-12 and Table 3-13.  
 
Fewer symptoms were found to be associated with SGA and percentage weight loss at 3 
months than were at baseline and fewer again at 12 months compared with 3 months: for SGA 
there were 11, 3 and 0 symptoms at baseline, 3- and 12 months respectively; for percentage 
weight loss, there were 7, 3 and 2 symptoms at baseline, 3- and 12 months respectively. Of 
note, dysphagia to solids, dysphagia to fluids, hard stools and constipation were found to be 
associated with both SGA category and percentage weight loss at baseline. Early satiety was 
the only symptom found to be associated with both SGA category and percentage weight loss 
at 3 months and there were no parallel associations at 12 months.  
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Table 3-11 Association between the presence of gastrointestinal symptoms (mild, moderate or severe) and Subjective Global Assessment 
(SGA) category and 3-6 month unintentional weight loss at baseline (n= 80) 
 
Baseline SGA, n (%) Weight loss in previous 3-6 months, n (%) 
SGA A SGA B+C p-value < 5% ≥ 5% p-value 
Dysphagia to solids 11 (23.4) 36 (76.6) 0.001 ** 23 (48.9) 24 (51.1) 0.006 ** 
Dysphagia to fluids 5 (19.2) 21 (80.8) 0.011 * 11 (42.3) 15 (57.7) 0.015 * 
Odynophagia to solids 9 (26.5) 25 (73.5) 0.030 * 18 (52.9) 16 (47.1) 0.128 
Odynophagia to fluids, n= 79 3 (15) 17 (85) 0.009 ** 9 (45) 11 (55) 0.081 
Regurgitation of solids, n= 78 9 (27.3) 24 (72.7) 0.062 14 (42.4) 19 (57.6) 0.004 ** 
Regurgitation of fluids 7 (25.9) 20 (74.1) 0.074 12 (44.4) 15 (55.6) 0.025 * 
Heartburn, n= 79 12 (42.9) 16 (57.1) 0.401 17 (60.7) 11 (39.3) 0.523 
Acid reflux 12 (34.3) 23 (65.7) 0.312 17 (48.6) 18 (51.4) 0.034 *  
Belching 15 (30) 35 (70) 0.033 * 30 (60) 20 (40) 0.478 
Nausea 3 (12) 22 (88) 0.001 ** 14 (56) 11 (44) 0.342 
Early satiety 7 (18.4) 31 (81.6) 0.000 *** 20 (52.6) 18 (47.4) 0.101 
Bloating 8 (34.8) 15 (65.2) 0.420 14 (60.9) 9 (39.1%) 0.580 
Abdominal grumbling 10 (27) 27 (73) 0.038 * 21 (56.8) 16 (43.2) 0.296 
Abdominal pain 13 (37.1) 22 (62.9) 0.489 21 (60) 14 (40) 0.511 
Flatulence, n= 76 16 (33.3) 32 (66.7) 0.163 29 (60.4) 19 (39.6) 0.520 
Loose stools, n= 78 10 (43.5) 13 (56.5) 0.380 15 (65.2) 8 (34.8) 0.420 
Diarrhoea 3 (20) 12 (80) 0.084 8 (53.3) 7 (46.7) 0.339 
Faecal urgency 10 (43.5) 13 (56.5) 0.380 17 (73.9) 6 (26.1) 0.110 
Faecal incontinence, n= 79 3 (27.3) 8 (72.7) 0.299 8 (72.7) 3 (27.3) 0.332 
Hard stools, n= 79 8 (22.9) 27 (77.1) 0.007 ** 16 (45.7) 19 (54.3) 0.013 * 
Constipation, n= 72 6 (16.7) 30 (83.3) 0.000 *** 17 (47.2) 19 (52.8) 0.018 *  
Incomplete evacuation 8 (25) 24 (75) 0.033 * 17 (53.1) 15 (46.9) 0.163 
Notes: Pearson chi-square tests were undertaken to determine the association between individuals with/without a symptom and SGA category A or 
category B+C and weight loss < 5% or ≥ 5%. Fisher’s Exact tests were performed where expected cell count was less than 5.  
Data presented are for the association of the presence of a symptom and SGA B+C and weight loss ≥ 5%.  
Key: * p< 0.05; ** p< 0.01; *** p< 0.001 
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Table 3-12 Association between the presence of gastrointestinal symptoms (mild, moderate or severe) and Subjective Global Assessment 
(SGA) category and 3-6 month unintentional weight loss at 3 months (n= 68) 
 
3 months 
SGA, n (%) Weight loss in previous 3-6 months, n (%) 
SGA A SGA B+C p-value < 5% ≥ 5% p-value 
Dysphagia to solids 6 (24) 19 (76) 0.055 13 (52) 12 (48) 0.479 
Dysphagia to fluids 4 (25) 12 (75) 0.171 6 (37.5) 10 (62.5) 0.103 
Odynophagia to solids 4 (26.7) 11 (73.3) 0.231 8 (53.3) 7 (46.7) 0.577 
Odynophagia to fluids, n= 67 1 (16.7) 5 (83.3) 0.240 2 (33.3) 4 (66.7) 0.242 
Regurgitation of solids 3 (20) 12 (80) 0.087 7 (46.7) 8 (53.3) 0.348 
Regurgitation of fluids 2 (18.2) 9 (81.8) 0.122 5 (45.5) 6 (54.5) 0.372 
Heartburn, n= 67 6 (35.3) 11 (64.7) 0.482 9 (52.9) 8 (47.1) 0.523 
Acid reflux 7 (30.4) 16 (69.6) 0.249 10 (43.5) 13 (56.5) 0.150 
Belching 17 (47.2) 19 (52.8) 0.085 23 (63.9) 13 (36.1) 0.078 
Nausea 14 (37.8) 23 (62.2) 0.569 21 (56.8) 16 (43.2) 0.429 
Early satiety 8 (21.1) 30 (78.9) 0.001 ** 14 (36.8) 24 (63.2) 0.001 ** 
Bloating  5 (29.4) 12 (70.6) 0.285 5 (29.4) 12 (70.6) 0.017 * 
Abdominal grumbling 16 (42.1) 22 (57.9) 0.314 22 (57.9) 16 (42.1) 0.343 
Abdominal pain 7 (30.4) 16 (69.6) 0.249 7 (30.4) 16 (69.6) 0.005 * 
Flatulence 17 (38.6) 27 (61.4) 0.569 25 (56.8) 19 (43.2) 0.387 
Loose stools, n= 67 12 (41.4) 17 (58.6) 0.449 15 (51.7) 14 (48.3) 0.483 
Diarrhoea 9 (32.1) 19 (67.9) 0.271 16 (57.1) 12 (42.9) 0.448 
Faecal urgency 10 (41.7) 14 (58.3) 0.431 15 (62.5) 9 (37.5) 0.232 
Faecal incontinence 5 (45.5) 6 (54.5) 0.414 6 (54.5) 5 (0.412) 0.628 
Hard stools 10 (33.3) 20 (66.7) 0.314 19 (63.3) 11 (36.7) 0.143 
Constipation 8 (25) 24 (75) 0.030 * 17 (53.1) 15 (46.9) 0.517 
Incomplete evacuation 6 (21.4) 22 (78.6) 0.015 * 12 (42.9) 16 (57.1) 0.088 
Notes: Pearson chi-square tests were undertaken to determine the association between individuals with/without a symptom and SGA category A or 
category B+C and weight loss < 5% or ≥ 5%. Fisher’s Exact tests were performed where expected cell count was less than 5.  
Data presented are for the association of the presence of a symptom and SGA B+C and weight loss ≥ 5%.  
Key: * p< 0.05; ** p< 0.01 
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Table 3-13 Association between the presence of gastrointestinal symptoms (mild, moderate or severe) and Subjective Global Assessment 
(SGA) category and 3-6 month unintentional weight loss at 12 months (n= 57) 
 
 12 months SGA, n (%) Weight loss in previous 3-6 months, n (%) 
SGA A SGA B+C p-value < 5% ≥ 5% p-value 
Dysphagia to solids 7 (33.3) 14 (66.7) 0.294 13 (61.9) 8 (38.1) 0.383 
Dysphagia to fluids 3 (27.3) 8 (72.7) 0.264 7 (63.6) 4 (36.4) 0.537 
Odynophagia to solids 2 (22.2) 7 (77.8) 0.204 3 (33.3) 6 (66.7) 0.030 * 
Odynophagia to fluids 0 (0) 4 (100) 0.117 1 (25) 3 (75) 0.103 
Regurgitation of solids 6 (37.5) 10 (62.5) 0.514 10 (62.5) 6 (37.5) 0.452 
Regurgitation of fluids 6 (37.5) 10 (62.5) 0.514 10 (62.5) 6 (37.5) 0.452 
Heartburn, n= 56 5 (33.3) 10 (66.7) 0.346 10 (66.7) 5 (33.3) 0.575 
Acid reflux 10 (41.7) 14 (58.3) 0.539 15 (62.5) 9 (37.5) 0.386 
Belching 13 (35.1) 24 (64.9) 0.209 22 (59.5) 15 (40.5) 0.100 
Nausea 8 (36.4) 14 (63.6) 0.419 14 (63.6) 8 (36.4) 0.459 
Early satiety 7 (28) 18 (72) 0.079 14 (56) 11 (44) 0.110 
Bloating 9 (47.4) 10 (52.6) 0.315 15 (78.9) 4 (21.1) 0.137 
Abdominal grumbling 14 (37.8) 23 (62.2) 0.402 24 (64.9) 13 (35.1) 0.465 
Abdominal pain 12 (35.3) 22 (64.7) 0.251 22 (64.7) 12 (35.3) 0.465 
Flatulence 14 (35) 26 (65) 0.166 26 (65) 14 (35) 0.465 
Loose stools 10 (30.3) 23 (69.7) 0.062 19 (57.6) 14 (42.4) 0.076 
Diarrhoea 8 (30.8) 18 (69.2) 0.140 16 (61.5) 10 (38.5) 0.319 
Faecal urgency 8 (29.6) 19 (70.4) 0.097 17 (63) 10 (37) 0.389 
Faecal incontinence n= 56 5 (33.3) 10 (66.7) 0.669 8 (53.3) 7 (46.7) 0.412 
Hard stools 7 (31.8) 15 (68.2) 0.223 11 (50) 11(50) 0.034 * 
Constipation 10 (43.5) 13 (56.5) 0.451 15 (65.2) 8 (34.8) 0.535 
Incomplete evacuation 10 (38.5) 16 (61.5) 0.503 16 (61.5) 10 (38.5) 0.319 
Notes: Pearson chi-square tests were undertaken to determine the association between individuals with/without a symptom and SGA category A or 
category B+C and weight loss < 5% or ≥ 5%. Fisher’s Exact tests were performed where expected cell count was less than 5.  
Data presented are for the association of the presence of a symptom and SGA B+C and weight loss ≥ 5%.  
Key: * p< 0.05 
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To determine the correlation between combined burden of GI symptoms (as opposed to 
individual symptoms) and nutritional status, the GSRS total scores and PG-SGA total scores 
were compared. There was a correlation coefficient of +0.55 at baseline (n= 80, p< 0.001). At 3 
months, where data for 68 patients were available, the correlation coefficient reduced to +0.51 
(p< 0.001). At 12 months, where data for 57 patients were available, the correlation coefficient 
reduced further to +0.42 (p= 0.001). At each time point, the positive correlation between the 
variables is considered ‘moderate’ as per Dancey and Reidy’s correlation categorisations 
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                                              Baseline, n= 80 
  
                                             GSRS total score 
                                           3 months, n= 68 
  
                                         GSRS total score 
                                          12 months, n= 57 
 
                                        GSRS total score 
Figure 3-11 Spearman’s rank correlation between Gastrointestinal Symptom Rating Scale 
total score and Patient Generated Subjective Global Assessment total score at: baseline 
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3.5.7.1 Hypothesis 3: Gastrointestinal Symptoms and Nutritional Status Association  
A moderate positive correlation between GSRS total scores and PG-SGA total scores has been 
identified at baseline, during the acute phase of management (3 months) and chronically (12 
months) in OG cancer patients. In addition, at each time point, association between some 
individual symptoms and both SGA category and percentage weight loss also occurs. 
Therefore, Hypothesis 3 can be accepted.  
 
3.5.8 Dietary Assessment  
For the 80, 68 and 57 patients assessed at baseline, 3- and 12 months, the sources of nutrition 
used during the month before each study visit is shown Figure 3-12. Of the 79, 62 and 53 
managing (at least) some oral intake at baseline, 3- and 12 months, 18 (22.8%), 13 (21%) and 5 
(9.4%) were consuming foods with a modified texture, either mostly or exclusively during the 
previous month. Of note, there were patients with an oesophageal stent in place at each time 
point: 3 (3.8%) at baseline, 5 (7.4%) at 3 months and 3 (5.3%) at 12 months.  
 
 
Figure 3-12 Sources of nutrition during the month prior to the baseline, 3 month and 12 
month study visits, where sources are not mutually exclusive  
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Detailed dietary intake data were available for 79, 66 and 57 patients at baseline, 3- and 12 
months respectively. The contribution of food, ONS and enteral formulas at baseline, 3- and 12 
months to mean daily energy and protein intakes are shown in Figure 3-13. There was 1 patient 
at 3 months whose only source of nutrition was parenteral nutrition (i.e. nothing by the 
oral/enteral route), who was not included in the 3-month analysis.  
 
Figure 3-13 Mean contributions of food, oral nutritional supplements and enteral 
formulas to mean daily energy (kcal) and protein (g) intake at baseline (n= 79), 3 months 
(n= 66) and 12 months (n= 57) 
 
There were 78, 61 and 53 FFQs analysed respectively. The reasons for the 13 unavailable 
FFQs were: (a) questionnaire not complete at visit for 1 patient at baseline; (b) incomplete 
questionnaire for 1 patient at 3 months; (c) no food being eaten for 1 patient at baseline, 6 
patients at 3 months and 4 patients at 12 months. For the patients who completed the FFQs, 
the mean (SD) daily intake of energy, fibre, 24 nutrients and 14 food groups from food at each 
study visit are reported in Table 3-14. 
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Table 3-14 Mean (SD) daily intake of energy, macronutrients, fibre, micronutrients and 
food groups from food alone at baseline, 3 months and 12 months  
 
 Baseline, n= 78 3 months, n= 61 12 months, n= 53 
Mean (SD) Mean (SD) Mean (SD) 
Energy, kcal/d 2226.3 (1567.2) 2095.3 (873.6) 2112.3 (836.4) 
Protein, g/d 90.2 (57.0) 86.1 (32.5) 85.7 (28.5) 
Carbohydrate, g/d 268.6 (208.8) 242.2 (101.9) 243.1 (106.7) 
Fat- total, g/d 88.0 (66.6) 89.7 (43.6) 90.8 (42.8) 
Alcohol, g/d 9.7 (17.0) 5.3 (11.1) 6.1 (9.8) 
Englyst Fibre, g/d 18.0 (15.5) 15.3 (7.4) 15.2 (7.8) 
Micronutrients- vitamins 
Vitamin A, µg/d 1693.2 (1333.0) 1776.9 (1673.5) 1715.3 (1288.1) 
Vitamin B1, mg/d 1.7 (1.2) 1.5 (0.6) 1.5 (0.6) 
Vitamin B2, mg/d 2.4 (1.4) 2.2 (0.9) 2.2 (1.0) 
Vitamin B3, mg/d 23.6 (14.7) 22.1 (9.0) 22.2 (8.6) 
Vitamin B6, mg/d 2.4 (1.5) 2.1 (0.8) 2.1 (0.7) 
Vitamin B12, µg/d 8.3 (5.5) 9.1 (7.4) 8.3 (4.5) 
Carotene, mg/d 4.1 (4.2) 3.8 (2.2) 3.3 (2.1) 
Vitamin C, mg/d 118.8 (80.4) 113.7 (61.2) 109.5 (69.7) 
Vitamin D, µg/d 3.5 (3.4) 3.5 (1.8) 3.4 (2.1) 
Vitamin E, mg/d 13.3 (11.4) 12.2 (5.8) 12.5 (6.5) 
Folate, µg/d 332.5 (213.8) 296.7 (126.7) 292.1 (122.8) 
Micronutrients- minerals 
Calcium, mg/d 1131.1 (723.7) 1052.2 (389.5) 1015.3 (444.9) 
Chloride, mg/d 4950.7 (3513.6) 4721.1 (1901.8) 4370.4 (1844.2) 
Iron, g/d 12.3 (8.6) 11.0 (4.9) 11.1 (4.4) 
Magnesium, mg/d 343.8 (217.9) 308.7 (119.4) 307.0 (118.5) 
Phosphorus, mg/d 1598.1 (1011.9) 1509.5 (534.5) 1480.9 (505.1) 
Potassium, mg/d 3943.4 (2454.2) 3534.4 (1245.1) 3492.2 (1242.5) 
Selenium, µg/d 67.1 (43.2) 67.4 (33.7) 64.5 (25.6) 
Sodium, mg/d 3337.6 (2469.9) 3179.8 (1298.3) 2947.6 (1258.0) 
Zinc, mg/d 10.4 (6.8) 9.8 (3.9) 9.6 (3.2) 
Food groups 
Alcoholic beverages, g/d 174.6 (371.7) 111.0 (263.3) 100.8 (189.6) 
Cereals, cereal products, g/d 278.4 (236.4) 238.0 (125.4) 243.2 (151.3) 
Eggs, egg dishes, g/d 24.4 (27.5) 22.8 (18.3) 20.1 (21.7) 
Fats, oils, g/d 26.1 (25.0) 28.0 (20.9) 28.6 (24.4) 
Fish, fish products, g/d 45.0 (39.4) 53.0 (58.7) 49.1 (42.3) 
Fruit, g/d 213.6 (235.0) 146.2 (122.1) 98.2 (223.3) 
Meat, meat products, g/d 102.2 (78.3) 113.4 (87.6) 114.5 (63.5) 
Milk, milk products, g/d 467.3 (324.8) 442.7 (224.0) 413.4 (236.2) 
Non-alcoholic beverages, g/d 937.7 (575.2) 894.2 (484.5) 799.9 (405.3) 
Nuts, seeds, g/d 3.5 (7.2) 4.6 (8.1) 11.5 (27.6) 
Potatoes, g/d 95.1 (73.5) 87.1 (84.0) 77.3 (47.9) 
Soups, sauces, g/d 149.3 (185.0) 112.7 (84.0) 101.6 (150.2) 
Sugars: preserves, snacks, g/d 67.5  (76.1) 64.2 (55.7) 59.9 (45.9) 
Vegetables, g/d 301.7 (314.2) 254.6 (163.8) 230.5 (151.8) 
Note: Vitamin A refers to retinol equivalents; Carotene refers to total carotene equivalents  
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There were 43 patients who completed a FFQ at each of the three study visits. The mean (SD) 
weight for these patients was 75.8 (14.1) at baseline, 74.2 (13) at 3 months and 70.4 (12.3) at 
12 months. This weight change was significantly lower at (a) 3 months compared with baseline 
(p= 0.022), (b) 12 months compared with baseline (p< 0.0001) and (c) 12 months compared 
with 3 months (p= 0.002) (i.e. paired score comparisons). This significant weight loss is of 
relevance for the interpretation of the dietary assessment results in this group providing data at 
each time point. For these 43 patients, the percentage energy provided by protein, 
carbohydrate, fat and alcohol at each study visit is shown in Figure 3-14. Results for the 
comparison of mean (SD) daily energy, fibre, nutrient and food group intakes at each visit, for 
these 43 patients, are shown in Table 3-15. There was no significant change in the intake of any 
of the variables over time following Bonferroni post-hoc testing.  
 
 
Figure 3-14 Percentage energy provide by protein, carbohydrate, fat and alcohol from 
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Table 3-15 Comparison of mean daily intake of energy, fibre, nutrients and food groups 
from food at each study visit in those 43 patients providing data at all 3 time points 
 
n= 43 Baseline 3 months 12 months p-value Mean (SD) Mean (SD) Mean (SD) 
Energy, kcal/d 2253.1 (1179.5) 2222.1 (957.4) 2162.8 (834.6) 0.869 
Protein, g/d 94.5 (46.1) 90.3 (42.8) 86.1 (29.8) 0.505 
Carbohydrate, g/d 273.8 (157.7) 261.0 (110.4) 248.6 (102.6) 0.583 
Fat- total, g/d 88.2 (52.5) 95.2 (47.5) 94.3 (43.7) 0.684 
Alcohol, g/d 7.9 (13.3) 3.7 (6.8) 5.7 (9.6) 0.022 * 
Englyst Fibre, g/d 18.9 (12.5) 17.0 (8.9) 15.6 (7.8) 0.191 
Micronutrients- vitamins 
Vitamin A, µg/d 1936.5 (1149.1) 1997.6 (1827.2) 1730.4 (1204.4) 0.609 
Vitamin B1, mg/d 1.7 (1.0) 1.6 (0.8) 1.5 (0.6) 0.239 
Vitamin B2, mg/d 2.5 (1.2) 2.4 (1.1) 2.2 (1.0) 0.458 
Vitamin B3, mg/d 24.4 (11.7) 23.0 (10.2) 22.0 (9.2) 0.502 
Vitamin B6, mg/d 2.5 (1.2) 2.3 (1.1) 2.1 (0.8) 0.157 
Vitamin B12, µg/d 9.1 (4.9) 9.2 (6.7) 8.3 (4.6) 0.664 
Carotene, mg/d 4.3 (3.4) 4.1 (2.4) 3.3 (2) 0.099 
Vitamin C, mg/d 131.1 (78.2) 130.5 (80.3) 113.6 (73.6) 0.165 
Vitamin D, µg/d 3.7 (2.8) 3.8 (1.8) 3.6 (2.3) 0.870 
Vitamin E, mg/d 14.3 (9.3) 13.2 (5.9) 12.8 (6.7) 0.586 
Folate, µg/d 351.7 (178.5) 329.5 (168.5) 296.8 (129.7) 0.125 
Micronutrients- minerals 
Calcium, mg/d 1181.1 (609.5) 1144.0 (542.1) 1058.3 (439.7) 0.297 
Chloride, mg/d 4874.0 (2720.9) 4773.8 (1649.6) 4348.0 (1705.6) 0.369 
Iron, g/d 12.6 (6.5) 11.3 (4.3) 11.2 (4.5) 0.282 
Magnesium, mg/d 362.9 (182.3) 331.3 (169.1) 315.6 (123.5) 0.204 
Phosphorus, mg/d 1665.7 (809.1) 1598.5 (673.8) 1511.3 (516.5) 0.416 
Potassium, mg/d 4177.6 (1934.9) 3773.1 (1581.0) 3548.6 (1269.1) 0.079 
Selenium, µg/d 72.3 (33.6) 69.5 (32.2) 63.6 (25.7) 0.253 
Sodium, mg/d 3277.3 (1905.6) 3235.6 (1175.8) 2930.8 (1180.2) 0.395 
Zinc, mg/d 10.8 (5.8) 10.3 (5.7) 9.8 (3.3) 0.488 
Food groups 
Alcoholic beverages, g/d 138.9 (273.6) 70.0 (138.7) 106.9 (205.9) 0.041 * 
Cereals, cereal products, g/d 270.1 (183.6) 257.9 (130.1) 246.3 (139.9) 0.731 
Eggs, egg dishes, g/d 23.4 (25.2) 22.0 (14.8) 20.5 (22.8) 0.739 
Fats, oils, g/d 28.0 (21.6) 30.7 (21.6) 30.4 (24.6) 0.726 
Fish, fish products, g/d 49.2 (35.0) 46.6 (32.7) 43.1 (35.9) 0.648 
Fruit, g/d 241.3 (261.9) 171.0 (184.0) 204.5 (210.8) 0.124 
Meat, meat products, g/d 103.2 (65.4) 113.7 (82.3) 110.5 (63.5) 0.722 
Milk, milk products, g/d 485.5 (272.7) 454.5 (206.3) 435.0 (225.9) 0.485 
Non-alcoholic beverages, g/d 1032.5 (532.5) 932.4 (471.1) 817.5 (406.4) 0.052 
Nuts, seeds, g/d 3.9 (6.4) 4.9 (8.3) 13.7 (30.2) 0.040 * 
Potatoes, g/d 100.2 (61.5) 89.1 (50.2) 74.3 (48.8) 0.062 
Soups, sauces, g/d 130.9 (157.1) 109.0 (93.9) 76.9 (67.5) 0.076 
Sugars: preserves/snacks, g/d 63.5 (55.4) 64.2 (60.0) 65.7 (47.8) 0.979 
Vegetables, g/d 319.9 (257.9) 284.0 (175.6) 238.2 (156.5) 0.108 
Notes: Vitamin A refers to retinol equivalents; Carotene refers to total carotene equivalents 
Repeated measures ANOVA with Mauchly's Test of Sphericity was performed: Greenhouse-
Geisser correction was made if the data violated the assumption of sphericity.  
For nutrient/food groups with significantly different means (* p< 0.05) using ANOVA, a 
Bonferroni post-hoc test was performed to determine which specific means differed.  
There was found to be no significant difference between any of the 3 study visits for alcohol, 
alcoholic beverages and nuts, seeds after post-hoc testing. 
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Analysis was performed to determine the proportion of patients meeting EAR for energy and 
RNI for protein, fibre and micronutrients from (a) food and (b) food, ONS and EN combined. 
Estimated average requirement for energy was met by ≤ 50% at all study visits (Table 3-16, 
orange and red shading). The RNIs for magnesium, potassium, selenium and zinc consistently 
failed to be met by at least 25% of patients, with proportions particularly low for potassium and 
selenium (orange and red shading). Food alone was not adequate in meeting the RNIs for iron 
in 28.3-32.8% of cases, while for calcium, only one study visit saw > 75% of patients achieving 
their RNI from food. Throughout the study duration, < 34% of the cohort met their RNI for fibre, 
while < 16% of those aged 65 or more met their RNI for vitamin D (a RNI for vitamin D is only 
available for those aged > 65 years). 
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 Table 3-16 Proportion of patients meeting EAR for energy and RNI for protein, fibre and 
micronutrients as provided by (a) food alone and (b) food, oral nutritional supplements 
and enteral nutrition combined 
 
 Meeting requirement 
at baseline, n (%) 
Meeting requirement 
at 3 months, n (%) 
Meeting requirement 









 n= 61 
Food, ONS 




 n= 53 
Food, ONS 
and EN, 
 n= 57 
Energy  29 (37.2) 34 (43.0) 23 (37.7) 33 (50.0) 22 (41.5) 28 (49.1) 
Protein 62 (79.5) 67 (84.8) 54 (88.5) 61 (92.4) 48 (90.6) 52 (91.2) 
Englyst Fibre 26 (33.3) 26 (32.9) 17 (27.9) 17 (25.8) 12 (22.6) 14 (24.6) 
Micronutrients- vitamins 
Vitamin A  63 (80.8) 69 (87.3) 52 (85.2) 59 (89.4) 47 (88.7) 51 (89.5) 
Vitamin B1 66 (84.6) 72 (91.1) 54 (88.5) 61 (92.4) 45 (84.9) 52 (91.2) 
Vitamin B2  65 (83.3) 70 (88.6) 52 (85.2) 60 (90.9) 46 (86.8) 51 (89.5) 
Vitamin B3  61 (78.2) 66 (83.5) 50 (82.0) 60 (90.9) 42 (79.2) 50 (87.7) 
Vitamin B6  65 (83.3) 72 (91.1) 53 (86.9) 60 (90.9) 45 (84.9) 50 (87.7) 
Vitamin B12  74 (94.9) 77 (97.5) 60 (98.4) 65 (98.5) 52 (98.1) 56 (98.2) 
Vitamin C  67 (85.9) 73 (92.4) 55 (90.2) 62 (93.9) 49 (92.5) 54 (94.7) 
Vitamin D * 2 (3.1) 3 (6.4) 0 (0) 6 (15) 0 (0) 4 (13.3) 
Folate  65 (83.3) 69 (87.3) 51 (83.6) 58 (87.9) 42 (79.2) 50 (87.7) 
Micronutrients- minerals 
Calcium  58 (74.4) 63 (79.7) 48 (78.7) 57 (86.4) 39 (73.6) 43 (75.4) 
Chloride  68 (87.2) 69 (87.3) 56 (91.8) 58 (87.9) 45 (84.9) 47 (82.5) 
Iron  54 (69.2) 54 (68.4) 41 (67.2) 41 (62.1) 38 (71.7) 47(82.5) 
Magnesium  47 (60.3) 52 (65.8) 35 (57.4) 46 (69.7) 27 (50.9) 32 (56.1) 
Phosphorus  75 (96.2) 77 (97.5) 60 (98.4) 64 (97.0) 53 (100) 55 (96.5) 
Potassium  44 (56.4) 47 (59.5) 29 (47.5) 36 (54.5) 20 (37.7) 22 (38.6) 
Selenium  30 (38.5) 38 (48.1) 27 (44.3) 41 (62.1) 22 (41.5) 29 (50.9) 
Sodium  68 (87.2) 69 (87.3) 56 (91.8) 59 (89.4) 46 (86.8) 50 (87.7) 
Zinc  45 (57.7) 54 (68.4) 34 (55.7) 47 (71.2) 30 (56.6) 41 (71.9) 
Abbreviations: EN, enteral nutrition; ONS, oral nutritional supplements 
Notes: Energy and protein intakes are based on average daily intakes.  
Vitamin A refers to retinol equivalents. 
* RNI for vitamin D only available for those aged 65+ years: there were 47, 38 and 28 patients 
providing data for food alone, at baseline, 3- and 12 months; there were 47, 40 and 30 patients 
providing data for food, ONS and enteral formulas respectively. 
Key:  
Red= < 50% of patients were meeting dietary reference value 
Orange= ≥ 50 - < 75% of patients were meeting dietary reference value 
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Further analysis was performed to determine the proportion of patients meeting EAR for energy 
and RNI for protein from food alone, according to GSRS total score and SGA category at each 
study visit (Table 3-17). Median GSRS total score was lower (fewer/less severe symptoms) for 
those not meeting energy and protein requirements as compared with those meeting 
requirements, with the exception of protein at 3 months. There were higher proportions of 
patients not meeting energy requirements that were considered malnourished (SGA B+C), as 
compared with those meeting requirements, at each of the three time points. 
  
Table 3-17 Median (range) Gastrointestinal Symptom Rating Scale total score and 
Subjective Global Assessment category for patients meeting and not meeting EAR for 
energy and RNI for protein from food 
 









Gastrointestinal Symptom Rating Scale 
Total Score Baseline, n= 78 
n= 29 n= 49 n= 62 n= 16 
Median (range) 15 (0-38) 10 (0-46) 12 (0-39) 11.5 (2-46) 
 3 months, n= 61 
 n= 23 n= 38 n= 54 n= 7 
Median (range) 12 (0-28) 8 (0-39) 9 (0-39) 15 (4-24) 
 12 months, n= 53 
 n= 22 n= 31 n= 48 n= 5 
Median (range) 13.5 (4-46) 9 (0-37) 13 (0-46) 5 (1-22) 
Subjective Global Assessment  
Category Baseline, n (%) 
SGA A, n= 31 10 (32.3) 21 (67.7) 27 (87.1) 4 (12.9) 
SGA B+C, n= 47 19 (40.4) 28 (59.6) 35 (74.5) 12 (25.5) 
 3 months, n (%) 
SGA A, n= 23 11 (47.8) 12 (52.2) 23 (100) 0 (0) 
SGA B+C, n= 38 12 (31.6) 26 (68.4) 31 (81.6) 7 (18.4) 
 12 months, n (%) 
SGA A, n= 22 9 (40.9) 13 (59.1) 20 (90.9) 2 (9.1) 
SGA B+C, n= 31 13 (41.9) 18 (58.1) 28 (90.3) 3 (9.7) 
Notes: Energy and protein intakes are based on average daily intakes from food.  
SGA A= well-nourished, SGA B= moderately/suspected malnourished, SGA C= severely 
malnourished 
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3.5.9 Small Intestinal Bacterial Overgrowth  
Throughout the study duration, there was a total of 38 GHMBTs performed in a sub-group of 17 
(21.3%) patients. All 17 underwent a baseline test, of which 4 (23.5%) were positive for SIBO, 
none of whom opted for treatment at that point. At 3 months, the same 17 underwent a second 
GHMBT, of which 7 (7/13= 53.8%) had a new positive result. At 12 months, of the only four who 
underwent a third test, 3 (3/4= 75%) had a new positive result (Figure 3-15). In total there were 
4 (10.5%) incomplete tests (i.e. the test was persistently negative but was not continued until 
180 minutes at the patient’s request). Using both complete and incomplete tests, the prevalence 
of SIBO at baseline was 23.5% (4/17) and its incidence after baseline was 76.9% (10/13). 
Therefore, the overall SIBO diagnosis at baseline and subsequent time points was 14/17 
(82.4% with 95% CI: 58-95%).  
 
All but 4 (28.6%) of these 14 correctly adhering to the pre-test guidelines described in Section 
2.4.1.2; 3 (21.4%) ate slowly absorbed carbohydrates during the previous 24 hours, while 1 
(7.2%) did not brush teeth or use mouthwash on the morning of the test. Of note, the three who 
ate slowly absorbed carbohydrates did not have raised basal H2 levels. As such, the non-
adherence to the diet did not cause a false positive at the basal measurement.  
 
Of the positive tests, 3 (21.4%) were positive for CH4 alone, 11 (78.6%) were positive for both 
gases and none were positive for H2 alone. The characteristics and treatment modalities of 
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Figure 3-15 Glucose hydrogen methane breath test results in the sub-group of 17 patients who underwent testing
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Table 3-18 Characteristics, gastrointestinal symptoms and treatment modalities of 
patients testing positive for small intestinal bacterial overgrowth using the glucose 
hydrogen methane breath test compared with those testing negative for it 
 
 SIBO Positive, n= 14 SIBO Negative, n= 3 
Demographics, characteristics and predisposing conditions for SIBO 
Male, n (%) 13 (92.8) 1 (33.3) 
Age in years, mean (SD) 64. 8 (8.4) 57 (10.1) 
Weight in kg, mean (SD) 74.1 (16.4) 62 (19.9) 
SGA B or C, n (%) 11 (78.6) 3 (100) 
IBS, n (%) 2 (14.3) 0 (0) 
Diabetes mellitus, n (%) 2 (14.3) 0 (0) 
Previous GI surgery, n (%) 2 (14.3) 0 (0) 
Medications in 1 month before testing: n (%) 
Antibiotics 1 (7.1) 0 (0) 
Antisecretory, pro-/antimotility agents 7 (50) 2 (66.6) 
Laxatives, stool softeners 3 (21.4) 1 (33.3) 
Gastrointestinal Symptom Rating Scale (GSRS) symptoms: n (%) 
Dysphagia to solids 5 (35.7) 1 (33.3) 
Dysphagia to fluids 3 (21.4) 1 (33.3) 
Odynophagia to solids 1 (7.1) 0 (0) 
Odynophagia to fluids 0 (0) 0 (0) 
Regurgitation of solids 4 (28.6) 1 (33.3) 
Regurgitation of fluids 4 (28.6) 1 (33.3) 
Heartburn 2 (14.3) 1 (33.3) 
Acid reflux 5 (35.7) 0 (0) 
Belching 9 (64.3) 3 (100) 
Nausea 5 (35.7) 1 (33.3) 
Early satiety 6 (42.9) 1 (33.3) 
Bloating 0 (0) 1 (33.3) 
Abdominal grumbling 6 (42.9) 1 (33.3) 
Abdominal pain 6 (42.9) 1 (33.3) 
Flatulence 10 (71.4) 2 (66.7) 
Loose stools 10 (71.4) 0 (0) 
Diarrhoea 8 (57.1) 0 (0) 
Faecal urgency 4 (28.6) 2 (66.7) 
Faecal incontinence 2 (14.3) 0 (0) 
Hard stools 7 (50) 0 (0) 
Constipation 6 (42.9) 0 (0) 
Incomplete evacuation 3 (21.4) 2 (66.7) 
GSRS total scores, median (range) 8.5 (2-46) 7 (4-13) 
Oncological treatment received: n (%) 
 SIBO Positive, n= 10 * SIBO Negative, n= 3 
Surgery 5 (50) 1 (33.3) 
Radiotherapy 8 (80) 3 (100) 
Chemotherapy 9 (90) 3 (100) 
Notes: Symptoms may be mild, moderate or severe. For those with a positive test, the 
symptoms are reported for the 1 month before test positivity. For those with all negative tests, 
the symptoms are reported for the 1 month before the 12 month time point. 
* The n= 4 patients diagnosed at baseline were not included as they had not yet received any 
oncological treatment  
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3.6 Discussion 
3.6.1 Gastrointestinal Symptoms and Nutritional Status 
In order to address GI and nutritional status deterioration in OG cancer, it is important to gather 
objective data on their evolution throughout the course of the disease. This is the first large 
prospective study to systematically record GI symptoms and nutritional status in OG cancer 
during the first year after diagnosis. As hypothesised, OG cancer and/or radical treatment cause 
the persistence or development of GI symptoms and malnutrition: in those assessed before 
treatment and 12 months later, moderate-severe GI symptoms and malnutrition persisted or 
developed in 71.9% and 59.7% respectively. There was an improvement seen in GI symptoms 
and nutritional status in less than one-third: 28.1% of patients went form having moderate-
severe GSRS symptoms at baseline to none-mild symptoms at 12 months; 22.8% went from 
being malnourished to being well-nourished. Thus, it can be said that GI symptoms and 
malnutrition are persistent during this first year post-diagnosis in the majority of patients with 
OG cancer and Hypotheses 1 and 2 were accepted. 
 
It is evident that the GI symptom burden of OG cancer patients is great. In fact, the prevalence 
of many symptoms was higher in the current cohort than has been reported for other OG cancer 
cohorts. For example, the prevalence of diarrhoea 12 months after oesophagectomy and 6-66 
months after gastrectomy was previously reported as 8% and 28% respectively (Mine et al. 
2010; Ludwig et al. 2001). The present study found higher diarrhoea prevalence rates: 41% and 
46% of patients had it at 3- and 12 months, with the majority of the cohort having undergone 
surgery by the latter time point. Likewise for nausea, other researchers have described its 
presence in 20-30% and 19-26% of patients at 6- and 12 months after surgery for OG cancer 
respectively (Ludwig et al. 2001; Ginex et al. 2013; Mine et al. 2010). However, in the current 
study, a higher percentage of patients reported feeling nauseous: 54% at 3 months and 38% at 
12 months. As a final example, abdominal pain was more frequently reported in the current 
cohort at 12 months (60%) as compared with the literature, where the symptom prevalence is 
said to be between 10% and 47% depending on the time since surgery (Ginex et al. 2013; 
Visick 1948; Olsson et al. 2007; Mine et al. 2010). As previously discussed in Section 1.1.3, 
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GSRS symptom scores were shown to be significant in explaining 50.3% of variance in QoL (F= 
13.646; p< 0.001). Considering the results in the current cohort, it is apparent that more 
emphasis needs to be placed on the optimisation of GI function during treatment. In doing so, 
QoL may too be improved, although this was not measured here.   
 
With regard to malnutrition, cancers of the GI tract are known to produce higher nutritional risk 
than other cancer sites (Koom et al. 2012; Hebuterne et al. 2014; Baldwin et al. 2006). In fact, 
Heburterne et al.’s prevalence study (using the NRI screening tool) indicated that patients with 
OG cancer had the second highest prevalence of malnutrition (60%) after pancreatic cancer 
patients (67%) in a cohort that included patients with a variety of cancer diagnoses. This 
supports earlier work where 61% of newly diagnosed OG cancer patients were shown to have > 
5% unintentional weight loss (Baldwin et al. 2006). These preceding malnutrition risk data for 
OG cancer (60-61%) are very similar to those in the current study (59.6-61.8% were found to be 
malnourished).  
 
Although this high prevalence of malnutrition is unsurprising, it is nonetheless alarming, 
considering this is a group undergoing radical treatment, which often necessitates multiple 
hospital attendances every month, and therefore, many interactions with healthcare 
professionals. Notably, 40%, 66% and 74% of the cohort had at least one dietetic consultation 
in the period before the baseline, 3 month and 12 month assessment respectively. As such, the 
majority of those followed-up after baseline had contact with a dietitan. However, it appears that 
the dietetic involvement was not sufficient, given that 26.4% became malnourished, while 33.3% 
maintained their malnourished status during the study, suggesting that malnutrition was not 
effectively treated in this majority. However, it should be mentioned that 17.5% were 
consistently well-nourished and 22.8% improved and became well-nourished, suggesting 
effective preservation or realisation of good nutritional status in 40.3%. Importantly, just 57 of 
the initial 80 patients completed a 12 month assessment, and therefore, the true number of 
malnourished and well-nourished patients may have differed had complete data been obtained 
for those who withdrew or were lost to follow-up.  
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The consequences of malnutrition in this setting are well established. However, measuring the 
consequences of malnutrition was not within the scope of this thesis and so one can only 
speculate as to whether malnutrition contributed towards increased toxicity to oncological 
treatments, lower response to treatment, deteriorating performance status, adverse effects on 
immunity, longer length of stay in hospital, poorer QoL and/or lower overall survival (van 
Cutsem & Arends 2005; Andreyev et al. 1998; Dewys et al. 1980; Hebuterne et al. 2014; Kyle et 
al. 2005; Lis et al. 2012). Of interest, the treatment modalities intended for patients at baseline 
differed from the actual treatment received by 12 months, with fewer patients undergoing 
surgery than was originally planned. The reason for deviation from the original treatment plan 
was not formally recorded in this study (though the MDT kept records), but the research dietitian 
noted cases where the patient’s performance status worsened and as a result, they were no 
longer deemed fit for surgery.  
 
With regard to the third study hypothesis, the data suggests that there is an imperfect positive 
relationship between GSRS total scores and PG-SGA total scores at all time points. Thus, 
Hypothesis 3 was accepted. In effect, high symptom burden tends to be associated with poorer 
nutritional status and low symptom burden tends to be associated with better nutritional status. 
A moderate correlation was found at all study time points and was strongest at baseline (r= 
+0.55). As such, a change in one variable at diagnosis was more likely to be accompanied by a 
change in the other variable at baseline, when compared with the 3- and 12 month points 
(where r= +0.51 and +0.42 respectively). This is supported by the baseline finding that 11 GI 
symptoms were significantly associated with malnutrition (using SGA), but at 3 months 
significant associations were seen for just three symptoms and at 12 months there were no 
significant associations. 
 
There has been previous research investigating the relationship between symptoms and 
nutritional status in cancer, though in most cases very few GI symptoms were included in the 
analysis and the assessment of nutritional status was based solely on unintentional weight loss 
rather than PG-SGA result. Also, there have been no studies specific to OG cancer. 
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Nevertheless, in various cancer cohorts, it has been demonstrated that dysphagia, nausea, 
bloating and early satiety are significantly associated with weight loss of varying degrees 
(Sánchez-Lara et al. 2012; Bovio et al. 2009; Khalid et al. 2007; Chate 2006; Petruson et al. 
2005; Grosvenor et al. 1989). This agrees with the findings from the current study, where 
dysphagia and nausea were found to be significantly associated with SGA category at baseline. 
Also, early satiety was significantly associated with SGA category at baseline and 3 months and 
percentage weight loss at 3 months. Bloating was not associated with SGA at any time point, 
but an associated with percentage weight loss was noted at 3 months.  
 
While a moderate relationship between symptoms and nutritional status was demonstrated, one 
cannot claim a cause and effect relationship. Many factors may be involved in the development 
of malnutrition including disease-related anorexia, increased macronutrient requirements and 
catabolic factors, rather than just the presence of GI symptoms. Likewise, numerous factors 
may be involved in the development of GI symptoms including treatment toxicity, motility 
irregularities, hormonal abnormalities, pharmacological agents and SIBO rather than just poor 
nutritional status. These confounding factors would need to be controlled for before a causal 
relationship could be established. In addition, many other important factors need to be 
considered before a causal inference could be made. For example, the cause (independent 
variable) must be shown to precede the effect (dependent variable) i.e. the presence of GI 
symptoms must have developed before the individual became malnourished. Also, a dose-
response relationship must be confirmed (i.e. the more severe the GI symptoms, the worse the 
nutritional status) as well as reversible association (i.e. the resolution of the GI symptoms 
should improve nutritional status). Furthermore, multiple studies in different geographical 
locations should produce similar effects before a cause and effect relationship can be 
determined, with biological plausibility also required (i.e. a robust biological mechanism for the 
development of malnutrition as a direct result of GI symptoms). One could speculate that an 
intervention to manage GI symptoms may positively influence nutritional status, but because of 
the difficulty in controlling for confounding factors, one may never be able to establish that the 
GI intervention was the sole cause for improved nutritional status. Nonetheless, even without 
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establishing a relationship, the intervention may still be effective, and this warrants future 
prospective research.   
 
3.6.1.1 Strengths and Limitations of Gastrointestinal Symptoms and Nutritional Status 
Assessment Methods and Results 
This study was designed to measure GI symptoms and nutritional status acutely and 
chronically, with the hope that the 12 month (chronic) time point would capture the patient’s 
status after the completion of treatment. Normally, in patients treated with curative intent, radical 
treatment is finished within 12 months and so this was chosen as the final time point. However, 
in this cohort, 29.8% of patients were still undergoing or planned for further oncological 
treatment at 12 months, often due to treatment delays. Therefore, for a minority of the cohort, 
their 12 month data is not a true reflection of the post-treatment period. If time were not limited, 
an additional two study visits at 18- and 24 months would have provided interesting data with 
regard to the actual chronic GI symptoms and nutritional status in this cohort, but practical 
issues of long term follow-up in the confines of a PhD prevented this from being possible.  
 
As with any longitudinal study, particularly involving patients with cancer, attrition due to the 
death and decline of patients is inevitable. There were 14 (17.5%) patients who died during the 
study, 6 (7.5%) who withdrew before 12 months and a further 3 (3.8%) who were lost to follow-
up at 12 months. Thus, 23 (28.8%) patients did not complete the study. It is likely that this group 
differed from those who completed the study, as many patients reported feeling too unwell or 
fatigued to complete the study assessments and so withdrew themselves or were lost to follow-
up, and of course those who died may themselves have had worse GI symptoms and nutritional 
status than the surviving patients. Therefore, the remaining group may not be representative of 
the original cohort and may offer a superior picture than is true with regard to GI symptoms and 
nutritional status.  
 
Conversely, sampling bias does not appear to be relevant in this study: the recruited population 
and the declined population were very similar with regard to gender spread, age, race and 
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performance status. As such, a systematic error caused by non-random sampling does not 
appear important here.  
 
It must be borne in mind that the content of the GSRS used in this study was the result of a 
multi-professional discussion. Obviously, the 22 symptoms included are not the only possible 
symptoms that a patient with OG cancer can experience. For example, vomiting, steatorrhoea 
and nocturnal defaecation were not included in the tool, though they may be relevant to this 
cohort. Consequently, this study may have underestimated the real symptom burden. This 
problem could have been minimised had the (modified) GSRS been validated (the process by 
which a questionnaire is assessed for its accuracy and reliability) for use in OG cancer patients 
undergoing multimodality treatment. However, this was not achievable due to time constraints. 
As it was not validated, one cannot be completely certain of the trustworthiness of the data 
produced (i.e. whether it has good reliability and validity). For example, when the reliability is not 
known, the degree to which the questionnaire will produce the same result if completed by the 
same patient, under the same conditions, more than once, is not known. Also, it is not possible 
to determine if the results of this study can be generalised beyond the current RM cohort, as we 
do not know its external validity. Despite these limitations, this is the first prospective study to 
measure a large number of both upper- and lower-GI symptoms in an OG cancer cohort over a 
period of one year. Thus, the symptom data presented will be a valuable contribution to the 
literature in this area.   
 
Interestingly, after the commencement of the current study, the Dysfunction After Upper 
Gastrointestinal Surgery (DAUGS20) tool was validated for use in patients with OG cancer 
(Nakamura et al. 2011). This is a 20-item objective evaluation tool designed to evaluate 
postoperative symptoms. Construct validity (i.e. how well the scale measures the construct it 
was designed to measure) was confirmed using the ‘known-group’ method. The DAUGS20 tool, 
if available when the current study was being designed, would have represented an acceptable 
alternative to the GSRS. Still, given that it was not validated for use in patients undergoing 
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multimodality treatment, nor in cohorts outside of Japan, it would not have been without its 
limitations in the current study.  
 
Another notable issue is that the current study did not measure the effect of the persistence or 
development of GI symptoms and malnutrition on QoL. The study dietitian did strongly consider 
measuring QoL in the study, but given the number of other questionnaires and components 
involved at each study visit, it was deemed too onerous to include another tool. It has been well 
established that QoL is compromised in patients with OG cancer at the time of diagnosis and 
also throughout the treatment pathway, particularly following surgery (Visser et al. 2006; 
Gillham et al. 2008; Viklund et al. 2006; Blazeby et al. 2000). Researchers have studied the 
correlation between nutritional status and QoL in patients with GI cancer for some time, with a 
2012 systematic review of the literature (eight studies) concluding that better nutritional status 
was positively associated with better QoL (Lis et al.). However, to date, there has been little 
research focusing on the correlation between GI symptoms and QoL in this setting. Given the 
low five-year survival rate in this patient group, it is important to gain an understanding of the 
QoL effects in individuals with persistent GI symptoms. Future research in this area is 
warranted.  
 
3.6.2 Nutrient and Food Group Intake Pattern 
This is the first prospective study to measure the nutrient and food group intake pattern over the 
time course of treatment in OG cancer patients. When interpreting the data, it should be borne 
in mind that 39%, 24% and 32% of patients reported taking vitamin or mineral supplements at 
baseline, 3- and 12 months, and these were not included in the dietary analysis. The use of 
ONS and EN improved the cohort’s ability to meet their requirements compared with food alone: 
6%, 12% and 7% more patients met their EAR for energy; 5%, 7% and 4% more met their RNI 
for protein at baseline, 3- and 12 months respectively. This highlights the importance of 
nutritional support, particular at the acute time point. However, even with this nutritional support, 
only 43-50% of patients were meeting their EAR for energy at each time point. Given that there 
was no increase in energy intake during the course of the study, it is likely that the chronic 
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energy deficit contributed, at least in part, to the significant weight loss recorded during the 
study.  
 
With respect to nutrients, vitamin D intake was inadequate in the over 65’s of this cohort, which 
is not unexpected considering the high prevalence of vitamin D insufficiency and deficiency in 
the general UK population (Zgaga et al. 2011; Hyppönen & Power 2007). This high prevalence 
is related to the high northern latitude of the countries, which reduces individuals’ exposure to 
the ultraviolet B wavelength necessary for vitamin D synthesis, thus leaving them reliant on 
exogenous sources of the vitamin (Zgaga et al. 2011; Pearce & Cheetham 2010). Also, it has 
previously been reported that serum levels of 25-hydroxyvitamin D are lower in gastrectomised 
patients compared with healthy controls (Zittel et al. 1997; Heiskanen et al. 2001). Vitamin D (in 
its active form, 1,25-dihydroxyvitamin D) plays an important role in bone metabolism as a 
calcium-regulating hormone, and so, optimising intake is essential for bone health. 
Unfortunately, metabolic bone disease is a well-known complication of gastrectomy, with data 
suggesting that bone resorption increases as early as one month after gastrectomy without a 
matching increase in bone formation (Baek et al. 2008; Zittel et al. 1997). The prevalence of 
secondary osteomalacia and osteoporosis in this group is reported to be as high as 55% (Lim et 
al. 2007; Zittel et al. 1997; Eddy 1971; Lim & Lee 2011).  
 
As well as vitamin D, other minerals important for bone metabolism include calcium, 
magnesium, zinc and potassium. In the current study, with the exception of calcium, the intake 
of all of these minerals from food was poor: 50-75% of individuals met their RNIs for magnesium 
and zinc; 38-60% met their RNI for potassium. Although, there are likely to be many factors 
involved in the pathogenesis of osteoporosis in OG cancer including old age, female sex, low 
body weight, hormonal imbalances, malabsorption, use of proton pump inhibitors and treatment 
effects (National Institute of Health 2001), the current study provides evidence that mineral 
insufficiencies exist in this group and should be targeted to help reduce the risk of metabolic 
bone disease.  
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Iron is another mineral that has received a lot of attention in OG cancer, particularly in post-
surgical patients, with 12%, 15% and 27-69% of individuals found to be iron deficient at one, 
two and three years after gastrectomy respectively (Lee et al. 2013; Lim 2012). Iron deficiency 
after gastrectomy is thought to be caused by decreased iron absorption due to reduced food 
intake and by-pass of the duodenum in some methods of reconstruction, as well as, reduced 
gastric acidity, which decreases the conversion of non-haem iron to the ferrous form, which is 
more absorbable (Lee et al. 2013). If a blind loop exists following surgery, SIBO may develop 
with subsequent ulceration and blood loss within the loop. This blood loss has been 
demonstrated in rats with experimental blind loops (Giannella & Toskes 1976). Also, in a cohort 
of patients post-gastrectomy, Brägelmann reported a tendency towards lower ferritin values and 
a higher frequency of positive faecal occult blood tests in patients with SIBO compared with 
those without SIBO (Brägelmann et al. 1997). Oral intake of iron has not been investigated 
previously in patients with OG cancer, but the current study indicates that intake is suboptimal 
with < 75% of patients meeting their RNI from food. The 12 month follow-up was the only time at 
which > 75% of the cohort met their RNI for iron from food, ONS and enteral formulas 
combined.   
 
3.6.2.1 Strengths and Limitations of Dietary Assessment Methods and Results 
The EPIC-Norfolk FFQ is known to significantly overestimate energy and fibre intake, as well as 
many macro- and micronutrients, including fat, protein, carbohydrate, potassium, calcium and 
carotene when compared with weighed records (Bingham 1997). This knowledge means that 
interpretation of the FFQ data must be done with caution. In those patients with three complete 
FFQs, the mean energy and protein intake falls by 90.3 kcal and 8.4 g respectively during the 
study (Table 3-15). The mean weight loss over this period for these patients was 5.4 kg. To get 
a sense of the accuracy of the FFQ, these variables can be assessed together. Assuming 
energy intake was reduced by 90.3 kcal/day for 12 months, this would mean a total reduction of 
32,960 kcal during this time. It is known that 1 kg weight loss (assuming only fat is lost, which is 
unlikely) requires a reduction in energy intake of 7,700 kcal (Hall 2008). Therefore, to lose 5.4 
kg, a total reduction of 41,580 kcal in 12 months would be needed. Although this is an over-
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simplified approach, and weight loss caused by an increase in energy expenditure has not been 
considered, these calculations (difference of 8,630 kcal over 12 months) suggest that the 
estimated ‘energy in’ using the FFQ is only slightly higher (23.6 kcal/day) than the ‘energy out’ 
as indicated by weight loss. This indicates that the dietary adequacy picture described in Table 
3-16 may be reasonably precise.  
 
Given the many inherent limitations associated with the food frequency approach, a more 
accurate dietary assessment approach may have yielded more robust dietary intake data. 
Weighed food diaries have been advocated as the most accurate method of assessing dietary 
intake but given their labourious nature, they were not felt to be a practical option in this OG 
cancer cohort. The 7-day food diary method is considered the next best approach as it has 
been found to correlate closely and approach the reliability of weighed food diaries (Bingham et 
al. 1994; Bingham et al. 1995). This approach is feasible within a clinical environment and was 
strongly considered for use in this thesis. Its advantages are manifold and include precision of 
portion sizes and no reliance on individual memory and recall. Apart from the 16-day weighed 
record method, it has the next highest correlation coefficients when compared with biomarkers 
(urinary nitrogen and potassium, serum vitamin C and carotenoids), followed by the FFQ 
approach and finally the 24-hour recall method (Bingham 1997). Also, no biases in mean 
intakes of either foods or nutrients have been found for the 7-day food diary approach, 
highlighting its robustness.  
 
However, the 7-day food diary method also has its limitations as described in Section 2.3. 
Previous use of the 7-day food diary in research at RM was reflected upon to determine the 
practicalities of using the tool in an OG cancer cohort. A prospective study assessing the 
management of bile acid malabsorption with low fat dietary interventions was undertaken at RM 
(Watson et al. 2014). Participants were asked to complete two 7-day food diaries, and the 
completion rate was poor: 79% (54/68) returned the first one; 57% (31/54) returned the second 
one. Although, this was a motivated group of patients who wished to change their diet so as to 
improve their GI function, these data suggest that the burden was too high for many. In 
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comparison, of the 194 FFQs due to be completed during the current study, just one diary 
(0.5%) was not returned and another one (0.5%) was incomplete on return, demonstrating the 
low respondent burden and the ability of patients to complete the questionnaire fully.  
 
The 7-day food diary approach was also used in a randomised controlled trial undertaken at RM 
(The Fibre Study: unpublished, with permission from Ms Linda Wedlake). The degree of 
variation between three investigators was assessed and the mean difference between them for 
the daily energy intake was 174 kcal and 189 kcal for two study groups, which amounted to 
approximately 10% of their daily energy intake. This suggests that the estimates of total energy 
intake from patient-reported records varied amongst investigators. Additionally, there was 
evidence of systematic error in that one of the investigators consistently estimated higher 
energy intakes compared with the other two. Cost was another practical issue raised in this 
study. The time and monetary expenses of entering the diaries was very high: it took an 
average of 1.8 hours to enter a 7-day food diary, with a price of £30/diary (based on a Band 6 
dietitian’s rate of pay).  
 
Also, with regard to dietary assessment, the use of EAR and RNI as a method of estimating 
whether individuals attained dietary adequacy deserves attention. Dietary reference values are 
intended for healthy people rather than those with a disease that may alter dietary needs, such 
as cancer. Given that healthy individuals obtain their nutrients from food sources alone, the 
reference values were not designed to cover ONS and EN too (Hurren & Ashwell 1996; 
Committee on Medical Aspects of Food Policy 1991). Also, the imprecision of the food 
frequency method in estimating an individual’s nutrient intake, means that caution should be 
used in applying the dietary reference values to the assessment of individuals’ diets. Even with 
the perfect measure of an individual’s habitual diet (which is not easy to achieve), the dietary 
reference values can give no more than a guide to the adequacy of that individual’s diet 
(Committee on Medical Aspects of Food Policy 1991). In addition, the period of time over which 
intakes need to be recorded varies from nutrient to nutrient, depending on the frequency of 
consumption of foods high in a particular nutrient, as well as, the body’s method of storing it. 
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Therefore, as the dietary assessment period used in the current study was just one month, it is 
possible that the average daily intake of certain micronutrients was underestimated.  
 
3.6.3 Small Intestinal Bacterial Overgrowth 
This is the first research where multiple tests for SIBO were undertaken in patients before the 
commencement of treatment and during treatment for OG cancer. The prevalence of SIBO at 
baseline and its incidence during the study in the sub-group who underwent testing was high at 
23.5% and 76.9% respectively. Despite the small number of patients who underwent testing for 
SIBO, the high number of positive results suggests that SIBO may be a common condition in 
patients with OG cancer, increasing following the start of treatment. Of those diagnosed with 
SIBO after baseline, 90% and 80% underwent chemotherapy and radiotherapy before test 
positivity. Also, those with SIBO had a number of known predisposing factors. However, as 
there were few (tested) individuals without SIBO it is not possible to infer causation. Likewise, 
although belching and nausea were reported by 43% and flatulence by 57% of those with SIBO, 
a much larger cohort would be required to determine which symptoms were predictive of SIBO.  
 
3.6.3.1 Strengths and Limitations of SIBO Methods and Results 
There are limitations with respect to the design of the SIBO component of this study. It had 
been intended that all patients in the current study would perform GHMBTs, but this was not 
possible because of patient reluctance to undergo the three-hour tests. This is likely to have 
caused a sampling bias, as the characteristics of the sub-group who underwent testing may not 
be comparable to the rest of the cohort. In future research, efforts to encourage all participants 
to perform the required GHMBTs should be made. As the test is simple to carry out and remote 
GHMBT kits are available, it would be possible for the patient to perform the test at home. This 
would reduce additional hospital attendances. In addition, patients should be encouraged to 
undergo testing by their medical team. A recent study explored researchers' and clinicians' 
perceptions of recruiting participants to clinical research and found that the formation of 
collaborative ties between researchers and clinicians aided recruitment, with the patient’s 
clinician believed to make positive contributions to recruitment if they expressed encouragement 
   190 
to patients (Newington & Metcalfe 2014). Also, to determine if there was a notable improvement 
in GI symptoms in those with a positive test, a symptom assessment after antibiotic treatment 
would have been ideal. In this way, only when a significant improvement in symptoms was 
objectively found, could SIBO be confirmed. Follow-up of this nature should ideally be 
incorporated into larger prospective studies to ensure a more robust diagnostic approach. 
 
This is the first study that tested for SIBO before the commencement of OG cancer treatment, 
allowing for its incidence to be measured. The results provide evidence for a high prevalence of 
SIBO in OG cancer. However, the sources of false positive results associated with the GHMBT 
should be considered: incomplete absorption of glucose, production of gas by oropharyngeal 
bacteria and failure to avoid slowly absorbed carbohydrates. Malabsorption may occur if there is 
damage to the small bowel enterocytes (e.g. following chemotherapy or radiotherapy) or if 
intestinal transit time is rapid, which can be a feature in OG cancer patients. This is because 
there will be insufficient time for glucose to be completely absorbed in the proximal jejunum, 
thus it rapidly enters the large bowel leading to false positivity (Sellin & Hart 1992). Ideally, oro-
caecal transit time would be measured alongside the GHMBT to determine if rapid motility was 
influencing the test result. A false positive result could also occur if bacterial fermentation by 
oropharyngeal bacteria is not minimised by patients maintaining good oral hygiene before the 
test (Thompson et al. 1985). However, in the current study, all but one patient with a positive 
test claimed to have cleaned their teeth before the test. Finally, the consumption of slowly 
absorbed carbohydrates in the 24 hours before the test can produce a high basal H2 level, 
potentially resulting in a false positive result. Although three patients with positive tests did not 
adhere to the carbohydrate restrictions, none had raised basal H2 levels, suggesting false 
positivity was not an issue here.  
 
3.7 Conclusion 
This prospective observational study is the first to focus on assessing GI symptoms and 
malnutrition in an OG cancer cohort during their first year after diagnosis. The burden of GI 
dysfunction is great and chronic: while there is some improvement in the number and severity of 
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symptoms acutely, the situation regresses, so that at one year, patients have reverted to pre-
treatment symptom levels. There is some evidence to suggest that the cause of these GI 
problems may be related, at least in part, to the development of SIBO during the treatment 
pathway. This avenue certainly merits further research. This study describes a worrying 
situation with regard to nutritional status: the majority of patients are malnourished throughout 
their first year with OG cancer. However, hope lies in the finding that there is a relationship 
between the presence of GI symptoms and nutritional status. Future work may focus on 
establishing whether an intervention to manage GI symptoms may lead to improved nutritional 
status, even though a cause and effect relationship may never to realised.  
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4.1 Introduction 
4.1.1 Rationale 
As described in Chapter 3, at least 56% of patients with OG cancer were found to be 
moderately/suspected malnourished and a further 2-3% were severely malnourished at all three 
study visits, using PG-SGA. Given these high rates of malnutrition, it is important that there are 
effective strategies to screen nutritionally compromised patients with OG cancer. Patient 
Generated Subjective Global Assessment is often considered a gold-standard method to 
assess nutritional status in cancer patients (Ottery 2000). However, nutritional assessment 
should only be undertaken by a trained professional, is time-consuming, and cannot be 
undertaken in every patient in routine clinical practice. Therefore, an effective nutritional 
screening tool is essential in the oncology setting. It ensures that dietetic resources are 
appropriately targeted towards those patients who are most likely to require a full nutritional 
assessment and intervention.  
 
European Society for Clinical Nutrition and Metabolism guidelines state that nutritional 
screening should be able to predict the clinical course based on nutritional status and whether 
patients could benefit from nutritional treatment (Kondrup et al. 2003). Many generic nutritional 
screening tools are available, but few are developed and tested in oncology. While the MSTC 
has been validated in an in-patient oncology population, this tool is based on a complex 
equation, which is not suitable for use in routine clinical practice (Kim et al. 2011). Therefore, 
despite the abundance of generic nutritional screening tools, there is no consensus on the 
optimal tool for use in the oncology setting.  
 
The MUST was developed for multidisciplinary use and is supported by BAPEN, the Royal 
College of Nursing and the Registered Nursing Homes Association. It is the most commonly 
used screening tool in the UK (Stratton et al. 2004). This tool is recommended by ESPEN as the 
preferred screening tool for patients in the community, which is the setting for which it was 
originally developed (Kondrup, Allison, et al. 2003b). It predicts the rate of hospital admissions 
and the number of visits to general practitioners in the community. It has also been shown to 
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have predictive validity in the elderly hospitalised population, with regard to mortality, both in 
hospital and after discharge, and length of hospital stay (Stratton et al. 2006). The MUST (a) is 
associated with high reproducibility (degree of agreement between measurements from the 
same patient collected by different observers) among health care providers, (b) is internally 
consistent (general agreement between the items of the tool) and (c) has fair-good to excellent 
concurrent validity (correlates with a measure that has been validated including NRS, MST, 
MNA and SGA) in hospital in- and out-patients (Stratton et al. 2004; Elia 2003). Moreover, its 
practicability has also been documented (Stratton et al. 2004). Given this, and in the absence of 
a definitive method to screen for malnutrition in oncology, demonstrating the sensitivity and 
validity of MUST in the oncology setting would be a significant advance. 
 
As outlined in Table 1-10, one well-conducted study has successfully attempted to validate 
MUST in the adult oncology setting against PG-SGA (Boléo-Tomé et al. 2011). This study was 
conducted in out-patients undergoing radiotherapy. However, these results cannot be 
generalised to patients with OG cancer having multimodality treatment, who may be in-patients. 
For instance, a surgical in-patient is likely to have more acute issues than an out-patient 
receiving radiotherapy and as such, the tool will perform differently. Given the widespread use 
of MUST around the UK, its excellent agreement with dietitians’ assessment of malnutrition and 
its acceptability, it is timely that another validation study be undertaken in the oncology setting.  
 
Sensitivity, specificity, and positive and negative predictive values are important features of 
nutritional screening tools. Sensitivity refers to the proportion of malnourished patients 
diagnosed by PG-SGA also found to be at risk of malnutrition by MUST (if a patient is truly 
malnourished using PG-SGA then it will be detected as such using MUST); a high sensitivity 
may give many false positives. Specificity refers to the proportion of well-nourished patients 
identified by PG-SGA also found to be at low risk by MUST (if a patient is truly well-nourished 
using PG-SGA then it will be detected as such using MUST); a high specificity may give many 
false negatives. Therefore an ideal nutritional screening tool will have high sensitivity 
(malnourished patients are detected as such) and high specificity (well-nourished patients are 
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detected as such) (Deeks 2001). This ensures that all nutritionally at risk patients are picked up, 
whilst also preventing any unnecessary use of dietetic resources.  
 
Furthermore, the positive predictive value of a nutritional screening tool is the probability that a 
patient classified as at risk of malnutrition by MUST is effectively found to be malnourished by 
PG-SGA. The negative predictive value is the probability that a patient classified as not at risk of 
malnutrition by MUST is also defined as well-nourished by the reference method.  
 
Sensitivity, specificity, and positive and negative predictive values are essential components of 
a nutritional screening tool in oncology, and were measured in this study. 
 
4.1.2  Hypothesis 
The MUST has an acceptable sensitivity and specificity (≥ 70% for both) in the OG oncology 
setting, by comparison with PG-SGA. 
 
4.2 Objectives and Outcome 
4.2.1 Study Objectives 
The primary study objective was to assess the sensitivity and specificity of MUST against PG-
SGA.  
 
The secondary objectives were to: 
1. Measure the positive and negative predictive values of MUST against PG-SGA 
2. Assess the association of BMI and percentage weight loss (two components of MUST) with 
PG-SGA total score 
 
4.2.2 Study Outcome 
The primary study outcome was the sensitivity and specificity of MUST compared with PG-SGA. 
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4.3 Study Design, Population and Organisation 
The study dietitian conducted this validation study as a sub-study of the GI and nutritional status 
study (Chapter 3), with the London-Riverside Research Committee ethical approval also 
covering the validation study (Appendix 8.9). As such, no additional written informed consent 
was required for the 80 patients with OG cancer previously described (Section 3.5.3). The study 
organisation and responsibilities defined in Section 3.3.2 also apply here. Nutritional screening 
with MUST and nutritional assessment with PG-SGA were undertaken at baseline in order that 
a patient’s data only appeared once in the sensitivity and specificity analysis.  
 
4.4 Methodology  
4.4.1 Data Collection 
For each patient, the same study dietitian (Ms Grace) undertook the nutritional screening 
(MUST) and nutritional assessment (PG-SGA) during the baseline study visit. The MUST 
screening was performed first, followed immediately by the PG-SGA. This was important as the 
availability of the PG-SGA results could influence the answering of the steps in MUST. 
 
4.4.1.1 The Malnutrition Universal Screening Tool and Patient Generated Subjective 
Global Assessment  
For MUST (details in Section 2.2.1, tool in Appendix 8.6), Step 1 involved the calculation of BMI 
using height and weight measurements. An account of the method used to measure these 
parameters has been described in Section 3.4.2.2 and was used to generate the patient’s BMI. 
Step 2 of MUST was to estimate the percentage of unintentional weight loss over the previous 
three-six months. Weight loss, if applicable during this time, was calculated using previously 
recorded weight(s) on the hospital’s EPR system. If there were no previous weight(s) recorded, 
the patient-reported change in weight was used.  
 
Step 3 (acute disease effect) was determined by (a) checking for the presence of acute illness 
and (b) assessing nutritional intake over the previous five days and predicting intake for the 
forthcoming five days. Step 3 is not an objective measure. Although, three examples are 
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provided to illustrate acute illness (i.e. dysphagia, head injuries, undergoing GI surgery), there is 
no comprehensive list of acute illnesses accompanying the tool (Elia 2003). In an attempt to 
overcome this issue, the study dietitian undertook a local survey of oncology nurses, as they are 
the healthcare staff most likely to screen an OG cancer patient. This involved asking 25 nurses 
to list which conditions they thought a patient needed to fulfil to be considered ‘acutely ill’. 
Having compiled these lists, the study dietitian referred to them when undertaking the screening 
(Table 4-1). Following the completion of the three steps, the MUST score was calculated and 
enabled the categorisation of patients as being at low, moderate or high risk of malnutrition 
(Table 2-1).  
 
Table 4-1 Conditions that oncology nurses report as ‘acute illness’ as used in Step 3 of 
the Malnutrition Universal Screening Tool 
 
• Gastrointestinal tract not functioning  
• Gastrointestinal bleeding 
• Cardiac emergency 
• Chest pain 
• Difficulty breathing or on oxygen 
• Having hourly observations taken 
• Unable to perform activities of daily living 
• Non-responsive or semi-conscious 
• Receiving palliative care 
• High temperature 
• Infection (any type) 
• Neutropenia 
• Septicaemia  
• Tumour lysis syndrome  
• Spinal cord compression  
• On intravenous fluids or antibiotics 
• Persistent nausea and vomiting  
 
A detailed description of the background and use of the PG-SGA tool has already been 
described in Sections 2.2.2 and 3.4.2.2. All the relevant sections of the PG-SGA were 
completed and the patient’s nutritional status was then classified into one of three categories: 
well-nourished (SGA A), moderately/suspected malnourished (SGA B), or severely 
malnourished (SGA C).  
 
4.4.2 Statistical Methodology 
To enable comparisons, two categories of MUST and PG-SGA were created. For MUST they 
were (1) low risk of malnutrition and (2) medium and high risk of malnutrition. For PG-SGA they 
were (1) well-nourished and (2) moderately/suspected malnourished and severely 
malnourished. 
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Statistical analyses were conducted using SPSS 22.0 (IBM, USA). A contingency table was 
used to determine the sensitivity, specificity and the predictive values of MUST compared with 
PG-SGA. The 95% confidence intervals for sensitivity and specificity were calculated using the 
Adjusted Wald method. The cut-off points for sensitivity and specificity values were considered: 
excellent at 90-100%; good at 80-90%; fair at 70-80%; insufficient at 60-70% and poor at 50-
60%. A sensitivity and specificity of 70% was set as a prerequisite for adequate performance of 
MUST (Academical Point System 2014).  
 
As per the standard technique, sensitivity vs. one minus specificity (i.e. false positive rate) was 
plotted on a scatter plot to create a ROC curve and the area under the curve (AUC) was 
calculated to determine the performance of MUST (DeLong et al. 1988). The AUC is a reflection 
of how good the test is at discriminating between patients at risk and not at risk of malnutrition: 
the greater the area, the better the test. The MUST was considered to have outstanding 
discrimination if AUC was ≥ 0.9; excellent discrimination if AUC was 0.8-< 0.9; acceptable 
discrimination if AUC was 0.7-< 0.8; no discrimination if AUC was 0.5 (Hosmer et al. 2013). The 
ROC curve was used to determine the best cut-off point of MUST i.e. where the number of false 
positives and false negatives were minimised. This was done using the Youden index, which 
uses the maximum vertical distance from the point (x,y) on the diagonal line (chance line) of the 
ROC curve (Fluss et al. 2005).  
 
Spearman’s rank correlation was used to examine the linear trend between (a) BMI and (b) 
percentage weight loss in the previous three-six months and PG-SGA total score. Dancey and 
Reidy’s categorisations aided the determination of the strength of the correlations: 1 is a perfect 
correlation; 0.7-0.9 is a strong correlation; 0.4-0.6 is a moderate correlation; 0.1-0.3 is a weak 
correlation; 0 is no correlation (Dancey & Reidy 2004).  
 
4.5 Results 
The baseline characteristics of the 80 newly diagnosed patients with OG cancer have previously 
been described (Section 3.5.3). The categorisation of malnutrition by PG-SGA and MUST are 
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presented in Table 4-2. The PG-SGA classified 31 (39%) as well-nourished and 49 (61%) as 
malnourished, of which 47 (59%) were moderately/suspected malnourished and 2 (2%) were 
severely malnourished. The MUST classified 42 (53%) as not being at risk of malnutrition and 
38 (47%) as being at risk, of which 25 (31%) were high risk and 13 (16%) were medium risk.  
 
Table 4-2 Cross-tabulation of Malnutrition Universal Screening Tool classification of 80 


























Low risk 23 19 0 42 (53) 
Medium risk 1 12 0 13 (16) 
High risk 7 16 2 25 (31) 
Total 31 (39) 47 (59) 2 (2) 80 (100) 
 
The ability of MUST to predict PG-SGA is shown in Table 4-3. Twenty-eight per cent (n= 23) of 
patients were correctly classified by MUST as being well-nourished (true negatives) and 38% 
(n= 30) of patients were correctly classified as being malnourished (true positives). Twenty-four 
per cent (n= 19) of patients were misclassified as being well-nourished (false negatives) and 
10% (n= 8) were misclassified as being malnourished (false positives).  
 
MUST had a sensitivity in detecting patients at risk of malnutrition of 61% (95% CI: 47-74%) and 
specificity in detecting the well-nourished patients of 74% (95% CI: 57-87%). The positive 
predictive value of the tool was 79% (95% CI: 63-89%), while the negative predictive value was 
55% (95% CI: 40-69%).  
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Table 4-3 Categorisation of patients according to the Malnutrition Universal Screening 
Tool in comparison with the Patient Generated Subjective Global Assessment, with 




























































The ROC curve is displayed in Figure 4-1. The AUC was 0.667 (95% CI: 0.545-0.789) for 
MUST, meaning the tool had a weak ability to discriminate between well-nourished individuals 
and those at risk of malnutrition (discrimination would have been acceptable if AUC was 0.7-< 
0.8) (Hosmer et al. 2013). Therefore, MUST is unable to accurately predict the PG-SGA 
assessment category. Youden’s index (Sensitivity + Specificity - 1) was used to establish the 
best cut-off point for malnutrition. The sensitivity and specificity of MUST was not improved 
when a cut-off score of 0.5 (rather than 1) was used: the values were the same at 61% and 74% 
respectively.  
 





Figure 4-1 Receiver operating characteristic curve for Malnutrition Universal Screening 
Tool compared with Patient Generated Subjective Global Assessment 
 
 
The relationships between (a) BMI and (b) percentage weight loss and PG-SGA total score 
were as follows: BMI and PG-SGA had a weak negative correlation, where Spearman’s rank 
correlation coefficient was -0.259 (p= 0.021); percentage weight loss and PG-SGA had a 
moderate-strong positive correlation, where Spearman’s rank correlation coefficient was +0.641 
















Weight loss in 3-6 months (%) 
Figure 4-2 Spearman’s rank correlation between Patient Generated Subjective Global 
Assessment total scores and (a) body mass index and (b) weight loss in previous 3-6 
months: the correlation coefficients and p-values were (a) r= -0.259 (p= 0.021) and (b) r= 
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4.6 Discussion  
The study hypothesis was that MUST has an acceptable sensitivity and specificity in the OG 
oncology setting, by comparison with PG-SGA. The prerequisite sensitivity and specificity for 
MUST was set at 70%, the cut-off at which MUST was considered to perform adequately. 
Although, the specificity can be considered ‘fair’ at 74%, the sensitivity is ‘insufficient’ at 61% 
(Academical Point System 2014). Therefore, the study hypothesis cannot be accepted. Thus, 
although validated to be applied to all types of patient groups, based on these results, MUST 
does not appear to be suitable for use in the OG oncology setting.  
 
The ideal nutritional screening tool would be 100% sensitive and 100% specific. However the 
ability to correctly classify all patients who are malnourished (sensitivity) takes precedence over 
misclassifying well-nourished patients as malnourished (specificity), because it is important that 
a screening tool does not let malnourished patients fall through the net and not be referred for 
detailed nutritional assessment and intervention, where required. Therefore a lower specificity is 
sometimes the compromise for high sensitivity. However, in this study, the MUST tool had a low 
sensitivity of 61% and a higher specificity of 74%. It failed to identify 19 patients who were 
malnourished according to PG-SGA.  
 
Percentage weight loss in the previous three-six months was moderately-strongly correlated 
with the PG-SGA total score. This supports the findings from Boléo-Tomé’s study, where three-
six month weight loss (%) revealed a sensitivity and specificity of 76% and 85% respectively as 
compared with PG-SGA. The positive predictive value was 79% and the negative predictive 
value was 85% (Boléo-Tomé et al. 2011). Reported unintentional weight loss is a semi-objective 
measure as it relies on an individual’s ability to correctly report their weight, with a systematic 
review of the evidence finding that adults have a tendency to underestimate their weight 
(Connor Gorber et al. 2007). Also, it relies on cut-offs that reflect the limits between normal and 
abnormal intra-individual weight changes. Despite these issues, percentage unintentional 
weight loss represents a valid and reliable nutritional parameter in cancer.  
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On the contrary, in the current study, the correlation of BMI with PG-SGA total score was weak, 
though the direction of the association was as expected. It is not surprising that percentage 
weight loss showed a stronger correlation with PG-SGA total score than BMI did, as the former 
is a component of the PG-SGA tool (it can contribute 5 points of a possible 49 points), while the 
latter is not. The results for BMI are in line with data from another study of cancer patients, 
where the relationship between PG-SGA total score and BMI was assessed: the correlation 
coefficient was -0.251 (p= 0.055) (Bauer et al. 2002). This highlights the limitation associated 
with using BMI as a surrogate marker of malnutrition. This is because, malnourished cancer 
patients may have a BMI within the healthy, overweight or obese ranges, with body fat masking 
loss of lean body mass (Yip et al. 2014). This is an important consideration as just 41% of men 
and 32% of women in England now have a BMI within normal range (Health and Social Care 
Information Centre 2014). In fact, the mean (SD) BMI of the current cohort was 26.7 (4.7) kg/m2 
as reported in Section 3.5.6, which places them in the overweight category. This is not 
surprising as previous research has shown that cancer patients often have BMIs within normal 
or overweight ranges e.g. the mean (SD) of 126 cancer in-patients was 26.1 (5.8) kg/m2, and 
87% of patients with metastatic cancer (n= 346) had normal or high BMIs (Shaw et al. 2014; 
Sarhill et al. 2003).  
 
The prevalence of cancer-related malnutrition ranges from 26% to 80% as described in Section 
1.1.4.2. The adverse effects of malnutrition in cancer are manifold: poorer responsiveness and 
tolerance to cancer therapies; poorer performance status; lower QoL; increased risk of 
infections; worse survival outcomes; and higher treatment costs (Dewys et al. 1980; van 
Cutsem & Arends 2005; Lis et al. 2012; Alexandre et al. 2003; Kyle et al. 2005; Andreyev et al. 
1998). However, early nutritional support for those patients identified as malnourished has been 
shown to improve nutritional parameters, functional status as well as QoL, suggesting a global 
effect of nutritional intervention (Baldwin & Weekes 2011; Ravasco et al. 2003; Isenring et al. 
2004; Marín Caro et al. 2007). Many studies report that nutritional counselling leads to an 
improvement in nutritional outcomes. A common intervention used by health-care professionals 
to treat malnutrition in cancer is the initiation of ONS. The use of these supplements provides a 
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benefit in patients who are malnourished, especially those with a BMI of < 20 kg/m2 (Baldwin et 
al. 2001; Stratton & Elia 2000). A Cochrane review of nutritional supplementation showed that 
ONS produce a small but consistent weight gain, improvement in mortality, and shorter hospital 
stays (Milne et al. 2009). Increased energy and protein intake (per kg of body weight) has also 
been demonstrated following adherence to a daily ONS prescription in a randomised controlled 
trial of radiotherapy out-patients (Isenring et al. 2007).  
 
Given the proven advantages of nutritional intervention in oncology, it is crucial that nutritional 
issues be addressed at the time of diagnosis and throughout the course of cancer care. To 
achieve this, effective nutritional screening is paramount, as it ensures that those requiring 
dietetic involvement are correctly identified. Nutritional screening tools should answer four 
questions (Kondrup, Allison, et al. 2003b): (1) What is the condition now? (2) Is the condition 
stable? (3) Will the condition get worse? and (4) Will the disease process accelerate nutritional 
deterioration? 
 
The MUST does not adequately answer Question 3 (i.e. Will the condition get worse?). This is 
because the acute disease effect score of MUST (Step 3) does not consistently measure food 
intake. A score is only allocated to patients who are acutely ill and have, or are likely to have, no 
nutritional intake for more than five days. Interestingly, none of the 25 surveyed oncology 
nurses suggested that a cancer diagnosis per se constituted acute illness. The proportion of 
patients given an acute disease effect score was just 11% in the current study, which is likely to 
be lower than the true number of acutely ill patients. Therefore, the tool does not adequately 
answer Question 3 and this may have caused the high number of false negative results 
reported. Intriguingly, when ten community nurses undertook the same acute disease effect 
score survey, five believed that a cancer diagnosis per se was enough to warrant a score for 
Step 3 (assuming a reduced dietary intake too). Thus, had the community nurses criterion been 
use, each of the 80 patients would have been considered acutely ill and therefore, there would 
likely have been a lower percentage of false negatives. As such, it seems that the approach to 
Step 3 of MUST is a decisive factor in determining whether the tool agrees with PG-SGA.  
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Alternatively, the high false negative rate may be a consequence of the absence of an important 
element in the MUST tool i.e. there is no question related to the nutritional impact of symptoms. 
In the GI and nutritional status study (Chapter 3), there was a median (range) score of 3 (0-15) 
for the nutrition impact symptoms component of PG-SGA (for these 80 patients), indicating the 
contribution of symptoms to malnutrition. The assessment of symptoms would have helped to 
answer Question 4 (i.e. Will the disease process accelerate nutritional deterioration?). 
 
The current study has shown that MUST lacks sensitivity and specificity in an oncology 
population. This confirms the findings of previous researchers. In their retrospective study, 
Roulston and McDermott examined the dietetic records of 52 oncology patients (primary cancer 
site and in-/out-patient status not reported) (2009). The MUST was compared with the clinical 
judgement of the oncology dietitian following a full nutritional assessment. The screening tool 
failed to identify 61.5% of patients considered at risk of malnutrition by the dietitian. Bauer and 
Capra also reported the unsuitability of MUST as a screening tool in oncology (2003). However, 
it should be mentioned that an early version of the tool was used in their study (the MAG 
screening tool) that did not yet include the acute disease effect score present in MUST. 
Nonetheless, their in-patient validation study (n= 65, primary cancer site not reported) of the 
MAG screening tool against SGA found a low sensitivity of 59% (even lower than seen here) 
and a specificity of 75% (a little higher than seen here). The positive predictive value was 88% 
and the negative predictive value 38% (negative predictive value lower than seen here). The 
MAG screening tool failed to identify 31% of patients who were malnourished according to SGA, 
one of whom was severely malnourished. Therefore, despite the adaption of the MAG screening 
tool to the one in use today (i.e. MUST), it appears that little has changed with regard to the 
tool’s ability to effectively detect those patients with cancer who are truly malnourished.  
 
The current study results, as well as those from the above two studies are not in agreement with 
data from a 450 patient cross-sectional study (Boléo-Tomé et al. 2011). In this study, MUST 
performed much better: it was successfully able to identify patients at risk of malnutrition with 
80% sensitivity, 89% specificity, 87% positive predictive value and 100% negative predictive 
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value. It may be that the patient characteristics, treatment modalities and prognosis of those in 
this positive study were different from those in the three negative studies discussed, potentially 
affecting the performance of MUST. Roulston and McDermott did not report the patient 
characteristics and treatment type, while just the primary diagnoses were described by Bauer 
and Capra, with lymphoma (49%) and breast cancer (13%) the most prevalent. The most 
common diagnosis in the Boléo-Tomé study was breast cancer (21%), followed by prostate and 
lung cancers (19% and 16%), 44% of the group had T4 disease and all underwent radiotherapy 
(37% had palliative treatment). The current study specifically recruited patients with OG cancer 
before the commencement of radical treatment, with 60% having T3 disease. It is likely that the 
tool would have performed differently had the patients had T4 disease and not been treatment 
naïve. This may help to explain MUST’s good performance in the radiation oncology cohort 
(Boléo-Tomé et al. 2011).  
 
4.6.1 Strengths and Limitations  
A limitation of the current validation study is the convenience sample used. However, the size of 
the error bands for the 95% CI for sensitivity and specificity of MUST relative to the PG-SGA 
were acceptable, indicating that the sample size was sufficient for this study. Also, given that 
only those patients with OG cancer planned for radical treatments were included in the cohort, 
the results cannot be generalised to the following patients: those planned for palliative therapy; 
those undergoing treatment or; those with cancer of another site.  
 
A strength of this study lies in that both MUST and PG-SGA were carried out by one trained 
research dietitian, therefore avoiding inter-investigator variation. By undertaking the MUST 
before PG-SGA, the potential observer bias caused by knowing the PG-SGA category was 
avoided. However, therein also lies a study weakness. A dietitian completed the nutritional 
screening rather than a non-expert in nutrition (e.g. nurse or healthcare assistant), as would be 
expected. While the tool has been documented to have a high degree of reliability (low inter-
observer variation), with κ= 0.88-1.00 (for nurse vs. healthcare assistant, nurse vs. student 
nurse, doctor vs. nurse and doctor vs. doctor), the agreement between a dietitian and a nurse or 
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healthcare assistant has not been studied (Elia 2000). Moreover, reliability was not measured in 
the current study, which is another limiting factor. As it was not measured here, one can only 
speculate as to whether an acceptable level of inter-observer agreement would have been 
achieved for a dietitian vs. a nurse/healthcare assistant. Given the nutrition knowledge of the 
dietitian, it is likely that MUST was completed with greater accuracy than might be expected if it 
were completed by a nurse/healthcare assistant. As such, the unsatisfactory results shown here 
may actually be an overestimate of the real sensitivity and specificity in routine clinical practice.  
 
4.7 Conclusion 
In conclusion, nutritional screening with a suitable tool should identify patients who are at the 
greatest risk of malnutrition. As such, dietary advice and appropriate nutritional support can be 
provided to those who need it. There is not yet sufficient evidence to deem one nutritional 
screening tool a gold-standard in the oncology setting. In this study, MUST had weak ability to 
discriminate between well-nourished individuals and those at risk of malnutrition. This provides 
evidence to suggest that MUST is unlikely to be an appropriate tool for use in OG cancer. 
Further validation work is required to establish if one tool is highly sensitive and specific in OG 
cancer as well as across all oncology groups.  








   
Chapter 5  
Exploring the Potential of Metabolomics Technology in 
Small Intestinal Bacterial Overgrowth Diagnosis 
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5.1 Introduction 
5.1.1 Rationale  
Small intestinal bacterial overgrowth has been recognised as a clinical entity for decades. There 
is some evidence to suggest that oncological treatments are predisposing factors for SIBO: 
pelvic radiotherapy has received attention in this regard (Husebye et al. 1994; Wedlake et al. 
2008; Swan 1974), as has surgery, particularly upper-GI surgery (Brägelmann et al. 1997; 
Bjorneklett et al. 1983; Lock et al. 1995; Paik et al. 2011), but research is limited for 
chemotherapy. Also, as reported in Chapter 3, the prevalence of SIBO in OG cancer at the point 
of diagnosis was 23.5% (4/17), and its incidence during the first year after diagnosis was 76.9% 
(10/13). Of the 14 patients with SIBO, 71.4% reported flatulence and loose stools, while 64.3% 
and 50% reported belching and hard stools respectively. In addition, 11 (78.6%) patients were 
malnourished. These results and clinical experience strongly suggest that SIBO may be 
common in oncology patients. However, large prospective studies focused on determining its 
prevalence in a mixed cohort of cancer patients are lacking.  
 
Although current testing techniques for SIBO aid with its diagnosis, they are cumbersome, 
insensitive and/or non-specific. A systematic review of diagnostic tests for SIBO identified 
neither a consistent definition nor an adequately validated test for it (Khoshini et al. 2008). Thus, 
the management of the condition remains difficult. Therefore, given the high prevalence of SIBO 
in OG cancer, the symptom burden it exerts, and the potential nutritional sequelae (Chapter 3), 
a test that detects the presence/absence of SIBO in patients with cancer would be a significant 
clinical advance. 
 
Nuclear magnetic resonance-based metabolomics is becoming a useful tool in the study of 
biofluids and has the potential to contribute to the diagnosis of SIBO. Metabolomics is the 
comprehensive assessment of metabolites within a biological sample and attempts to 
systematically identify and quantify these small molecules. By identifying biomarkers, it could 
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lead to a simple, accurate, sensitive and specific objective test for SIBO. This would have major 
implications for the detection, and therefore, clinical management of this troublesome condition. 
At RM, there is an excellent opportunity to measure the prevalence of SIBO in oncology, 
describe the range of GI symptoms that it causes, as well as any biochemistry or 
haematological abnormalities associated with it. Additionally, the use of metabolomics 
technology can be trialled in this setting. It is hoped that such research will lead to an improved 
understanding of SIBO, more effective identification of it and ultimately, better management of 
the patients affected by it.  
 
5.1.2 Hypothesis 
In patients previously or currently being treated for cancer, qualitative and quantitative analyses 
of metabolites in urine will indicate the presence or absence of SIBO.  
 
5.2 Study Objectives and Outcomes 
5.2.1 Study Objectives 
The primary study objective was to establish whether 1H NMR technology allows the 
identification of metabolites indicative of SIBO in patients with cancer.  
 
The secondary objectives were to:  
• Describe the baseline characteristics of patients with cancer under investigation for 
SIBO and to compare the characteristics of the SIBO categories (Definite SIBO, 
Possible SIBO, No SIBO and Excluded) 
• Report the prevalence and severity of GI symptoms and stool type in patients with 
cancer and compare these variables for the four SIBO categories in order to investigate 
whether specific symptoms are characteristic of SIBO 
• Report the prevalence of positive and negative GHMBTs and values for H2 and CH4 in 
patients with cancer and compare results for the four SIBO categories to determine 
whether specific breath profiles are characteristic of SIBO  
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• Report the organisms grown following jejunal aspiration in patients with cancer and 
compare results for the four SIBO categories so as to explore whether specific 
organisms are characteristic of SIBO 
• Describe baseline biochemistry and haematological levels in patients with cancer and 
compare results for the four SIBO categories to investigate whether specific variables 
are characteristic of SIBO 
• Report the outcomes of further clinical investigations for the four SIBO categories to 
determine whether confounding factors were involved in SIBO diagnosis 
 
5.2.2 Study Outcomes 
The primary outcomes include: 
• Four SIBO categories: Definite SIBO, Possible SIBO, No SIBO and Excluded  
• Metabolite levels in baseline urine samples of patients with Definite SIBO and No SIBO 
 
Secondary outcomes include: 
• Baseline characteristics  
• At baseline and follow-up (following treatment of SIBO): GSRS scores for 26 individual 
symptoms (0-3), GSRS total scores (0-78) and stool type when ‘at best’ and ‘at worst’ 
• Values for H2 and CH4 from the GHMBT and overall test result 
• Microbiology results following jejunal aspiration: bacterial strains grown and microbial 
growth category 
• Baseline biochemistry and haematological levels 
• Other GI-related conditions diagnosed after the baseline measurement 
 
5.3 Study Design, Population and Organisation 
5.3.1 Study Design and Population 
This was a prospective observational case-control study conducted at RM. Patients were 
recruited from four specialist gastroenterology out-patient clinics. The patients included in the 
study were those with a historical diagnosis of cancer of any location who were either having 
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ongoing oncological treatment or who had previously completed treatment. There was no cut-off 
for how long ago this treatment was received. Treatment may have been provided for curative 
or palliative intent, and have been single- or multimodality in nature. Patients attended these 
clinics for the management of new onset GI symptoms, thought to be related to their cancer 
treatment. Following the baseline study visit, there was one follow-up visit to assess the impact 
of any antibiotic treatment on symptoms.  
 
The study’s inclusion criteria were as follows: 
• Previous cancer diagnosis (any site) 
• Ability to give written informed consent to participate 
• Age ≥ 18 years  
• Referral to the specialist gastroenterology clinic 
• Suspected of having SIBO, based upon GI symptoms and clinical suspicion and 
investigated for such at RM 
 
The study’s exclusion criteria were as follows: 
• Did not have a previous cancer diagnosis 
• Inability or unwillingness to give informed consent 
• Had already undergone testing for SIBO 
• Had already been treated for SIBO  
• Incapacity to comply with the demands of the study  
• Inability to adequately understand verbal or written information given in English    
 
5.3.2 Study Organisation and Responsibilities  
The study (CCR 3736) was granted ethical approval by the National Research Ethics Service 
Committee (NHS London Central) on 19th December 2011 (Appendix 8.14). The RM Committee 
for Clinical Research authorised the study on 17th February 2012. It was approved as a single-
centre study, with recruitment taking place at the hospital’s London and Sutton sites. The RM 
Charitable Trust funded the study. 
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As with the GI and nutritional status study, accountability for this study rested with the Principal 
and Chief Investigator, Dr Jervoise Andreyev, while Dr Clare Shaw, Prof Kevin Whelan and Ms 
Eva Grace were co-investigators. All individuals were involved in the study design, while study 
progress and the daily organisation of the study was the responsibility of Ms Grace. The study 
was conducted in accordance with the ethical requirements of the Declaration of Helsinki (1996) 
and good clinical practice.  
 
Mr Amyn Lalji was the study’s database manager, with responsibilities of data protection and 
preservation, as well as data entry into the study database in accordance with the requirements 
of the Data Protection Act (1998) and with RM data protection and confidentiality arrangements. 
All data were treated as strictly confidential and held in a secure location. The statisticians from 
the Research Data Management and Statistics Unit of RM who assisted with statistical work 
were as follows: Ms Karen Thomas and Mr Kjell Pennert at the study design phase, Mr Pennert, 
Ms Clare Peckitt and Mr Kabir Mohammed at the database development, data extraction and 
analysis phases.  
 
Ms Grace undertook sample processing, metabolite extraction and 1H NMR analysis in the 
laboratories of Prof Kevin Whelan (KCL) and Dr Lindsay Edwards, Lecturer in Physiology at the 
Centre of Human and Aerospace Physiological Sciences, KCL. Dr Edwards and Dr Andrew 
Atkinson (NMR Facility Manager, Centre for Biomolecular Spectroscopy and Randall Division of 
Cell and Molecular Biophysics, KCL) provided support with the 1H NMR spectroscopy data 
analysis. Following analysis, all usable data was transferred to RM as per the trust’s guidelines 
on data transfer.  
 
The study was discussed in the monthly research meetings as described previously. 
Recruitment trends, ethical issues, withdrawals and any other matters arising were discussed in 
this forum.  
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5.4 Methodology 
5.4.1 Clinical Methodology 
5.4.1.1 Screening, Inviting and Consenting 
Each patient who attended one of the specialist gastroenterology clinics for investigation and 
management of GI symptoms associated with cancer or its treatment was managed with a peer-
reviewed investigation and treatment algorithm (Andreyev et al. 2014). This algorithm has been 
shown to be highly effective in a randomised controlled trial of patients with new-onset GI 
symptoms persisting six months after pelvic radiotherapy (Andreyev et al. 2013). The algorithm 
assists clinicians to identify the cause of troublesome GI symptoms, with potential causes 
including: SIBO, bile acid malabsorption, exocrine pancreatic insufficiency, lactose or other 
disaccharide intolerance and pelvic floor dysfunction. According to this algorithm, if a patient 
presents to the clinician with one or more of the following GI symptoms, they are referred to the 
RM Endoscopy Unit for SIBO testing: bloating, flatulence, abdominal grumbling, nausea, 
vomiting, diarrhoea, steatorrhoea, nocturnal defaecation and constipation.  
 
When a patient was suspected of having SIBO and had agreed to undergo investigation, they 
were screened against the study’s inclusion/exclusion criteria and those who were eligible were 
invited to participate. Eligible patients were given a Patient Information Sheet by the consultant 
gastroenterologist, nurse consultant or study dietitian (Appendix 8.15) and informed that the 
study was voluntary, to prevent coercion. With permission, the study dietitian contacted the 
patient by telephone (or email if favoured) to determine if the information sheet had been read 
and if participation was considered. Any questions or queries were answered and contact 
details were provided.  
 
It was important that at least 24 hours had passed before an interested patient was consented 
into the study. This ensured that the patient had sufficient time to fully consider all aspects of 
the research. If the patient agreed to participate, the baseline study visit took place at the 
Endoscopy Unit at the London site of RM to coincide with the appointment for SIBO testing. 
This avoided any additional visits to the hospital, which was important as patients had ongoing 
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GI symptoms, often debilitating in nature. Each patient signed a study consent form before 
study data were collected (Appendix 8.16). After the consent process, patients were registered 
into the study, but were free to withdraw at any point, without needing to provide a reason and 
without it affecting their management. 
 
Each patient completed a follow-up study visit, which occurred when the patient returned to the 
specialist gastroenterology clinic for their routine follow-up out-patient appointment, thus 
avoiding unnecessary hospital visits. The modified GSRS tool captures symptom burden for the 
previous two-week period (Section 5.4.1.3). As the diagnosis of SIBO is largely based on the 
change in reported GI symptoms after treatment with antibiotics (Section 5.4.1.8), patients who 
received this treatment were assessed at least two weeks after the completion of the last 
course(s) of antibiotics. However, the actual time between baseline and follow-up study visit 
varied and was dependent on whether: 
• The patient cancelled, postponed or did not attend their out-patient clinic appointment 
• The patient received antibiotic treatment for SIBO  
• There was a delay in treating the patient for SIBO  
• The patient received more than one course of antibiotics  
 
5.4.1.2 Data Collection and Entry 
Once enrolled, the study dietitian collected data on a case report form (paper copy) at the two 
study visits. The data included on the case report form are described in Table 5-1. Details of the 
modified GSRS, the GHMBT, the endoscopic aspiration of jejunal fluid, sample handling and 
storage and the antibiotic treatment for SIBO are discussed in Sections 5.4.1.3, 5.4.1.4, 5.4.1.5, 
5.4.1.6 and 5.4.1.7 respectively. The data from the case report forms was entered into a secure 
RM study database in a timely manner. Checks on 10% of all entered data were performed by 
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Study visit Where collected 
from Baseline Follow-up 
Demographic and clinical information 
Baseline demographics ✓ ✗ EPR, patient 
Tumour site and histological stage ✓ ✗ EPR 
Presence of clinical conditions 
that may predispose to SIBO ✓ ✗ EPR, patient 
Length of time since new onset 
gastrointestinal symptoms ✓ ✗ Patient 
Biochemistry and haematology  ✓ ✗ EPR 
Current medications that may 
predispose to SIBO ✓ ✓ EPR, patient 
New gastrointestinal diagnoses 
made since baseline ✗ ✓ EPR 
Nutritional information 
Body mass index ✓ ✓ Dietitian measured height and weight 
Presence of Ileostomy/colostomy  ✓ ✓ Patient 
Treatment information 
Oncology treatment start and 
completion dates  ✓ ✗ EPR, patient 
Oncological treatment received ✓ ✗ EPR, patient 
Antibiotic treatment for SIBO ✗ ✓ EPR, patient 
Questionnaire 
Modified GSRS ✓ ✓ Patient 
Tests for small intestinal bacterial overgrowth 
GHMBT ✓ ✗ Dietitian 
Endoscopic aspiration and 
quantification of jejunal fluid  ✓ ✗ 
Gastroenterologist 
and microbiologist 
Samples for hydrogen nuclear magnetic resonance 
Jejunal fluid  ✓ ✗ Dietitian collected 
Urine  ✓ ✓ Patient collected 
Stool  ✓ ✓ Patient collected 
Abbreviations: EPR, electronic patient record; GHMBT, glucose hydrogen methane breath 
test; GSRS, Gastrointestinal Symptom Rating Scale; SIBO, small intestinal bacterial 
overgrowth 
 
5.4.1.3 Modified Gastrointestinal Symptom Rating Scale  
The modified GSRS was used to measure the prevalence and severity of 26 upper- and lower-
GI symptoms experienced over the preceding two weeks (Section 2.1.1, Appendix 8.5). An 
extra four symptoms were added compared with the tool used in Chapter 3, as they were 
believed to be relevant to patients with SIBO. The tool will be referred to as GSRS for the 
remainder of this chapter. 
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5.4.1.4 Glucose Hydrogen Methane Breath Testing 
For those patients willing and eligible to undertake the GHMBT, the equipment and substrate 
(Section 2.4.1.1), the preparation for the test (Section 2.4.1.2, Appendix 8.8), and the test 
protocol (Section 2.4.1.3) have previously been described.  
 
5.4.1.5 Endoscopic Aspiration and Culture Technique 
An OGD was also performed as per the investigation and treatment algorithm. This is a direct 
method of SIBO detection. During the procedure, jejunal fluid was aspirated for analysis. A 
detailed description of the test protocol for endoscopic aspiration and microbiological 
quantification (by culture) of the jejunal fluid has been discussed (Section 2.4.2). The 
microbiological cut-off values needed for test interpretation are shown in Table 2-5.  
 
5.4.1.6 Sample Handling and Storage 
When a patient agreed to participate in the study, a sample collection kit was mailed to them so 
that baseline stool and urine samples could be collected and delivered at the baseline study 
visit. The kit included the following items: 
• Written instructions on the use of the kit (Appendix 8.17) 
• Two 50 ml sealed screw-top, labeled collection pots (Sarstedt, UK) for storing the urine 
and stool samples 
• Two small sealable, labeled plastic bags for holding the collection pots  
• A cardboard tray for collecting the stool sample 
• A wooden tongue depressor for transferring the stool from the tray to the collection pot 
• Two pairs of soft vinyl examination gloves for wearing during sample collection 
• A sealable, labeled opaque carrier bag for transporting the samples to RM 
 
Patients were advised to collect the samples less than 24 hours before the baseline study visit, 
but ideally as close to the time of the visit as possible. When the samples were delivered to the 
study dietitian, they were temporarily stored in a dedicated study refrigerator, which was 
temperature checked daily to ensure that it was maintained between 0 and 4°C. During the 
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OGD, 10 ml of the jejunal aspirate sample was removed from the sterile Pennine trap before it 
was sealed and was transferred to a 20 ml universal container (Sarstedt, UK) and refrigerated 
until freezing.   
 
Aliquots of stool, urine and jejunal aspirate samples were taken from the refrigerator and frozen 
at -20°C within 36 hours of having been passed/collected. The stool samples were frozen in 15 
ml screw top tubes (Sarstedt, UK), and urine and jejunal aspirate samples were frozen in 5 ml 
cryogenic vials (Fisherbrand, UK).  
 
At the end of the baseline study visit, each patient was provided with another sample collection 
kit (for urine and stool) for use before the follow-up study visit. The same collection guidelines 
from baseline applied at follow-up.  
 
5.4.1.7 Antibiotic Treatment 
The consultant gastroenterologist or nurse consultant commenced a regimen of antibiotic 
treatment in those patients with a positive GHMBT and/or aspirate culture. In situations where 
the patient had a positive GHMBT, the clinician chose the first, and sometimes the second line 
antibiotic based on whether the test was positive for H2, CH4 or both gases. In addition, the 
sensitivities of the isolates provided by the microbiology department informed the treatment 
decision. If both tests proved negative, the clinician may still have treated the patient with 
antibiotics, especially if symptoms indicated a nocturnal need to defaecate and there was still no 
identified cause for the ongoing GI symptoms. The choice of first and second line antibiotics 
was determined as per Table 5-2. Following treatment, each patient returned to the specialist 
gastroenterology clinic to determine the effect on GI symptoms. For patients not treated with 
antibiotics for SIBO, they also returned to clinic, as other interventions may have been initiated 
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Table 5-2 Standard approach to determine choice of antibiotic treatment for small 
intestinal bacterial overgrowth 
 
 
5.4.1.8 Diagnostic Categorising of Small Intestinal Bacterial Overgrowth  
Only those patients: (a) with at least one complete test for SIBO (GHMBT or aspirate culture), 
(b) who attended a follow-up study visit, and (c) had completed the GSRS at both visits were 
considered for diagnostic categorisation. Small intestinal bacterial overgrowth status was 
determined by an experienced gastroenterologist (Dr Jervoise Andreyev) using a consistent 
approach. The diagnostic categorisation was primarily based on the patient’s response to the 
antibiotic treatment for SIBO (i.e. change in reported GI symptoms), although the 
gastroenterologist was not blinded to the GHMBT and aspirate culture results. The four possible 
categories for SIBO status were Definite SIBO, Possible SIBO, No SIBO and Excluded and 
were defined using a systematic approach as described in Table 5-3. 
Test results Antibiotic choice, 1st line 
Antibiotic choice, 
2nd line 
Glucose hydrogen methane breath test only 
H2 positive, CH4 positive Ciprofloxacin Doxycycline 
CH4 positive, H2 negative Doxycycline Clarithromycin 
H2 positive, CH4 negative Ciprofloxacin Doxycycline 
H2 negative, CH4 negative 
… but nocturnal defaecation/ongoing 
symptoms with no other identified cause 
Ciprofloxacin Doxycycline 
Glucose hydrogen methane breath test and jejunal aspirate 
Breath test: Any result 
Aspirate culture: Positive  
 As per sensitivities 
of the isolates 
 
- 
Breath test: H2 positive, CH4 positive 
Aspirate culture: Negative Ciprofloxacin Doxycycline 
Breath test: CH4 positive, H2 negative 
Aspirate culture: Negative Doxycycline Clarithromycin 
Breath test: H2 positive, CH4 negative 
Aspirate culture: Negative Ciprofloxacin Doxycycline 
Breath test: Negative 
Aspirate culture: Negative  
… but nocturnal defaecation/ongoing 
symptoms with no other identified cause 
Ciprofloxacin Doxycycline 
Abbreviation: CH4, methane 
Note: If a patient reported an allergy/previous adverse reaction to a specific antibiotic, that 
drug was not prescribed.    
Antibiotic Dosages: Ciprofloxacin 1,000 mg/day for 7 days; Doxycycline, 200 mg/day on day 
1 and 100 mg/day for 6 days; Clarithromycin, 1,000 mg/day for 2 days 
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Table 5-3 Standard approach employed by the gastroenterologist to determine small 




Patient had an absolute unequivocal positive clinical response to the antibiotic treatment, with 
no other possible factors accountable for it. Plus, the patient had at least one positive test for 
SIBO (GHMBT or aspirate culture) and the gastroenterologist felt completely confident that he 
would give the patient a repeat course/courses of antibiotics should their symptoms return. 
Possible SIBO 
 
(a) Patient had an absolute unequivocal positive clinical response to the antibiotic treatment 
but this could possibly have been produced by factors other than antibiotics (e.g. if they had 
other interventions during the study period). Plus, the patient had at least one positive test for 
SIBO. 
      or 
(b) Patient had an absolute unequivocal positive clinical response to the antibiotic treatment, 
with no other known factors accountable for it, but did not have a positive test for SIBO.  
      or 
(c) Treatment was not given/the response to treatment was not recorded, but the patient had 
at least one positive test for SIBO. 
      or 
(d) Patient did not have a positive clinical response to the antibiotic treatment, but had two 




Patient did not have a positive clinical response to antibiotics and had at least one negative 
test for SIBO.  
Excluded 
 
Patient had a positive clinical response to antibiotics but factors other than antibiotics (i.e. 
other interventions during the study period) were strongly felt to be involved. 
 
Abbreviations: GHMBT, glucose hydrogen methane breath test; GSRS, Gastrointestinal 
Symptom Rating Scale; SIBO, small intestinal bacterial overgrowth  
 
5.4.2 Laboratory Methodology for 1H NMR   
The urine samples (baseline and follow-up) were analysed for metabolites using 1H NMR. The 
laboratory methodology was adapted from that described by Beckonert and colleagues (2007). 
Although jejunal aspirate and stool samples were also collected as described in Section 5.4.1.6, 
they were not analysed for this thesis and thus will not be discussed hereafter. Due to time 
limitations, the pre-processing of the follow-up urine samples has not yet been performed. 
Therefore, for the remainder of this chapter, there will be no further reference to the follow-up 
urine samples. 
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5.4.2.1 Hydrogen Nuclear Magnetic Resonance: Urine Sample Preparation 
An NMR buffer solution was made up in a graduated glass bottle, to which the following were 
added: 
• 200 ml pre-made phosphate buffered saline 0.2 M, pH 7.4 (Sigma-Aldrich, Germany) 
• 0.04 g sodium azide (Sigma-Aldrich, Germany) 
• 0.04 g 4, 4-dimethyl-4-silapentane-1-sulfonic acid (Sigma-Aldrich, Germany) 
• 50.02 ml deuterium oxide 99.9% atom % D (Sigma-Aldrich, Germany) 
 
The solution was shaken thoroughly and placed on a heated stirring plate for 10 minutes. The 
urine samples were defrosted at room temperature, after which the samples were placed on a 
vortex for 30 seconds to ensure uniformity. Samples were aliquoted; 1.6 ml was aliquoted into 
Cryo-vials (Alpha Laboratories, UK) and re-frozen. The remaining 800 µL of each sample was 
mixed with 400 µL of the buffer solution in 1.5 ml microcentrifuge tubes.  
 
The microcentrifuge tubes were then spun at 13,000 g for five minutes at 4°C (Forcemicro 
Force 1624 and Eppendorf MiniSpin Ambient microcentrifuge). Samples were frozen at -80°C 
until the day of analysis, when 600 µL of each sample was transferred to 5 mm NMR tubes in 
96 tube racks (Bruker Biospin, Germany; Figure 5-1 a and b) using a SoftAide Pipette controller 
(Hamilton, Switzerland; Figure 5-1 c) and Volac 270 mm glass Pasteur pipettes (Poulten & Graf, 
Germany). The holes in the tube caps were then sealed using the balls provided (Bruker 
Biospin, Germany; Figure 5-1 d).   
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 (a)  (b) 
 (c)  (d) 
 (e)  (f) 
 
Figure 5-1 (a) 5 mm NMR tube, (b) 96 NMR tubes in rack, (c) SoftAide Pipette controller, 
(d) sealed NMR tube caps, (e) external and (f) internal views of 700 MHz Avance III 
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5.4.2.2 Hydrogen Nuclear Magnetic Resonance: Measurements (1D and 2D)  
Hydrogen nuclear magnetic resonance was performed on a 700 MHz Avance III NMR 
Spectrometer (Bruker Biospin, Germany) that was equipped with a quadrupole resonance (QCI-
P) cryoprobe and SampleJet sample changer with sample cooling (Figure 5-1 e). All 
experiments were performed at 298 Kelvin. Samples were moved to the SampleJet heating 
block to equilibrate for a minimum of one minute prior to insertion into the magnet (Figure 5-1 f). 
While one sample was in the magnet, the next one was moved to the heating block. Further 
temperature equilibration of the sample in the probe was allowed for 5 minutes. 
 
For each sample, the probe was tuned and matched, shimming performed and the 90° pulse 
measured. Water suppression was achieved using the nuclear overhauser effect spectroscopy 
(NOESY) presaturation pulse sequence (Bruker 1D) on all samples with a spectral width of 
20.52 ppm and 64,000 data points, giving an acquisition time of 2.28 seconds, a NOESY mixing 
time of 10 milliseconds and an inter-scan delay of 4 seconds. All spectra were recorded with an 
identical receiver gain.  
 
For structure elucidation purposes, a standard 2D total correlation spectroscopy (TOCSY) 
experiment was recorded using a mixing time of 60 milliseconds, 224 complex points in the 
indirect dimension and an inter-scan delay of 5 seconds. As with 1D analysis, this was 
performed on a 700 MHz Avance III NMR spectrometer (Bruker Biospin, Germany) at 298 
Kelvin. The 2D NMR spectroscopy is useful for increasing signal dispersion and for elucidating 
the connectivities between signals by plotting data in a space defined by two frequency axes 
rather than one. In effect, a TOCSY experiment helps to link clusters that are thought to belong 
to the same compound and reveal new compounds whose 1D NMR signatures could not be 
resolved alone.  
 
5.4.2.3 Hydrogen Nuclear Magnetic Resonance: Data Pre-processing  
Data pre-processing was performed on the baseline urine sample data using Topspin™ (Bruker 
Biospin, Germany) and MNova™ 9.01 (Mestrelab Research, Spain) software packages. The 1D 
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spectra (‘raw data’) were pre-processed by applying a line broadening of 0.3 Hertz prior to 
Fourier transformation and phased using a zero order phase correction (to obtain absorption 
line shape). A small number of measurements gave rise to run errors. These were repeated 
before proceeding to the next rack of samples. Baseline correction was then performed followed 
by the adjustment of peaks shifts (alignment) using spectral referencing. Spectra were 
referenced to the deuterium oxide resonance at 0 ppm. Regions of the NMR spectrum that 
displayed significant resonance shifting due to variations in pH were aligned using a correlation-
optimised method.  
 
In order to reduce the data redundancy in preparation for multivariate analysis, the most widely 
used method is called ‘binning’. Binning is a procedure that reduces data by grouping spectral 
responses, with each group called a ‘bin’. The binning algorithm method used in this study was 
the Adaptive Intelligent Binning algorithm (De Meyer et al. 2008). With this approach, a bin edge 
is a point on the frequency axis, which splits the set of spectra into two new sets of partial 
spectra i.e. new bins. Each point in the NMR spectral range of a specific bin is evaluated as a 
potential (candidate) new bin edge: the best candidate bin edge is selected and the original bin 
is accordingly divided into two new bins. This process is repeated for each bin assuming the 
summed bin values of the two new bins surpass the original bin value (De Meyer et al. 2008). 
 
Finally, samples may exhibit variable total metabolite concentrations due to instrument stability, 
or even the samples themselves (i.e. biological variation). For example, such inter-individual 
differences may occur in urine because of slight variations in pH caused by differing glomerular 
filtration rates. To ensure spectral intensities were directly comparable and related to 
concentrations, a normalisation step was needed. A probabilistic method called PQ 
normalisation was used, where the median quotient between all corresponding spectral data 
points was used as an estimate of the true dilution factor (Dieterle et al. 2006). 
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Following 2D analysis, the spectrum was processed in Topspin™ (Bruker Biospin, Germany) 
applying shifted sine-bells in both dimensions and zero-filling to the next power of two prior to 
Fourier transformation.  
 
5.4.3 Statistical Methods 
5.4.3.1 Sample Size Calculation 
The sample size was based on a convenience sample of patients referred to the specialist 
gastroenterology clinics with symptoms suggestive of SIBO. Records showed that the number 
of eligible patients would be approximately 300 within the study recruitment period of 18 
months. If 67% of these patients consented to the study (based on the research group’s 
previous recruitment rates), a sample size of 200 was thought to be possible.  
 
Previous data from the GI unit suggested that, of those patients tested for SIBO using the peer-
reviewed algorithm, 66% were treated for SIBO, of which 50% showed a positive clinical 
response to treatment. Using these data and assuming a sample size of 200, this would be 
sufficient to fit a multivariate model using up to five variables to predict SIBO status. With a total 
of 66 in the Definite SIBO category, an exact 95% confidence interval for this percentage could 
be calculated with a lower limit of not less than 5%.  
 
5.4.3.2 Statistical Analysis Methods 
5.4.3.2.1 Clinical Outcome Statistics 
Statistical analyses were conducted using SPSS (version 22.0, IBM, USA). In all statistical 
testing a 2-sided alpha level of 0.05 was used to assess statistical significance.  
 
Descriptive statistics were used to describe the baseline characteristics, GI symptoms, GHMBT, 
microbiology and laboratory results for the whole cohort. Categorical variables were expressed 
as mean (SD), while continuous variables were expressed as median (range). Following the 
categorisation of patients (Definite SIBO, Possible SIBO, No SIBO, Excluded), analyses were 
performed to determine if there was any difference between the categories with respect to the 
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above data. For the baseline characteristics, group comparisons were performed using Kruskal-
Wallis and chi-square tests.  
 
For the individual GSRS symptoms, numerical values for each of the 26 symptoms were 
reported for baseline and follow-up (0= none, 1= mild, 2= moderate, 3= severe). The maximum 
GSRS total score was 78. Summary statistics were reported at each time point using count 
(percentage) of patients reporting individual symptoms, the median (range) number of 
symptoms and the median (range) GSRS total score. Kruskal-Wallis tests were used to 
determine any significant difference between the categories with respect to GSRS total score at 
baseline and follow-up and change in GSRS total score between the time points.  
 
For the Bristol Stool Form Scale, the frequency of stool types ‘at best’ and ‘at worst’ were 
described for baseline, with groupings as follows: (a) Types 1 and 2, (b) Types 3, 4 and 5 and 
(c) Types 6 and 7. For patients with Definite- and No SIBO, the change in Bristol Stool Form 
Scale results between baseline and follow-up were reported using the cross-tabulation method.  
 
The GHMBT results were reported as count (percentage) of positive, negative and incomplete 
tests for all patients at baseline. The mean (SD) highest values for H2 and CH4 were reported 
for those with positive and negative results. For the positive tests, the count (percentage) 
positive for H2 alone, CH4 alone and both gases together were reported and the proportions 
testing positive (for the first time) at each 20-minute time point were described. Chi-square tests 
were undertaken to compare the overall GHMBT results for the four diagnostic categories.   
 
For microbiological results, the following data were reported for all patients with an OGD at 
baseline, using count (percentage) or median (range): aspirate appearance, microorganisms 
grown, strains isolated and microbiology classification (negative, intermediate or positive). Chi-
square and Kruskal-Wallis tests were used to compare these data for the four SIBO categories. 
The results from the GHMBT were cross-tabulated against the results from the OGD, taking the 
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OGD to be the gold-standard: for comparison purposes the ‘intermediate’ and ‘positive’ OGD 
results were both considered positive (i.e. suggestive of SIBO).  
 
Where biochemistry and haematological data were available at baseline, levels were expressed 
as median (range) for the whole cohort. To assess any differences in the four diagnostic 
categories Kruskal-Wallis tests were performed.  
 
Binary logistic regression was used to compare those with Definite- and No SIBO, so as to 
establish any predictors of SIBO based on baseline characteristics, treatment modalities, 
tumour stage and selected biochemistry and haematological variables. Logistic regression was 
performed in a forward stepwise manner for the two patient categories, with univariate entry 
testing based on a score statistic of p< 0.20. Odds ratios were calculated to determine whether 
any variables were risk factors for SIBO, with the 95% CI reported and used to estimate the 
precision of the OR. There were considerable amounts of missing data for the univariate 
variables. In addition, the two patient categories had small numbers and there were many 
variables included in the univariate analysis. Therefore, it was not deemed appropriate to fit a 
multivariate model, due to the strong risk of over-fitting the model.  
 
5.4.3.2.2 Primary Endpoint Statistical Methods: 1H NMR Data Analysis and Modeling 
Analysis and modeling was undertaken in RStudio™ 0.98.507 (RStudio, USA) and MATLAB™ 
8.2.0.20 (MathWorks Inc., USA). The data sets described in Section 5.4.2.3 were used in 
dimension reducing analyses. Only the data sets of those patients considered to have Definite 
SIBO and No SIBO were included in the statistical procedures. Therefore, the data sets for 
those in the Probable SIBO and Excluded categories did not undergo data analysis or modeling.  
 
Two approaches were taken for the untargeted analysis of baseline urine data for the two 
diagnostic categories (Definite SIBO, No SIBO). Firstly individual variables (bins) were 
compared between categories using a Welch 2-sample t-test. The false discovery rate was 
controlled using the standard method of Benjamini-Hochberg (false discovery rate held at 0.02 
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i.e. one in five would be a false discovery) (Benjamini & Hochberg 1995). Secondly, the 
multivariate data were reduced using PCA and PLSDA. These are both techniques used to 
reduce the dimension of a matrix firstly by obtaining transformed predictors and then, by fitting 
the model using these predictors (James et al. 2013). Principle component analysis is an 
unsupervised technique that involves the manipulation of a data matrix containing rows of 
spectra and columns of spectral descriptors. It is a bilinear decomposition method used for 
overviewing ‘clusters’ within multivariate data and allows the expression of most of the variance 
within the data set. Data were visualised by plotting the PC scores i.e. the new coordinates 
describing the variation in the data, where each point on the scores plot represents an individual 
observation or sample. Partial least squares discriminatory analysis is a supervised alternative 
to PCA that first identifies a new set of features that are linear combinations of the original 
features, and then fits a linear model via least squares using these new features. Whereas PCA 
works to describe maximum variation between samples, PLSDA describes maximum separation 
between defined class samples in the data. 
 
Principle component analysis and PLSDA indicated the bins that were the best candidates for 
being significant variables in the two diagnostic categories. Each bin contained multiple 
metabolites and the metabolite(s) causing the bin to be significant were identified. A pattern 
recognition, non-parametric technique called the k-Nearest Neighbours algorithm was used for 
classification using the metabolite(s). The output from this machine-learning algorithm was a 
class membership. A sample was classified by a majority vote of its neighbours, with the sample 
being assigned to the class most common among its k-nearest neighbours (k is a positive 
integer, typically small). The contributions of the neighbours were weighted, so that the nearer 
neighbours contributed more to the average than the more distant ones.  
 
The beeswarm plot analysis method was also used for classification. This is a 2D visualisation 
technique where data points are plotted relative to a fixed reference axis so that no two data 
points overlap. It is a useful technique when the measured values of interest for each data point 
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wish to be seen, but also the distribution of these values. All of the data points in the plot are 
non-overlapping; hence, they are all visible.  
 
The Human Metabolite Database (electronic) (Wishart et al. 2013) and Chenomx NMR Suite 
metabolite libraries (version 7.5 Chenomx Inc., Canada) assisted analysis of the 2D TOCSY 
spectra. Information from both the 1D and 2D NMR spectra confirmed assignments. Targeted 
profiling using Chenomx NMR Suite provided quantitative analysis. 
 
5.4.3.3 Violations and Deviations 
A patient was considered to violate the study protocol if they (a) did not have a complete GSRS 
at baseline or (b) had not completed at least one of the two tests for SIBO (i.e. GHMBT and 
aspirate culture) at baseline. Any violations resulted in the patient being excluded from the 
statistical analysis.  
 
5.5 Results 
5.5.1 Data Checking  
There was a high accuracy of data entry into the study’s database, with an error rate of < 1%, 
which was considered acceptable. 
 
5.5.2 Screening 
The study opened on 5th March 2012. A total of 284 patients were screened at the 
gastroenterology clinics, with 238 considered eligible and 46 being excluded for reasons shown 
in Figure 5-2. In total, 221 were invited to participate between March 2012 and May 2013. Of 
these patients, 21 (9.5%) declined, of which 7 (33.3%) were male and 14 (66.7%) female. The 
median (range) ages were 72 (69-82) years for the males and 69.5 (51-90) years for the 
females. The ethnic grouping of those who declined was as follows: White, 17 (81%); Other, 4 
(19%); Asian/British Asian, 0 (0%); Black/Black British, 0 (0%). 
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5.5.3 Enrolment, Baseline Characteristics and Diagnostic Categorisations 
In total, 200 patients were recruited into the study: 92 (46%) males and 108 (54%) females. The 
baseline characteristics of these patients are described in Table 5-4. Of the patients who 
consented, 179 (89.5%) were followed-up. Reasons for failed follow-up are shown in Figure 5-2. 
  













Followed-up (n= 179)  
 
 Consented and 
completed (n= 200) 
 
 
  Excluded (n= 46) 
- Investigator logistics (n= 25) 
- Plan change (n= 16) 
- Recurrence/previous  
treatment for SIBO (n= 2) 
- Unable to comply (n= 2) 
- Language issues (n= 1) 
 
 
  Declined (n= 21) 
- Acopia (n= 8) 
- Patient logistics (n= 5) 
- No reason given (n= 4) 
- No trials (n= 2) 
- Too complicated (n= 2) 
 
 
Suitable (n= 238) 
 
 
Assessed for eligibility (n= 284) 
 
 
  Uncontactable (n= 7) 
 
 
Invited (n= 221) 
 
 
  Missed (n= 10) 
 
 
Lost to follow-up (n= 15)  
Withdrawn (n= 3)  
Died (n= 3) 
 
Given diagnostic category (n= 171)  
 
Incomplete GSRS (n= 8) 
 
 
Figure 5-2 CCR 3736: screening and flow of patients through the study 
   233 
Table 5-4 Baseline characteristics in recruited cohort of 200 patients with suspected 
small intestinal bacterial overgrowth 
 
 n= 200 
Age                                                                                                  median (range) years 
Males  69 (20-89) 
Females 60 (25-89) 
Ethnicity  n (%) 
White 189 (94.5) 
Asian/British Asian  6 (3) 
Black/Black British 3 (1.5) 
Other 2 (1) 
Primary tumour site                                                                                     n (%) 
Urological 65 (32.5) 
Gastrointestinal 56 (28) 
Gynaecological 54 (27) 
Lymphoma 5 (2.5) 
Haematological 6 (3) 
Other 14 (7) 
Histopathological tumour (T) staging                                                        n (%) 
0-1  26 (13) 
2 48 (24) 
3 46 (23) 
4  18 (9) 
Not applicable 15 (7.5) 
Not recorded  47 (23.5) 
Oncological treatment   
Treatment complete, n (%) 183 (91.5) 
Months (median, range) since completion (n= 183) 35.5 (0-512) 
                                                                                                  n (%) 
Surgery  105 (52.5) 
Hormone therapy 55 (27.5) 
Chemotherapy 106 (53) 
Radiotherapy/brachytherapy 153 (76.5) 
Anthropometry (n= 195)                                                                          mean (SD) 
Body weight  74.6 (17.6) 
Body mass index 26.4 (5.7) 





Hernia repair  
Colonic resection  
Colostomy formation 




Pancreatic resection  
Gastric ulcers  
Whipple’s procedure  
Liver resection  
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 n= 200 
Irritable bowel syndrome 26 (13) 
Diabetes mellitus 19 (9.5) 
Colorectal cancer 16 (8) 
Lactose intolerance 6 (3) 
Pancreaticobiliary disease 4 (2) 
Motility disorder 2 (1) 
Small bowel diverticula 2 (1) 
Coeliac disease 1 (0.5) 
Liver cirrhosis 1 (0.5) 
Fistula 1 (0.5) 
Atrophic gastritis  
0 (0) 
Inflammatory bowel disease 


















Of the 179 patients followed-up, there were 8 (4.5%) with incomplete GSRS at the follow-up 
visit (Figure 5-2). Therefore, 171 (95.5%) were given a diagnostic category for SIBO by the 
gastroenterologist, as described in 5.4.1.8. The time that had lapsed between the baseline and 
follow-up visit for these 171 patients was: < 4 weeks for 6 (3.5%), 4-6 weeks for 9 (5.3%), 6-8 
weeks for 23 (13.4%), 8-10 weeks for 13 (7.6%), 10-12 weeks for 16 (9.4%) and > 12 weeks for 
104 (60.8%). The number of patients within each diagnostic category was as follows: Definite 
SIBO for 38 (22.2%), Possible SIBO for 70 (40.9%), No SIBO for 45 (26.4%) and Excluded for 
18 (10.5%). The 18 patients were excluded as factors other than antibiotics (i.e. other 
interventions during the study period) were strongly felt to be involved in the improvement of GI 
symptoms. 
 
Many of the remaining results will be reported firstly for the whole cohort (n= 200) and 
subsequently for the sub-group with diagnostic categories for SIBO (n= 171). The baseline 
characteristics of the 171 categorised patients are presented in Table 5-5. The data suggests 
that the proportions within the four diagnostic categories were similar for all variables, except for 
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hormone therapy, where 40% of the patients who received hormone therapy were within the No 
SIBO category.  
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Table 5-5 Differences between the diagnostic categories (total n= 171) for baseline characteristics  
 
 Definite SIBO, n= 38 Possible SIBO, n= 70 No SIBO, n= 45 Excluded, n= 18 p-value 
Gender, Age, Ethnicity 
Gender, n (%): Male 








11 (12) 0.516 
Age: Median (range) years 70 (33-85) 65.5 (20-89) 67 (31-79) 59 (39-81) 0.115 
Ethnicity, n (%): White 








1 (14.3) 0.955 
































Prostate cancer 10 (19.6) 17 (33.3) 20 (39.2) 4 (7.9) 0.096 
 0-1  
 2 
 3 
 4  
Not applicable 


























Oncological treatment, n (%) 
Surgery  24 (24.5) 39 (39.8) 21 (21.4) 14 (14.3) 0.123 
Hormone therapy 11 (24.4) 12 (26.7) 18 (40) 4 (8.9) 0.038 * 
Chemotherapy 19 (21.3) 42 (47.2) 19 (21.3) 9 (10.2) 0.307 
Radiotherapy, brachytherapy 26 (19.8) 50 (38.2) 39 (29.8) 16 (12.2) 0.089 
Predisposing factors for small intestinal bacterial overgrowth, n (%) 
One or more 29 (22.1) 51 (38.9) 36 (27.5) 15 (11.5) 0.642 
Notes: Categories were compared using Kruskal-Wallis tests for age and chi-square tests for all other variables. For hormone therapy, there was a 
higher proportion of patients in the No SIBO category, as compared with the other three categories.  
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5.5.4 Antibiotic Treatment 
Of the 200 study participants, 118 (59%) received antibiotics, 76 (38%) did not receive 
antibiotics and it was unknown if 6 (3%) had received them for the treatment of suspected 
SIBO. Of the treated patients, 58 (49.2%), 53 (44.9%) and 7 (5.9) received one, two and three 
courses respectively. A description of the antibiotic treatment given between the baseline and 
follow-up time points is shown in Table 5-6. 
 
Table 5-6 Antibiotics administered to 118 patients for the treatment of suspected small 
intestinal bacterial overgrowth  
  
 1st line treatment  
n= 118 
2nd line treatment 
n= 60 
3rd line treatment 






























Course completion as per prescription 
Completed 
Not completed 










Notes: Data presented as counts and percentages 
Of the 118 patients given antibiotics, 58 were given 1st line treatment only, 53 were given 1st 
and 2nd line treatment and 7 were given 1st, 2nd and 3rd line treatment.  
 
Of the 171 patients with a diagnostic category, 106 (62%) were treated with antibiotics. The 
antibiotic types administered to these patients are listed in Table 5-7. Overall, ciprofloxacin was 
the most commonly prescribed drug, followed by doxycycline. The compliance to treatment was 
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No antibiotics given  0 17 38 10 
Received at least one 
course of antibiotics  
38 53 7 8 




































All course(s) completion as per prescription 
Completed 
Not completed 













Notes: Data presented as counts and percentages 
* Patient may have received one or more antibiotic regimens and each antibiotic listed may 
have been given as 1st, 2nd or 3rd line treatment. If a patient received the same antibiotic 
twice/three times, this was only counted once.  
 
 
5.5.5 Gastrointestinal Symptoms 
At baseline, the median (range) time since the onset of new GI symptoms for the whole cohort 
was 24 (2-372) months and the median (range) GSRS total score was 21.5 (3-56). The median 
(range) number of GI symptoms was 13 (3-26). The reported prevalence of the individual GI 
symptoms at baseline is shown in Figure 5-3. The most commonly reported symptoms (any 
severity rating) were flatulence (95%), faecal urgency (87%), loose stools (83%) and a negative 
change in the frequency of stool (77%). The symptoms that were reported least often were 
dysphagia, odynophagia and regurgitation (all apply to solids and fluids), with between 6% and 
26% of patients reporting them.  
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Figure 5-3 The prevalence of symptoms at baseline using the Gastrointestinal Symptom Rating Scale (n= 200)
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At baseline, the median (range) GSRS total score was 22 (3-56) for the 171 categorised 
patients, which is the very similar to that of the whole cohort (n= 200). The reported prevalence 
of the individual GI symptoms at baseline for the four categories is shown in Figure 5-4 and 
Figure 5-5.  
 
In those with Definite SIBO, the most commonly reported symptoms were flatulence (97%), 
faecal urgency (92%), loose stools (89%), abdominal grumbling (89%) and incomplete 
evacuation (84%). Comparing the prevalence of the 26 symptoms between the Definite- and 
No-SIBO, 18 of the 26 symptoms were more prevalent in those with Definite SIBO, five were 
more prevalent in those with No SIBO and three had the same prevalence between the 
categories. The symptoms with the greatest difference between the two categories were 
steatorrhoea (20% points higher in Definite SIBO), abdominal grumbling (20% points higher in 
Definite SIBO), belching (19% points higher in Definite SIBO), regurgitations of fluids (16% 
points higher in Definite SIBO), heartburn (12% points higher In No SIBO) and loose stools 
(11% points higher in Definite SIBO).  
 
For the 171 categorised patients, median (range) number of GI symptoms was 13 (3-26) at 
baseline and 3 (0-11) at follow-up. Table 5-8 shows the comparison of (a) number of GI 
symptoms, (b) GSRS total scores and (c) change in GSRS total scores at baseline and follow-
up, so as to determine any significant difference between the four SIBO categories for these 












































































































































Definite SIBO Possible SIBO No SIBO Excluded 
 
Figure 5-4 The prevalence of upper-gastrointestinal symptoms (rated as mild, moderate or severe) at baseline in the 171 categorised 
patients: Definite SIBO (n= 38), Possible SIBO (n= 70), No SIBO (n= 45), Excluded (n= 18) 










































































































































Definite SIBO Possible SIBO No SIBO Excluded 
 
Figure 5-5 The prevalence of lower-gastrointestinal symptoms (rated as mild, moderate or severe) at baseline in the 171 categorised patients: 
Definite SIBO (n= 38), Possible SIBO (n= 70), No SIBO (n= 45), Excluded (n= 18) 
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Table 5-8 Differences between the diagnostic categories (total n= 171) for (a) number of gastrointestinal symptoms, (b) Gastrointestinal 
Symptom Rating Scale (GSRS) total scores and (c) change in GSRS total scores  
 







n= 18 p-value 
Number of GI symptoms 
Baseline 
Median (range) 13.5 (5-26) 13 (4-24) 13 (3-20) 13 (6-24) - 
Follow-up 
Median (range) 3 (0-10) 3 (0-11) 2 (0-8) 3 (0-9) - 
 
GSRS total scores 
Baseline 
Median (range) 23.5 (7-52) 22 (4-56) 20 (3-44) 20 (8-50) 0.377 
Follow-up 
Median (range) 19 (4-53) 16.5 (0-49) 16 (1-40) 16 (2-45) 0.916 
 
GSRS total score change between baseline and follow-up 
Median (range) 7 (-7: 27) 5 (-22: 48) 4 (-15: 22) 3 (-15: 25) 0.259 
 
Notes: Categories were compared using Kruskal-Wallis tests. Post-hoc tests were not conducted, as there were no significant differences between 
the categories.  
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The baseline Bristol Stool Form Scale results for the 200 patients are reported in Figure 5-6. 
There were 79.5% of patients who reported having Type 3, 4 or 5 ‘at best’ but 72% who 
reported having Type 7 when ‘at worst’. 
 
 
Figure 5-6 The reported prevalence of Bristol Stool Form Scale stool types ‘at best’ and 
‘at worst’ at baseline (n= 200) 
 
For the patients categorised as having Definite SIBO (n= 38) and No SIBO (n= 45), the change 
in Bristol Stool Form Scale results between baseline and follow-up are reported in Table 5-9. At 
baseline, 27 (72.9%) and 30 (66.7%) of those with Definite- and No SIBO respectively had Type 
6 or 7 stool when ‘at worst’. Of these 27 (Definite SIBO) and 30 (No SIBO) patients, 14 (51.9%) 
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Table 5-9 Cross-tabulation of stool types ‘at best’ and ‘at worst’ at baseline and follow-up 
for those with Definite SIBO and No SIBO using the Bristol Stool Form Scale  
 
‘At best’ 
Definite SIBO a Baseline Type 1, 2 Type 3, 4, 5 Type 6, 7 Total 
Follow- 
up 
Type 1, 2 0 1 0 1 
Type 3, 4, 5 3 31 2 36 
Type 6, 7 0 0 0 0 
Missing 0 1 0 1 
Total 3 33 2 38 
 
No SIBO b 
Baseline 
Type 1, 2 Type 3, 4, 5 Type 6, 7 Total 
Follow- 
up 
Type 1, 2 1 3 0 4 
Type 3, 4, 5 4 33 3 40 
Type 6, 7 0 0 1 1 
Total 5 36 4 45 
‘At worst’ 
Definite SIBO c Baseline Type 1, 2 Type 3, 4, 5 Type 6, 7 Total 
Follow- 
up 
Type 1, 2 3 0 4 7 
Type 3, 4, 5 1 4 10 15 
Type 6, 7 2 0 13 15 
Missing 0 0 1 1 
Total 6 4 28 38 
 




Type 1, 2 8 1 2 11 
Type 3, 4, 5 2 1 8 11 
Type 6, 7 1 2 20 23 
Total 11 4 30 45 
Notes: Data expressed as number of patients.  
Key: Blue cell= looser stool; yellow cell= firmer stool. 
a 31/37 (84%) no change, 3/37 (8%) looser stool, 3/37 (8%) firmer stool 
b 35/45 (78%) no change, 4/45 (9%) looser stool, 6/45 (13%) firmer stool 
c 20/37 (54%) no change, 3/37 (8%) looser stool, 14/37 (38%) firmer stool 
d 2/45 (64%) no change, 5/45 (11%) looser stool, 11/45 (25%) firmer stool 
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5.5.6 Glucose Hydrogen Methane Breath Testing 
One hundred and ninety three (96.5%) patients underwent a GHMBT. Of these, there were 191 
complete tests and 2 incomplete tests. Of the 191 assessable tests, there were 79 (41.4) that 
proved positive and 112 (58.6) that proved negative at three hours. The mean (SD) highest H2 
and CH4 values for those with positive results were 28.3 (27.1) and 20 (15); the mean (SD) 
highest H2 and CH4 values for those with negative tests were 4.9 (4.3) and 3.7 (3.3). Of the 
positive tests, there were 9 (11.4%) positive for H2 alone, 27 (34.2%) positive for CH4 alone and 
43 (54.4%) positive for both gases. As such, there were 52 tests positive for H2 and 70 positive 
for CH4 in total. The timings of test positivity are described in Figure 5-7. Of note, no test 
became positive after the 140-minute sampling point and there were just 5 patients (6.3%) with 
a positive test at the 120- and 140 minute sampling points (one of whom was positive for both 
gases).  
 
Figure 5-7 Timing of positivity of 79 glucose hydrogen methane breath tests, where a test 
can be positive for hydrogen, methane or both gases   
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Ten (12.7%) patients with a positive test did not adhere to the pre-test guidelines described in 
Section 2.4.1.2: 5 (6.3%) ate slowly absorbed carbohydrates during the previous 24 hours; 3 
(3.8%) did not brush teeth/use mouthwash on the morning of the test; 1 (1.3%) took sugar-
coated medication on the morning of the test; 1 (1.3%) ate food during the 12-hour fasting 
period and did not brush teeth/use mouthwash on the morning of the test. Of these ten patients, 
two had raised H2 levels at baseline (i.e. positive test at baseline), one of which was also 
positive for CH4. 
 
Of the 171 categorised patients (Definite SIBO, Possible SIBO, No SIBO and Excluded), 169 
(98.8%) undertook a GHMBT, 2 (1.2%) of which were incomplete. The counts and proportions 
of those with positive and negative tests are summarised in Table 5-10. Overall, a positive 
GHMBT can be associated with Definite- and Possible SIBO categories, rather than No SIBO 
and Excluded categories.  
 
Table 5-10 Glucose hydrogen methane breath test results for the 171 patients with a 















Test result according to the H2 and CH4 components 
H2 negative, CH4 negative  10 (10.3) a 34 (35.1) 44 (45.4) 9 (9.2) 
< 0.001 
H2 positive, CH4 negative 2 (22.2) 7 (77.8) 0 (0) 0 (0) 
H2 negative, CH4 positive 11 (44) 12 (48) 1 (4) 1 (4) 
H2 positive, CH4 positive 15 (41.7) 17 (47.2) 0 (0) 4 (11.1) 
Incomplete - - - 2 
- Missing - - - 2 
Overall result 
Positive 28 (40) 36 (51.4) 1 (1.4) 5 (7.2) 
< 0.001 
Negative 10 (10.3) 34 (35.1) 44 (45.3) 9 (9.3) 
Incomplete or missing - - - 4 - 
Abbreviations; CH4, methane; SIBO, small intestinal bacterial overgrowth.  
Notes: Data expressed as counts (percentages).  
a All 10 patients had a positive jejunal aspirate culture result.   
Chi-square tests were performed to assess difference in proportions between the categories, 
excluding those with incomplete tests: overall, a positive GHMBT can be associated with 
Definite- and Possible SIBO categories, rather than No SIBO and Excluded categories. 
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5.5.7 Endoscopic Aspiration and Culture  
Of the 200 recruited patients, 182 patients (91%) underwent an OGD with jejunal aspiration and 
microbiological quantification of the sample. The appearance of the aspirate on collection, the 
number and types of microorganism isolated during microbiological assessment and the 
microbiological classification of these patients is presented in Table 5-11. There were 15 (8.2%) 
patients considered to have a positive result based on the pre-defined microbiological cut-off 
levels (Table 2-5). Of the 171 categorised patients, 157 (92%) underwent endoscopic aspiration 
and their microbiological results are presented in Table 5-12. Overall, having isolated bacterial 
strains and higher bacterial counts was associated with Definite- and Possible SIBO categories, 
rather than No SIBO and Excluded categories.  
 
Table 5-11 Endoscopic aspiration and microbiological results for the 182 patients who 
underwent an oesophago-gastroduodenoscopy with jejunal fluid aspiration 
 
Aspirate appearance, n (%) 
Crystal clear 26 (14.3) 
Cloudy 47 (25.8) 
Bile stained 84 (46.2) 
Not recorded 25 (13.7) 
Microorganisms grown in CFU/ml, median (range) 
Aerobic Gram-positive bacillus 0 (0-1,000,000) 
Aerobic Gram-negative bacillus 0 (0-1,000,000) 
Anaerobic bacteria 0 (0-55,000) 
Candida 0 (0-10,000) 
Total 0 (0-1,055,000) 

















Microbiology classification, n (%) 
Negative 139 (76.4) 
Intermediate 28 (15.4) 
Positive  15 (8.2) 
* Multiple strains may be isolated in a single aspirate 
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Table 5-12 Endoscopic aspiration and microbiological results for the 157 patients with a diagnostic category who underwent an oesophago-
gastroduodenoscopy with jejunal fluid aspiration and comparison between categories 
 










Aspirate appearance, n (%): n= 135 
Crystal clear 
Cloudy 














Microorganisms grown in CFU/ml, median (range) 
Aerobic Gram-positive bacillus 0 (0-100,000) 0 (0-1,000,000) 0 (0-10,000) 5,000  (0-10,000) < 0.001 
Aerobic Gram-negative bacillus 0 (0-1,000,000) 0 (0-1,000,000) 0 (0-500,500) 55,000 (0-150,000) < 0.001 
Anaerobic bacteria 0 (0-55,000) 0 (0-10,000) 0 (0-0) 0 (0-0) 0.344 
Candida 0 (0-10,000) 0 (0-10,000) 0 (0-0) 0 (0-0) 0.007 
Total  12,750 (0-1,000,000) 5,864 (0-1,055,000) 0 (0-500,500) 65,000 (0-150,000) < 0.001 




     Coliforms 
     Giardia 
     Streptococcus 
     Candida 
     Klebsiella 




































Microbiology classification, n (%) 
Negative 19 (50) 56 (80) 43 (95.5) 1 (25)  
Intermediate 14 (36.8) 9 (12.9) 2 (4.5) 1 (25) 
Positive 5 (13.2) 5 (7.1) 0 (0) 2 (50) 
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Notes: * Multiple strains may be isolated in a single aspirate. 
Chi-square tests were performed to assess differences between the categories for the aspirate appearance and strains isolated and Kruskal-Wallis 
tests were performed to assess differences between the categories for the microorganisms grown. Significant variables were adjusted for multiple 
comparisons. Post-hoc tests (pair-wise comparisons) revealed the following significant differences: 
 
Definite SIBO vs. No SIBO: There were significantly higher levels of aerobic Gram-positive bacillus (p= 0.001), aerobic Gram-negative bacillus (p< 
0.001), Candida (p= 0.011) and total growth (p= 0.001) in those with Definite SIBO.  
 
Definite SIBO vs. Possible SIBO: There were significantly higher levels of aerobic Gram-negative bacillus (p= 0.018) and Candida (p= 0.015) in 
those with Definite SIBO.  
 
Possible SIBO vs. No SIBO: There were significantly higher levels of aerobic Gram-positive bacillus (p< 0.001) and total growth (p< 0.001) in those 
with Possible SIBO.  
 
Possible SIBO vs. Excluded: There were significantly higher levels of aerobic Gram-negative bacillus (p= 0.032) in those with Possible SIBO.  
 
Excluded vs. No SIBO: There were significantly higher levels of aerobic Gram-negative bacillus (p= 0.004) in those Excluded. 
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Of the whole cohort, there were 153 patients who underwent a jejunal aspirate and had a 
complete GHMBT. The two test results are compared in Table 5-13. When the ‘positive’ and 
‘intermediate’ aspirates were combined and taken as being indicative of SIBO (i.e. a positive 
result), concurrent results occurred in 58.2% of available cases, with non-concurrent results 
occurred in the remaining 41.8% of available cases. 
 
Table 5-13 Cross-tabulation of glucose hydrogen methane breath test and jejunal 
aspiration results (n= 200) 
 
 Glucose hydrogen methane breath test 
Positive Negative Missing Total 
Jejunal 
aspirate 
Positive 5 5 2 12 
Intermediate 13 12 1 26 
Negative 47 71 1 119 
Missing 14 24 5 43 
Total 79 112 9 200 
‘Missing’ breath tests include those that are missing or incomplete.  
‘Positive and ‘Intermediate’ jejunal aspirate results were both considered a positive result.  
Concurrent results: 89/153 = 58.2% (green shading).  
Nonconcurrent results: 64/153= 41.8% (red shading). 
 
 
5.5.8 Biochemistry and Haematological Results 
For all biochemistry and haematological variables, there were data available for at least some of 
the 200 patients at baseline, although there were no variables with data available for every 
patient (Table 5-14). Results for the 171 categorised patients are shown in Table 5-15. 
Following adjustments for multiple comparisons, there was found to be no significant differences 
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Table 5-14 Available biochemistry and haematological results at baseline for the cohort 
of 200 patients 
 
 Number of patients Median (range) 
General biochemistry 
Creatinine, µmol/L 195 71 (31-145) 
Glucose, mmol/L 186 5.5 (3.1-9) 
Urea, mmol/L 190 5.2 (1.8-9.9) 
Full blood count 
Haemoglobin, g/dL 188 13.2 (10-16.7) 
Platelets, x109/L 197 233 (101-461) 
Red blood cells, x1012/L 195 4.4 (3-5.6) 
Liver function tests 
Alanine transaminase, µ/L 193 22 (8-91) 
Alkaline phosphatase, µ/L 193 63 (29-770) 
Aspartate transaminase, µ/L 9 24 (13-45) 
Bilirubin (total), µmol/L 194 11.5 (0-77) 
Gamma-glutamyl transpeptidase, µ/L 101 22 (1-440) 
Protein levels 
Albumin, g/L 194 41 (23-49) 
C-reactive protein, mg/L 182 2 (0-61) 
Ferritin, ng/mL 10 87.5 (30-161) 
Hormone levels 
Thyroid-stimulating hormone, µmol/L 180 1.5 (0.03-6.6) 
Free thyroxine, pmol/L 179 14.2 (1.9-26.2) 
Vitamin levels 
Vitamin A, µmol/L 101 1.9 (0.7-3.5) 
Vitamin B12, pg/mL 170 254.5 (101-998) 
Vitamin D, µmol/L 111 48 (19-255) 
Vitamin E, µmol/L 101 31.7 (16.9-62) 
Red cell folate, ng/mL 170 476.5 (192-1,289) 
Serum folate, ng/mL 168 7.3 (1.6-725) 
Trace elements 
Iron, µmol/L 179 13 (3-50) 
Selenium, µmol/L 93 1.1 (0.2-3.5) 
Zinc, µmol/L 84 12.7 (10-29.3) 
Miscellaneous 
Erythrocyte sedimentation rate, mm/hr 133 15 (1-93) 
Total iron-binding capacity, µmol/L 177 58 (31-86) 
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Creatinine, µmol/L 37 75 (39-143) 69 68 (31-128) 44 73.5 (31-134) 18 66.5 (48-145) 0.177 
Glucose, mmol/L 35 5.7 (3.4-8.9) 64 5.5 (3.1-9) 44 5.6 (4.5-8.1) 16 5.4 (4.5-6.5) 0.336 
Urea, mmol/L 35 5.7 (3.7-9) 69 5 (1.9-9.9) 43 5.5 (1.8-8.9) 17 5.3 (3.1-9.3) 0.225 
Full blood count 
Hb, g/dL 37 13.2 (10-16.5) 65 13.2 (10.4-15.4) 43 13.3 (10-3-16.7) 15 13.6 (10.1-15.3) 0.736 
Platelets, x109/L 38 235.5 (101-456) 68 234 (109-405) 44 237 (109-461) 18 247 (116-395) 0.856 
RBC, x1012/L 38 4.4 (3.2-5.3) 67 4.3 (3-5.6) 43 4.5 (3-5.4) 18 4.5 (3.1-5.1) 0.201 
Liver function tests 
ALT, µ/L 36 19 (8-73) 68 25.5 (11-91) 44 22 (10-62) 18 22 (13-55) 0.055 
AP, µ/L 36 64 (32-109) 68 62 (29-770) 44 66.5 (29-123) 18 58 (47-139) 0.903 
AST, µ/L 2 21.5 (13-30) 5 24 (20-45) 2 26.5 (18-35) 0 - 0.657 
Bilirubin (total), µmol/L 36 11.5 (3-19) 69 12 (3-36) 44 11 (6-25) 18 10 (0-27) 0.332 
GGT, µ/L 20 20.5 (1-155) 36 23.5 (10-250) 23 20 (9-70) 8 23.5 (8-440) 0.637 
Protein levels 
Albumin, g/L 36 41 (23-49) 69 41 (26-48) 44 42 (35-48) 18 39.5 (32-46) 0.250 
CRP, mg/L 31 2 (1-42) 63 2 (0-55) 42 1 (1-39) 18 1 (1-46) 0.801 
Ferritin, ng/mL 2 64 (52-76) 5 99 (30-161) 1 38.5 (38.5-38.5) 0 - 0.465 
Hormone levels 
TSH, µmol/L 34 1.5 (0.1-6.2) 64 1.4 (0.03-6.7) 40 1.4 (0.2-6.4) 17 1.8 (0.9-6.6) 0.434 
Free T4, pmol/L 34 14.3 (11.4-21.5) 64 14.4 (11.1-26.2) 39 14.5 (11.7-24.6) 16 12.8 (9.2-19) 0.051 
Vitamin levels 
Vitamin A, µmol/L 16 1.8 (1.2-2.9) 37 2 (1.1-3.5) 22 1.8 (0.7-3.2) 7 1.7 (0.7-2.3) 0.256 
Vitamin B12, pg/mL 30 244 (133-998) 58 274.5 (119-934) 40 246.5 (114-701) 16 246 (101-522) 0.811 





















Vitamin D, nmol/L 20 45.5 (20-116)  39 45 (20-152)  25 53 (20-108)  7 63 (19-255) 0.860 
Vitamin E, µmol/L 16 32.4 (22.2-43.9) 38 29.1 (16.9-62) 21 32.5 (19.4-45.2) 7 32.8 (20-39.3) 0.617 
Red cell folate, ng/mL 33 443 (253-1,289) 56 512.5 (200-1,250) 38 472.5 (2131,236) 17 490 (192-1,185) 0.639 
Serum folate, ng/mL 32 7.2 (2.5-725) 53 6.7 (1.9-596) 39 7.3 (2-25) 15 10.6 (1.6-25) 0.570 
Trace elements 
Iron, µmol/L 34 12.5 (4-32) 62 14 (4-50) 40 14.5 (5-27) 17 11 (3-27) 0.523 
Selenium, µmol/L 18 0.9 (0.7-1.4) 32 1.1 (0.2-1.6) 21 1.2 (0.5-1.7) 7 1.2 (0.7-3.5) 0.066 
Zinc, µmol/L 16 13.8 (10.7-16.6) 29 12.8 (10.3-29.3) 19 12.4 (10.7-19.4) 5 13.7 (10-14.7) 0.964 
Miscellaneous 
ESR, mm/hr 30 17 (4-57) a 40 15 (1-56) 29 10 (1-93) a b 13 30 (1-54) b 0.032 * 
TIBC, µmol/L 34 53.5 (31-80) c d 61 58 (40-81) e 39 60 (40-81) c  17 61 (47-86) d e 0.012 * 
 
Abbreviations: ALT, alanine transaminase; AP, alkaline phosphatase; AST, aspartate transaminase; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate; GGT, gamma-glutamyl transpeptidase; Hb, haemoglobin; RBC, red blood cells; T4, thyroxine; TIBC, total iron-binding capacity, 
TSH, thyroid-stimulating hormone. 
Notes: Data expressed as median (range).  
Kruskal-Wallis tests were performed to assess differences between the categories. Significant variables were adjusted for multiple comparisons.  
Post-hoc tests revealed that differences for ESR were between (1) Definite- and No SIBO categories (unadjusted: p= 0.022; adjusted: p= 0.131) 
(marked a) and (2) No SIBO and Excluded categories (unadjusted: p= 0.009; adjusted: p= 0.052) (marked b). The differences for TIBC were between 
(1) Definite- and No SIBO categories (unadjusted: p= 0.026; adjusted p= 0.153) (marked c), (2) Definite SIBO and Excluded categories (unadjusted: p= 
0.002; adjusted: p= 0.011) (marked d) and (3) Possible SIBO and Excluded categories (unadjusted: p= 0.027; adjusted: p= 0.160) (marked e). 
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5.5.9 Binary Logistic Regression Analysis 
Binary logistic regression was used to compare the 83 patients categorised as having Definite-
SIBO (n= 38) and No SIBO (n= 45) to predict which variables were predictive of SIBO (Table 
5-16). In the univariate setting, one variable was a significant predictor of SIBO at the p< 0.05 
significance level: selenium (p= 0.045), where a one-unit (µmol/L) increase in the trace element 
decreased the risk of SIBO by 0.06 times. Also, previous treatment with 
radiotherapy/brachytherapy showed marginal significance (p= 0.05). For this variable, those 
who underwent previous radiotherapy and/or brachytherapy were three times less likely to 
develop SIBO than those individuals not receiving this treatment. The next strongest predictive 
variables (in order of strength) were total-iron binding capacity, tumour stage, prostate cancer 
and age, where the p-values were 0.056, 0.071, 0.090 and 0.131 respectively.   
 
Table 5-16 Univariate odds ratio table for the prediction of small intestinal bacterial 




n=  Categories OR (95% CI) p-value 
Age (years) 83 Continuous 1.03 (0.99-1.07) 0.131 
Gender 83 Female 
Male 
1 
1.39 (0.58-3.30) 0.458 
Ethnicity 83 Other 
White 
1 
1.72 (0.15-19.75) 0.663 





















0.37 (0.12-1.09) 0.071 
Surgery 83 No 
Yes 
1 
1.96 (0.81-4.73) 0.135 




Chemotherapy 83 No 
Yes 
1 





3.00 (1.00- 8.99) 
1 0.050 
Creatinine  82 Continuous 1.00 (0.98 -1.02) 0.881 
Glucose  79 Continuous 1.15 (0.72-1.84) 0.554 
Urea  78 Continuous 1.11 (0.82-1.52) 0.503 
Haemoglobin  80 Continuous 0.93 (0.68-1.26) 0.623 
Red blood cells  81 Continuous 0.77 (0.31-1.87) 0.559 
Albumin  80 Continuous 0.92 (0.83-1.03) 0.153 
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Variables 
 
n=  Categories OR (95% CI) p-value 
Vitamin B12  70 Continuous 1.00 (0.99-1.00) 0.859 
Selenium  39 Continuous 0.06 (0.00-0.93) 0.045 * 
ESR  59 Continuous 1.03 (0.99-1.07) 0.169 
TIBC  73 Continuous 0.95 (0.90-1.00) 0.056 
Abbreviations: ESR, erythrocyte sedimentation rate; TIBC, total iron-binding capacity 
Notes: * p< 0.05 
The Box-Tidwell test was conducted to test the assumption that the relationship between the 
continuous predictors and the logit (log odds) was linear: tests revealed that the assumption 
was not violated for any of the continuous predictors. 
 
5.5.10 New Gastrointestinal Diagnosis  
As each recruited patient was managed using a peer-reviewed investigation and treatment 
algorithm, they generally underwent multiple investigations, so as to determine the cause for 
their GI symptoms. As such, apart from SIBO, patients may have received other GI diagnoses 
between the baseline and follow-up visits, as described in Table 5-17. There were more new 
diagnoses in those with Possible SIBO (60%) and No SIBO (58%) as compared with Definite 
SIBO (50%). In those with Definite SIBO, 26.3% were also diagnosed with bile acid 
malabsorption.  
 
Table 5-17 New gastrointestinal diagnoses other than small intestinal bacterial 
overgrowth for the 171 patients with a diagnostic category 
 
  







No 19 (50) 28 (40) 19 (42.2) 12 (66.7) 
Yes * 19 (50) 42 (60) 26 (57.8) 6 (33.3) 
Bile acid malabsorption 10 (26.3) 26 (37.1) 16 (35.6) 3 (16.7) 
Gastritis 3 (7.9) 3 (4.3) 2 (4.4) 2 (11.1) 
Pancreatic insufficiency  3 (7.9) 4 (5.7) 0 (0) 0 (0) 
Inflammatory changes  0 (0) 2 (2.9) 3 (6.7) 0 (0) 
Coeliac disease 0 (0) 1 (1.4) 1 (2.2) 0 (0) 
Motility disorder 1 (2.6) 0 (0) 0 (0) 1 (5.6) 
Drug-related issues 0 (0) 1 (1.4) 2 (4.4) 0 (0) 
Bile acid reflux 0 (0) 2 (2.9) 0 (0) 0 (0) 
Infection 1 (2.6) 2 (2.9) 0 (0) 0 (0) 
Hiatus hernia 0 (0) 2 (2.9) 0 (0) 0 (0) 
Diverticular disease 2 (5.2) 0 (0) 0 (0) 0 (0) 
Oesophageal lesion  0 (0) 0 (0) 2 (4.4) 0 (0) 
* One patient in each of the Definite SIBO and Possible SIBO categories had two diagnoses 
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5.5.11 Primary Outcome: Metabolite Levels in Baseline Urine Samples Using 1H NMR 
Hydrogen Nuclear Magnetic Resonance was performed on 196 baseline urine samples: 
samples were available for all patients in the Definite SIBO (n= 38) and No SIBO (n= 45) 
categories. Principal component analysis and PLSDA were performed on all of the spectral 
variables, with no separation of the categories noted. Single variable analysis was performed 
using independent t-testing. Following this, using only the variables that had a p-value of < 0.05 
(after correcting for multiple testing), PCA was performed again. There was some, albeit not 
distinct separation of the categories noted, as shown in Figure 5-8. A support vector machine 
classifier was used to predict which points on this PCA plot belonged to the Definite SIBO 
category and which belonged to the No SIBO category, with good discriminatory ability noted.  
 
 
Figure 5-8 Principal component (PC) analysis plot derived from the 700 MHz 1H NMR 
spectra of baseline urine samples. Comparison of the mean metabolic PC1/PC2 
trajectories: Definite SIBO, green; No SIBO, red  
 
Following Adaptive Intelligent Binning, there were 68 bins deemed possible candidates for being 
significant variables (p-values were < 0.05) in the separation of the two diagnostic categories. 
Each bin was ranked according to statistical significance with the bin ranked number 1 having 
the lowest (most significant) p-value (Table 5-18). Individual spectra were visualised to 
determine the presence of ‘real’ peaks in the region of these 68 bins, rather than ‘noise’ 
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variables (which are insignificant). After the elimination of ‘noise’ variables and considering the 
proximity of bins to one another on a spectrum, the following five bins were considered worthy 
of further investigation: Bins 264, 265, 266, 267 and 268, as highlighted in Table 5-18. 
 
Table 5-18 Results of Adaptive Intelligent Binning performed on the spectra of urine 
samples from Definite SIBO and No SIBO patients 
 
Bin number p-value Rank Lower ppm Upper ppm 
21 0.050 68 8.4496 8.4302 
23 0.042 54 8.3842 8.366 
44 0.033 38 8.0834 8.0751 
53 0.010 11 7.9865 7.9756 
63 0.048 67 7.8882 7.876 
71 0.044 59 7.7843 7.7706 
72 0.038 43 7.7706 7.749 
73 0.021 26 7.749 7.7329 
94 0.015 15 7.4267 7.4162 
95 0.011 12 7.4162 7.4056 
96 0.016 16 7.4056 7.3945 
103 0.036 41 7.3279 7.3167 
108 0.021 25 7.2783 7.2672 
117 0.040 44 7.1895 7.1815 
118 0.030 34 7.1815 7.1772 
138 0.040 47 7.0035 6.9959 
140 0.040 46 6.9913 6.9837 
142 0.041 49 6.9752 6.9677 
154 0.018 22 6.8713 6.8583 
155 0.043 57 6.8583 6.8531 
165 0.030 36 6.765 6.7114 
179 0.036 40 6.5555 6.5287 
264 0.016 17 4.1954 4.1845 
265 0.005 4 4.1845 4.1789 
266 0.007 5 4.1789 4.1733 
267 0.018 24 4.1733 4.1664 
268 0.004 3 4.1664 4.1615 
269 0.007 6 4.1615 4.1525 
355 0.017 19 3.6662 3.6563 
358 0.042 51 3.6454 3.6398 
359 0.047 64 3.6398 3.6366 
399 0.043 55 3.4057 3.4013 
431 0.025 31 3.2016 3.1962 
  259 
Bin number p-value Rank Lower ppm Upper ppm 
437 0.031 37 3.1601 3.1523 
454 0.034 39 3.0503 3.0428 
459 0.008 7 3.0112 3.0053 
460 0.003 2 3.0053 3.0002 
467 0.010 10 2.9465 2.9353 
482 0.042 52 2.8315 2.8251 
502 0.026 32 2.6367 2.6267 
504 0.040 45 2.6151 2.61 
507 0.017 21 2.5995 2.5962 
509 0.041 50 2.5921 2.586 
522 0.041 48 2.4896 2.4858 
544 < 0.001 1 2.3236 2.3197 
546 0.042 53 2.3136 2.3039 
552 0.013 14 2.2745 2.264 
554 0.010 9 2.261 2.2494 
555 0.008 8 2.2494 2.2364 
557 0.048 66 2.2291 2.2241 
574 0.047 63 2.1087 2.0998 
575 0.022 28 2.0998 2.096 
576 0.016 18 2.096 2.0896 
577 0.025 30 2.0896 2.0835 
578 0.047 65 2.0835 2.0775 
596 0.017 20 1.9468 1.9377 
597 0.046 62 1.9377 1.9305 
598 0.043 58 1.9305 1.9251 
602 0.030 35 1.9035 1.8906 
611 0.038 42 1.8181 1.8095 
614 0.045 61 1.7926 1.7842 
626 0.022 27 1.7085 1.6967 
627 0.013 13 1.6967 1.689 
650 0.044 60 1.4568 1.4504 
674 0.043 56 1.2946 1.2848 
686 0.023 29 1.1893 1.1844 
698 0.018 23 1.1027 1.0917 
699 0.029 33 1.0917 1.0802 
 
Abbreviation: Ppm, parts per million 
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Focusing on these five bins, the 1H NMR spectra for all Definite SIBO and No SIBO samples 
were stacked one on top of another to display the spectral area that encompassed them, as 
shown in Figure 5-9. Within this area, there was a multiplet (an NMR signal that is split) at 4.20-
4.15 ppm, containing six peaks (sextet), which appeared to be causing separation of the two 
categories. An example spectrum (from a Definite SIBO patient) containing the highest level of 
this multiplet is shown in Figure 5-10. 
 
 
Figure 5-9 700 MHz 1H NMR spectra of baseline urine samples of Definite SIBO (red 
spectra) and No SIBO (black spectra) patients zoomed into the spectral area of interest 
containing the multiplet: the highest intensity of the multiplet can be identified in Definite 
SIBO samples 
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Figure 5-10 700 MHz 1H NMR spectrum of the baseline urine sample from a Definite SIBO 
patient with the highest intensity of the multiplet at 4.20-4.15 parts per million: top figure 
shows the full spectrum; bottom figure shows the area of interest zoomed into 
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The k-Nearest Neighbours algorithm was used for classification of the two categories using Bin 
268 from this multiplet, as it had the smallest p-value of the five bins. As shown in Figure 5-11, 
when all of the samples in Definite SIBO and No SIBO were combined, 11 of the top 12 highest 
spectral intensities were from the Definite SIBO category. To test Bin 268 further, a small 
amount of noise (jitter) was added to the numeric vector, which prevents observations with the 
same spectral intensity from covering each other up. The resulting 1D beeswarm jitter plot also 
shows relatively good separation of the patient categories (Figure 5-12). 
 
 
Figure 5-11 Classification of the Definite SIBO patients (green dots) and No SIBO patients 
(red dots) with respect to intensity of the signals within Bin 268 using a k-Nearest 
Neighbours plot 
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                                  No SIBO                                   Definite SIBO 
Figure 5-12 Beeswarm jitter plot derived from the classification of Definite SIBO and No 
SIBO by the intensity of the signals within Bin 268 
 
The 2D spectrum of one sample (i.e. the one with highest intensity of signals within the five 
bins) was analysed so as to clarify the structure of the metabolite(s) found within that region of 
the spectrum. The peaks in the spectrum correspond to a compound called N-acethylglutamine 
(Figure 5-13). The chemical structure of N-acethylglutamine is displayed in Figure 5-14. 
 
 




Figure 5-13 1H NMR 2D spectrum: the structural pattern of N-acethylglutamine is zoomed 
into in the bottom figure  
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 Figure 5-14 Chemical structure of N-acethylglutamine: C7H12N2O4  
 
 
5.5.11.1 Hypothesis 1: Metabolomics Will Indicate the Presence or Absence of Small 
Intestinal bacterial Overgrowth 
This study’s hypothesis was that qualitative and quantitative analyses of metabolites in urine 
would indicate the presence or absence of SIBO in patients previously or currently being treated 
for cancer. Using selected data modeling techniques, the results available thus far suggest that 
metabolomics may have some ability to separate patients with SIBO from those without it based 
on the metabolite N-acethylglutamine. However, the concentration of N-acethylglutamine was 
not consistently higher in those with SIBO compared with those without SIBO. Therefore, the 
compound does not yet appear sensitive or specific enough to indicate the presence or absence 
of SIBO. Thus, this research hypothesis cannot be accepted at this stage. Further research is 
required in order to investigate whether this compound, or others, would be suitable candidate 
metabolites to discriminate between individuals with and without SIBO.  
 
5.6 Discussion 
5.6.1 Small Intestinal Bacterial Overgrowth Characteristics  
This is the first prospective study to measure the prevalence of SIBO in a cohort of patients 
previously diagnosed with cancer and reporting the new onset of GI symptoms. In this study, 
the prevalence of Definite SIBO was 22.2%, with a further 26.5% also potentially having the 
condition (i.e. Possible SIBO). Previous retrospective data from RM (n= 435) suggested that the 
prevalence of SIBO in cancer was somewhat lower; 11% were found to have Definite SIBO and 
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17% had Possible SIBO (unpublished data). The baseline characteristics of that cohort were 
very comparable to the current study’s cohort: 50% were male; the median age of the males 
and females was 69 (22-89) and 59 (28-90) years respectively; 31% had GI cancer, 32% 
urological, 27% gynaecological, 4% haematological and 6% had another cancer type. 
Considering the categorisation of patients was done in a comparable way for both studies, one 
can surmise that the true prevalence of SIBO may have been higher in the retrospective study 
had there been less unavailable data (46% could not be assessed for SIBO status due to 
missing data).   
 
While there are no other studies, retrospective or otherwise, of SIBO in such a diverse cohort of 
cancer patients, one prospective observational study investigated SIBO in a mixed cohort of GI, 
gynaecological and urological cancer patients undergoing pelvic radiotherapy (Wedlake et al. 
2008). In this study, 38 patients underwent a glucose-H2 breath test before commencing 
radiotherapy and again after four-five weeks of treatment. Of these patients, 10 (26%) had a 
positive breath test at the follow-up time point, after having had a negative baseline test. The 
design of this pilot study was not akin to the current study: assessment of SIBO was done in the 
acute phase of cancer therapy; direct aspiration and quantification of jejunal fluid was not 
undertaken; and patients’ GI symptoms were not assessed following antibiotic treatment. 
Nonetheless, the prevalence of SIBO appears to correspond to that reported in the current 
study (22.2%).  
 
One of the objectives of this investigative study was to identify the variables that are 
characteristic of SIBO. It is the first study to measure an extensive number of both upper- and 
lower-GI symptoms systematically in patients undergoing testing for SIBO. At baseline, in those 
with Definite SIBO, the median (range) number of symptoms reported was 13.5 (5-26), which 
highlights the burden of the condition. In this regard, the most commonly reported symptoms 
were flatulence, faecal urgency, loose stools, abdominal grumbling and incomplete evacuation, 
ranging from 84-97%. Other notable symptoms included belching, nausea, early satiety, 
bloating, abdominal pain, diarrhoea, constipation, and faecal incontinence found to occur in 47-
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79% of those with Definite SIBO. These results show some parallels with the literature. 
Diarrhoea, abdominal pain and constipation in this study were at the upper-end of the 
prevalence figures reported in previous prospective and retrospective studies: 79% (literature: 
13-89%), 74% (literature: 13-86%) and 53% (literature: 10-77%) respectively. The prevalence of 
bloating in the current study (68%) was higher than previously reported (10-50%) (Lombardo et 
al. 2010; Tursi et al. 2003; Marie et al. 2009; Compare et al. 2010; Pimentel et al. 2000; George 
et al. 2012; Davidson et al. 1984; Roberts et al. 1977). However, analysis was not undertaken to 
determine if individual symptoms were significantly higher in those with Definite SIBO compared 
with No SIBO, so these data should be interpreted with caution. 
 
Remarkably, the current study appears to be the first to recognise the following symptoms 
associated with SIBO: faecal urgency (reported in 92%), abdominal grumbling (89%), 
incomplete evacuation (84%), belching (79%), faecal incontinence (68%) and early satiety 
(50%). This indicates that the GI characteristics of SIBO have not been fully understood due to 
consistently poor GI symptom assessment to date. However, on a positive note, this study 
demonstrates an improvement in GI function following the treatment of antibiotics in those with 
Definite SIBO: median (range) number of symptoms was 13.5 (5-26) at baseline and 3 (0-10) at 
follow-up; median (range) GSRS total score was 23.5 (7-52) at baseline and 19 (4-53) at follow-
up. In addition, patients reported less loose stools following treatment.  
 
In addition to measuring the symptoms associated with SIBO, this study also assessed 
biochemistry and haematological variables in the cohort. Early animal studies suggested that 
SIBO may be associated with reduced haemoglobin levels as a result of GI bleeding within a 
blind loop (Giannella & Toskes 1976). More recently, in a study of 51 patients with systemic 
sclerosis, those with SIBO had significantly lower median levels of haemoglobin than those 
without it (12.25 vs. 13.9 g/dL, p= 0.002) (Marie et al. 2009). Similarly, in a study of 43 
gastrectomised patients, haemoglobin concentration tended to be lower in the patients with a 
maximum H2 concentration in the glucose-H2 breath test (p= 0.056) (Iivonen et al. 1998). 
However, the current study does not support these previous data: the median (range) 
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haemoglobin level of those with SIBO (13.2 (10-16.5) g/dL) was neither significantly different to 
those without SIBO nor low according to standard reference ranges (Thomas & Bishop 2007). 
Theoretically, SIBO may be associated with raised total iron-binding capacity (marker of 
inflammation), but in the current study, Definite SIBO was not associated with significantly 
higher levels of it as compared with No SIBO (after adjusting for multiple comparisons).  
 
Vitamin B12 has also received some attention with regard to SIBO, as facultative Gram-negative 
aerobes and anaerobes have been shown to be capable of competitively utilising vitamin B12 
(Welkos et al. 1981). However, data with regard to deficiency of the vitamin have proven 
inconsistent to date. For example, a study of 16 elderly patients with confirmed SIBO (as per 
lactulose-H2 breath test) reported that 10 (62.5%) had subnormal serum vitamin B12 levels 
(Haboubi & Montgomery 1992). Conflictingly, in the aforementioned systemic sclerosis cohort, 
no significant difference in vitamin B12 levels was noted between patients with and without SIBO 
(p= 0.133) (Marie et al. 2009). Also, in a 35-patient study (n= 22 with GI disease, n= 13 
controls), there was no significance difference in vitamin B12 levels between those with and 
without SIBO (SIBO was confirmed using the direct aspiration method) (Hamilton et al. 1970). 
The current study supports the latter two, with no significant difference noted between those 
with Definite- or No SIBO with regard to vitamin B12 and a median (range) value of 244 (133-
998) pg/mL noted for those with Definite SIBO.  
 
Fat-soluble vitamin status has been explored in SIBO as intraluminal bacteria have been shown 
to deconjugate bile acids possibly causing malabsorption of fat and fat-soluble vitamins (Shindo 
et al. 1998). However, to date, there have only been case-reports of vitamin E deficiency 
syndromes (neuropathy, T-cell abnormalities) and night blindness caused by vitamin A 
deficiency in patients with SIBO (Brin et al. 1985; Kowdley et al. 1992; Hasan & Finucane 
1993). Similarly, although vitamin D deficiency is believed to be a complication of SIBO, there 
have been few data strongly demonstrating this to be the case (Stotzer et al. 2003). With regard 
to these fat-soluble vitamins, the current study does not indicate that their levels are lower in 
those with SIBO, as compared with the other patient categories, nor below normal reference 
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ranges (Thomas & Bishop 2007). In fact, there were no biochemistry or haematological 
variables that appeared to be abnormal in patients with Definite SIBO. This suggests that, 
contrary to common belief, there may be no suitable non-invasive surrogate markers of SIBO.  
 
As discussed, there is no consensus on the optimal test for use in detecting SIBO. In the current 
study, two commonly used approaches were utilised- the GHMBT and jejunal aspiration with 
microbiological quantification. There were 153 patients for whom results were available for both 
tests. Interestingly, concurrent results for the two tests occurred in just 58.2% of these patients. 
If the direct aspiration method was taken to be the gold-standard, as was traditionally the case 
(although not justifiably), 47 (30.7%) of the GHMBTs would be considered false positives and 
17 (11.1%) would be considered false negatives.  
 
These results can be compared with the findings of a review of different cross-validation studies 
between the glucose-H2 breath test and jejunal aspirate culture. The reviewers aimed to 
determine the diagnostic accuracy of the breath test for SIBO by taking the jejunal aspirate to be 
the gold-standard (Gasbarrini et al. 2009). Although, the eight studies were very heterogeneous, 
the authors determined that the glucose-H2 breath test had a sensitivity of 62.5%, a specificity of 
81.7%, a positive predictive value of 80% and a negative predictive value of 65.5% compared 
with the gold-standard. Therefore, because the sensitivity is not high, it is unlikely that the 
breath test overestimated SIBO (i.e. produced false positives) in the current study, as appears 
to be the case. Rather, one can assume that the lack of appropriate anaerobic microbiological 
techniques at RM may have caused the overgrowth of anaerobic organisms to be missed, thus 
making it seem that the GHMBT produced high numbers of false positive results. Though, of 
course, one cannot be certain on this, as the review was specific to the glucose-H2 breath test, 
not the GHMBT and the sensitivity and specificity of the latter has not yet been estimated. 
However, the addition of CH4 should, in theory, make the test more sensitive, as it can detect 
CH4 in the subgroup of H2 non-producers (2-43%) (Cloarec et al. 1990; Saltzberg et al. 1988; 
Read et al. 1985; Joseph & Rosenberg 1988; Gilat et al. 1978; Bjorneklett & Jenssen 1982; 
Flatz et al. 1985; Corazza et al. 1994). Therefore, some of the perceived false positives in the 
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current study may be actual false positives, and some may have been a spurious finding 
caused by poor anaerobic laboratory methods. This emphasises the inconsistency between the 
testing techniques and the need for a true gold-standard test for the diagnosis of SIBO. 
 
One of the objectives of this study was to identify the variables that are predictive of SIBO. 
Following univariate analysis, selenium showed significance (0.045), OR (CI): 0.06 (0.00-0.93). 
Selenium is an essential trace element, primarily absorbed in the duodenum (Thomas & Bishop 
2007). It has a key role in antioxidant defence, thyroid hormone metabolism and immune 
function, with growing evidence to suggest that selenium deficiency affects both cell-mediated 
and humoral components of the immune response (Fairweather-Tait et al. 2011; Speckmann & 
Steinbrenner 2014). While there have been no previous data suggesting that higher plasma 
selenium levels decreased the risk of SIBO, one can speculate why this may be the case. 
Patients with SIBO are known to have abnormalities in intestinal mucosal immunity, which could 
potentially be associated with selenium insufficiency, although this has not yet been 
investigated (Riordan et al. 1999; Riordan, McIver, Wakefield, et al. 1997b). Also, there are 
animal data indicating that dietary selenium intake affects the gut microbiota, and vice versa, 
but this has not yet been studied in the context of SIBO (Hrdina et al. 2009; Kasaikina et al. 
2011). Because of its antioxidative effects, selenium has received considerable attention with 
regard to cancer prevention and treatment, particularly for prostate cancer (Chen et al. 2013; 
Mandair et al. 2014). Given that 26% of those with Definite SIBO had a prostate cancer 
diagnosis, selenium’s significance in the univariate model may have been an artifact of 
selenium supplementation by these men. Also, individuals with diarrhoea are likely to have 
lower serum selenium due to losses of the trace element in diarrhoea and this may offer an 
alternative explanation for selenium being a significant variable. Nonetheless, one should be 
cautious when interpreting the OR for selenium as data was missing in 53% of cases. 
 
Radiotherapy/brachytherapy showed marginal significance in the univariate model, p= 0.05, OR 
(CI): 3.00 (1.00-8.99). In effect, those patients that did not undergo radiotherapy and/or 
brachytherapy were three times more likely to develop SIBO than those individuals receiving 
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this treatment. This is an unexpected finding, considering the aforementioned 38-patient study, 
which reported a SIBO incidence of 26% in pelvic radiotherapy patients (Wedlake et al. 2008). 
In addition, Husebye et al. recruited 41 consecutive female patients with symptoms of late 
radiation enteropathy following gynaecological cancer (1995). Following duodenal aspiration 
and quantification, microorganisms were detected in samples from 71% of patients and Gram-
negative bacilli were detected in 29%. Intestinal motor patterns were also investigated in this 
cohort, and the results suggested that the chronic motility changes caused by radiotherapy were 
the main cause for SIBO. The data suggested a high prevalence of SIBO following pelvic 
radiotherapy, and a case-report also suggested that radiotherapy was the cause for SIBO in a 
gynaecological patient (Swan 1974).  
 
The disagreement between the current study and the Wedlake and Husebye studies may be 
caused by the heterogeneity of the cohorts and the time of testing for SIBO. Husebye et al. 
included women with long-term GI complaints following treatment for gynaecological cancer, 
where the median (range) time since end-treatment was 10 (1-43) years. Wedlake et al. 
included patients undergoing pelvic radiotherapy for GI, gynaecological or urological cancer in 
the acute setting. The current study recruited patients with GI, gynaecological, urological, 
haematological cancers, lymphomas and other cancer types, where the median (range) time 
lapsed since treatment completion was 35.5 (0-512) months. Effectively, the current study offers 
neither an acute nor a chronic picture of SIBO in cancer, rather somewhere in between the two. 
In addition, it must be borne in mind that injury to the Gl tract depends on the type of 
radiotherapy given, the dose delivered to tissues, the way it is delivered, and how radiation 
energy scatters through tissues, variables that were not measured in any of the three studies 
discussed.   
 
5.6.1.1 Strengths and Limitations of SIBO Methods and Results 
This is the first large prospective study to investigate the characteristics of SIBO in patients with 
cancer. However, there are some inherent limitations associated with the study design. 
Generally with a case-control study, one identifies subjects by outcome status at the outset of 
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the investigation. Once outcome status is identified and subjects are categorised as cases, 
controls (subjects without the outcome but from the same source population) are selected. In 
the current study, the approach was different in that it was unknown which patients would 
become cases and which would become controls at the study outset. This is because patients 
were selected from the same gastroenterology clinics, where they presented with similar GI 
symptoms. This sampling method means that the control group is not ideal for this case-control 
study, although they do represent a clinically relevant group, as the differences detected in 
baseline characteristics and laboratory variables detected here are important. However, had an 
appropriate age- and sex-matched healthy control group been used, there would almost 
certainly have been greater differences in baseline characteristics and GI symptoms between 
the categories.  
 
The control of extraneous variables, in particular with regard to interventions for other GI 
conditions, was considered when categorising patients, leading to the exclusion of 18 patients 
and the classification of others as having Possible SIBO. However, one cannot be certain that 
confounding was not involved in more of the Definite SIBO cases, particularly as half of this 
category was also concurrently diagnosed with another GI condition. As such, it is not possible 
to be confident that the GI symptoms reported at baseline by those with Definite SIBO are solely 
the consequence of overgrowth. Also, if the improvement in GI symptoms was related to the 
treatment of another GI condition (not SIBO), this may have led to the misclassification of 
patients in the Definite SIBO category. To correct for this, one could have ensured that patients 
were not treated for any other condition (apart from SIBO) during the study. This would have 
created a cleaner cohort but because of the high symptom burden experienced by these 
patients, such a decision would have been unethical. Alternatively, it would have been 
appropriate to record the proportion of patients who received interventions, other than 
antibiotics for SIBO, during the study.  
 
Potential bias may have been caused by the large differences in the length of time between 
baseline and follow-up; some (4%) were followed-up < 4 weeks after baseline, while 61% were 
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followed-up > 12 weeks after baseline. Where there was a longer time period between the study 
visits, there may have been a (a) higher chance that the patient commenced treatment for 
another GI condition and (b) longer post-antibiotic treatment period before GI symptoms were 
re-assessed, in comparison to a shorter follow-up period. The variability in the time lapsed 
between study visits was partly due to the decision to only see patients for study purposes on 
the day of another routine appointment. However, this attempt to avoid unnecessary hospital 
visits may have introduced bias caused by the lack of a robust approach towards the timing of 
follow-ups.  
 
Although the approach used in this study to categorisation patients (in terms of SIBO) was the 
consensus of a multi-professional discussion, one can question its robustness. Firstly, the 
diagnosis of SIBO by the gastroenterologist was based largely on the improvement in GI 
symptoms following antibiotic treatment, as measured by the GSRS tool. It has previously been 
noted that this symptom tool was a modified version of the original tool and was not validated 
for use in a cohort of cancer patients with suspected SIBO. Secondly, reporting bias needs to 
be considered as patients may have falsely reported an improvement in symptoms in the belief 
that this is what the researcher wished to hear. Thirdly, by virtue of the fact that these unwell 
patients were undergoing investigations and interventions for their GI problems, this may have 
improved emotional and psychological well-being. As a result, the perceived severity of 
symptoms may have been less than the actual reality at follow-up.  
 
The introduction of an objective element to the follow-up visit would have helped to remove 
these biases. For example, if every patient deemed to have Definite SIBO underwent a repeat 
GHMBT, and the test was negative, Definite SIBO could then be confirmed. This approach may 
also have helped to reduce the size of the Possible SIBO category, as some of these patients 
were categorised as such because it was unsure if the positive clinical response exhibited was 
produced by factors other than antibiotics. However, in practice, an extra breath test would 
require considerably more resources (money and time) and the willingness of patients to 
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undergo a second test, with all that this entails. Also, repeating the test would not actually 
change the patient’s management as they had already received antibiotic treatment.  
 
Missing data represents a challenge to most research studies, including this one. In the current 
study, the inability to fit a multivariate model for SIBO prediction was a consequence of missing 
data, as well as small numbers within the Definite- and No SIBO categories. There were just 38 
patients in the Definite SIBO category, which is 28 less than the number used to power the 
study. Although, every effort was made to ensure data completeness, this was not always 
achievable. For instance, the number and type of biochemistry and haematological tests 
requested for patients was not always consistent, as this depended upon the patient’s GI 
symptoms and differential diagnoses (Andreyev et al. 2014). Also, the majority of the recruited 
cohort was referred from the primary or secondary care setting to RM and as such their full 
medical history was not always available. If the study dietitian had requested additional 
biochemistry and haematological tests when needed, and contacted the patient’s previous 
caregiver for additional medical records, this would have reduced the amount of missing data. 
Alternatively, the recruitment of more patients would have ensured that the categories were 
bigger, which would have alleviated the problem of over-fitting (i.e. random error or noise 
instead of a true underlying relationship) in the multivariate setting.  
 
5.6.2 Primary Outcome 
The primary objective of this pilot study was to generate valid data on a wide range of 
metabolites present in the urine samples of patient who underwent testing for SIBO to 
determine if there was any metabolite(s) that could separate those with SIBO from those without 
it. The obtained data suggest that there is an up-regulation of N-acetylglutamine production in 
patients with SIBO. N-acethlyglutamine is a modified amino acid, which activates the carbamoyl 
phosphate synthase in the urea cycle. It is biosynthesised from glutamic acid and acetyl-CoA by 
the enzyme N-acetylglutamate synthase. It is an acetylated analogue and pre-curser of 
glutamine- a substrate which is the major fuel for enterocytes (Bergana et al. 2000). In fact, N-
acetylglutamine has been considered as a source of glutamine in both enteral and parenteral 
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nutrition (Magnusson et al. 2013; Arnaud et al. 2004). It is a metabolite which is located on the 
surface of tubular cells and has been detected in the urine of healthy individuals (Sugahara et 
al. 1994; Sachse et al. 2012).  
 
There are some conditions that have been associated with the up-regulation of N-
acetylglutamine. For example, researchers investigating lung cancer metabolic signatures in 
urine (using 1H NMR-based metabolomics) demonstrated metabolic differences between 
controls (n= 54) and cancer subjects (n= 71) (Carrola et al. 2011). It was found that N-
acetylglutamine was consistently elevated in patients with cancer compared with controls. 
Similarly in a study of autosomal dominant polycystic kidney disease, significantly elevated 
levels of N-acetylglutamine were detected in the urine of cases (n= 54) as compared with 
controls (n= 46) (Gronwald et al. 2011). Raised levels have also been linked to low estimated 
glomerular filtration rates in non-proteinuric patients with type 2 diabetes (Ng et al. 2012). 
However, the cause for the elevation in N-acetylglutamine has not been elucidated in any of 
these three patient groups.  
 
The Human Metabolome Database, which is the complete and comprehensive curated 
collection of human metabolite and human metabolism data in the world, does not indicate that 
increased concentrations of N-acetylglutamine are associated with any disorder of the GI tract 
(Wishart et al. 2013). As such, one can only speculate as to the reason for elevated levels of 
this metabolite in the urine of individuals believed to have SIBO. As mentioned, N-
acetylglutamine is biosynthesised from glutamic acid, which is a component of the cell-wall 
complex of Gram-positive bacteria. The degradation of these bacteria would release glutamic 
acid, making it available for N-acetylglutamine production, leading to its appearance in urine. 
Alternatively, high urinary excretion of this compound could potentially be the result of bacterial 
synthesis of it, leading to enzyme system saturation, and thus, the removal of the excess in 
urine. However, to date, there have been no reports suggesting that N-acetylglutamine is a 
bacterial metabolite. Instead, it is possible that N-acetylglutamine is a marker of cancer, 
considering it was found to be consistently elevated in patients with lung cancer compared with 
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controls (Carrola et al. 2011). In support of this, a metabolomics study of colorectal cancer 
patients found that those with cancer had higher serum levels (p< 0.05) of N-acetyl signals from 
glycoproteins compared with controls (Bertini et al. 2012).  
 
The current study was performed with no a priori information regarding the composition of the 
urine samples in patients with suspected SIBO (i.e. it was untargeted). Thus, it can be 
considered a hypothesis-generating study, where a metabolite of interest was discovered. The 
discovery of N-acetylglutamine represents just the first of many steps needed before a 
compound could be considered a biomarker of SIBO. In the current study, a second urine 
sample was collected from patients after the completion of antibiotic treatment. Therefore, the 
most appropriate next step would be to establish whether antibiotic treatment resulted in a lower 
spectral concentration of N-acetylglutamine in the follow-up samples of those with Definite 
SIBO. If this were found to be the case, there would be a strong case for continued research 
into this metabolite. 
 
Following this, there would be two further steps in the metabolomics biomarker discovery 
process: (1) study validation and (2) cohort validation (Dunn et al. 2010). The ‘study validation’ 
would effectively involve another case-control pilot study, with participant numbers still quite 
small i.e. in the range of 20-100s for each class. However, a more robust study design would be 
required, whereby the patients and controls were more appropriately selected. This would mean 
having three patient groups in total, with the latter two groups acting as controls: (1) patients 
with GI symptoms and Definite SIBO; (2) age-, gender-, race- and BMI-matched patients with GI 
symptoms but No SIBO and; (3) age-, gender-, race- and BMI-matched healthy individuals with 
no GI symptoms and No SIBO. This process of carefully matching comparison groups would 
mean that the validated test would be appropriate for use in clinical practice. This is important 
because all individuals presenting to the gastroenterologist will have GI symptoms, and the 
gastroenterologist will need the diagnostic test to determine whether they have SIBO or not. At 
this point, one may also wish to undertake an inter-laboratory repeatability study that uses 
replicate specimens from the same cases and controls, but the experiment is performed in a 
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different laboratory using a different instrument (potentially the same manufacturer) and a 
different observer (Xia et al. 2012).  
 
Assuming, the study validation supported the discovery of the original pilot study and there was 
low variability due to independent laboratory practices, the final cohort validation study could 
then be undertaken. This would be a medium to large-scale epidemiological study (i.e. 1,000’s) 
of the complete at-risk population. Large numbers would be required to take account of the 
substantial diversity observed in physiology, metabolic status, diet and lifestyle in the general 
population. A large sample size will also serve to boost the power of statistical analysis, so that 
subtle differences within the subject cohort would be detected, thereby reducing the probability 
of false discovery. This final study would define the true utility of the ‘discovered’ biomarker in 
the target population. Only then could one be sure that the biomarker was reproducible, with 
optimal sensitivity and specificity. 
 
5.6.2.1 Strengths and Limitations of Metabolomics Methods and Results 
The conditions under which the urine samples were stored and prepared for this study needs 
consideration, as storage conditions are likely to have a major impact on the content of the 
multivariate data set presented (Dunn et al. 2011). A good understanding of the analytical 
variation is critically important in any metabolic profiling study as it allows the separation of 
artifactual and analytical variation from the biological variations of interest (i.e. the disease). 
Therefore, in recent years, urine sample preparation guidelines for metabolomics studies have 
been proposed (Lauridsen et al. 2007; Maher et al. 2007). These guidelines will now be 
discussed in the context of the current study.  
 
Maher et al. investigated the effect of long-term storage of urine at different temperatures (-
80°C, -40°C, -20°C, 4°C and room temperature) with the aim of assessing the consequences of 
delayed freezing (2007). Samples were analysed the day after collection, at 1 month and at 3 
months. From PCA, it was evident that the major source of variation was time-dependent 
changes associated with 1 month and 3 month room-temperature storage. However, apart from 
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this cause of variation, the remainder of the data (i.e. for -80°C, -40°C, -20°C and 4°C) was 
clustered together, thus showing little systematic variation. This suggests that the storage of the 
urine samples in the current study (at -20°C) was acceptable. This is supported by the 
recommendations of Lauridsen et al., who proposed that human urine samples should be stored 
at or below -25°C, as no changes in the 1H NMR fingerprints were observed at this temperature 
for 26 weeks (2007). However, in the current study, samples were generally not frozen ≤ 2 
hours after collection (i.e. they may have been at room temperature and refrigerated for up to 36 
hours), as was the case with Maher and Lauridsen’s samples. Also, some samples were 
analysed < 26 weeks after collection but others were not analysed until 18 months after 
collection. There has been no research to date focused on measuring sample stability when 
frozen for > 26 weeks and therefore, one cannot be certain of the trustworthiness of the data 
produced for the samples with longer freezing periods.  
 
Previous experiments on human urine indicate that preservatives (sodium azide or sodium 
fluoride) extend the stability of urine at 4°C (Lauridsen et al. 2007). In the current study, a 
preservative was not used, but ideally should have been, as it may have alleviated any 
microbial contamination caused by holding samples at room or refrigeration temperatures for up 
to 36 hours. In addition, the collection of urine samples on site (rather than at home) would have 
resulted in a shorter collection to freezing time. However, such a measure to ensure 
consistency of sample collection may have negatively affected the number of samples obtained. 
Of note, participants’ medication, dietary (including alcohol) intake and physical activity level 
during the 24-hour period prior to sample collection can influence the metabolomic spectrum 
(Holmes et al. 1994; Zuppi et al. 1998; Maher et al. 2007). Ideally these variables should have 
been recorded to reduce the chance of introducing systematic bias into the data. 
 
At the 1H NMR analysis stage, there were some study strengths. Given the relatively low 
numbers of patients in the study, all samples were analysed in a single analytical batch. This 
removed the possibility of batch effects i.e. technical sources of variation that have been added 
to the samples during handling. Also, the sample preparation order and injection order (i.e. 
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injection into NMR tubes) was randomized so that controls and test samples were run on the 
spectrometer in a random order i.e. avoiding run-order bias.  
 
In addition to these sample handling and storage issues, metabolomics studies have been 
criticised for being ‘fishing expeditions’ i.e. one is likely to discover biomarkers that are randomly 
correlated to the effect of interest. In the current study, the t-testing significance value was set at 
p< 0.02. This is not ideal even when just one t-test is performed, but as many tests were 
performed, this hugely increases the chance of false discoveries i.e. random findings. Although, 
the Benjamini-Hochberg procedure was used to correct for multiple testing, the validity of this 
methods in ‘omic’ type studies has been questioned (Dunn et al. 2010). Also, supervised 
classification is an inherently biased technique: Adaptive Intelligent Binning was used in the 
current study, with multiple comparisons necessary to complete the binning procedure. 
Normally, Bonferroni corrections would be made to correct for familywise error, but this was not 
possible because the variables (bins) were not independent of one another. As a result, there is 
a risk that the metabolite identified as significant was the result of a false discovery.  
 
Evidently, a drawback of all metabolomics research is the need to use complex data-
interpretation techniques and combinations of analytical methods (Nicholson & Lindon 2008). 
For example, when modeling data, it is possible to obtain a model that provides a good fit to the 
data, as was the case with the current study. However, if the model was over-fitted because of 
the modeling of noise, then the predictive ability will be negatively affected, as any new data set 
will have a different noise component (Lindon et al. 2005). In the current study, although the 
data was visuaIised to assess for the presence of noise, ideally other more sophisticated 
methods would have been employed (Lindon et al. 2005). For example, internal cross-validation 
is a method that ensures that the model size can be determined directly from the data. This 
method can differentiate the regularities in the data from noise and give a realistic estimate of 
the predictive capability of the model/metabolite (i.e. prevent over-fitting) (Lindon et al. 2005).  
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5.7 Conclusions 
Small intestinal bacterial overgrowth is prevalent in symptomatic patients following oncological 
treatment: one in five of those tested were confirmed to have the condition. The GI burden of 
SIBO is great, with more upper- and lower-GI symptoms accompanying it than have previously 
been described. The current study was unable to define risk factors for the development of 
SIBO, but univariate results suggest which variables should be considered in future modeling 
studies (selenium status and previous radiotherapy/brachytherapy treatment). There exists no 
ideal test to detect the presence of SIBO, with inconsistencies between methods demonstrated 
here. This has been the first attempt to investigate the potential of metabolomics in SIBO by 
comparing the urine metabolic fingerprints in those with and without SIBO. Although, there is 
not yet any conclusive indication that metabolomics can separate those with SIBO, it remains 
an exciting avenue to explore in the hope of finding a more superior test for the diagnosis of this 
troublesome condition.  












Chapter 6  
Final Discussion and Conclusions 
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6.1 Summary of Key Findings 
The assessment of the development and persistence of GI symptoms and malnutrition in 
patients with OG cancer were two objectives of this thesis. The symptom burden was high for 
the first year following diagnosis: for the majority, symptoms either persisted without any 
improvement or developed, during this time (Chapter 3). At one year, seven in ten patients 
reported having at least one GI symptom that bothered them ‘quite a bit’ or ‘a great deal’. 
Similarly, malnutrition was a significant feature in this cancer cohort, with six in ten patients 
either becoming malnourished or remaining malnourished at one year. Additionally, high GI 
symptom burden tended to be associated with poorer nutritional status and low symptom 
burden tended to be associated with better nutritional status. Considering the high prevalence of 
malnutrition in OG cancer patients, there is a need to validate a nutritional screening tool for use 
in this group. A validation study was undertaken in this thesis to establish the sensitivity and 
specificity of MUST against an accepted standard (Chapter 4). The tool was found to be 
insufficiently sensitive and thus, failed to identify patients at risk of malnutrition. Therefore, it 
does not appear to be suitable for use in the OG oncology setting.  
 
Interestingly, the incidence of SIBO in this OG cancer cohort was also high at 77%. This 
indicates, for the first time, that disease processes and/or oncological treatments may lead to 
the development of SIBO. It is reasonable to hypothesise that SIBO may be contributing to the 
chronic GI symptoms and poor nutritional status experienced by OG cancer patients (Chapter 
3). This thesis has also established that SIBO is not unique to the OG cancer setting, but rather 
it is a common finding in cancer patients, in general. One in every five patients presenting to the 
gastroenterologist with GI symptoms following treatment for (any) cancer was found to have 
SIBO (Chapter 5). The range of symptoms reported by these patients was extensive: flatulence, 
faecal urgency, loose stools, abdominal grumbling, incomplete evacuation, steatorrhoea and 
faecal incontinence were the most common. Some of these symptoms, namely faecal urgency, 
abdominal grumbling, incomplete evacuation and faecal incontinence, as well as some others, 
including belching and early satiety, have never been considered relevant to SIBO before. As 
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such, this research has exposed SIBO as being a more troublesome condition that was 
previously believed.  
 
There did not appear to any defining traits of SIBO, nor strong predictors for its development, 
which further stresses the need for a sensitive and specific test to diagnose it. The analysis of 
metabolites in urine using metabolomics was trialled in this thesis, in an attempt to ascertain 
whether this approach could eventually lead to a new diagnostic test for SIBO. The technology 
showed some ability to classify those with and without SIBO based on N-acethylglutamine, thus 
demonstrating its potential in this setting.  
 
6.2 Management of Gastrointestinal Symptoms and Malnutrition in 
Oesophagogastric Cancer  
The persistence of moderate-severe GI symptoms during the first year following OG cancer 
diagnosis was established in this thesis. Considering these patients had ongoing troublesome 
symptoms, it is evident that the current symptom detection and treatment processes are not 
optimal. This raises two questions: (1) What is the best way to detect GI symptoms? and (2) 
Who are the best clinicians to manage GI symptoms? 
 
Focusing on Question 1 firstly (What is the best way to detect GI symptoms?). When patients 
are first diagnosed with OG cancer, they undergo extensive staging investigations, where the 
central emphasis is on treatment planning. As such, GI function tends to become a peripheral 
factor in their overall management. However, this thesis has demonstrated that GI symptoms 
are already prevalent at this stage. Therefore, those initial out-patient appointments should 
represent a key moment to undertake a comprehensive GI symptom assessment. During and 
after the completion of treatment, the emphasis tends to shift, with an increased awareness of 
the acute and chronic GI side-effects of cancer therapies. Moreover, the recently published 
London Cancer Alliance (LCA) guidelines include a section dedicated to identifying post-
treatment symptoms during follow-up (Oesophageal and Gastric Cancer Clinical Guidelines, 
London Cancer Alliance 2014). They highlight the need for ongoing assessment of GI function 
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and recommend that follow-up (including GI symptom assessment) should occur as follows: (a) 
two weeks post-discharge, (b) regularly in the first year- the frequency should be determined by 
the post-treatment symptoms, (c) six monthly for two years and, (d) annually until five years in 
total. If implemented, this guideline would ensure that GI symptom assessment became a core 
component of all follow-ups, leading to improved symptom detection.  
 
Focusing on Question 2 now (Who are the best clinicians to manage GI symptoms?). The LCA 
guidelines suggest that the approach to follow-up should be uniform irrespective of discipline. 
Therefore, any member of the MDT could undertake the GI symptom assessment and then 
communicate the outcome to the other members, thus avoiding duplication. This approach 
would ensure that all clinicians are mindful of potential GI symptoms. However, there is no 
guidance on which clinicians are best equipped to manage complex symptoms once they’ve 
been detected. As the type of treatment modality/modalities received will determine whether a 
patient is followed-up by a surgeon and/or clinical oncologist, and assuming these clinicians 
would manage symptoms differently, this means there is no standard approach for managing 
symptoms. An ongoing prospective, observational cohort study at RM (The FOCCUS Study: 
Focusing on Cancers Chemotherapys' Untreated Symptoms) will address this issue. Aims of the 
study include (a) defining the competencies required of nursing personnel to use a monitoring, 
investigation and treatment algorithm and (b) developing simple protocols for clinicians to use to 
assist with symptom management. The results of this novel study will provide guidance on the 
most appropriate method for managing and treating GI symptoms in OG cancer patients, which 
could greatly reduce the prevalence and persistence of troublesome symptoms.  
 
With regard to nutritional status, this thesis has demonstrated that malnutrition is not being 
effectively detected and treated in all OG cancer patients. Therefore, current detection and 
treatment processes do not appear to be optimal. There is a need for change. The LCA 
guidelines also include a section on nutrition (2014). The alliance recommends that all OG 
cancer patients should have a nutritional assessment carried out at presentation, which 
conforms to national and international best practice. In addition, depending on which treatment 
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modalities apply, they advise (a) ongoing nutritional assessment during chemotherapy, (b) 
weekly nutritional assessment during chemoradiotherapy, (c) ongoing follow-up after the 
completion of chemotherapy/chemoradiation and, (d) long-term follow-up in surgical patients.  
 
Thus, the guidelines suggest that the best way to improve nutritional status is to provide 
sufficient dietetic resources to meet the needs of patients. In practice this will prove difficult to 
achieve, as dietetic resources are limited. Even the systematic introduction of one of these 
targets would have major cost implications caused by an increased number of referrals to 
dietetic departments and an increased use of nutritional support. But while this may cause 
short-term financial losses, it is likely to be counteracted by long-term gains produced by clinical 
benefits. This is because dietetic counselling and intervention have been shown to improve 
energy intake, weight gain, functional status and QoL in cancer patients (Persson et al. 2002; 
Ravasco, Monteiro-Grillo, Vidal & Camilo 2005a; Kim et al. 2014; Isenring et al. 2004; Ravasco, 
Monteiro-Grillo, Vidal & Camilo 2005b). These clinical benefits may also lead to reduced 
complications and lengths of hospital stay.  
 
Nonetheless, a great deal of collaborative planning is essential before the LCA nutritional 
guidelines can be incorporated into routine clinical practice. While the cost and feasibility issues 
are being considered, it is paramount that nutritional screening processes are fully embedded in 
the standard care of OG cancer patients as per National Institute for Health and Clinical 
Excellence guidance: all out-patients should be screened at their first clinic appointment and 
when there is clinical concern thereafter; all in-patients should be screened on admission and 
weekly thereafter (National Institute for Health and Care Excellence 2006). In this way, only 
those at risk of malnutrition would undergo a full nutritional assessment (rather than those not at 
risk), thus saving dietetic resources. Importantly, this can only be achieved if the screening tool 
is highly sensitive and specific, which emphasises the significance of choosing a suitable tool 
for use in OG cancer patients. This thesis has established that MUST is not a suitable tool for 
use in this patient group because of its low sensitivity. Its use would cause some of those OG 
cancer patients at greatest risk of malnutrition to remain undetected, making the screening 
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process ineffective. Considering MUST is the most commonly used nutritional screening tool in 
the UK, this finding has significant implications for the management of this high-risk patient 
group.  
  
Another matter of great importance in the management of OG cancer patients is that a patient-
centred approach is ensured at all times. Historically, clinicians tend to follow a prescriptive 
approach resulting in patients being told what to do and when to do it. Therefore, patients are 
not taught to be pro-active if problems arise e.g. persistence of symptoms, weight loss or eating 
difficulties. However, if all patients were given information explaining what issues were 
abnormal, and they were encouraged to self-monitor, then this would empower them to know 
when to seek help from the appropriate professional(s), rather than waiting for the next follow-
up appointment. This collaborative approach is also endorsed by the LCA and they provide a 
noteworthy suggestion in their clinical guidelines: ‘Information on anticipated or possible 
consequences of cancer treatment and what to do if they occur should be routinely provided to 
all patients. This should be done from the time of discussion of treatment onwards, with the 
information reiterated during the end of treatment consultation’ (London Cancer Alliance 2014). 
If this were realised, it would allow patients to seek early intervention and avoid having to 
endure ongoing unresolved GI or nutritional issues. 
 
6.2.1 Future Research Considerations  
This thesis demonstrated that symptom burden showed an association with nutritional status in 
OG cancer patients, whereby the presence of symptoms tended to be associated with poorer 
nutritional status and vice versa. As such, it seems reasonable to hypothesise that the effective 
treatment of GI symptoms that are negatively impacting on dietary intake would improve 
nutritional status. This would be an interesting focus for future research. In addition, as MUST 
was found to be inappropriate for use in OG cancer patients, and the relationship between GI 
symptoms and nutritional status was established in this cohort, one can postulate that a 
screening tool which incorporates symptom assessment may perform better than MUST. The 
Royal Marsden Nutrition Screening Tool, which assesses nutrition-impact symptoms, has 
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recently been validated (against PG-SGA) in an mixed in-patient cancer cohort (Shaw et al. 
2014). Therefore, the next, most logical step would be to establish its performance in patients 
with OG cancer, who may be in- or out-patients. 
 
This thesis has also provided evidence to suggest that SIBO may be contributing to the chronic 
GI symptoms and malnutrition experienced by OG cancer patients. Due to the low number of 
patients undergoing testing for SIBO in this part of the study, further prospective research is 
needed to establish such relationships. If the cause for their persistent symptoms and 
malnutrition was found to be related to SIBO, this would have significant implications for their 
management during and after treatment. 
 
6.3 Feasibility of Metabolomics in Clinical Practice for Small 
Intestinal Bacterial Overgrowth Detection  
In the past 10-15 years, continuous advances in the application of NMR to the diagnosis and 
characterisation of diseases have made metabolomics a useful clinical option, rather than just a 
scientific curiosity. Metabolomics technology has the potential to provide fast, accurate, non-
invasive diagnosis of complex medical problems. The successful application of urine 
metabolomics as a non-invasive strategy could circumvent and/or complement the established 
invasive and time-consuming clinical procedures used for SIBO detection. However, the 
challenges and needs in disease metabolomics require careful consideration, namely in relation 
to study design, sample collection and quality, data quality assurance, reliable means of data 
analysis and model validation and, finally, confirmation of metabolite biomarkers (as discussed 
in Section 5.6.2). All of these aspects would need to be perfected before one could envisage the 
application of NMR in SIBO detection, as has already been achieved to allow discrimination of 
the inflammatory bowel diseases from each other and from healthy individuals (Williams et al 
2009). Assuming these aspects were achieved for SIBO, further practical considerations of 
NMR would need to be considered before a link between the laboratory and clinic could be 
established.  
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Firstly, the cost of NMR deserves attention. Analytical platforms are expensive (£100,000 per 
spectrometer) and require a facility manager to oversee the day-to-day running of the 
technology (Dunn et al. 2011). As a result, the majority of spectrometers are currently located in 
industrial or university settings rather than clinical settings. Therefore, until a time comes when 
spectrometers are routinely found in hospitals, samples will continue to require freezing and 
transportation at a later date and of course this introduces bias, as discussed in Section 5.6.2.1. 
On a positive note, once the equipment is in place, there are actually few costs associated with 
running the NMR experiments: for a basic 1D experiment, the cost is approximately £10 per 
sample. For structural elucidation experiments (i.e. 2D analysis), the cost rises but the total cost 
compared with other ‘omic’ platforms (e.g. transcriptomics or proteomics) is still much lower 
(Dunn et al. 2011). If a biomarker was found to be robust enough to supersede an established 
test for SIBO, it is possible that the cost of metabolomics would be no greater than the 
combined (average) cost of a GHMBT (£125) and OGD with jejunal aspiration (£490) to the 
NHS (Gov UK 2014; University College London Hospitals 2013).  
 
Secondly, one must consider how quickly clinically relevant results can be obtained from the 
metabolomics platform. Encouragingly, sample preparation is composed of a limited number of 
processes, and many steps (e.g. liquid handling and extraction) can be automated. Also, the 
high throughput nature of metabolic profiling means that each sample can be analysed (by the 
spectrometer) typically in less than 30 minutes. Despite the efficiency in obtaining the spectra, 
the complex pre-processing and data interpretation techniques require much more time. It may 
take days or even weeks before any meaningful results can be relayed to the patient. However, 
if the technology can be proven superior to the direct aspiration and breath testing methods for 
detecting SIBO, then it may be worth the wait.   
 
Thirdly, as metabolomics is a novel discipline encompassing comprehensive metabolite 
evaluation, pattern recognition, and statistical analyses, the skills required are typically the remit 
of the trained scientist, rather than the clinician. Consequently, there exists a perception that 
metabolomics technology is complicated, unreliable and inaccessible to the clinical world. 
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Changing this perception may be challenging but it is essential that clinicians become more 
familiar with metabolomics data, as a good working knowledge will be required to make optimal 
use of this promising technology. If this were achieved, the time period between sample 
collection and obtaining clinical meaningful results would be reduced. Accordingly, prompt 
intervention could be commenced, as required, without the need for an intermediary in the 
pathway. This need to expand systems biology from the borders of the basic biology and 
mathematical communities into the clinical world has been highlighted in a European 
Commission report (Directorate of Health 2010). Also, the Medical Research Council in the UK 
is supporting ‘discipline hopping’ through fellowship schemes that enable scientists and 
clinicians to do research in fields different from their own (Medical Research Council 2014). 
Metabolomics technology is a discipline that is still in its infancy and multidisciplinary efforts are 
essential to ensure the gap between the laboratory and the clinic is bridged.  
 
6.3.1 Future Research Considerations  
This thesis has demonstrated the potential of urine metabolomics technology in the pursuit of a 
new diagnostic test for SIBO, advocating future research in this area. Urine was the sample of 
choice in Chapter 5 because, to date, this biofluid has received the greatest attention with 
regard to metabolite elucidation as compared with duodenal aspirate or faecal water samples. 
However, one can envisage that the metabolic profiles of the duodenal aspirate and faecal 
water samples (also collected in this cancer cohort) could hold even more potential, as they are 
the direct product of gut microbiome-host co-metabolism. As such, significant metabolite signals 
may be more easily detected from these samples than from urine. Therefore, in the coming 
months, as well as assessing the metabolic profiles of the follow-up urine samples (i.e. post-
antibiotic treatment) from the SIBO Study, the duodenal aspirate and faecal water samples will 
also be analysed and interpreted using metabolomics technology. Ultimately, a combination of 
biomarkers from two or three biofluids could prove superior to the currently available diagnostic 
tests for SIBO.  
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6.4 Concluding statement 
Cancer is a complex disease resulting in multifaceted effects. The management of localised OG 
cancer is aggressive and as such, the GI and nutritional consequences are pronounced during 
the first year following presentation. Many patients endure unrelenting symptoms while in a 
state of malnutrition and the association between these variables is strongest at diagnosis. In 
OG cancer and cancer in general, SIBO is likely to be contributing to the GI symptoms 
experienced following treatment. Despite SIBO’s relevance across the field of gastroenterology, 
there is still no appropriate method to diagnose it. Urine metabolomics has, however, shown 
great potential in its ability to detect patients with SIBO, making it an exciting prospect in the 
quest for a simple, accurate and objective test for SIBO. 
 
In summary, this thesis has developed and tested the following hypotheses: 
1. The hypothesis that disease processes and/or radical treatment result in the persistence or 
development of moderate-severe GI symptoms at 12 months in OG cancer patients was 
accepted (Chapter 3).  
2. The hypothesis that disease processes and/or radical treatment result in the persistence or 
development of malnutrition at 12 months in OG cancer patients was accepted (Chapter 3). 
3. The hypothesis that there is a positive association between GI symptom scores (higher 
score equals worse GI symptoms) and nutritional status scores (higher score equals worse 
nutritional status) at diagnosis, during the acute phase of management and chronically in 
OG cancer patients was accepted (Chapter 3). 
4. The hypothesis that MUST has an acceptable sensitivity and specificity (≥ 70% for both) in 
the OG oncology setting, by comparison with PG-SGA was not accepted (Chapter 4).  
5. The hypothesis that qualitative and quantitative analyses of metabolites in urine will indicate 
the presence or absence of SIBO in patients treated for cancer was not accepted (Chapter 
5). 
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8.1 TNM Classification of Malignant Tumours; 7th Edition  
 
TNM Clinical Classification: Oesophagus and Gastro-oesophageal Junction  
(Sobin et al. 2009) 
 
T: Primary Tumour  
Tx Tumour cannot be assessed  
T0 No evidence of tumour 
Tis High-grade dysplasia 
T1 Tumour invades lamina propria, muscularis mucosae or submucosa 
T2 Tumour invades into but not beyond the muscularis propria  
T3 Tumour invades the paraesophageal tissue, but does not invade adjacent structures 
T4 Tumour invades adjacent structures  
 T4a Resectable tumour invades adjacent structures, such as pleura, pericardium,          
          diaphragm 
 T4b Unresectable tumour invades other adjacent structures, such as aorta, vertebral 
         body, trachea 
 
N: Regional Lymph Nodes 
Any perioesophageal lymph node from cervical lymph nodes to celiac node 
Nx Lymph nodes cannot be assessed  
N0 No lymph node metastasis  
N1 1-2 positive lymph nodes  
N2 3-6 positive lymph nodes 
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M: Distant Metastasis 
Mx Distant metastasis cannot be assessed  
M0 No distant metastasis  
M1 Distant metastasis 
 
Note: Gastro-oesophageal junction includes cancers with an epicenter in the distal thoracic 
esophagus, GOJ, or within the proximal 5 cm of the stomach (cardia) that extend into the GOJ 
or oesophagus and are stage grouped similar to adenocarcinoma of the oesophagus.  
 
 
TNM Clinical Classification: Stomach (Washington 2010) 
      
T: Primary Tumour  
Tx Tumour cannot be assessed  
T0 No evidence of tumour  
Tis Carcinoma in situ 
T1 Tumour invades lamina propria, muscularis mucosae or submucosa.  
T2 Tumour invades muscularis propria  
T3 Tumour invades subserosa connective tissue without invasion of visceral peritoneum or  
  adjacent structures 
T4 Tumour invades serosa (visceral peritoneum) or adjacent structures 
  T4a: Tumour invades serosa but not adjacent structures 
  T4b: Tumour invades adjacent structures such as spleen, transverse colon, 
            liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small 
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N: Regional Lymph Nodes 
Nx Lymph nodes cannot be assessed 
N0 No lymph node metastasis 
N1 1-2 positive lymph nodes  
N2 3-6 positive lymph nodes 
N3 >6 positive lymph nodes  
 
M: Distant Metastasis 
Mx Distant metastasis cannot be assessed 
M0 No distant metastasis     









8.2 Academy/A.S.P.E.N. Clinical Characteristics that the Clinician Can Obtain and Document to Support a 
Diagnosis of Malnutrition  




Malnutrition in the Context of 
Acute Illness or Injury 
Malnutrition in the Context of 
Chronic Illness 
Malnutrition in the Context of 

















(1) Energy intake 
Malnutrition is the result of inadequate food and 
nutrient intake or assimilation; thus, recent intake 
compared with estimated requirements is a primary 
criterion defining malnutrition. The clinician may 
obtain or review the food and nutrition history, 
estimate optimum energy needs, compare them with 
estimates of energy consumed and report inadequate 
intake as a percentage of estimated energy 









































for ≥1 mo 
 
(2) Interpretation of weight loss 
The clinician may evaluate weight in light of other 
clinical findings, including the presence of under- or 
over-hydration. The clinician may assess weight 
change over time reported as a percentage of weight 
lost from baseline. 
 
1-2% in 1 wk 
5% in 1 mo 




>2% in 1 wk 
>5% in 1 mo 




5% in 1 mo 
7.5% in 3 mo 
10% in 6 mo 
20% in 1y 
 
 
>5% in 1 mo 
>7.5% in 3 mo 
>10% in 6 mo 
>20% in 1y 
 
 
5% in 1 mo 
7.5% in 3 mo 
10% in 6 mo 
20% in 1y 
 
 
>5% in 1 mo 
>7.5% in 3 mo 
>10% in 6 mo 
>20% in 1y 
 
Physical Findings 
Malnutrition typically results in changes to the physical exam. The clinician may perform a physical exam and document any one of the physical exam findings below as 
an indicator of malnutrition. 
(3) Body fat 






Malnutrition in the Context of 
Acute Illness or Injury 
Malnutrition in the Context of 
Chronic Illness 
Malnutrition in the Context of 

















(4) Muscle mass 
Muscle loss (e.g. wasting of the temples [temporalis 
muscle], clavicles [pectoralis and deltoids], shoulders 
[deltoids], interosseous muscles, scapula [latissimus 














(5) Fluid accumulation 
The clinician may evaluate generalized or localized 
fluid accumulation evident on exam (extremities, 
vulvar/scrotal edema, or ascites). Weight loss is often 
masked by generalized fluid retention (edema), and 














(6) Reduced grip strength 
Consult normative standards supplied by the 


















A minimum of 2 of the 6 characteristics above is recommended for diagnosis of either severe or nonsevere malnutrition. NA, not applicable. 
 
Notes: 
Height and weight should be measured rather than estimated to determine body mass index (BMI). 
Usual weight should be obtained to determine the percentage and to interpret the significance of weight loss. 
Basic indicators of nutrition status such as body weight, weight change, and appetite may substantively improve with refeeding in the absence of inflammation. 
Refeeding and/or nutrition support may stabilize but not significantly improve nutrition parameters in the presence of inflammation. 
The National Center for Health Statistics defines chronic as a disease/condition lasting 3 months or longer. 
Serum proteins such as serum albumin and prealbumin are not included as defining characteristics of malnutrition because recent evidence analysis shows that serum 
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8.3 Patient Generated Subjective Global Assessment  
Reference: Ottery 2000 
  History  (Boxes 1-4 are designed to be completed by the patient.)
2.  Food Intake:  As compared to my normal intake, I would
      rate my food intake during the past month as:
    unchanged (0)
    more than usual (0)
    less than usual (1)
I am now taking:
  normal food but less than normal amount (1)
  little solid food (2)
  only liquids (3)
  only nutritonal supplements (3)
  very little of anything (4)
  only tube feedings or only nutrition by vein (0)
1.  Weight  (See Worksheet 1)
In summary of my current and recent weight:
I currently weigh about _______ pounds
I am about _________ feet _________ tall
One month ago I weighed about _________ pounds
Six months ago I weighed about  _________ pounds
During the past two weeks my weight has:
   decreased (1)      not changed (0)        increased (0)
3.  Symptoms: I have had the following problems that have kept me from
eating enough during the past two weeks (check all that apply):
   no problems eating (0)
no appetite, just did not feel like eating (3)
nausea (1)   vomiting (3)
constipation (1)   diarrhea (3)
mouth sores (2)   dry mouth (1)
things taste funny or have no taste (1)   smells bother me (1)
  problems swallowing (2)   feel full quickly(1)
pain; where? (3)________________   fatigue(1)
other** (1) ______________________________________________
** Examples: depression, money, or dental problems
Scored Patient-Generated Subjective
Global Assessment (PG-SGA)
Additive Score of the Boxes 1-4
Patient ID Information
 A
4.  Activities and Function:  Over the past month, I
      would generally rate my activity as:
 normal with no limitations (0)
 not my normal self, but able to be up and about with fairly normal
activities (1)
 not feeling up to most things, but in bed or chair less than half the day (2)
    able to do little activity and spend most of the day in bed or chair (3)
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     ( >30mg prednisone
        equivalents/day)
The remainder of this form will be completed by your doctor, nurse, dietitian, or therapist.  Thank you.
  7. Worksheet  4 - Physical Exam
Scored Patient-Generated Subjective Global Assessment (PG-SGA)
Additive Score of the Boxes 1-4
5. Worksheet  2 - Disease and its relation to nutritional requirements
All relevant diagnoses (specify)  ________________________________________
                  Numerical score from Worksheet 1 
         Numerical score from Worksheet 3       C
                  Numerical score from Worksheet 4       D
6. Work Sheet 3 - Metabolic Demand
 A
One point each:
      Cancer        AIDS          Pulmonary or cardiac cachexia           Presence of decubitus, open wound, or fistula
      Presence of trauma       Age greater than 65 years                   Chronic renal insufficiency
Score for metabolic stress is determined by a number of variables known to increase protein & calorie needs.  The score is additive so that a patient who has a  fever  of > 102
degrees (3 points) and is on 10 mg of prednisone chronically (2 points) would have an additive score for this section of 5 points.
Stress           none (0)      low (1)      moderate (2) high (3)
Fever         no fever       >99  and <101       >101 and <102   >102
 Fever duration         no fever       <72 hrs       72 hrs > 72 hrs
Corticosteroids         no corticosteroids  low dose      moderate dose  high dose steroid
  (<10mg prednisone
      equivalents/day)
    (>10 and <30mg prednisone
                    equivalents/day)
Physical exam includes a subjective evaluation of 3 aspects of body composition: fat, muscle, & fluid status.  Since this is subjective, each aspect of the exam is rated for degree of deficit.  Muscle deficit
impacts  point score more than fat deficit. Definition of categories: 0 = no deficit, 1+ = mild deficit, 2+ = moderate   3+ = severe
   Muscle Status:
temples (temporalis muscle)    0 1+ 2+ 3+
clavicles (pectoralis & deltoids)    0 1+ 2+ 3+
shoulders (deltoids)    0 1+ 2+ 3+
interosseous muscles    0 1+ 2+ 3+
    Scapula  (latissimus dorsi, trapezius, deltoids)   0 1+ 2+ 3+
thigh (quadriceps)    0 1+ 2+ 3+
calf (gastrocnemius)    0 1+ 2+ 3+
      Global muscle status rating    0 1+ 2+ 3+
Fluid Status:
   ankle edema 0 1+ 2+ 3+
               sacral edema 0 1+ 2+ 3+
   ascites 0 1+ 2+ 3+
Global fluid status rating 0 1+ 2+ 3+
   Fat Stores:
orbital fat pads  0 1+ 2+ 3+
triceps skin fold  0 1+ 2+ 3+
fat overlying lower ribs  0 1+ 2+ 3+
Global fat deficit rating  0 1+ 2+ 3+
Clinician Signature ___________________________ RD RN PA MD DO Other ___       Date _______
©FD Ottery, 2005   email: fdottery@savientpharma.com or noatpres1@aol.com
(See Side  1)Worksheet 1 - Scoring Weight  (Wt) Loss
To determine score, use 1 month weight data if available.  Use 6 month data
only if there is no 1 month weight data.  Use points below to score weight
change and add one extra point if patient has lost weight during the past 2
  Wt loss in 1 month
         10% or greater
          5-9.9%
          3-4.9%
          2-2.9%
          0-1.9%
Points
   4
   3
   2
   1
   0
Wt loss in 6 months
         20% or greater
         10 -19.9%
           6 -  9.9%
           2 -  5.9%
           0 - 1.9%
                         Numerical score from Worksheet 2        B
                                    Total PG-SGA score
          (Total numerical score of A+B+C+D above)
                        (See triage recommendations below)
Worksheet 5 -  PG-SGA Global Assessment Categories    Stage A Stage B       Stage C
Category    Well nourished Moderately malnourished     Severely malnourished
Weight      No wt loss < 5% wt loss in 1 month      > 5% wt loss in 1 month
    OR Recent  wt gain (or 10% in 6 mos)      (or >10% in 6 mos)
OR  Progressive wt loss      OR Progressive wt loss
Nutrient intake     No deficit
    OR Significant recent Definite decrease in intake      Severe deficit in intake
    improvement
Nutrition Impact  None Present of nutrition impact      Present of nutrition impact
Symptoms     OR Singificant recent symptoms (PG-SGA Box 3)      symptoms (PG-SGA Box 3)
    improvement allowing
    adequate intake
Functioning      No deficit OR Moderate functional deficit      Severe functional deficit
    Recent improvement OR Recent deterioration      OR recent significant deterioration
Physical Exam     No deficit OR Evidence of mild to moderate     Obvious signs of malnutrition
    Chronic deficint but loss of muscle mass /  SQ fat /     (eg, severe loss muscle, SQ tissue,
    recent improvement muscle tone on palpation       possible edema)
Nutritional Triage Recommendations: Additive score is used to define specific nutritional interventions
including patient & family education, symptom management including pharmacologic intervention, and appropriate
nutrient intervention (food, nutritional supplements, enteral, or parenteral triage).
First line nutrition intervention includes optimal symptom management.
Triage based on PG-SGA point score
0-1 No intervention required at this time.  Re-assessment on routine and regular basis during treatment.
2-3 Patient & family education by dietitian, nurse, or other clinician with pharmacologic intervention as
indicated by symptom survey (Box 3) and lab values as appropriate.
4-8 Requires intervention by dietitian, in conjunction with nurse or physician as indicated by symptoms (Box 3).
> 9 Indicates a critical need for improved symptom management and/or nutrient intervention options.
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8.4 CCR 3703 Modified Gastrointestinal Symptom Rating Scale  
Patient Information: to be completed by the dietitian 
 
Step 1, Step 2 and Step 3: to be completed by the study participant 
 




Study number: ______________ 
 
        Is it a baseline measurement?              ☐ yes     ☐ no 
 
        Is it a follow-up measurement?              ☐ yes     ☐ no 
 




STEP 1 (to be completed by the study participant) 
 
Please take a few moments to think about any bowel symptoms you have had 
over the past 4 weeks. Please indicate whether you have had bowel symptoms 
during this time and how severe they were using the scale below. 
 
 In the past month, I 
would rate my overall 
bowel symptoms as: 
(please tick one) 
1. None: I didn’t have any symptoms  
2. Mild: I had a/some symptoms but they didn’t 
bother me 
 
3. Moderate: I had symptoms often, they 
bothered me quite a bit 
 
4. Severe: I had a lot of symptoms, they bothered 
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STEP 2 (to be completed by the study participant) 
 
Please rate your bowel symptoms over the past 4 weeks by placing a tick in the 




have this   
symptom 
I had it a   
















  None 
 
           Mild 
 
    Moderate 
 
    Severe 
     
1. Abdominal pain / discomfort         
      (any kind of pain in your belly) 
 
2. Heartburn          
      (burning / discomfort behind breastbone) 
 
3. Acid reflux / acid regurgitation         
      (flow of sour fluid into your mouth) 
 
4. Nausea          
      (feeling of wanting to be sick) 
 
5. Abdominal rumbling / gurgling         
     (bubbling or noise in the stomach) 
 
6. Abdominal bloating / distension         
     (swelling in the stomach or belly) 
 
7. Belching / burping         
     (bringing up gas through the mouth) 
 
8. Flatulence / passing wind         
      (release of gas from the bottom) 
 
 
9. Constipation         
      (stools are infrequent / difficult to pass) 
 
10. Diarrhoea         
      (loose or watery stools) 
 
 
11. Loose stools          
      (mushy or watery stools) 
 
 
12. Hard stools         
      (lumpy or dry stools) 
 
 
13. Urgency to open bowels         
      (rushing to do a poo) 
 
 
14. Incomplete evacuation         
      (feeling of something left behind after  
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you have done a poo) 
      None                 Mild              Moderate   Severe 
          
15. Difficulty swallowing fluids         
  
16. Difficulty swallowing solids         
      (feeling of foods sticking)  
17. Pain on swallowing fluids         
  
18. Pain on swallowing solids         	  
19. Feeling fuller sooner than normal         
      (feeling full up after a few mouthfuls) 
 
 
20. Regurgitation of fluids         
      (flow of fluids back into your mouth) 
 
 
21. Regurgitation of solids         
     (flow of food back into your mouth) 
  
22. Faecal incontinence         
      (accidents with bowels/ soiling/ some    





STEP 3 (to be completed by the study participant) 
 
In this step, we will talk about your stools. Please take a few moments to think 
about any problems you have had with your stools over the past 4 weeks (e.g. 
constipation, diarrhoea). Please indicate whether you have had problems during 
this time and how severe they were using the scale below. 
 
 In the past month, I would 
rate the overall problems 
with my stools as: (please 
tick one) 
1. None: I didn’t have any problems  
2. Mild: I had some problems but they didn’t 
bother me 
 
3. Moderate: I had problems often, they 
bothered me quite a bit 
 
4. Severe: I had a lot of problems, they 
bothered me a great deal 
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The Bristol Stool Chart below helps to describe what your stool consistency 




A. In general, what stool type best describes your stools over the past                        
4 weeks, when you have been “at your best”? Please tick one. 
 
 Type    ☐1  ☐2  ☐3  ☐4  ☐5  ☐6  ☐7 
 
B. In general, what stool type best describes your stools over the past                            
4 weeks, when you have been “at your worst”? Please tick one. 
 
        Type   ☐1  ☐2  ☐3  ☐4  ☐5  ☐6  ☐7 
 
C. How often would you say you were “at your best” over the past             
4 weeks? Please tick one.       
 ☐ none of the time  ☐ 1/4 of the time   ☐ 1/2 of the time   
     ☐ 3/4 of the time        ☐ all of the time 
 
D. How often would you say you are “at your worst” over the past   
4 weeks? Please tick one.        
 ☐ none of the time  ☐ 1/4 of the time   ☐ 1/2 of the time             
     ☐ 3/4 of the time        ☐ all of the time 
  335 
8.5 CCR 3736 Modified Gastrointestinal Symptom Rating Scale 
Patient Information: to be completed by the dietitian 
 
Step 1, Step 2 and Step 3: to be completed by the study participant 
 




Study number: ______________ 
 
        Is it a baseline measurement?              ☐ yes     ☐ no 
 





STEP 1 (to be completed by the study participant) 
 
Please take a few moments to think about any bowel symptoms you have had 
over the past 2 weeks. Please indicate whether you have had bowel symptoms 
during this time and how severe they were using the scale below. 
 
 In the past 2 weeks, I 
would rate my overall 
bowel symptoms as: 
(please tick one) 
5. None: I didn’t have any symptoms  
6. Mild: I had a/some symptoms but they didn’t 
bother me 
 
7. Moderate: I had symptoms often, they bothered 
me quite a bit 
 
8. Severe: I had a lot of symptoms, they bothered 
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STEP 2 (to be completed by the study participant) 
 
Please rate your bowel symptoms over the past 2 weeks by placing a tick in the 




have   this   
symptom 
I had it a   









I had it a   
lot, 
it bothered 





  Mild 
 
     Moderate 
 
    Severe 
     
15. Abdominal pain / discomfort         
      (any kind of pain in your belly) 
 
16. Heartburn          
      (burning / discomfort behind breastbone) 
 
17. Acid reflux / acid regurgitation         
      (flow of sour fluid into your mouth) 
 
18. Nausea          
      (feeling of wanting to be sick) 
 
19. Abdominal rumbling / gurgling         
      (bubbling or noise in the stomach) 
 
20. Abdominal bloating / distension         
      (swelling in the stomach or belly) 
 
21. Belching / burping         
      (bringing up gas through the mouth) 
 
22. Flatulence / passing wind         
      (release of gas from the bottom) 
 
 
23. Constipation         
      (stools are infrequent / difficult to pass) 
 
24. Diarrhoea         
      (loose or watery stools) 
 
 
25. Loose stools          
      (mushy or watery stools) 
 
 
26. Hard stools         
      (lumpy or dry stools) 
 
 
27. Urgency to open bowels         
      (rushing to do a poo) 
 
 
28. Incomplete evacuation         
      (feeling of something left behind after     
       you have done a poo) 
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       None                 Mild              Moderate      Severe 
 
15. Difficulty swallowing fluids         
  
16. Difficulty swallowing solids         
      (feeling of foods sticking)  
 
17. Pain on swallowing fluids         
  
18. Pain on swallowing solids         	  
19. Feeling fuller sooner than normal         
      (feeling full up after a few mouthfuls) 
 
 
20. Regurgitation of fluids         
      (flow of fluids back into your mouth) 
 
 
21. Regurgitation of solids         
      (flow of food back into your mouth) 
  
22. Faecal incontinence         
      (accidents with bowels/ soiling/ some    




23. Wakening at night to do a poo         
 
24. Fatty stools         
      (floating, oily, sticky or smelly)  
 
25. Change in frequency of stools         
      (more stools than normal or less than    
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STEP 3 (to be completed by the study participant) 
 
In this step, we will talk about your stools. Please take a few moments to think 
about any problems you have had with your stools over the past 2 weeks (e.g. 
constipation, diarrhoea). Please indicate whether you have had problems during 
this time and how severe they were using the scale below. 
 
 In the past 2 weeks, I 
would rate the overall 
problems with my stools 
as: (please tick one) 
5. None: I didn’t have any problems  
6. Mild: I had some problems but they didn’t 
bother me 
 
7. Moderate: I had problems often, they 
bothered me quite a bit 
 
8. Severe: I had a lot of problems, they bothered 
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The Bristol Stool Chart below helps to describe what your stool consistency 




A. In general, what stool type best describes your stools over the past                      
2 weeks, when you have been “at your best”? Please tick one. 
 
 Type    ☐1  ☐2  ☐3  ☐4  ☐5  ☐6  ☐7 
 
B. In general, what stool type best describes your stools over the past            
    2 weeks, when you have been “at your worst”? Please tick one. 
 
        Type   ☐1  ☐2  ☐3  ☐4  ☐5  ☐6  ☐7 
 
B. How often would you say you were “at your best” over the past  
2 weeks, Please tick one.     
☐ none of the time  ☐ 1/4 of the time   ☐ 1/2 of the time  
    ☐ 3/4 of the time        ☐ all of the time 
 
D. How often would you say you are “at your worst” over the past            
     2 weeks? Please tick one. 
☐ none of the time  ☐ 1/4 of the time   ☐ 1/2 of the time    
  ☐ 3/4 of the time        ☐ all of the time 
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8.6 Malnutrition Universal Screening Tool   
Reference: Elia 2003 
‘MUST’ is a five-step screening tool to identify adults, who are malnourished, at risk of malnutrition
(undernutrition), or obese. It also includes management guidelines which can be used to develop
a care plan.
It is for use in hospitals, community and other care settings and can be used
by all care workers.
This guide contains:
A flow chart showing the 5 steps to use for screening and management
BMI chart
Weight loss tables
Alternative measurements when BMI cannot be obtained by measuring weight and height.
Please refer to The ‘MUST’ Explanatory Booklet for more information when weight and height cannot be measured, and
when screening patient groups in which extra care in interpretation is needed (e.g. those with fluid disturbances,
plaster casts, amputations, critical illness and pregnant or lactating women). The booklet can also be used for training.
See The ‘MUST’ Report for supporting evidence. Please note that ‘MUST’ has not been designed to detect
deficiencies or excessive intakes of vitamins and minerals and is of use only in adults.
The 5 'MUST' Steps
Step 1
Measure height and weight to get a BMI score using chart provided. If unable to obtain
height and weight, use the alternative procedures shown in this guide.
Step 2
Note percentage unplanned weight loss and score using tables provided.
Step 3
Establish acute disease effect and score.
Step 4
Add scores from steps 1, 2 and 3 together to obtain overall risk of malnutrition.
Step 5
Use management guidelines and/or local policy to develop care plan.
Malnutrition Advisory Group
A Standing Committee of BAPEN
AG'Malnutrition Universal Screening Tool'
B A P E N
Advancing Clinical Nutrition
'MUST'
BAPEN is registered charity number 1023927 www.bapen.org.uk
© BAPEN
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Step 1 – BMI score (& BMI)















Note : The black lines denote the exact cut off points ( 30,20 and 18.5 kg/m2), figures on the chart have been rounded to the nearest whole number.
© BAPEN
 

















Document dietary intake for
3 days
If adequate – little concern and
repeat screening
Hospital – weekly
Care Home – at least monthly
Community – at least every
2-3 months
If inadequate – clinical concern
– follow local policy, set goals,
improve and increase overall
nutritional intake, monitor and
review care plan regularly
Treat*
Refer to dietitian, Nutritional
Support Team or implement
local policy
Set goals, improve and increase
overall nutritional intake
Monitor and review care plan
Hospital – weekly
Care Home – monthly
Community – monthly
* Unless detrimental or no benefit is
expected from nutritional support
e.g. imminent death.
If unable to obtain height and weight, see
reverse for alternative measurements
and use of subjective criteria
Acute disease effect is unlikely to
apply outside hospital. See ‘MUST’
Explanatory Booklet for further
informationStep 4
Overall risk of malnutrition
Add Scores together to calculate overall risk of malnutrition
Score 0 Low Risk Score 1 Medium Risk Score 2 or more High Risk
Re-assess subjects identified at risk as they move through care settings
See The ‘MUST’ Explanatory Booklet for further details and The ‘MUST’ Report for supporting evidence.
All risk categories:
Treat underlying condition and provide help and
advice on food choices, eating and drinking when
necessary.
Record malnutrition risk category.
Record need for special diets and follow local policy.
Obesity:
Record presence of obesity. For those with
underlying conditions, these are generally
controlled before the treatment of obesity.
BMI kg/m2 Score
>20 (>30 Obese) = 0









If patient is acutely ill and
there has been or is likely
to be no nutritional





Care Homes – monthly
Community – annually
for special groups
e.g. those >75 yrs
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Step 2 – Weight loss score
© BAPEN
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Step 1: BMI (body mass index)
If height cannot be measured
Use recently documented or self-reported height (if reliable and realistic).
If the subject does not know or is unable to report their height, use one of the alternative
measurements to estimate height (ulna, knee height or demispan).
Step 2: Recent unplanned weight loss
If recent weight loss cannot be calculated, use self-reported weight loss (if reliable and realistic).
Subjective criteria
If height, weight or BMI cannot be obtained, the following criteria which relate to them can assist your
professional judgement of the subject’s nutritional risk category. Please note, these criteria should be
used collectively not separately as alternatives to steps 1 and 2 of ‘MUST’ and are not designed to
assign a score. Mid upper arm circumference (MUAC) may be used to estimate BMI category in order to
support your overall impression of the subject’s nutritional risk.
1. BMI
Clinical impression – thin, acceptable weight, overweight. Obvious wasting (very thin) and obesity
(very overweight) can also be noted.
2. Unplanned weight loss
Clothes and/or jewellery have become loose fitting (weight loss).
History of decreased food intake, reduced appetite or swallowing problems over 3-6 months and
underlying disease or psycho-social/physical disabilities likely to cause weight loss.
3. Acute disease effect
Acutely ill and no nutritional intake or likelihood of no intake for more than 5 days.
Further details on taking alternative measurements, special circumstances and subjective criteria can
be found in The ‘MUST’ Explanatory Booklet. A copy can be downloaded at www.bapen.org.uk or
purchased from the BAPEN office. The full evidence-base for ‘MUST’ is contained in The ‘MUST’ Report
and is also available for purchase from the BAPEN office.
BAPEN Office, Secure Hold Business Centre, Studley Road, Redditch, Worcs, B98 7LG. Tel: 01527 457 850. Fax: 01527 458 718.
bapen@sovereignconference.co.uk BAPEN is registered charity number 1023927. www.bapen.org.uk
© BAPEN 2003 ISBN 1 899467 90 4 Price £2.00
All rights reserved. This document may be photocopied for dissemination and training purposes as long as the source
is credited and recognised.
Copy may be reproduced for the purposes of publicity and promotion. Written permission must be sought from BAPEN if reproduction or
adaptation is required. If used for commercial gain a licence fee may be required.
Alternative measurements and considerations
© BAPEN. First published May 2004 by MAG the Malnutrition Advisory Group, a Standing Committee of BAPEN.
Reviewed and reprinted with minor changes March 2008 and September 2010
‘MUST’ is supported by the British Dietetic Association, the Royal College of Nursing and the Registered Nursing Home Association.
© BAPEN
 
  345 
Alternative measurements: instructions and tables
If height cannot be obtained, use length of forearm (ulna) to calculate height using tables below.
(See The ‘MUST’ Explanatory Booklet for details of other alternative measurements (knee height and
demispan) that can also be used to estimate height).
Estimating height from ulna length
Measure between the point of the elbow
(olecranon process) and the midpoint of the prominent
bone of the wrist (styloid process) (left side if possible).
Estimating BMI category from mid upper arm circumference (MUAC)
The subject’s left arm should be bent at the elbow at a 90 degree angle,
with the upper arm held parallel to the side of the body. Measure the
distance between the bony protrusion on the shoulder (acromion) and
the point of the elbow (olecranon process). Mark the mid-point.
Ask the subject to let arm hang loose and measure around
the upper arm at the mid-point, making sure that the tape
measure is snug but not tight.
If MUAC is <23.5 cm, BMI is likely to be <20 kg/m2.
If MUAC is >32.0 cm, BMI is likely to be >30 kg/m2.
The use of MUAC provides a general indication of BMI and is not designed to generate an actual score for
use with ‘MUST’. For further information on use of MUAC please refer to The ‘MUST’ Explanatory Booklet.
Men(<65years) 1.94 1.93 1.91 1.89 1.87 1.85 1.84 1.82 1.80 1.78 1.76 1.75
Men(>65years) 1.87 1.86 1.84 1.82 1.81 1.79 1.78 1.76 1.75 1.73 1.71 1.70
Ulna length(cm) 32.0 31. 1.0 30. 0.0 29. 9.0 28.5 28.0 27.5 27.0 26.5
Women (<65 years) 1.84 1.83 1.81 1.80 1.79 1.77 1.76 1.75 1.73 1.72 1.70 1.69
Women (>65 years) 1.84 1.83 1.81 1.79 1.78 1.76 1.75 1.73 1.71 1.70 1.68 1.66
Men(<65years) 1.69 1.67 1.66 1.64 1.62 1.60 1.58 1.57 1.55 1.53 1.51 1.49 1.48 1.46
Men(>65years) 1.65 1.63 1.62 1.60 1.59 1.57 1.56 1.54 1.52 1.51 1.49 1.48 1.46 1.45
Ulna length(cm) 5.0 24. 4.0 23. 3.0 22. 2.0 21. 1.0 20. 0.0 19. 9.0 18.5
Women (<65 years) 1.65 1.63 1.62 1.61 1.59 1.58 1.56 1.55 1.54 1.52 1.51 1.50 1.48 1.47
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8.7 European Prospective Investigation into Cancer-Norfolk Food 
Frequency Questionnaire Version 6  
Reference: Bingham 1997 
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This  food frequency questionnaire (CAMB/PQ/6/1205) was originally designed for the EPIC-Norfolk Study. 
www.epic-norfolk.org.uk  
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This  food frequency questionnaire (CAMB/PQ/6/1205) was originally designed for the EPIC-Norfolk Study. 
www.epic-norfolk.org.uk  
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This  food frequency questionnaire (CAMB/PQ/6/1205) was originally designed for the EPIC-Norfolk Study. 
www.epic-norfolk.org.uk  
 
  350 
This  food frequency questionnaire (CAMB/PQ/6/1205) was originally designed for the EPIC-Norfolk Study. 
www.epic-norfolk.org.uk  
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This  food frequency questionnaire (CAMB/PQ/6/1205) was originally designed for the EPIC-Norfolk Study. 
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This  food frequency questionnaire (CAMB/PQ/6/1205) was originally designed for the EPIC-Norfolk Study. 
www.epic-norfolk.org.uk  
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This  food frequency questionnaire (CAMB/PQ/6/1205) was originally designed for the EPIC-Norfolk Study. 
www.epic-norfolk.org.uk  
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This  food frequency questionnaire (CAMB/PQ/6/1205) was originally designed for the EPIC-Norfolk Study. 
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This  food frequency questionnaire (CAMB/PQ/6/1205) was originally designed for the EPIC-Norfolk Study. 
www.epic-norfolk.org.uk  
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8.8 Glucose Hydrogen Methane Breath Test Information Booklet 
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8.9 CCR 3703 Ethical Approval Letter 
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 ‘Monitoring nutrition and gastrointestinal symptoms during and after treatment for 
disorders of the oesophagus and stomach’ 
Introduction 
We would like to invite you to take part in our research study. Before you decide we 
would like you to understand why the research is being done and what it would involve 
for you. One of our team will go through the information sheet with you and answer any 
questions you have. Ask us if there is anything, which is unclear to you, or if you would 
like more information. Take time to decide whether or not you wish to take part. Thank 
you for taking the time to read this. 
 
Why have I been invited to take part? 
You have been invited to take part in this study because you are a patient at The Royal 
Marsden NHS Foundation Trust. You have just been diagnosed with a disorder of the 
oesophagus (gullet) or stomach and after discussion with you, an appropriate treatment 
pathway has been chosen for you. This study will recruit men and women who will 
undergo surgery and/or receive radiotherapy/chemotherapy for disorders of the 
oesophagus or stomach. Therefore, you fit the criteria for the patient-type we are 
looking for. 
 
What is the purpose of the study? 
The study has objectives, which include gathering information on the symptoms and 
nutritional issues that patients may experience after their diagnosis. Also, in some 
patients, we will be collecting data on the number of patients who develop a condition 
called small bowel bacterial overgrowth during and after treatment for their disorder.   
 
Symptoms and nutritional issues caused by treatment  
As a result of your disorder and the treatment you will receive for it, you may develop 
symptoms and nutritional issues. The symptoms may include abdominal 
pain/discomfort, nausea, reflux, difficult swallowing, diarrhoea or constipation. One or 
more of these symptoms may develop in the early stages of your treatment and/or 
continue for months after you have finished it. We would like to find out more about the 
specific symptoms which patients experience, as they can affect many aspects of your 
life, including your nutritional status. 
 
The nutritional issues, which patients may face when undergoing treatment for their 
condition may include difficulty swallowing, reflux, nausea, vomiting, and changes in 
taste and food preferences. In addition, patients may become malnourished. 
Malnutrition is a word used to describe a condition resulting from poor or inadequate 
food intake. Patients can become malnourished for many reasons e.g. as a result of 
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having the symptoms mentioned above, the effect of your cancer or reduced appetite. 
As part of this study, you will be assessed for malnutrition on a regular basis. This will 
provide us with information on the numbers of patients who become malnourished. 
 
The numbers of patients who develop small bowel bacterial overgrowth 
Firstly, a brief background on what small bowel bacterial overgrowth is. In most healthy 
people, very few bacteria are able to survive in the upper part of the small bowel. It is 
usually a very sterile area. Nearly all of the bacteria living along the gastrointestinal 
tract (gut) live in the large bowel. Their role here is very important for our health. 
Sometimes, often in illness, these bacteria move upwards into the small bowel, where 
they can multiply. If they reach large enough numbers, they start to cause symptoms 
e.g. diarrhoea, bloating/gasiness, weight loss and nutritional deficiencies. This is called 
‘small bowel bacterial overgrowth’. 
 
There are many reasons why small bowel bacterial overgrowth can occur in patients 
like you. It may develop following surgery, where the anatomy of the gastrointestinal 
tract has been changed. Patients who receive chemotherapy and/or radiotherapy may 
also be at risk of developing it, as the healthy cells of the gut may become damaged 
and so bacterial numbers can increase. However, to date, there has been very little 
research looking at the condition in patients undergoing treatment for oesophageal and 
gastric disorders. By finding out how often the condition occurs, and in which patients, 
we hope that we can gather information to allow early detection and so improve the 
care of these patients. 
 
Do I have to take part? 
It is up to you whether or not you decide to join this study. We will describe the study 
and go through this information sheet with you. If you agree to take part we will then 
ask you to sign a consent form. You are free to withdraw at any time without giving a 
reason. Your usual treatment will not be affected in any way. 
 
What will happen to me if I take part? 
If you decide to take part you will be seen by a dietitian before you begin your 
treatment – she will see you throughout the duration of the study. Whenever possible, 
this will be on the same days that you have other appointments at the Royal Marsden 
Hospital. You will see her three times in total; at the start of your treatment, after 3-
months and then after another 9-months. Each appointment will include a glucose 
breath test. 
 
The glucose breath test, a simple, low risk procedure, is used to get an idea of the 
number of bacteria in your small bowel by measuring the gases in your breath. It helps 
with diagnosing small bowel bacterial overgrowth. The test will take place in the 
morning and you will be asked to have been fasting since the night before. The dietitian 
(or a nurse) will give you a sugary liquid and will ask you to drink it. You will then 
breathe into a bag once every 20 minutes for the next 1.5 hours (maximum of 2.5 
hours) and your breath will be analysed using a machine. 
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At each appointment with the dietitian, you will be asked to fill in some questionnaires. 
One questionnaire will ask you about your symptoms and another about your food 
intake. In addition, the dietitian will ask you questions about your nutrition, which will 
identify malnutrition if it is present. She will also take your temperature and examine 
you to assess your muscle and fat stores. On average, each appointment should take 
approximately 1.5 hours in total. 
 
What are the possible risks and disadvantages of taking part? 
This study is low risk as the breath test is non-invasive and the questionnaires will just 
involve you answering the questions asked. The examination component of the study 
requires you to be able to stand or sit on scales to be weighed and involves you 
undergoing an examination while lying in bed or sitting in a chair.  Before any 
examination is carried out the dietitian will speak to you and assess if you would 
experience any difficulty being examined in this way.  All examinations would be done 
in private with you wearing your own clothes. 
 
What are the possible benefits of taking part? 
There are two potential benefits of this study for you. As we are specifically looking at 
the development of small bowel bacterial overgrowth, should you at any stage develop 
symptoms of it, we will ask your medical team to look into it. Therefore, we could pick 
up on a case of small bowel bacterial overgrowth or another condition much earlier 
(and so treat it earlier) than if you had not taken part in the study. Similarly, as we will 
be using questions and measurements to detect malnutrition, we can quickly recognize 
if you have or are at risk of becoming malnourished. You will then be referred to a 
dietitian for advice on your diet. We also hope the study may benefit patients in the 
future as it will allow us to gather invaluable data, which in the longer term will allow us 
to deliver improved care to them. 
  
What happens when the research study stops? 
Your normal care will continue in the usual way. 
 
Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential.  
 
Who is organising and funding the research? 
The Royal Marsden NHS Foundation Trust is sponsoring this research. 
 
Who has reviewed the study? 
The Royal Marsden Committee for Clinical Research (CCR) and the London-Riverside 
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Further Information 
Before you make a decision about your participation in this study, remember that you 
can ask us any questions. Allow yourself as much time as you need to think through 
your decision. If you then decide that you still wish to take part, you will be asked to 
confirm in writing that you have read and understand this patient information and that 
all of your questions have been answered completely and that you wish to continue in 
the study. If you would like further information about the study, or have any concerns 
during the study, please contact Eva Grace, Research Dietitian, Tel. 020 7352 8171 
(ext.4653) or Dr. Jervoise Andreyev, Consultant Gastroenterologist in Pelvic Radiation 
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8.11 CCR 3703 Consent Form 
 
Study Protocol Number: 
Ethics Protocol Number: 




Study title: “An observational study to assess the prevalence and profile of 
oesophagogastric cancer patients who develop small intestinal bacterial overgrowth 
during or after cancer treatment” 
 
Name of Principal Investigator: Dr. Jervoise Andreyev 
           Please initial box 
 
1. I confirm that I have read and understand the information sheet dated  
10th Oct 2012 for the above study. I have had the opportunity to consider the  
information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw  
at any time, without giving any reason, and my medical care and legal rights 
will not be affected. 
 
3. I give permission for individuals from regulatory authorities or from The Royal  
Marsden NHS Foundation Trust, to have access to relevant sections of my  
medical notes and data collected during the study 
 
4. I consent to the researcher keeping the anonymous data in a locked office  
for a maximum of fifteen years post commencement of the study for confirmation  
purposes during preparation for publication. 
 
5. I have been assured strict confidentiality will be maintained. 
 
6. I agree to my GP being informed of my participation in the study. 
     
  7.   I agree to take part in the above study. 
                  
                  8.  I would/ would not like to be informed of the results of this study. Please circle one. 
 
 
Please sign here: 
 
 
-------------------------------  ---------------------- ------------------------------- 
Signature of Participant           Date           Print Name  
 
-------------------------------  ----------------------- -------------------------------- 
Signature of Researcher           Date                      Print Name  !
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8.12 Subjective Global Assessment Physical Examination Guidance 
Sheet 
Reference: (Shaw 2011) 





Head      
Orbit Fat Slightly bulged 
fat pads 














side to side 
Shoulder      
Clavicle Muscle Not visible in 






























Arm      
Triceps skinfold Fat Ample fat tissue  Very little space 
between fingers 
or fingers touch 
Arm bent; be 
careful not to 
include muscle 


















Back of hand, 
move thumb 
and fore finger 
back / forth 


































Fat Lower rib well 
covered 
Lower rib visible Depression 
between lower 




Legs      
Thigh 
(quadriceps) 
Muscle Well rounded 
no depressions.  
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Muscle Well developed 
bulb 






Ankles   Check for 
pitting oedema 
Sacral oedema Can use nurse 
if help required 









pillow of fluid 
at base of 
spine 
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8.13 CCR 3703 Ethical Approval Letter for Amendment to Protocol 





NRES Committee London - Riverside 
Bristol Research Ethics Committee Centre 






Tel: 0117 342 1390 
Fax: 0117 342 0445 
 
27 July 2012 
 
Ms Eva Grace 
C/O Dr Andreyev, GI Unit 





Dear Ms Grace 
 
Study title: An observational study to assess the prevalence and 
profile of oesophago-gastric cancer patients who develop 
small intestinal bacterial overgrowth during or after 
cancer treatment 
REC reference: 11/LO/1583 
Protocol number: CCR3703 
Amendment number: 1 
Amendment date: 24 May 2012 
 
Thank you for submitting the above amendment, which was received on 20 July 2012.  It is 
noted that this is a modification of an amendment previously rejected by the Committee (our 
letter of 13th July 2012 refers). 
 




There were no ethical issues.  
 
I am pleased to confirm that the Committee has given a favourable ethical opinion of the 





The documents reviewed and approved are: 
 
 Document  Version  Date  
Participant Information Sheet  3  17 July 2012  
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A Research Ethics Committee established by the Health Research Authority 
 
 
Modified Amendment  1  24 May 2012  




All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 









Copy to:  Ms Jane  Lawrence, Royal Marsden NHS Foundation Trust 
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8.14 CCR 3736 Ethical Approval Letter 
 
NRES Committee London - Central 
Level 7N019, Maternity Block 






 Telephone: 020 8869 3775  
Facsimile: 020 8869 5222 
19 December 2011 
 
Miss Eva Grace 
The Royal Marsden 







Full title of study: 
An observational study to develop a new method for diagnosing small intestinal bacterial 
overgrowth. 







Thank you for your email of 16/12/2011. I can confirm the REC has received the documents listed 
below as evidence of compliance with the approval conditions detailed in our letter dated 30 
November 2011. Please note these documents are for information only and have not been reviewed 




The documents received were as follows: 
  
Document    
Version    
Date    
 Participant Information Sheet  
2  
08 December 2011  
  
You should ensure that the sponsor has a copy of the final documentation for the study.  It is the 
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We would like to invite you to take part in our research study. Before you decide we 
would like you to understand why the research is being done and what it would involve 
for you. One of our team will go through the information sheet with you and answer any 
questions you have. Ask us if there is anything, which is unclear to you, or if you would 
like more information. Take time to decide whether or not you wish to take part. Thank 
you for taking the time to read this. 
 
Why have I been invited to take part? 
You have been invited to take part in this study because you are a patient at The Royal 
Marsden NHS Foundation Trust. You are suffering from symptoms related to your 
cancer or the treatment you received/are receiving for it. You have been referred to one 
of Dr Andreyev’s clinics because of these symptoms. This study will recruit men and 
women who meet these two criteria. This is why you have been selected to take part. 
 
What is the purpose of the study? 
The study has objectives, which includes finding out more about a condition called 
small bowel bacterial overgrowth. To date, there has been very little research looking at 
the condition in patients undergoing treatment for their cancer, or in the aftermath of 
that treatment. The condition typically causes symptoms as follows; abdominal 
pain/discomfort, nausea, diarrhoea, constipation, bloating, excessive gas, vomiting or a 
change in the frequency of stools. These symptoms may develop before treatment, in 
the early stages of your treatment and/or continue for months or years after you have 
finished it. We would like to find out more about the specific symptoms which patients 
experience, as they can affect the patient’s quality of life.  
 
What is small bowel bacterial overgrowth? 
In most healthy people, very few bacteria are able to survive in the upper part of the 
small bowel. It is usually a very sterile area. Nearly all of the bacteria living along the 
gastrointestinal tract live in the large bowel. Their role here is very important for our 
health. Sometimes, often in illness, these bacteria move upwards into the small bowel, 
where they can multiply. If they reach large enough numbers, they start to cause 
symptoms e.g. diarrhoea, bloating, gasiness, weight loss and nutritional deficiencies. 
This is called ‘small bowel bacterial overgrowth’. 
 
There are many reasons why small bowel bacterial overgrowth can occur in patients 
with cancer. It may develop following surgery, where the anatomy of the 
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gastrointestinal tract has been changed. Patients who receive chemotherapy and/or 
radiotherapy may also be at risk of developing it because the healthy cells of the 
gastrointestinal tract may become damaged and so bacterial numbers can increase. 
We hope that this study will provide us with more information about the condition and 
this will allow early diagnosis of it and so quicker improvement in the symptoms that it 
causes. 
 
Do I have to take part? 
It is up to you whether or not you decide to join this study. We will describe the study 
and go through this information sheet with you. If you agree to take part we will then 
ask you to sign a consent form. You are free to withdraw at any time without giving a 
reason. Your usual treatment will not be affected in any way. 
 
What will happen to me if I take part? 
If you decide to take part you will be seen by the research dietitian who is running the 
study– she will be in touch with you during the study, which will last for 3-months. You 
will see her when you are at The Royal Marsden Hospital for the appointments, which 
Dr Andreyev has made/will make for you. You will not have to make any additional trips 
to the hospital outside of your normal clinic appointments. However, we will record the 
information gathered at these appointments.  
 
Dr Andreyev will ask you to carry out a glucose breath test. It is a simple, low risk 
procedure, which is used to get an idea of the number of bacteria in your small bowel 
by measuring the gases in your breath. It helps with diagnosing small bowel bacterial 
overgrowth. The test will take place in the morning and you will be asked to have been 
fasting since the night before. The dietitian (or a nurse) will give you a sugary liquid and 
will ask you to drink it. You will then breathe into a bag once every 20 minutes for the 
next 1.5 hours and your breath will be analysed using a machine. 
 
At this appointment, you will be asked to fill in a questionnaire, which can be done 
during the breath test. It will ask you about your gastrointestinal symptoms. On the day 
of the appointment, the dietitian will collect two pots from you; one containing a urine 
sample and one containing a stool sample. You will have been provided with the pots 
prior to your appointment. 
 
Dr Andreyev may make an endoscopy appointment for you too. This is to allow him to 
take a look down your gullet and into your gastrointestinal tract. As a part of the 
procedure, a sample of the fluid in the tract is collected. If this test is done, some 
additional fluid will also be collected for our study. The fluid collected, as well as the 
urine and stool samples will be used to help with developing a new diagnosis for small 
bowel bacterial overgrowth. 
 
When you return to Dr Andreyev’s clinic for a review appointment, you will see the 
dietitian again. She will ask you to complete the same symptom questionnaire as 
before. She will also collect a urine sample and a stool sample from you in pots, which 
she has previously provided you with. 
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What are the possible risks and disadvantages of taking part? 
Taking part in this study poses no additional risk to you than if you refuse to take part. 
This is because the only extra requirement would be for you to complete some 
questionnaires and to provide samples of urine and stool. The breath test and 
endoscopy appointment are a part of routine clinical practice.  
 
What are the possible benefits of taking part? 
There is one main benefit of the study. We hope the study may help patients in the 
future, as it will allow us to gather invaluable data, which in the longer term may allow 
us to develop a new test for diagnosing small bowel bacterial overgrowth. This will 
allow us to deliver improved care to them. 
  
What happens when the research study stops? 
Your normal care will continue in the usual way. 
 
Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. If 
you consent to take part in the study, you will receive a study number so that none of 
the information gathered about you can be traced back to you. There will be other 
organisations involved in the study also. This is because a special technique (called 
NMR spectroscopy) is needed to help us analyse the samples which you provide. 
These organisations include King’s College London, the University of Reading and 
Korrigan Sciences Limited. We will ensure that all data is kept completely confidential 
at each step along the way.  
 
Who is organising and funding the research? 
The Royal Marsden NHS Foundation Trust is sponsoring this research. 
 
Who has reviewed the study? 
The Royal Marsden Committee for Clinical Research (CCR) and the London Central 
National Research Ethics Committee.  
 
Further Information 
Before you make a decision about your participation in this study, remember that you 
can ask us any questions. Allow yourself as much time as you need to think through 
your decision. If you then decide that you still wish to take part, you will be asked to 
confirm in writing that you have read and understand this patient information and that 
all of your questions have been answered completely and that you wish to continue in 
the study. If you would like further information about the study, or have any concerns 
during the study, please contact Ms Eva Grace, Research Dietitian, Tel. 020 7352 8171 
(ext. 4653) or Dr Jervoise Andreyev, Consultant Gastroenterologist in Pelvic Radiation 





8.16 CCR 3736 Consent Form 
 
Study Protocol Number: 
Ethics Protocol Number: 




Study title: “An observational study to develop a new method for diagnosing small 
intestinal bacterial overgrowth” (SIBO II Study).  
 
Name of Principal Investigator: Dr. Jervoise Andreyev 
           Please initial box 
 
1. I confirm that I have read and understand the patient information sheet (version 
3) dated 2nd October 2012 for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw  
at any time, without giving any reason, and my medical care and legal rights 
will not be affected. 
 
3. I give permission for individuals from regulatory authorities, from The Royal  
      Marsden and the other relevant organizations as mentioned in the patient                                
      information sheet (version 3, dated 2nd October 2012), to have access to relevant 
      sections of my medical notes and data (including samples) collected during the  
      study. 
 
4. I consent to the researcher keeping the anonymous data in a locked office  
for a maximum of fifteen years post commencement of the study for confirmation  
purposes during preparation for publication. 
 
5. I have been assured strict confidentiality will be maintained. 
     
  6.   I agree to take part in the above study. 
                 




Please sign here: 
 
 
-------------------------------  ----------------------       ------------------------------- 
          Signature            Date                            Name of Participant 
 
 
-------------------------------  -----------------------      --------------------------------- 












Thank you very much for agreeing to take part in the SIBO II study. As 
discussed, I would like you to provide me with a stool sample and a urine 
sample. Ideally the samples should be collected on the day of your endoscopy 
appointment with Dr Andreyev.  
 
Appointment Date:                           
 
Appointment Time:  
 
I have enclosed some stool and urine sample collection items and have 
provided instructions below.  
 
Instructions for stool collection: 
 
1) Please wear a pair of disposable gloves.  
2) Use the card tray to collect the stool before it drops into the pan. 
3) Decant enough stool to fill the yellow-top container (labelled ‘stool’) using 
the wooden spatula. 




Instructions for urine collection: 
 
1) The sample can be collected at any time. 
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2) Please wear a pair of disposable gloves.  
3) Start to urinate but don’t collect the first part of urine that comes out i.e. 
collect a mid-stream sample. 
4) Screw the lid of the yellow-top container (labelled ‘urine’) shut.  
 
Note:  
Please fill up the yellow-topped containers as otherwise we will not have 




1) Place each of the yellow-top containers in a separate clear bag and seal 
each bag. 
2) Put both of these bags into the white carrier bag.  
3) Bring the samples with you when you come to your endoscopy 
appointment and please ask one of the endoscopy nurses to call me 
when you arrive (ext. 4653). 
 
 
I look forward to seeing you and many thanks again. 
 







Tel: 0207 352 8171 (ext. 4653) 
 
 
